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Towards Microarray Diagnosis of Infection in the Newborn
Background & Aims
Infection causes significant morbidity and mortality in newborn infants. Current
methods for diagnosing infection are unreliable. It would be beneficial if a test could
be found that could diagnose infection sensitively, accurately and reliably -
particularly ifmore rapid and from smaller samples. Microarrays are a useful means
of global analysis of gene expression. One particularly exciting application of
microarrays could be in diagnosing infection by detecting alteration in host RNA
phenotype in response to infection. I set out to investigate whether small volumes of
neonatal blood could yield RNA of sufficient quality and quantity to carry out
microarray analysis and to identify suitable methods of sample handling and RNA
extraction. I then went on to determine if differences in gene expression profiles
could be detected between infants with confirmed infection and a group of controls
using microarray technology.
Methods
Umbilical cord blood was used to optimise blood collection tube, RNA extraction
method and sample storage conditions. RNA quality and yield were assessed for
each. RNA samples from neonatal blood taken from infants with confirmed infection
and controls were then run on microarray: initially on CodeLink™ Whole Human
Genome Microarray and later on Illumina® Human Whole-Genome Expression
BeadChips. Normalised, validated microarray data was analysed to examine
differences between control and infected samples. Functional annotation according to
gene ontology and pathway analysis was performed.
Results
High quality RNA yields sufficient for microarray work were obtained. The optimum
blood collection tube, RNA extraction method and sample handling conditions are
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described. Results from the Codelink™ arrays are presented along with discussion
of problems encountered using this platform. Results from 28 infected and 35 control
samples run on the Illumina® platform are presented. 6221 features were
significantly differentially expressed between infected and control groups (adjusted
p-value < 0.001). 448 features had > 2-fold up-regulation and 341 features > 2-fold
down-regulation (p < 0.001). Functional annotation and pathway analysis revealed a
notable proportion of these are involved in immune functions.
Conclusions
Sufficient high quality RNA for microarray analysis can be obtained from small
neonatal blood samples. Differential RNA expression profiles of host response can
be detected between infected and non-infected infants. Such data may provide an
alternative way for diagnosing infection in infants in the future. Large-scale studies
are required to explore this further.
Word Count: 89776 (including tables and references)
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Central Hypothesis
• Distinct patterns of host transcriptional response detected from neonatal
whole blood may enable diagnosis of neonatal infection.
Secondary Hypotheses (Questions Arising from Central
Hypothesis)
• It is possible to extract RNA of sufficient quality and quantity from neonatal
blood to carry out successful microarray analysis.
• Host gene expression profiles differ between infected and non-infected
infants.
Aims
To define a robust, reliable, reproducible method ofRNA extraction from neonatal
whole blood I aimed to:
• Determine if RNA of sufficient quality and quantity for microarray analysis
can be extracted from clinically applicable volumes of umbilical cord blood
& neonatal blood.
• Determine a suitable blood collection tube for RNA extraction from neonatal
whole blood.
• Determine a suitably small blood volume to collect into the blood collection
tube to be sufficient, provide accuracy and to be clinically applicable.
• Determine a suitable method for RNA extraction from neonatal whole blood.
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• Determine an optimal time period between blood sampling and RNA
extraction.
• Determine whether freezing of blood samples prior to RNA extraction was
feasible.
To examine whether it is possible to detect differences in blood RNA expression
profiles between infected and non-infected infants I set out to:
• Compare microarray results of infected and non-infected infants.
Ethical Consideration
A favourable ethical opinion was obtained from Lothian Local Research Ethics
Committee for both the umbilical cord blood studies (LREC/2004/6/1) and the
neonatal blood studies (05/S1103/3) presented here. Permission was also granted
from the local NHS Research and Development Office for both phases of the project





1.1 The burden of neonatal infection
Despite advances in neonatal care, infection remains a significant cause of morbidity
and mortality in newborn infants. The incidence of congenital infection is between 1
and 10 per 1000 live births (1). 65 % of extremely low birth weight infants develop
presumed sepsis in the neonatal period (2). With mortality rates of 10-50 %, a 4-fold
increase in cerebral palsy and increased risk of hearing, growth and neuro-
developmental impairments as sequelae in this particularly vulnerable group, the
costs are great (2). In Scotland, the overall neonatal mortality rate is 2.6 per 1000
live births, with the rate due to infection being 0.4 per 1000 live births (3). In other
words 15 % of neonatal deaths in Scotland have infection identified as cause of
death. Very low birth weight infants with late onset sepsis, especially those with
gram negative or fungal infections, have prolonged hospital stays and are more likely
to die than uninfected infants (4). Worldwide neonatal infection is a significant
problem. Suspected infection is the commonest reason for admission to neonatal
intensive care units in the USA (5). Infection is the commonest cause of neonatal
mortality in South East Asia: overall mortality of 46.3 per 1000 live births with 30-
40 % of these due to infection (6, 7). This makes it imperative that work should be
done not only on prevention and treatment of infection but also on methods that
could be used to diagnose infection more reliably and rapidly. It would be hugely
beneficial if a test could be found that could diagnose infection sensitively,
accurately and reliably - particularly if smaller samples could be used to achieve
more rapid results. Such a test could help avoid unnecessary treatment in babies who
are not infected and therefore reduce neonatal unit admissions, separation of mother
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and baby and iatrogenic complications. Importantly, it would also allow more
tailored anti-microbial therapy. Such progress would also be expected to reduce the
financial burden ofneonatal infection.
Figure 1.1: Clinical Signs of Neonatal Infection
1.2 Presentation of Neonatal Infection
Infection in neonates can present clinically in a multitude ofways. Clinical signs can
range from very subtle and gradual to catastrophic with rapid progression. The
source of infection is often difficult to pinpoint. It is therefore important that
clinicians have a low threshold for considering infection, investigate expediently and
treat whenever infection is suspected. Figure 1.1 displays possible signs of infection
in the neonate and illustrates the variability in presentation for any given sign. This is
not an exhaustive list. Current practice is to treat all babies with suspected sepsis
with broad-spectrum antibiotics pending culture results. It is clear however that there
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who are suspected of having neonatal sepsis (5). If identification of a causative
organism occurs at all, and it often does not, it is usually after antimicrobial therapy
has already been started empirically. Clinical judgement still plays a large part in the
diagnosis and management of suspected sepsis.
1.3 Definitions of Infection
Sepsis can be defined as a systemic illness caused by microbial invasion of normally
sterile parts of the body (8). Consensus definitions for infection, sepsis, systemic
inflammatory response syndrome (SIRS), severe sepsis and septic shock have been
drawn up, e.g. International Pediatric Sepsis Consensus Conference 2002 and by The
American College of Chest Physicians, the Society of Critical Care Medicine (9-11).
These were designed to allow standardised discussions between groups and are rather
long. The definition of infection I have chosen to use in this study is the summary
definition from the International Sepsis Definitions Conference 2001. Infection was
defined as "a pathological process caused by the invasion of normally sterile tissue or
fluid or body cavity by pathogenic or potentially pathogenic microorganisms" (9).
1.4 Types of Neonatal Infection
When considering infection in infants less than 1 month of age, the most common
causative bacteria may vary depending on the geographical location of the
population. Common culprits include Group B Streptococcus, Escherichia Coli (and
other gram negative enteric organisms), Listeria monocytogenes, Streptococcus
pneumoniae, Haemophilus influenzae and Staphylococcus aureus (12, 13). Other
important causative organisms worldwide include Streptococcus pyogenes,
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Klebsiella species, Coagulase Negative Staphylococci, Neisseria meningitidis,
Enterococcus species, Pseudomonas aeruginosa, Enterobacter cloacae, Chlamydia
trachomatis, Salmonella species, Citrobacter species and Neisseria gonorrhoeae
(13-15).
Neonatal sepsis is traditionally described as either early or late onset with congenital
and vertically acquired infection most commonly presenting early (exceptions
include Herpes Simplex Virus and late onset Group B Streptococcus) (15). Early
onset sepsis is frequently defined as infection presenting within 72 hours of birth but
definitions do vary from two to seven days postnatal life. Early onset sepsis (within
72 hours of birth) in very low birth weight infants in the USA is most commonly due
to Group B Streptococcus, then E.coli and H.influenzae however Coagulase Negative
Staphylococci have also been noted to have emerged as a cause of early onset sepsis
(16). Although blood culture positive early onset infection is uncommon (1.9 % of
very low birth weight infants), in a study by Stoll and colleagues, more than half of
very low birth weight infants were considered to have clinical sepsis (16). Better
means of diagnosis are therefore needed to identify those infants with infection and
to enable safely stopping antibiotics in those without infection.
Late-onset sepsis (culture proven) occurs in 21 % of very low birth weigh infants
surviving beyond three days (4). In these infants the majority of infections (70 %)
are caused by gram positive organisms with Coagulase Negative Staphylococci
accounting for 48 % of infections (4).
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Group B Streptococcus or Streptococcus agalactiae is worth a particular mention as
it can cause a particularly rapid deterioration if not treated expediently. It is an
organism that is carried asymptomatically in the genital tract of a significant
proportion of women and can colonise neonates asymptomatically or cause invasive
disease up to around 90 days after birth (17). There is significant debate regarding
the use of antenatal screening and prophylactic antibiotics and there is a wide
variation in practice in this respect.
Infections due to organisms other than bacteria can also be important sources of
morbidity and mortality in neonates. Viral illnesses can and do present in a similar
manner to bacterial infections and although antibiotics will not be effective in such
cases, the risk of severe adverse consequences should a bacterial infection be missed
is too great to omit antibiotics unless viral infection is definitively confirmed.
Enterovirus infections for example, are common in infants under 3 months of age
(18). Herpes simplex virus infections are particularly important to detect due to
serious potential sequelae. Fungal infections, most commonly with Candida species
are also found, particularly in very premature and vulnerable sick infants who may
have been exposed to broad-spectrum antibiotics.
1.5 Diagnosis of Neonatal Infection and Infection Markers
Investigation of infection almost universally involves obtaining a blood culture in
addition to other blood tests that may include full blood count, coagulation screen,
sugar, lactate, blood gas and C reactive protein. Completion of the "septic screen"
would usually consist of a CSF sample being obtained by lumbar puncture, a urine
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sample being obtained by clean catch or supra-pubic aspirate and a chest x-ray. In
addition, swabs and samples of secretions may be taken if the clinical picture
indicates. The problem with these investigations is that none are completely reliable
and negative or normal results do not completely rule out infection. Each of these
investigations and some additional tests and their drawbacks are discussed in turn
below.
Blood cultures are still considered the "gold standard" for diagnosis of neonatal
infection. However, they do not give a rapid result (generally taken as up to 48 hours
incubation) and have poor sensitivity of 50-80 % at best (19, 20) although it has been
argued that 36 hours of observation is sufficient to rule out infection in asymptomatic
neonate with negative cultures (21). In addition, blood cultures require blood
volumes that represent a significant proportion of an infant's circulating volume.
The blood culture system in use in the neonatal unit in the Royal Infirmary of
Edinburgh at present is the BacT/ALERT®PF. The manufacturers recommend 4 ml
of blood be used in these bottles although they state that less blood can be used but
that this would reduce the chance of organism detection (22). Our local guidelines
recommend using 1.5 ml/kg of blood up to a maximum of 4ml (or 1.2 ml for infants
weighing less than 1 kg) for blood culture. In order to maximise sensitivity and
specificity of blood cultures attention should be paid to thorough skin preparation,
culturing peripherally rather than (or in addition to) through existing access devices,
sampling as early as possible when infection is suspected and paying attention to
volume and number of cultures as appropriate (23). Although some would argue that
multiple site culture gives optimal results, Sarkar and colleagues found that single
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site cultures with volume of 1ml or more can detect sepsis with no loss of accuracy
(24). Some researchers have suggested the use of umbilical cord blood instead of
neonatal blood for culture to look for early onset infection (25, 26). This is an
attractive option in some respects but would essentially be a screening tool, requiring
that a large number of samples be taken and would be expensive. In addition, from
experience, it is not always possible to obtain blood from umbilical cords. Use of
blood culture results, as with other medical investigations, cannot be taken at face
value or in isolation. An understanding of the limitations of the investigation and an
evaluation of the whole clinical picture by the clinician are essential.
Gram-staining and microscopy of isolated organisms, while potentially giving an
early indication of the organism responsible for an infection, can be misleading. This
may be due to the subjectivity, training and experience of the technician, the quality
of the staining or the uptake of the stain by the organisms (27). In addition,
microscopy is only possible if the load of pathogen is great enough for visual
detection (27). Furthermore, if antibiotics have been administered prior to obtaining
clinical samples the likelihood of being able to detect organisms under the
microscope may be reduced and the appearance of organisms seen may be altered.
Culture of body fluids remains the mainstay of pathogen detection. However, it is
known to sometimes yield negative results in cases of bacterial infection. In some
cases this can be attributed to antibiotics being administered prior to taking the
clinical samples but false negative cultures can be obtained even without prior
administration of antibiotics (27). Other factors leading to false negatives could
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include use of the wrong culture medium, especially for more unusual or fastidious
organisms and suboptimal sample handling, e.g. delay in reaching laboratory, drying
out or handling at suboptimal temperature. In addition, there are some organisms
that simply cannot be cultured in the laboratory and organisms that although cultured
may not be successfully identified (27). In the past, gastric aspirate culture has been
used in the investigation of neonatal infection. In general this has been found not to
be a useful indicator of neonatal infection but it may indicate exposure to
chorioamnionitis (20). A further drawback of working with live organisms in the
laboratory is the potential threat to the health of laboratory workers (27).
Full blood counts can generate useful supporting information for infection. White
cell and neutrophil counts may be elevated but this is not specific to infection and is
seen with other inflammatory conditions. White cell, neutrophil and platelet counts
can also be very low in neonatal infection, e.g. in overwhelming sepsis but again this
is not specific to infection. Presence of toxic granulation and an elevated
immaturedotal (I:T) neutrophil ratio may be considered to be more specific for
infection, however these are of limited value in neonatal infection (1, 28). Blood
film examination has been known to reveal bacteria within neutrophils in some cases
of neonatal infection (29).
CRP is an acute phase protein produced in the liver approximately 6-8 hours
following an inflammatory insult (20). It may not be elevated in early infection and
the use of CRP in isolation to exclude infection could be dangerous as it does not
have sufficient sensitivity or negative predictive value (20, 30). The positive
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predictive value of an elevated CRP is also low and an elevated CRP is not specific
to infection as it is also raised in conditions such as asphyxia (1, 20). Several groups
feel that CRP may be more useful in monitoring response to treatment (1) or in
aiding the decision to discontinue antibiotics (31). However, the sensitivity may not
be sufficient to allow early discontinuation of antibiotics either (30). Gestational age
is also a factor in whether CRP may rise in infection. A rise in CRP more likely with
increasing gestation (32). In summary CRP of limited value in diagnostic tests in
neonatal infection (28).
Antigen detection tests such latex agglutination tests can be used to identify
organisms such as Group B streptococcus (20). Serological tests (antibody detection
and microbial antigen detection) have limitations in that antibody responses may not
be apparent if testing too early in the infection process and antigen detection may
require a large pathogen load (27). Such tests are very specific and if a narrow
differential diagnostic approach is not possible then such tests will be of little utility.
Serological approaches may also be of limited use if the host is immuno¬
compromised in such a manner as to not mount an antibody response (27). ELISA-
based tests to detect antibody response can require large amounts of time, sample
volume and reagents (33). Newer tests however are trending towards using smaller
sample volumes, e.g. D Bianchi and N Weinschenks' test to identify infant sepsis
looking at leukocyte expression of cell surface antigens by labelled antibodies uses
around 200 microlitres of blood (34). Multiplexed whole bacterial antigen
microarrays are now emerging that allow automation of serodiagnosis, e.g. for
culture negative endocarditis (35).
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Until recently, testing for infection would mean looking at either single or small
numbers of analytes. Simultaneous measurement of multiple analytes is now
possible. Nucleic acid based methods and especially microarrays are discussed in
detail later in this section but multi-analyte testing is not confined to the field of
genomics. Recent advances in flow cytometry for example, allow simultaneous
measurement of multiple markers from small blood volumes - careful selection of
markers could aid in diagnostic decision making (36). As an example of this,
Skogstrand and colleagues measured 25 inflammatory markers (23 cytokines,
TREM-1 and CRP) simultaneously from blood spots (37).
There are a multitude of lab tests that are mentioned in the literature that have been
used in the past but appear to have fallen out of favour, including nitroblue
tetrazolium tests and acridine orange leucocyte cytospin test (38). Micro-ESR is
more specific than CRP but less sensitive which, combined with risk of false
positives with haemolysis and false negatives with disseminated intravascular
coagulopathy, limits its usefulness (20). Other acute phase reactants such as
orosomucoid and fibronectin are of limited value due to slower response to infection
than CRP (20). Elastase-alpha-1 -proteinase inhibitor rises rapidly in infection, is
100% sensitive but not particularly specific (20).
Despite an increase in the number of available potential markers of infection (many
still in a research capacity) there is currently no single test or group ofmarkers that
will reliably diagnose infection enough to influence the initial decision to start or
withhold antibiotics (36, 39). Several cytokines have been studied perhaps most
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notably IL-6, IL-8, CDllb, CD64, TNFa, IL-lp and E-selectin (36, 40). IL-6 is
elevated in infected infants giving high sensitivity in detection of infection, is
increased earlier than CRP but is limited in usefulness due to short duration of
elevation and the fact that it is also elevated in necrosis (1, 41). Another specific
leukocyte marker that has been looked at as a marker of infection is CDllb - this
looks promising with negative predictive value quoted as 100 %, positive predictive
value of 99 %, sensitivity of 96 % and specificity of 100 % (42, 43). Neutrophil
CD64 expression has been shown to be sensitive in predicting infection but with only
moderate specificity of 81 % with Ng and colleagues suggesting it may allow
discontinuation of antibiotics at 24 hours in infants with CD64 below cut-offwho are
clinically stable (44). TNF has an early peak after onset of infection (1). Cord blood
TNFa is elevated in early onset sepsis with high sensitivity but is limited by low
specificity (45). IL-lp is significantly decreased in neonates with sepsis (46).
Several screening tests utilising various CRP and cytokines such as IL-ip, IL-6 and
IL-8, TNFa and the soluble receptor of IL-2 have been described (42, 47-49). These
invariably show that no individual test can reliably identify infected neonates and
that combinations tend to be limited in either sensitivity or specificity (47, 48, 50).
Some groups such as Franz and colleagues have suggested that in stable infants use
of combinations of results can reduce the number of infants being commenced on
antibiotics (49). However, in this example which looked at the combination of IL-8
and CRP, 14.5 % of infants with infection were not detected initially (49). Most
would agree that such tests do not allow safe withholding of initial antibiotics but it
may be that they could be used to help with early discontinuation of antibiotics
where clinical condition permits (40, 41). Other notable markers of infection that
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have been studied include procalcitonin and complement levels. Serum procalcitonin
has been shown to rise rapidly in infants with sepsis and to have a better sensitivity
than neutrophil count, CRP or IL-6 (50-55), but is still not reliable enough alone to
be sole marker of neonatal sepsis (56). Procalcitonin is considered by some as a
useful adjunct in sepsis diagnosis and serial measurements of procalcitonin have
been described as useful in monitoring response to therapy (57). In terms of
complement, although preterm infants have a relative deficiency ofmost complement
components, they are still able to generate significant amounts of activation products
of the complement cascade which temporally precede other lab indicators of
infection such as white cell count and CRP (58). Specific complement related
molecules that have been studied include C3a-desArg, C3bBbP, sC5b-9 (58), C3d
which has been described as having a "reasonable" predictive value (20), C4d and
Ba, with Ba performing better than CRP (1, 59). G-CSF , which is elevated in
infected infants of all gestational ages has also been considered as a marker but has
limited specificity (73 %) and poor positive predictive value (40 %) (60). ICAM-1,
which is elevated in infection, has also been put forward as potentially having role in
confirmation or prediction of infection (61). It has however also been noted to be
elevated in RDS (62). Combinations of neutrophil CD64, procalcitonin and
triggering receptor expressed on myeloid cells (TREM-1) are currently being
investigated (63). Inter-alpha inhibitor proteins are independent of gestational age
and significantly reduced in sepsis leading to the suggestion that their measurement
may act as an adjuvant diagnostic marker (64). To re-iterate, none of these markers
alone or in combination are reliable enough for confident diagnosis of infection.
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Some groups have attempted to create reliable clinical scoring systems for neonatal
sepsis or to use physiological parameters such as heart rate characteristics to add to
laboratory information (65, 66). To date however none of these can confidently be
relied on. In developing countries sepsis diagnosis using clinical algorithms is useful
in areas where access to hospital care is limited (67). Some groups describe using
close clinical observation rather than empirical antibiotics in selected infants, e.g.
Chiu and colleagues observed febrile infants who were "low risk" according to
criteria that included normal CRP, WBC and well appearance (68). Many
neonatologists would be uncomfortable with such an approach. Clinical assessment
however remains important in sepsis evaluation and should not be underestimated.
It is clear to me on reviewing the literature that currently available diagnostic tools
and markers of infection are not ideal. This concurs with the view of Malik and
colleagues who reviewed the literature and found few studies examining laboratory
diagnosis of neonatal infection that were methodologically sound, with a few tests
looking promising but with insufficient data to support their use as clinical tools (69)
There is a real need to find an accurate and rapid means of diagnosing neonatal
infection. It is my belief that microarray gene expression profiling is an important
area to explore in this quest.
1.6 Host Response and Immunity
Host immune and inflammatory responses play a significant role in the
pathophysiology of sepsis (8). As mentioned already the symptoms and signs of
sepsis can range from very subtle to catastrophic. Factors that affect the symptoms
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and signs at any given time can be considered to include: the virulence of the
offending pathogen, the pathogen load, the route of entry (i.e. the site of infection),
individual susceptibility of the host and the time in the course of infection (8). In the
following sections I present current information on neonatal immunity and on host
response to infection.
1.7 Neonatal Immunity
Neonates have generally been supposed to be immunologically immature. Reduced
opportunity for trans-placental antibody acquisition is an important factor in
increased risk of premature infants to infection (13). In addition, there are birth-
weight related deficiencies in type-specific antibodies and complement opsonins,
reducing efficiency of opsonisation (13). Sub-optimal cell mediated responses are
also seen (70). Neonatal increased susceptibility to pathogens is due to a
combination of immaturity of innate and adaptive immune responses with defects in
phagocytic ability, and immaturity and dysregulation of T-cell mediated immunity.
This does not mean that neonates are completely defenceless against infection and it
does not mean that they fail to mount an immune response. It is increasingly
recognised that neonates do mount a significant response to infection but that there
are differences from the responses seen in adults. As in all aspects of examining
immunity, outcome is a question of balance, e.g. fetal gut cells will mount a robust
inflammatory response to lipopolysaccharide but this could be dangerous in the
period shortly after birth where gut colonisation occurs (71). In this section I attempt
to provide an overview of the neonatal immune system, looking at different aspects
in turn and listing known deficiencies and differences from adult immunity.
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Innate immunity: Skin andMucosal Surfaces
When a baby is born, they move from a sterile environment to one that is full of
antigens to challenge the immune system. The innate immune system plays a
significant role in neonatal defence against infection. Physical barriers to microbial
invasion are an important initial line of defence in the neonate and include the skin,
respiratory tract, eye, gastrointestinal and urinary tracts. In preterm infants these
barriers are more fragile, increasing their vulnerability to microbial invasion. In
addition, in the setting of a neonatal unit such barriers are often breached through
clinical necessity by the use of catheters and lines. As well as this barrier function,
neonatal skin and mucosal surfaces provide defence against infection by their
abundance of host defence proteins, lysozyme and lactoferrin, some of which
increase with gestational age (71, 72). Vemix, which coats the skin at birth, also
contains lysozyme, alpha defensins, ubiquitin, psoriasins and APPs - antimicrobial
peptides and proteins (71).
Neutrophils andPhagocytic Function
Neonates are deficient in both quantitative and qualitative phagocytic cell responses.
There is a relative inability to produce adequate numbers of neutrophils in response
to infection due to insufficient numbers ofmyeloid progenitor cells, a decreased bone
marrow neutrophil storage pool and high ratio of cells in the proliferative state (73)
Neonatal neutrophils have impaired function and although this is not as yet
completely characterised they show reduced chemotaxis, migration, opsonisation,
phagocytic and intracellular bacterial killing ability, reduced oxidative responses and
an inability to form extracellular traps that mediate extracellular killing of pathogens
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(13, 74). Reactive oxygen species production tends to increase with birth weight and
gestational age meaning that preterm infants are relatively more deficient in this
respect (75). Neutrophil recruitment is also impaired due to low integrin and selectin
proteins (71). In addition, neonatal neutrophils have impaired apoptosis and
therefore are not expediently removed from inflamed tissues by monocytes trying to
minimise injury (76).
Monocytes, Macrophages, Dendritic Cells, Antigen Presenting Cells
There are many papers in the literature looking at the function of adult monocytes
compared to neonatal or cord blood lymphocytes. Satwani and colleagues, showed
dysregulation of several cytokine and immunoregulatory genes in cord blood which
may in part explain the relative immaturity of neonatal cell-mediated immunity (77).
They showed reduced production of phagocytosis activating cytokines such as G-
CSF, GM-CSF and M-CSF and of negative regulators of haematopoesis TGF-pi,
MlP-la, IL-8 (77). Cord blood monocytes have been also shown to have
comparative down regulation of cytokine genes such as TGF-P, IL-8, IL-11, IL-12,
IL-15, IL-18, IL-24, cytokine receptors such as IL-2Ra, IL-2RP, chemokines
including RANTES, GCP-2, MIP-3P, surface antigens/molecules SLAM, IL-1R-
antagonist, oncostatin M and lower expression of transcription factors such as NF-kB
genes (78). There are also differences in expression of various phosphatases, kinases
and cell regulatory genes (78). Neonatal monocytes also have reduced chemotactic
and cytotoxic ability (13). Despite normal basal expression of Toll-like receptors
(79), neonatal monocytes and macrophages have impaired responses to multiple TLR
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ligands (80). In addition, TLR-induced monocyte TNFa release is inhibited by
soluble factors found in neonatal blood (79).
Many studies go further and compare adult and neonatal monocyte responses to
stimulation with bacterial antigens such as LPS. Significant differences in gene
expression profiles are found (81). In neonates there is comparatively higher
expression of IL-ip, IL-15, IL-15R, IL-17R, IL-2Rcc, IL-2Rp, IL-4R, IL-6, IL-8, IL-
7R, G-CSF, GM-CSF and relatively lower expression of MHC class II molecules
(78). Neonatal monocytes show normal basal expression of Toll-like receptors and
membrane CD14 but LPS stimulation leads to relatively reduced release of Thl
polarising TNFa and IFNy with preservation of Th2 polarising anti-inflammatory
cytokines (79). Term neonates stimulated with specific bacterial antigens show a
relatively down-regulated response compared to premature infants, i.e. premature
infants may respond with uncontrolled inflammation to antigenic stimulation from
organisms (82). Neonatal monocytes show impaired expression of IFNp and IFN-
inducible genes compared to adults when stimulated by LPS and also reduced IRF-3
and CREB-binding protein (IFN response dependent on this) (83). There are also
differences within regulation of apoptosis (84).
Neonatal macrophages also show impaired type 1 responses to IFNy and LPS (80).
When compared with mature dendritic cells, cord blood dendritic cells show
relatively reduced expression of chemokines, cytokine receptors and cell surface
molecules, and also lower expression of transcription factor, interferon regulatory
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factors and structural regulatory genes (85). Delayed maturation of certain dendritic
cells means limited IL-2 production (86). Cord blood dendritic cells also show
relatively reduced TH1 response-related genes (87). Neonatal dendritic cells can be
stimulated to express maturation surface molecules (towards specific immune
response) but require combined stimulation with multiple pro-inflammatory signals
(88).
Neonatal antigen presenting cells show functional changes, producing low levels of
cytokines which could lead to defects of adaptive T cell response (89). They show
impaired production of IFNa and IFNp and reduced expression ofTNF, IFNa, IFNy,
IL-12 and IL-ip (71). Neonatal antigen presenting cells and monocytes can however
produce IL-6, IL-10, IL-23 in greater magnitude than adults when stimulated (71).
Overall, antigen presenting cells show selective impairment of TH1 response
following innate immune recognition (71).
Natural killer cell numbers present in cord blood increase with gestational age (90).
Toll Like Receptors
Toll like receptors (TLRs) play a key role in innate immunity, from pathogen
recognition through to activation of adaptive immunity, and TLR polymorphisms can
lead to increased susceptibility to infection (91). TLR 2 and TLR 4 receptors play a
role in the gut and respiratory tract (71). There is conflicting data in the literature as
to whether TLR 2 levels differ with age (71, 92). TLR4 expression and cytokine
secretion following stimulation with LPS increases with gestational age (92).
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Stimulation of neonatal blood with TLR activating stimuli is associated with a high
IL-6/TNFa ratio and this is higher in the first week of life than in cord blood (93).
TLR8 agonists are particularly proficient in activating co-stimulatory responses in
neonatal antigen presenting cells (94). Cord blood TLR agonist induced production
of Thl polarising cytokines IL-12 and IFNa are generally impaired but for TLR3,
TLR7 and TLR9 agonists increase to adult levels within a month whereas TLR4
shows slower maturation meaning low IL-12 and high IL-10 in response to LPS (95).
Certain patterns (route, duration, load) of exposure to microbial TLR agonists in
early life accelerate maturity of Thl response and are protective against allergy - this
is part of the hygiene hypothesis (71).
T cells
During fetal life, the immune system is necessarily skewed to avoid inflammatory
responses that could precipitate delivery. The neonatal immune system is therefore
biased against a pro-inflammatory Thl response and towards a Th2 response leaving
the neonate at risk of infection (71, 96). Antigen specific T cell responses can be
mounted by neonates but CD4 T cell responses are often slower to mature and are
biased towards a Th2 response (97). Exceptions to Th2 bias do exist: neonates can
produce Thl polarizing cytokines robustly in response to certain stimuli that can
activate TLR pathways or complement pathways, e.g. Group B Streptococcus, BCG
vaccine (71). In addition, Hassan and colleagues looked at the immune response to
CMV in congenitally infected neonates and found a predominant Thl response but
with lower IFN-y and higher IL-8 compared to adults (98). Omar and colleagues
showed that neonates show a predominance of nai've T cells but are capable of
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increasing memory T cell expression in response to infection (99). Mature memory T
cells are higher in infected infants than controls even after recovery (99, 100). T
regulatory and Thl7 cell function are impaired at birth (101). Zhao and colleagues
show that neonatal mice show much stronger inflammatory response to LPS
stimulation than adults due to inadequate T cells with lack of regulation leading to a
hyper-innate response and potentially increased morbidity and mortality (102).
Gamma-delta T cells are important for immunoprotection at birth and could
compensate for immaturity of alpha-beta cells (103). In addition they may have a
role in rapid response to pathogen associated molecular patterns in the absence of
antigen presenting cells (104). Gamma delta cells are relatively impaired in preterm
infants in terms of TLR3 and TLR7 expression and suboptimal cytokine production
(103).
Antibodies
As stated previously, there is reduced opportunity for trans-placental antibody
acquisition in infants born prematurely. The number of immunoglobulin secreting
cells is usually low at birth and rises with age. Infants with early onset sepsis have
low levels of immunoglobulins in first 5 days but higher levels in week 2: elevated
levels soon after birth may therefore be a surrogate marker for in-utero infection
(105). T cell independent B cell antibody responses are impaired in infancy (97). T
cell dependent antibody responses mature earlier but multiple immune encounters
may be required to achieve the response of adults (97).
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Milk
Human milk can be thought of as an important part of the immune defences of the
neonate. Without trying to cover all of the benefits of breast milk, it contains
secretory immunoglobulin while cytokines, cytokine receptors, TLR agonists and
antagonists, hormones, anti-inflammatory agents and nucleotides in milk modulate
inflammation (106). Ingestible glycans found in milk act as prebiotics and inhibit
pathogen binding (106). In addition, human milk has been found to have a capacity
to modulate TLR-mediated responses specifically and differentially thereby
influencing neonatal pathogen recognition (107).
Cytokines
Cytokines play a key role in the pathophysiology of sepsis. They are crucial in the
response to infection but also contribute to tissue damage. A lot of the difference in
cytokine production in neonates can be explained by the cellular characteristics
described above. Neonatal cellular immune deficiency includes decreased
production of IL-2/IL-23, IL-18, interferons, and other pro-inflammatory cytokines
(80). Deficient IL-12 production may in part be compensated for by increased IL-27
production in neonatal dendritic cells in response to TLR agonists (IL-27 initiates
Thl responses in naive T cells) (108). There is reduced IL-10 receptor expression on
neonatal immune regulatory T lymphocytes and this, along with impaired IL-10, may
play a role in the deficient neonatal anti-inflammatory response (109). From a study
of dried blood spots at a few days of age: increased levels of IL-lf3, IL-6, soluble IL-
6r alpha, IL-8, matrix metalloproteinase and TGF-pi and decreased levels of IL- 18,
brain derived neurotrophic factor and CRP were associated with preterm birth (110).
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Plasma concentrations of acute phase proteins change over the first few days of life :
IL-1 and IL-6 rise in the first week and can trigger production of MBL, solCD14,
CRP, LPS binding protein (71). IL-2 and IL-4 levels tend to be high and IFNy low at
birth and then trend towards normal over the first week of life (111). IL-6 acute
phase response along with preserved a IL23-IL17 axis mobilises plasma
antimicrobial peptides and proteins (71). IL-1 p, IL-6, IL-8 have been seen to be
elevated in fetal inflammatory response and may be indicators of in utero infection
(112, 113). Mode of delivery influences the pattern of cytokines seen in neonatal
blood at birth with caesarean section being associated with increased levels of IL-13
and IFNy (114, 115).
Complement
Neonatal complement levels are low compared to adults: this means an impaired
ability to halt bacterial replication and impaired adaptive responses (71). There is
also reduced expression of complement receptor 3 (CD11/CD18) and L-selectin (71).
Maternal Immunity
Maternal immunity has an important part to play in fetal and neonatal immunity.
Transplacental transfer of antibodies and transfer of antibodies in breast milk are
well known as being important in protecting infants from infection. The protection
provided will depend on the mother's own exposure to microorganisms. As an
example of this, previous maternal exposure to varicella would be expected to lead to
neonatal protection against varicella until the natural waning of maternal antibodies
occurs. There is emerging evidence that other aspects of maternal exposure and
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immunity also influence neonatal immunity. For example maternal farm exposure
has been found to modulate neonatal immunity through regulatory T cells leading to
reduction in the development of allergy (116). In addition, there is evidence that
maternal leukocytes transferred from colostrum promote T cell immune development
in calves (117).
Miscellaneous
There is reduced expression ofmany immune related pathways (TLR pathway, Jak-
STAT pathway, cytokine-cytokine receptor interaction) in neonatal blood compared
to maternal blood (118).
Preterm infants' susceptibility to Coagulase Negative Staphylococcal infection may
in part be due to relative deficiency of serum proteins such as transplacental anti-
coagulase negative staphylococci immunoglobulin and complement leading to
suboptimal opsonisation and impaired bacterial killing (119). Neonates in general
have a lower IL-6 response to Coagulase Negative Staphylococcus than adults and
this may in part contribute to their vulnerability to this organism (82). Coagulase
Negative Staphylococcus-induced production of pro-inflammatory cytokines IL-6
and TNFa in cord blood is dependent on gestational age, but of anti-inflammatory
cytokines TGF(3 and IL-10 is not (120).
1.8 Host Response to Infection
To discuss fully the host response to infection could fill volumes. The purpose of
this section is rather to demonstrate the importance of host-pathogen interactions
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and that microarrays have a place both in increasing knowledge in this area and in
potentially using such knowledge to diagnose infection.
Put simply, when the host recognises presence of a pathogen, the initial response
will be pro-inflammatory to try and eradicate the organism and later anti¬
inflammatory responses will work to restore the normal balance. Balance is
important because either excessive inflammation or deficient anti-inflammatory
response will result in pathology and can lead to shock or organ failure.
Many review articles are emerging that describe the promise of microarrays in
monitoring host response and in monitoring bacterial gene expression in infection
(121, 122). They also describe the potential for increased understanding of host-
pathogen interactions and for discovering molecular signatures for infection (123).
On the whole, there is a lot of optimism regarding the potential use ofmicroarrays in
microbial diagnostics (124).
Pathogens express molecules that activate the immune system by interacting with
Toll-like receptors on immune cells (125). Different pathogens bind to different
Toll-like receptors and Toll-like receptors are expressed differentially by various
tissues, supporting the theory that the innate immune system is pathogen and tissue
specific (125).
A large body of the work presented in the literature on host response to infection
describes in vitro stimulation of specific cells with a particular bacteria, virus, yeast
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or toxin, or of examination of immune cell response to stimulation (78, 126-145).
Some of these immune responses may differ depending on strain of pathogen (135).
There are now emerging views of a common response to infection characterised
mainly by innate immune responses as well as pathogen specific host responses (125,
137, 145, 146). Some examples of this are listed here. Ren and colleagues
compared host response in vitro to monocytes in response to Coxiella burnetti and
Chlamydia trachomatis and found shared and pathogen-specific responses (147).
Schnappinger and colleagues looked at macrophage responses to tuberculosis
showing non-specific as well as pathogen specific response with tuberculosis
inducing changes in TLR dependent and TLR independent transduction pathways
(144). Das and colleagues looked at host gene expression profiles in monocytes in
response to biological threat agents, e.g. anthrax using arrays (148). They found
some expression patterns that were pathogen unique and others in response to
multiple agents (148).
There are also papers emerging looking at in vivo host response to infection.
Chinnaiyan and colleagues in a rat model looked at gene expression in several organs
in response to sepsis following bowel perforation (149). They found a highly
complex transcriptional response, with parts that were organ specific and others
found in more than one organ, with pro-inflammatory genes often being balanced by
genes with anti- inflammatory effects (149). Calvano and colleagues examined
innate immune response to in vivo stimulation with endotoxin compared with healthy
volunteers and found an initial pro-inflammatory phase and a subsequent anti¬
inflammatory phase (150). Reghunathan and colleagues compare monocytes from
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the blood of SARS patients to those from healthy controls to examine differential
gene expression and found that affected patients seemed to be mounting a mainly
innate rather than specific immune response to virus (151). Whole blood whole
genome expression profiling of children with septic shock by Wong and colleagues
put forward the possibility that altered zinc homeostasis may be associated with poor
outcome (152, 153). They found that although SIRS in children, sepsis and septic
shock shared some common gene expression patterns, septic shock in particular
displays down-regulation of genes involved in adaptive immunity and zinc related
biology (154). Johnson and colleagues also found a unique gene expression profile
in sepsis compared to uninfected SIRS (155). TLR and downstream signalling genes
have been seen to be differentially expressed in sepsis compared with uninfected
SIRS before phenotypic diagnosis using microarray (156). Gene expression
profiling of children with uncomplicated Dengue showed a group host response
profile of cytokines, IFN signalling, oxidative metabolism, protein ubiquination, and
apoptosis whereas children with Dengue shock showed a more "benign response"
(157). A gene signature for acute lung injury in adults with sepsis has been
described (158).
There are several studies that examine facets of common host response to pathogens.
Host pathogen recognition receptors, e.g. CD14, TLRs, Nodl/2, scavenger receptors,
CD18, CD55, CDllb, TREM-1, CXCR4 can trigger a common immune response
(146). Cell wall components such as CpG DNA, flagellin and peptidoglycan interact
with TLRs (e.g. TLRs 2,5,6,9), and CD 14 may also be involved to produce a
common response (125). Jenner and colleagues (159) defined a common host
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response of 511 genes from 77 different host-pathogen interactions (from 32 studies)
that included pro and anti -inflammatory mediators, chemokines, interferon-regulated
genes, transcriptional regulators, signal transducers, and NF kB pathway signalling.
Manger and colleagues eloquently describe host-pathogen interactions as "diverse,
choreographed and regulated" (160). When looking closely at pathogen specific
molecular patterns of LPS lipid A, lipotechoic acid and peptidoglycan, they found
common responses of innate and acute phase responses as well as unique responses
which were dependent among other things on timing and place of interaction (160).
Host-host variability needs to be taken into account and more in vivo work carried
out before diagnostic signatures can be confidently found (160).
Early host immune and inflammatory responses may differ greatly for infections
caused by gram positive and gram negative organisms (134). Feezor and colleagues
showed that comparison between cytokine profiles in patients with gram positive and
gram negative sepsis show some commonality but also display distinct cytokine and
gene expression patterns (134). Toll like receptors have been shown to differentially
recognise and signal in response to gram negative and gram positive related antigens
(161, 162). Zeyton and colleagues describe distinct cytokine and chemokine
induction depending on stimulation with LPS (TLR4), peptidoglycan (TLR2) or
dsRNA (TLR3) of antigen presenting cells (163).
Gram positive organisms cause sepsis by stimulating immune cells with cell wall
components (lipotechoic acid, peptidoglycans) through TLR-2 or by toxin production
acting as superantigens (125). Toxins bind to MHC 2 molecules and Vf3 Chains of T
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cell receptors leading to pro-inflammatory cytokine production (125). Recognition
of bacterial components by cell receptors, e.g. toll like receptor 2 starts a NF-kB
mediated response leading to secretion of IL1 and TNF (146). IL6 and IL8 are also
involved in an early common response to gram positive organisms (146). A later
host reaction to gram positive organisms has been shown to be triggered by inter-
cellar pathogen activity or by metabolites secreted by the pathogen, leading to either
elimination of the bacteria or of survival of the pathogen (146).
Lipopolysaccharide found on the outer membrane of gram-negative bacteria is key in
inducing gram-negative sepsis. Epithelial cells exfoliate in an attempt to avoid
colonisation when bacteria attach at mucosal surfaces (146). Interaction of LPS
through TLR-4, with involvement of membrane proteins CD 14 and MD-2, plays a
role in inducing a specific response (125, 164).
It is also important to look at expression profiling of non-bacterial infection, e.g.
Candida (141) and of non-infectious pathologies. There are, for example, groups
who have been investigating the host response to injury (165). Oberholzer and
colleagues show that IL-18 levels are higher when comparing septic patients with
those with severe injury (166). This is important if distinction between different
types of infection and between infection and other pathologies is to be made. Chung
and colleagues showed that sepsis induces changes in mouse leukocyte genes that
can be used to distinguish between sepsis and systemic inflammation (167).
Expression of lymphocyte mRNA for chemokines are different in inflammation due
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to perinatal infection to those in perinatal asphyxia, with IL-8 elevated in infection
and MCP-1 increased in asphyxia (168).
Pathogens will cause differential gene expression depending on site and time of
sampling with common and unique responses. In addition, there is large variation in
clinical manifestation and response to identical infecting organisms due to effects of
genetic variation in both host and pathogen: these variations may affect outcome as
well as susceptibility (169). HLA associations with various infections are well
known (169). Investigations into genetic susceptibility to infection are taking place
and show that, as well as immune system related genes, mitochondrial DNA may
play a role in differences in survival (170). Polymorphisms in IL-10, IL-6 and CD 14
may affect risk of sepsis in very low birthweight infants (171). There is now
emerging research to look at whether there are predispositions to specific
symptomatic infections that are not directly linked to the immune response, e.g. Kerr
and colleagues looked at single-nucleotide polymorphisms associated with
symptomatic infection and differential gene expression in healthy people with
previous infection with human parvovirus B19 implicating the cytoskeleton, integrin
signalling and oncosuppression in B19 pathogenesis (172). Inherited or acquired
mutations of genes involved in the innate immune response may affect susceptibility
to infection, e.g. polymorphisms in TNFa, lymphotoxina and IL-1 receptor agonists
and variation in the MHC complex on chromosome 6 and HLA genes (125, 173,
174). Genetic/genomic factors may also play a role in variations in the outcome of
sepsis (175, 176). Balding and colleagues have shown that genetic variability in
the IL-6, IL-10 and IL-1RN gene are associated with poor outcome of
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meningococcal disease (177). Specific genetic variants have been shown to be
important for particular infections, e.g. Roy and colleagues showed that a C reactive
protein polymorphism is associated with susceptibility to invasive pneumococcal
infection (178). Deficiency of mannose-binding lectin (component of innate
immunity) is associated with increased risk of neonatal sepsis (179, 180). Genetic
variation in the IL-6 gene may also be associated with increased risk of sepsis in
preterm infants (181).
Infection leads to physiological changes in host and pathogen, and gene expression
changes occur in both (182). Host expression changes can help elucidate host
response and may also allow classification of organisms based on host response
(182). Microarrays are increasingly giving more insight into host-pathogen
interaction. Diehn and colleagues performed comparative analysis of published
datasets of human gene expression in response to two respiratory pathogens,
Bordatella pertussis and Pseudomonas aeruginosa, looking at overlap in up- and
down- regulated genes and found a large set of co-induced and co-repressed genes
(182).
Experimental conditions are important when considering gene expression profiling of
infection (182). Consistency and reproducibility are important so it is important to
understand any limitations and to adhere to standard operating protocols (183).
Choice of cell type to study is important and if mixed cell types are used care should
be taken not to extrapolate results inappropriately (184). Microarray related
technical differences such as different platforms, alternative splicing, different
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methods of producing labelled cDNA, use of total RNA or mRNA, and amplification
steps can influence results (182). In addition infection-related factors such as site of
infection, strain of infection and timing of sampling in the course of infection may be
important (182). Responses to non-infectious stimuli must also be considered when
attributing expression patterns to infection (182). It is also necessary to compare
host response to different species and stimuli before attributing any response to a
single pathogen (182).
1.9 Microarray Technology
Microarrays allow the simultaneous measurement of expression of tens of thousands
of genes. While there was initially the impression of a great deal of scepticism and
caution over the potential clinical applications of microarray technology there was
also hopefulness that it may fulfil a significant role in the clinical setting and at the
bedside (185-187) including within clinical paediatrics (188). In recent years
research and clinical applications have emerged in numerous medical fields and this
is reflected in the increase in the volume of literature describing such applications.
There are ever increasing numbers of review articles and commentaries describing
potential and actual applications of microarrays in healthcare and as diagnostic tools
(189-199) as well as in paediatric and neonatal research (200, 201). Some examples
of such applications are: in the field of oncology in classification and prognosis of
tumours (202, 203), in the fields of toxicological, environmental and dental practice
looking at the effects of various chemicals and substances on human tissues (204-
207), in blood screening for the purposes of transfusion (196), in neurology to
investigate migraine (208), examination of the effects of valproate in paediatric
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epilepsy (209) and in identifying surrogate markers of neurological disease such as
neurofibromatosis 1 and Tourette syndrome (210). Further applications include
diagnosis of chromosomal abnormalities in children (211), genetic analysis of
variation in gene expression (212), examination of gene expression in paediatric
heart disease (213), investigation of the pathogenesis of neonatal
hyperbilirubinaemia at neuronal level (214) in dermatological research (215) and
research into inflammatory disease-related genes in rheumatoid arthritis, SLE and
asthma (216-218). There are also papers describing expression profiling in
Huntington's disease (219) and in experimental bronchopulmonary dysplasia
induced by oxidative stress (220). In paediatrics, applications include classification
in oncology, pathogen detection, detection of genetic mutations including in newborn
screening and prediction of adverse drug reactions (188). There is also ongoing
research to try and identify potential targets for therapy in children with diabetes
(221). Genome-wide association studies attempting to identify causal genes of a
number of diseases are now being described, e.g. asthma, inflammatory bowel
disease (222-224). It is very encouraging to see research such as that by Tang and
colleagues who found that blood genomic patterns in rats were different after stroke,
seizures, hypoglycaemia and hypoxia (225). The ability to differentiate between
different pathologies using blood gene expression profiling is clearly necessary when
considering diagnostic tests.
As early as 1999 it was suggested that DNA microarrays could be used for neonatal
screening of genetic conditions such as sickle cell disease, alpha-1-antitrypsin
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deficiency, MELAS and Factor V Leiden from newborn blood cards (DNA) (226).
Use ofmicroarrays for newborn screening is still of significant interest (227).
Microarray technology can be used both to detect pathogens and the host response to
pathogens. Interaction between pathogen and host consists of both host response to
pathogen and pathogen response to host.
As my research has progressed, particularly in the past couple of years, there has
been increasing discussion in the literature of the benefits of high-throughput array-
type pathogen detection technologies. As well as the diagnostic applications of
organism detection there are also the benefits gained from increased knowledge of
virulence and resistance characteristics (228-232). The shortcomings of such
technology are also described in terms of lack of knowledge of nucleic acid in the
normal host, the difficulties posed by small organism load in small samples, cost,
lack of expertise among microbiologists and the need for new methods of validation
(233). These concerns are not likely to be insurmountable. Such microarrays do not
determine pathogen viability however (234) and this point is key to the potential
importance of considering the host response to infection in conjunction with
pathogen detection. In addition, molecular assays can detect asymptomatic carriage
of pathogens, e.g. Kumar and colleagues found this for S. aureus and S. pneumoniae
in secretions while examining detection of organisms causing community acquired
pneumonia in adults (235). Increasing data on genome sequences of important
pathogenic organisms are emerging providing important insights into specific genes
which may allow identification of organisms and greater understanding of
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heterogeneity between strains of a particular organism, e.g. Streptococcus agalactiae
(236). Whole-genome sequencing has been completed for many pathogens including
Borrelia burgdorferi, Campylobacter jejuni, Chlamydia pneumoniae, Chlamydia
trachomatis, Haemophilus influenzae, Helicobacter pylori, Mycobacterium
tuberculosis, Ureaplasma urealyticum (237, 238) and is in progress for many others
(238). Microbial genome sequencing will allow enhanced study of host pathogen
interaction, allow identification of sequences to use for microbial identification in
diagnosis and for markers of resistance, and may allow prediction of severity of
disease (239).
Protein microarrays ofmicrobial antigens have been developed to detect the presence
or absence of specific antibodies, e.g. to ToRCH antigens (Toxoplasma gondii,
rubella virus, Cytomegalovirus and HSY1&2 (33). Multiplex detection of multiple
pathogens from clinical samples by bacterial protein microarray is also emerging
(240).
PCR can be used to amplify small amounts of microbial RNA or DNA that would
have been impossible to detect using conventional methods. Multiplex real-time
PCR has been investigated in the diagnosis of late onset neonatal sepsis (241). PCR-
based assays can be extremely sensitive - to the extreme of being able to amplify a
single copy of a microbial gene fragment and detect it (27, 242). PCR based assays
can also be very specific by using primers to unique segments of DNA (27). PCR
based investigations have the advantage of speed but limitations of false positives
from DNA contamination of samples or the laboratory process, and false negatives if
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there are inhibitors present within the sample or if the volume of sample examined is
too small (27, 243, 244). The sample volume issue is relevant for neonatal blood
sampling. Other drawbacks could be considered to include cost and the importance
of careful sample collection and handling (243, 244). Use of gene sequencing for
pathogen detection is restricted to those transcripts for which homologous probes are
available (245). Also, any mismatch between the primer used and target sequence
will decrease the efficacy of hybridisation: this is an issue for variant and evolving
viruses (243). Development of panels of diagnostic PCR-based assays to diagnose
meningitis or pneumonia for example have emerged as well as more specific
organism detection, e.g. of Group B Streptococcus or Enterovirus (246, 247). There
are ever increasing examples of such tests including Kim and colleagues describing
rapid detection of twelve respiratory viruses using PCR (248) and of microarray
"Virochip" detection of respiratory viruses from nasopharyngeal aspirates (249).
There is much interest within the field of blood transfusion for the detection of
blood-borne viruses such as HIV and Hepatitis C (250) and within military spheres
for rapid pathogen detection (148, 251). There are several groups who have been
developing rapid and portable tests for microbial DNA or RNA and many also test
antibiotic resistance. An example of rapid diagnostic testing for neonatal bacterial
infection is described by Shang and colleagues in their paper describing PCR testing
for bacterial 16S rRNA (252). This paper is pretty convincing of the utility of such
testing, presenting data showing higher sensitivity and specificity than blood culture
(252). Shang's group have focussed on the use of bacterial DNA detection in the
realms of neonatal septicaemia (253) and used 0.5-lml of blood or CSF. Jordan and
colleagues compared a 16S rDNA PCR assay to blood culture in early onset neonatal
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sepsis - this showed a specificity of 97.5 % and negative predictive value of 99.2 %
but it failed to detect a significant number of culture-proven cases (254). Caution is
therefore necessary when using molecular amplification based testing in neonates.
There are several other papers describing microarrays being developed for use in
pathogen detection/screening particularly using PCR amplification of 16S rRNA
(255, 256). Most bacterial species have a unique 16S rRNA gene sequence allowing
identification of isolated organisms and classification of novel agents (27). Other
groups have used 16S rDNA detection (257) and microarray using detection of
sequences of 23S ribosomal DNA to detect organisms such as Pseudomonas
aeruginosa and Acinetobacter baumannii in clinical specimens including blood,
stool, pus, CSF and urine (258-260). 16S rRNA may also be used to help in the
identification of pathogens that are uncultured (261). Yoo and colleagues developed
a diagnostic DNA microarray for 39 pathogenic bacteria using 23 S ribosomal DNA
and 16S-23S rDNA regions as targets for pathogen detection (262). Microarray
assays based on specific gene sequences and using other conserved bacterial gene
regions, e.g. topoisomer genes gyrB and parE (263, 264), can be used to rapidly
detect and identify specific microorganisms such as Mycobacterium species (265),
Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa (266).
More complete bacterial genomic information is emerging all the time. With time,
more reference sequences, standardisation of techniques aiding comparison and
increased understanding of bacterial and host responses under different conditions
are expected (245). Multi-pathogen arrays looking at viruses or combinations of
bacteria, viruses and yeasts are also emerging (267-274). Such methods can be seen
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to be more rapid, accurate and cost-effective compared to culture-based methods
(275, 276).
As well as detection of pathogens, microarrays are being increasingly used to
examine interactions between host and pathogen (277) and in gaining greater
understanding of the immune system (223, 224). Fjaerli and colleagues compared
whole blood mRNA expression in 5 infants hospitalised with respiratory syncytial
virus (RSV) bronchiolitis with 5 controls using microarray and QRT-PCR and found
that around half of the thirty most differentially expressed genes were involved in
immunological processes (278). Kawada and colleagues looked at peripheral blood
gene expression profiles of children with influenza and compared acute and
convalescent profiles (279). They showed 200 up-regulated and 20 down-regulated
genes in the acute compared with the convalescent phase - immune response genes
were over-represented in the up-regulated genes and interferon-regulated genes were
strongly up-regulated in the acute phase (279). Thach and colleagues used
microarrays to classify army recruits with respiratory illness into febrile vs. non
febrile, healthy vs. convalescent and febrile with adenovirus vs. febrile without
adenovirus using host signature transcripts (280). Ardura and colleagues examined
the host response of mononuclear cells from children with invasive S. aureus
infection and found distinctive expression profiles with over-expression of innate and
under-expression of adaptive immunity in invasive disease with decreased memory
CD4 and CD8 T cells and increased numbers of monocytes (281). Tang and
colleagues examined expression of peripheral blood mononuclear cells to identify




and Gram negative sepsis (282). They found signatures to differentiate sepsis and
SIRS but not between Gram positive and Gram negative infection (282). Tang's
group had previously examined differences in gene expression between sepsis and
control patients describing a common non specific septic response (283) and had
examined neutrophil gene expression in sepsis generating a set of signature genes
(284). Examination of gene expression during recovery from sepsis is also being
undertaken (285). Investigation of survivors of septic shock compared to non
survivors shows over-expression of innate immune cytokines, chemokine receptors
and TLR pathways, i.e. restoration of inflammatory and immune response is a key
step in survival following septic shock (286).
Microarrays, therefore, should lead to greater understanding of host-pathogen
interactions, microbial pathogenesis, innate immunity and gene expression during
various stages and severity of infection (287-292). Although this is not without
problems, for example rapid changes in expression with time, diversity of pathogens,
heterogeneity of human samples and complex data analysis, there is work ongoing to
overcome these issues (290). Increasing human genome sequence knowledge will
also facilitate progress in understanding of human host interaction with pathogens
(293).
Each microbe offers a distinct combination of pathogen-associated molecular
patterns that interact with specific receptors on immune cells. The host is likely to
discriminate between different classes of organisms and some host genes may be
implicated in pathogenesis of microbes (293). This notion was backed by Ramilo
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and colleagues in 2007 when they examined gene expression profiles from 131
paediatric patients with influenza A, E.coli, S. aureus and S.pneumoniae and found
different signatures for each pathogen (294). Microarrays are well-placed to be a
vital tool in exploring this exciting area of research which has the potential to
revolutionise infection diagnostics.
1.10 Expression Profiling
Peripheral blood cells express a large proportion of the genes in the human genome
(295). Changes in gene expression may occur in response to small changes in tissues
and organs due to disease, with the continuous interaction between blood and tissue
allowing blood cells to act as biosensors for such changes and thus have diagnostic
potential (295). Cotten and colleagues in their paper "Genomic analyses: a
neonatology perspective" describe examples of candidate gene studies in premature
infants including for RDS and infectious diseases (181).
Gene expression in healthy people varies. Peripheral blood is a mixture of cell types.
Expression differences may reflect age, gender, race, drugs, timing of sample
collection or variation in the relative proportion of cell types present rather than
pathology (194, 296, 297). Study of peripheral blood mononuclear cells from
healthy volunteers showed variation related to time of collection in less than 1 % of
genes with none noted in more than 1 individual (of 3) (296). Identifying variation
in gene expression in health is important in order to recognise and understand
patterns associated with pathology such as infection (297). Variation can reflect both
physiological and inter-individual variation (297). Variation in gene expression
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between healthy people is smaller than in blood from patients with bacterial infection
or cancer, i.e. disruptions due to pathology cause greater than normal background
variation thus supporting whole genome assessment for disease signatures (297).
As well as variation arising from pathology and inter-individual variation, technical
factors such as sample collection, sample handling, method of nucleic acid extraction
and sample storage can contribute to differences in expression profile (298, 299).
Timing of sample collection within the course of a pathological process, time to
RNA extraction and storage times also need to be considered carefully. RNA is
particularly prone to degradation and RNA expression profiles can change if the
RNA is not stabilised. If specific transcripts are to be studied it is important to
determine if the methods being used are suitable for the study question (300). In
addition, comparability of gene expression results between laboratories is affected by
variables such as microarray platform, labelling and hybridisation protocols and
approach to data analysis (301). Results have been found to be most comparable
when GO nodes of biological theme are used rather than gene-by gene comparison
(301). All of these factors are important when planning studies of gene expression.
In summary, the whole process of gene expression profiling from sampling,
transport, RNA extraction, labelling, detection and data analysis will affect the
quality, reliability and reproducibility of the final result. Standardisation of the entire
process is therefore necessary (194). Optimisation of the process from sample
collection to RNA processing forms a significant proportion of the work contained in
this thesis.
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1.11 Foreword to Thesis
The prospect of using microarrays to investigate host response to infection in
neonatal blood is exciting. Looking at the host response has several theoretical
advantages over pathogen detection. Traditional culture-based pathogen detection
requires that there is a certain load of viable organisms. Molecular methods of
detection can detect tiny amounts of microbial material and do not require organisms
to be viable. This raises the possibility of detection of tiny amounts of contaminant
and also detection of organism where the host has already rendered it harmless.
Given the important contribution that the host response makes to the pathogenesis of
sepsis, it would provide valuable information to examine the host response to a
microbial pathogen. Each of us likely experiences numerous host-pathogen
encounters on a daily basis but only becomes ill relatively infrequently.
Theoretically it could be possible to have a bacteraemia with a low load of pathogen
that could be rapidly eradicated by the host response without causing discernable
symptoms of sepsis. Microarray pathogen detection methods could detect these
organisms but without the host response information it would be impossible to
tell/predict the clinical relevance of the pathogen-host interaction. Ultimately,
combining both pathogen detection and examination of host response is likely to
yield the most useful and reliable information, and I believe that this will have an
important role to play in infection diagnostics in the future.
When considering the aim of achieving a diagnostic tool for infection using
microarray technology one could be easily discouraged by the apparently
overwhelming number of obstacles to be considered. Potential obstacles to success
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include variations introduced by differences in sampling technique, sample handling,
RNA extraction, labelling, hybridisation and the microarray platform chosen.
Biological differences depending on stage of infection, route of entry or site of
infection, strain of infection and load of infection may also affect the results
achieved. I felt strongly that this should not be a deterrent to working towards this
aim. In fact, the main aims of this study were to examine many of these factors and
to work to minimise their impact.
For this study, I set out to investigate and produce a standardised procedure for
sampling neonatal blood in order to minimise technical variation. The original scope
of this study was to determine whether it was possible to use RNA obtained from
neonatal blood in microarray experiments, thus facilitating future microarray studies
using neonatal blood derived RNA. In actual fact, after achieving these aims, due to
promising results and the reducing costs ofmicroarrays, I have been privileged to be
able to continue further in this study as part of a research group to examine
comparisons between control and infected groups. Some of this further data is
presented in this thesis.
When I embarked on this research, there was no data in the literature regarding
expression profiling of infection in children and more particularly not in the neonatal
population. As well as the technical difficulties of collecting blood from neonates
and the absolute necessity of any test being carried out on small samples due to the
relatively small circulating volume of such patients, the fact that neonates have
relatively immature immune systems and may be encountering infection for the first
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time, made the prospect of studying neonatal infection profiles a challenging but
exciting prospect. Over the time that I have been working on this project, there have
been publications starting to emerge that are looking at gene expression profiling of a
variety of conditions within the field of paediatrics. In addition there have been
increasing numbers of publications using microarray technology to examine the host
response to infection. It is both encouraging and exciting to see the increasing
knowledge in this area. It reflects increasing acceptance of microarray use and of
expression profiling as valid and useful tools. Although it would be potentially
possible to create a diagnostic tool using the data from a single research group, the
use of concurring data from a number of groups would create a more robust tool. I
believe that the data presented in this thesis brings a useful contribution to this





This chapter contains the methods that were used for the blood sampling and
experimental work that is discussed in the chapters that follow. This chapter also
contains discussion as to the rationale behind the choice of methods used. This
chapter is split into the following sections:
• Methods used for blood sampling
• Methods used for RNA extraction
• Methods used for RNA quality assessment
• Methods used for labelling and hybridisation ofmicroarrays
2.1 Methods Used for Blood Sampling
All blood samples were taken with written, informed, parental consent.
Umbilical Cord Blood Sampling
As discussed in chapter 3, umbilical cord blood was used a surrogate for neonatal
blood for the initial work in this study. Umbilical cord blood sampling was
performed as soon as possible after delivery of the placenta and in all except one case
sampling was within 15 minutes of delivery of the baby (the exception was sampled
at 20 minutes). Study samples were taken only after any samples that were required
clinically had been obtained. The cord blood sampling method described here is
similar to that described for established stem cell gathering techniques (302).
Locally, clinical cord blood samples are taken routinely from every delivery. In all
cases where consent for the study had been granted, I took both the clinical and the
study samples. Gloves, apron and goggles were worn at all times. The clinical
samples were taken using a needle from the umbilical cord as near to the cord clamp,
i.e. as far from the placenta as possible. The umbilical cord was then cleaned with
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filter-sterile phosphate buffered saline solution (Gibco®) and sterile swabs. Sterile
scissors were then used to cut the cord nearer the placenta than the site of clinical
blood sampling. The end of the cord still attached to the placenta was cleaned
further with sterile swabs soaked in phosphate buffered saline and the umbilical vein
catheterised with a sterile nasogastric tube (NG) (size 5) that was advanced until
good blood flow was obtained. Blood samples were drawn off into sterile syringes
connected to the end of the NG tube. The blood was then distributed immediately
into tubes - either dripped directly into neonatal blood collection bottles or injected
directly into a PAXgene™ Blood RNA tube through a sterile needle. Each sample
bottle was inverted several times after sampling.
Samples were taken directly to the laboratory in sealed plastic containers. Those
samples collected into PAXgene™ Blood RNA tubes were transported at room
temperature. All other samples were transported on ice.
Neonatal Blood Sampling
The volume of blood sampled for the study in each case was between 0.5 - 1 ml.
These values were chosen in order to display the natural variation in sampling
volume that occurs clinically where precision measuring is not possible and at the
same time reflecting the need to keep sample volumes as small as possible in this
population. The circulating blood volume of a newborn is 75-80 ml per kg body
weight. In general, for consistency, I aimed for samples to be around 0.6 - 0.7 ml in
volume.
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No extra venepuncture was performed for the sake of the study; extra blood was
taken at the same time as clinical sampling only. If, after the required clinical
samples were obtained, the needle or cannula did not bleed back or was dislodged, it
was not re-sited for the sake of the study.
All samples for blood culture were taken according to the neonatal unit policy as
much as possible. The skin was cleaned with iodine antiseptic as per unit policy,
however instead of wiping the iodine antiseptic off with an alcohol swab, a sterile
swab soaked in sterile saline was used to wipe the antiseptic off and the skin dried
with a sterile swab. Blood culture samples were taken where possible from a closed
system (syringe attached to cannula). The study sample was then aspirated from the
hub of the cannula/ needle using a needle and syringe. The study sample was
injected immediately into the PAXgene™ blood RNA tube. For safety, the
PAXgene™ tube was in a test-tube rack to avoid risk of needle-stick injury. The
PAXgene™ blood RNA tube was then inverted several times and transferred either
directly to the lab or put straight into a -20 °C freezer. All samples were transferred
to the laboratory in sealed plastic containers. Those that had been frozen in the
neonatal unit were transferred on ice and immediately placed in a -20 °C freezer in
the laboratory to ensure that defrosting did not occur.
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2.2 Methods of RNA Extraction from Neonatal Whole Blood
Literature Review & Planning
At the time of study design (autumn 2003 to spring 2004), I performed searches of
the literature to determine up-to-date information on methods of RNA extraction
from human whole blood. The searches revealed that there were a variety of
methods used to extract RNA from human whole blood but that there were no studies
detailing extractions from small volumes, (as would necessary in using neonatal
blood samples) that sought the yields necessary for microarray analysis.
Examination of the literature revealed that many groups opted for isolation of
peripheral blood mononuclear cells (PBMCs) (303, 304) using methods such as
Ficoll-Hipaque gradients / Percoll centrifugation when extracting RNA from human
blood (305-312) or alternative methods such as using gelatine (313). From the
outset it was decided that I would not to go down this route for several reasons.
Firstly we wanted to find a method that utilised whole blood as this would simplify
the journey of samples from the clinical area to the laboratory. Secondly we did not
wish to restrict our examination ofRNA expression profile to monocytes. Thirdly, it
would avoid the additional time involved in cell separation and culture and fourthly
we were conscious of cost. In addition, we made the decision not to opt for methods
that would require amplification of sample RNA not only because of the extra time
involved to incorporate such steps but also because this would be an additional
source of variation.
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Several papers used a guanidine-isothiocyanate-phenol-chloroform method of
extraction (209, 305, 311, 314-319). Studies directly comparing three of these
methods showed that Trizol-LS gave consistently better results (320). I therefore
chose TRIzol®LS as my example of this method to try out. Other methods
described, included on-column methods either alone or as clean-up (209, 307, 316).
After reviewing the manufacturer's information on a few alternatives, I chose the
QIAamp® RNA mini kit as our example of an on-column method as it looked as
though it should be suitable for use with neonatal blood.
Filter paper dried blood spot techniques of sample collection were of particular
interest with a neonatal population in mind. The literature I reviewed on blood spots
was generally describing their use with forensic specimens for DNA or PCR analysis
or were from mouse blood (321, 322). For example, blood stains can have RNA
extracted using a guanidine-isothiocyanate-phenol-chloroformmethod and yield 170-
260 ng RNA from a 50 pi stain (323). There have been reports of blood spots from
Guthrie cards being used to successfully isolate mRNA using RNeasy, however these
were pooled samples that went on to have nested PCR carried out (324). More
recently Haak and colleagues have shown that RNA can be isolated and amplified
from stored blood spot cards that can be analysed by quantitative microarray and
qPCR (325). Another recent paper describes that DNA can be obtained from blood
cards to allow whole genome microarray analysis for genetic testing (326). The
method of filter-paper based RNA extraction that I chose was the Whatman®
system. This decision was made on availability and cost at the time ofplanning.
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PAXgene™ Blood RNA system is marketed as a technology that:
"consolidates and integrates the key steps of whole blood collection, nucleic acid
stabilization and RNA purification... minimizing the unpredictability associated with
RNA processing...enhanced accuracy of intracellular RNA analysis" (PreAnalytix
website: www.preanalvtix.com).
According to PreAnalytix, PAXgene™ tubes contain a proprietary reagent that
immediately stabilizes intracellular RNA. This system looks at whole blood which,
unlike if using separated peripheral blood mononuclear cells, will look at neutrophil
expression. There were several encouraging papers comparing PAXgene™ RNA
extraction to other methods with some going on to run RNA on array expression
studies (327-330). This made the PAXgene™ system a very attractive option that
was therefore included in this study.
After selecting one example of each method of extraction, a protocol for use on
neonatal blood samples was drawn up. This was not always straightforward as the
techniques had not been described for use with neonatal blood which generally has a
higher white cell content than adult blood. There therefore followed several personal
communications between myself and the companies involved to enable me to
optimise protocols where possible - these are referenced at the appropriate places in
this section.
Towards the end of my methodology experiments I came across MagaZorb®, a
magnetic bead based method ofRNA extraction which had just come on the market.
As this was a completely different method to the others already examined, I went on
to investigate it further.
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Since my comparison of the methods described in this study, there have been
several new RNA extraction kits on the market but these were not examined in
retrospect as my goal of finding a method which would consistently extract high
quality RNA from small neonatal blood samples of sufficient quantity to carry out
microarray experiments had already been achieved.
Methods
In order to ensure absolute consistency and eliminate variation, checklists were
compiled for each method ofRNA extraction used. The checklists and the following
formal descriptions of the methods used were compiled following the manufacturers'
instructions and the general laboratory practice protocols for the Centre of Genomic
Technology and Informatics (now Division of Pathway Medicine) with a few
modifications. The modifications are discussed in detail in italics beneath each
method. For all laboratory work described in this work, disposable gloves were
worn both as personal protection and also to prevent RNase contamination of
samples. Sterile disposable plastic ware was used at all times and the pipettes used
were reserved solely for this work.
TRIzo^LS Extraction (Invitrogen™, Life Technologies)
1. 0.5 ml ofRNase-ffee water was added to 0.5 ml of blood.
2. 3 ml of TRIzol®LS were then added and the cells lysed by repetitive pipetting.
3. The TRIzol®LS/Blood/water mix was then left to sit at room temperature for 5
minutes.
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4. 800 microlitres of chloroform were then added, the samples capped securely
and shaken vigorously by hand for 15 seconds.
5. The samples were then sat at room temperature for 2-3 minutes.
6. Samples were centrifuged at 4,000 rpm in a table top Eppendorf 581OR
centrifuge for 1 hour at 4 °C.
7. The colourless aqueous phase was carefully removed with a pipette and
transferred to fresh tubes: 0.5 ml per tube. (The volume of the aqueous phase is
~ 70 % of the volume of TRIzol®LS reagent used for homogenisation, i.e.
around 2.1 ml).
8. The tubes that had been removed last sometimes needed a further period of
centrifugation at 12,000 rpm for 10 minutes and the aqueous layer transferred
to a new tube. This and all subsequent centrifugation steps were carried out in
a Heraeus Biofuge fresco.
9. The RNA was precipitated by mixing with 0.5 ml isopropyl alcohol per tube.
10. The tubes were then incubated at room temperature for 10 minutes.
11. Centrifugation at 12,000 rpm for 10 minutes at 4 °C was carried out and the
RNA precipitate was seen to form a gel-like pellet on the side of the tubes.
12. The supernatant was removed and discarded.
13. The RNA pellet was washed once with 75 % ethanol: 1 ml per tube.
14. Each tube was vortexed & centrifuged at 8,800 rpm for 5 minutes at 4 °C.
15. Some samples required a further 5-10 minutes centrifugation.
16. Most of the supernatant was removed by pipetting.
17. The RNA pellet was air-dried without letting the pellet dry out completely.
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18. The RNA was dissolved in 100 microlitres ofRNAse-free water by passing the
solution a few times through a pipette tip and incubating for 10 minutes at 55 -
60 °C.
Notes on TRIzol®LS method:
• Invitrogen recommended that the blood be diluted 1:1 with water
(step 1 above) in order to optimise results (personal communication
and TRIzol®LS Reagent informationform no. 18057N).
• The centrifugation speed of 4,000 rpm on the Eppendorf Centrifuge
581OR in step 6 above was set after Invitrogen advised using a table-
top centrifuge for 30-60 minutes (personal communication), i.e.
longer time at lower force. This was necessary as I did not have
access to a centrifuge that would have both achieved the
recommended 15 minutes at 12,000 x g and taken tubes that could
withstand TRIzol®LS and chloroform.
QIAamp® RNA Mini Protocol for RNA Cleanup (Qiagen)
1. 350 microlitres of Buffer RLT was added to the 100 microlitres of dissolved
RNA and the sample was mixed by pipetting.
2. 250 microlitres of 100 % ethanol were added to the lysate and mixed by
pipetting.
3. 700 microlitres of sample was pipetted into a spin column sitting in a 2 ml
collection tube and centrifuged for 15 seconds at 9,200 rpm.
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4. Flow through and collection tube were discarded.
5. Using a new collection tube, any remaining sample was pipetted into the spin
column and centrifuged at 9,200 rpm for 15 minutes.
6. The flow through and collection tube were discarded and the column placed
into a new collection tube.
7. 350 microlitres of Buffer RW1 were pipetted into the column and centrifuged
at 9,200 rpm for 15 seconds to wash.
8. Flow through was discarded.
9. Separately, 10 microlitres of DNase 1 stock solution (per sample) were added
to 70 microlitres (per sample) Buffer RDD and mixed gently by tapping the
tube.
10. 80 microlitres of DNase 1 incubation mix from step 9 was pipetted directly
onto the column membrane.
11. The column was left at room temperature for 15 minutes.
12. 350 microlitres of Buffer RW1 were pipetted into the column and centrifuged
at 9,200 rpm for 15 seconds.
13. Flow through was discarded and the column placed in a new collection tube.
14. 500 microlitres of Buffer RPE were added to the column and centrifuged for
15 seconds at 9,200 rpm.
15. Flow through and collection tube were discarded and a new collection tube
used.
16. A further 500 microlitres of Buffer RPE were added to the column and
centrifuged at full speed for 3 minutes.
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17. The collection tube and flow through were discarded and the column placed in
a new collection tube.
18. The column was centrifuged for 1 minute at full speed.
19. The column was transferred to a new 1.5 ml collection tube and 50 microlitres
ofRNase-free water was pipetted directly onto the column membrane.
20. After 1 minute, the column was centrifuged at 9,200 rpm for 1 minute to elute.
21. Keeping the same collection tube a further 50 ml of RNase-free water was
pipetted onto the membrane.
22. After 1 minute the sample was centrifuged at 9,200 rpm for 1 minute.
23. The column was centrifuged for a further minute at 9,200 rpm.
24. The eluate was transferred into a new tube at stored at -80 °C.
Notes on the QIAamp® RNA Mini Protocolfor RNA Cleanup:
• The method was taken from the QIAamp® RNA BloodMini Handbook
- version January 1999, p24).
• An on-column DNase step was incorporated (steps 9-13 above).
• The optional extra 1 minute centrifugation step (steps 17-18 above)
was incorporated.
• All centrifugation steps were performed using a Heraeus Biofuge.
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QIAamp® Blood RNA MiniKit Extraction (Qiagen)
1. 0.5 ml of cord blood (in EDTA) was mixed with 2.5 ml ofBuffer EL. In order to
allow sufficient volume for efficient mixing 2 aliquots of 0.25 ml of blood were
each mixed with 1.25 ml ofBuffer EL for each sample.
2. Samples were incubated on ice for 20 minutes, being vortexed briefly twice
during this period.
3. The samples were then centrifuged at 2,000 rpm for 10 minutes at 4 °C.
4. The supernatant was removed and discarded.
5. 0.5 ml of Buffer EL was added to each cell pellet and the cells re-suspended by
vortexing briefly.
6. The tubes were then incubated for an additional 10 minutes on ice.
7. The tubes were centrifuged for 10 minutes at 4 °C at 2,000 rpm.
8. The supernatant was removed and discarded.
9. 300 microlitres ofBuffer RLT were added to each tube and mixed by pipetting.
10. The lysate from each pair of tubes was combined and pipetted directly into a
QIAshredder spin column,
11. The column was centrifuged at maximum speed for 2 minutes.
12. The shredder column was discarded and the homogenized lysate retained.
13. 600 microlitres of 70 % ethanol were added to the homogenized lysate and
mixed by repetitive pipetting.
14. 700 microlitres of the sample were pipetted into a new QIAamp spin column
sitting in a 2 ml collection tube.
15. The column was centrifuged at 9,200 rpm for 15 seconds.
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16. The flow-through and collection tube were discarded and the column placed in a
new collection tube.
17. Any remaining sample was pipetted into the QIAamp spin column and
centrifuged at 9,200 rpm for 15 seconds.
18. The flow-through and collection tube were discarded and the column placed in a
new collection tube.
19. 350 microlitres of Buffer RW1 were pipetted into the column and centrifuged at
9,200 rpm for 15 seconds to wash.
20. Flow through was discarded.
21. Separately, 10 microlitres of DNase 1 stock solution (per sample) were added to
70 microlitres (per sample) Buffer RDD and mixed gently by tapping the tube.
The tube was centrifuged for up to 2 seconds at 2,000 rpm to collect droplets
from the lid.
22. 80 microlitres of DNase 1 incubation mix from step 21 was pipetted directly
onto the column membrane.
23. The column was left at room temperature for 15 minutes.
24. 350 microlitres of Buffer RW1 were pipetted into the column and centrifuged at
9,200 rpm for 15 seconds.
25. The flow-through and collection tube were discarded and the column placed in a
new collection tube.
26. 500 microlitres of Buffer RPE were added the column and the column
centrifuged for 15 seconds at 9,200 rpm.
27. The flow-through and collection tube were discarded and the column placed in a
new collection tube.
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28. A further 500 microlitres of Buffer RPE were added to the column and the
column centrifuged at full speed for 3 minutes.
29. The flow-through and collection tube were discarded and the column placed in a
new collection tube.
30. The column was centrifuged at full speed for 1 minute.
31. The column was transferred into a new 1.5 ml collection tube and 50 microlitres
ofRNase-free water were pipetted directly onto the QIAamp membrane.
32. After 1 minute, the column was centrifuged at 9,200 rpm for 1 minute to elute.
33. Using the same collection tube, a further 50 microlitres of RNase-free water
were pipetted onto the column membrane.
34. After 1 minute, the column was centrifuged for 1 minute at 9,200 rpm.
35. The column was centrifuged for a further 1 minute at 9,200 rpm.
36. The eluate was transferred into a new tube and was stored at -80 °C.
Notes on the QIAamp® RNA Mini Protocol
• The method was taken from the QIAamp® RNA Mini Protocol for
Isolation of Total Cellular RNA from Whole Human Blood found on
pages 13 — 16 of the QIAamp® RNA Blood Mini Handbook, version
January 1999.
• Each sample was split into two aliquots that were processed in parallel
until merged again in step 10 above. This was so that the sample did not
exceed 3A of the volume of the tube to allow efficient mixing as
recommended.
74
The additional time needed to allow the suspension to become translucent
was incorporated into the incubation time in step 2 above.
An additional 10 minute incubation on ice was incorporated (step 6
above) as recommended in the trouble shooting section on page 25 of the
QIAamp® RNA Blood Mini Handbook, version January 1999. This was
incorporated because the pellet obtained after step 3 above was red,
indicating incomplete erythrocyte lysis.
A total of 600 microlitres (300 microlitres to each aliquot of sample) of
Buffer RLT was added to each sample in step 9 above. The larger amount
ofBuffer RLT was used in expectation that the cord blood would be rich
in leukocytes.
An on column DNase digestion was incorporated: steps 19-23 above.
The optional centrifugation step after addition of Buffer RPE (step 30)
was incorporated.
All centrifugation steps were performed using a Heraeus Biofuge.
This method can only be performed on fresh blood and cannot be used on
frozen blood samples.
The amounts used above were specifically worked outfor 0.5 ml ofblood.
A single QIAamp spin column can process 1.5 ml of adult blood or a
maximum of 1 x 10 leucocytes: greater amounts would mean that the
leucocytes would not befully lysed. The number ofleucocytes in neonates
would be expected to be in the range of9 - 30 x 106per ml, i.e. 0.9 -3.0 x
j10 per ml. Considering this, and after discussion with a Qiagen
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representative, Ifelt that it was reasonable to use 0.5 ml ofcord blood in
the above protocol.
PAXgene™ Blood RNA System (PreAnalytix: Qiagen, BD)
All centrifugation was carried out at room temperature.
1. Each sample was incubated at room temperature for aminimum of 2 hours (4
hours after removal from freezer if frozen).
2. Each PAXgene tube was centrifuged for 10 minutes on a table-top centrifuge
set to 4,000 rpm using a swing-out rotor (Eppendorf 581 OR centrifuge).
3. The supernatant was decanted off and the rim of the tube dried with a clean
tissue.
4. 5 ml ofRNase-free water was added to the tube and the tube closed.
5. The pellet was then re-suspended by thorough vortexing and the sample
centrifuged at 4,000 rpm in the Eppendorf 581 OR centrifuge for 10 minutes.
6. The entire supernatant was then decanted and the rim dried with a clean
tissue.
7. The pellet was re-suspended in 360 microlitres of Buffer BR1 by vortexing.
8. The sample was then pipetted into a fresh 2 ml microcentrifuge tube.
9. 300 microlitres ofBuffer BR2 was added to the tube.
10. 40 microlitres of proteinase K was then added and the sample mixed by
vortexing.
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11. The sample was incubated for 10 minutes in a water bath at 56 °C with a brief
vortex carried out after 5 minutes (cooling was avoided).
12. The sample was then centrifuged at maximum speed in a microcentrifuge for
10 minutes. This and all subsequent centrifuge steps were carried out using a
Heraeus Biofuge.
13. The supernatant was transferred into a fresh 2 ml microcentrifuge tube using
a pipette. A small amount of debris in the supernatant was accepted.
14. 350 microlitres of 100 % ethanol were added.
15. The sample was mixed by vortexing and centrifuged for less than 2 seconds
at 2,000 rpm to remove droplets from the inside of the lid.
16. 700 microlitres of sample was added to a PAXgene column sitting in a 2 ml
processing tube.
17. The column was then centrifuged at 9,200 rpm for 1 minute.
18. The flow-through and processing tube was discarded and the column placed
in a new processing tube.
19. Any remaining sample was then pipetted into the column and centrifuged at
9,200 rpm for 1 minute.
20. The flow-through and processing tube was discarded and the column placed
in a new processing tube.
21. 350 microlitres of Buffer BR3 was pipetted into the column and centrifuged
for 1 minute at 9,200 rpm.
22. The flow-through and processing tube were discarded and the column placed
in a new processing tube.
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23. Separately, 10 microlitres of DNase 1 stock solution (per sample) was added
to 70 microlitres (per sample) of Buffer RDD and mixed by tapping the wall
of the tube. The tube was then centrifuged briefly to collect all droplets from
the side/lid.
24. 80 microlitres of the DNase 1 incubation mixture from step 23 were pipetted
directly onto the spin column membrane,
25. The column was then left on the benchtop for 15 minutes.
26. 350 microlitres of Buffer BR3 were pipetted into the column and the column
centrifuged for 1 minute at 9,200 rpm.
27. The flow-through and processing tube were discarded and the column placed
in a new processing tube.
28. 500 microlitres of Buffer BR4 were added to the column and the column
centrifuged for 1 minute at 9,200 rpm.
29. The flow-through and processing tube were discarded and the column placed
in a new processing tube.
30. A further 500 microlitres of Buffer BR4 were added to the column and the
column centrifuged for 3 minutes at maximum speed.
31. The flow-through and processing tube were discarded and the column placed
in a new processing tube.
32. The column was then centrifuged at full speed for 1 minute.
33. The flow-through and processing tube were discarded and the column placed
in a 1.5 ml elution tube.
34. To elute, 40 microlitres of Buffer BR5 were pipetted directly onto the
column membrane.
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35. After 1 minute, the column was centrifuged at 9,200 rpm for 1 minute.
36. Using the same elution tube, a further 40 microlitres of Buffer BR5 were
pipetted onto the column membrane.
37. After 1 minute, the column was centrifuged at 9,200 rpm for 1 minute.
38. The column was centrifuged at 9,200 rpm for a further 1 minute.
39. The elution tube was then incubated in a water bath set to 66 °C for 5
minutes.
40. The tube was then immediately transferred onto ice and chilled for at least 3
minutes.
41. The sample was then transferred into a new tube and stored at -80 °C.
Notes on the PAXgene™ BloodRNA Extraction:
• The above method was taken from the PAXgene™ Blood RNA Kit
Handbook, version April 2001.
• The centrifugation in step 12 above was increased to 10 minutes to
ensure that the supernatant separated adequately — early experiments
showed that the 3 minutes recommendedwas not sufficient.
• Steps 19 & 20 above were necessary as there was usually just over
700 microlitres ofsample to be transferred onto the spin column.
• The optional on-column DNase digestion step was incorporated (steps
23-27 above) as described in Appendix A of the PAXgene™ Blood
RNA Kit Handbook, April 2001.
• The optional additional centrifuge step (step 32 above) was
incorporated. In order to maximise elution the columns were left for 1
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minute in steps 35 and 37 prior to centrifugation. In addition an
additional 1 minute centrifuge step was added (step 38).
• Note: Later versions of the PAXgene™ Blood RNA Kit Handbook
(February 2004) suggested a 10 minute centrifuge step after the 1st
waterbath incubation (as I had done anyway) or to use a QIAshredder
spin column after the 1st waterbath incubation. I never used the
QIAshredder as I had been achieving good results with the above
protocol. Later versions also included the 2nd application of sample
to the spin column.
MagaZorb® RNA Mini-Prep Kit Extraction (Cortex Biochem™)
1. All reagents and samples were equilibrated to room temperature.
2. 20 microlitres of proteinase K solution was pipetted into the bottom of a 2 ml
microcentrifuge tube.
3. 200 microlitres of whole blood (EDTA sample) was added to the tube and
mixed gently by pipetting.
4. 200 microlitres of Lysis Buffer were added and the tube vortexed for 15
seconds.
5. The tube was incubated at 56 °C for 10 minutes.
6. 500 microlitres ofBinding Buffer was added.
7. 20 microlitres ofwell-mixed MagaZorb® Reagent were added.
8. The tube was mixed gently and then incubated at room temperature using an
end-over-end rotator.
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9. The MagaZorb® RNA bound particles were sedimented using a magnetic
rack.
10. The supernatant was aspirated and discarded.
11. The tube was then removed from the magnetic rack.
12. The particles were washed by adding 1 ml of Wash Buffer and inverting the
tube several times.
13. The particles were sedimented using the magnetic rack.
14. The supernatant was aspirated and discarded.
15. Separately, a DNase 1 working solution was prepared by combining 20
microlitres (per sample) of DNase 1 with 80 microlitres (per sample) of
DNase 1 Buffer.
16. The tube from step 14 was removed from the magnetic rack.
17. 4 microlitres of SUPERase FN was added to the tube and mixed gently.
18. 100 microlitres of the DNase 1 working solution from step 15 was added and
mixed gently.
19. The tube was incubated at room temperature for 15 minutes while mixing in
an end-over-end rotator.
20. The tube was removed from the end-over-end rotator and 1 ml of wash
buffer was added and mixed by inverting the tube several times.
21. The tube was placed in the magnetic rack and the particles sedimented.
22. The supernatant was aspirated and discarded.
23. The tube was removed from the magnetic rack and a further 1 ml of Wash
Buffer was added to the tube and the tube inverted several times.
24. The particles were sedimented using the magnetic rack.
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25. The supernatant was aspirated and discarded.
26. 50 microlitres ofRNase-free water was added to the tube.
27. The tube was placed in an end-over-end rotator and mixed for 10 minutes at
room temperature.
28. The tube was placed into the magnetic rack and the particles sedimented.
29. Separately, a clean tube had 4 microlitres of SUPERase IN added.
30. The supernatant from step 28 was then transferred into the tube containing
SUPERase IN, mixed gently and frozen at -80 °C.
Notes on the MagaZorb®RNA Mini-Prep Kit Extraction:
• MagaZorb® RNA Mini-Prep Kit can only be used on fresh whole
blood samples. Frozen samples cannot be used.
• The above method was taken from the MagaZorb® RNA Principle and
Procedure Leaflet (2001-Rev3-04G08) and from the MagaZorb®
Supplementary Protocol B (2004-RevA) supplied with the kit.
• The supplementary protocol B to remove DNA contamination was
incorporated (steps 15- 22 above).
Whatman FTA® Extraction Method
For the Whatman FTA® extraction method, 3M sodium acetate pH 5.2 was prepared
in advance of the experiment. In addition, RNA processing buffer was made up fresh
on each occasion and stored on ice. RNA processing buffer contained 10 mM Tris-
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HC1 pH 8.0, 0.1 mM EDTA, 800 U/ml ofRNase Out, 200 pg/ml glycogen and 2 mM
DTT achieved in the final volume.
• The samples on the Whatman FTA® cards were left to air dry at room
temperature for at least 2 hours (minimum recommended is 1 hour).
For each Whatman FTA® experiment the following was carried out:
1. The sample disc was removed from the dried blood spot using the Harris
punch and cutting mat as per manufacturer's instructions.
2. The disc was placed in a 0.2 ml RNase-free and DNAse free PCR tube.
3. 750 pi of RNA processing buffer was added to the tube and pipetted up and
down twice.
4. The tube was capped and incubated on ice for 15 minutes - mixing by
pipetting every 5 minutes.
5. The RNA was precipitated by adding 75 pi of 3M Sodium acetate pH 5.2 and
750 pi of ice cold 100 % isopropanol.
6. The sample was then incubated at -20 °C for 1 hour.
7. The tube was placed in a microcentrifuge tube and spun down at 12,000 x g
for 5 minutes.
8. Supernatant was removed by pipetting.
9. The "pellet" was washed with 500 pi of ice cold 75 % ethanol and spun for 5
minutes at 12,000 x g.
10. Additional steps in those samples with DNase treatment:
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• A DNase working solution was prepared by combining 20 pi of
DNase 1 with 80 pi of10XDNase 1 Buffer
• The 75 % ethanol from the microcentrifuge tube containing the pellet
was removed bypipetting.
• 100 microlitres of DNase working solution was added to the tube
containing the pellet and incubated at room temperature for 15
minutes.
• The DNase working solution was removed bypipetting.
• The 'pellet' was washed with a further 500 pi of ice cold 75 %
ethanol and spun for 5 minutes at 12,000 x g.
11. The supernatant was removed by pipetting and the "pellet" was air dried.
12. The pellet was re-suspended in 50 pi of TE~' buffer.
13. Sample was stored at -80 °C until quality control checks could be carried out.
Notes on the Whatman FTA® Extraction Method:
• The above method was taken from Whatman FTA Protocol BR01: Applying
and Preparing Blood and Tissue/Cell Culture Samples on FTA® Cards for
RNA Analysis. Reference was also made to: "Removing a Sample Disc from
an FTA or CloneSaver card for Analysis" (protocol number BD09) and to
"FTA® Protocols: Collect, Transport, Archive and Access Nucleic Acids...
All at Room Temperature" by Whatman®. 2002. WB 120047.
• A few points in the protocol were noted to be inaccurate/vague, eg. the
section describing the need to use the whole disc ofcells to be processedfor
Northern blot stated that the wash step be "increased to 750 pi sterile
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waterthen it goes on to describe the wash step being in RNA processing
buffer. I sought clarification from the company directly by telephone and e-
mail and have incorporated their advice into the method described above.
• An additional DNase step was incorporatedfor some samples.
Additional Information on RNA Extractions
1. DNase Steps.
For the on-column DNase steps described in the methods for the QIAamp® RNA
Mini Protocol for RNA Cleanup, QIAamp® Blood RNA Mini Kit Extraction and the
PAXgene™ Blood RNA System, I used the RNase-Free DNase Set from QIAgen.
The DNase 1 solution was made up according to manufacturer's instructions:
• The lyophilised DNase 1 (1,500 Kunitz units) was dissolved in 550
microlitres of the RNase-free water provided in the kit.
• Mixing was performed by gently inverting the tube.
• The DNase 1 solution was then pipetted into aliquots of 20 microlitres and
the aliquots stored at -20 °C until needed.
The DNase 1 solution in the MagaZorb® RNA Mini-Prep Kit Extraction was made
using DNase 1 (2 U/pl) and the 10X DNase 1 Buffer from Ambion (Cat. No. 2222)
as recommended in the MagaZorb® Supplemental Protocol B. These were also used
in the Whatman FTA® extraction experiments.
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2. Centrifuge speeds
For all RNA extractions it is important that the correct rotational speed/ g-force are
used.
Relative centrifugal force (in g) = 1.12 x rotor radius (in cm) x (rpm/1000)
A. Heraeus Biofuge Fresco and Biofuge Pico
The rotor number for these centrifuges was #7500 3325 and the technical data is:
Max speed 13,000
Max rcf (at max speed) 16,060
Min speed 2,000
Min RCF 380
Max radius 8.5 cm
Min radius 5.9 cm
Angle 40 0
The manufacturer's instruction manual provided a graph to calculate the speed/g, I
used this graph to calculate the following values which were essential to the study:
For TRIzol® LS:
• For the steps requiring centrifuge at less than 7,500 x g, the centrifuge was
run at 8,800 rpm (7,500 x g = 9,000 rpm).
• For the steps requiring centrifuge at 12,000 x g, the centrifuge was run at
12,000 rpm (12,000 x g = 12,000 rpm).
For QIAamp®:
• For the steps requiring centrifuge at 400 x g, the centrifuge was run at 2,000
rpm (400xg = 2,000 rpm)
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• For the steps requiring centrifuge at over 8,000 x g, the centrifuge was run at
9,200 rpm (8,000 xg= 9,000 rpm)
• For the steps requiring centrifuge at 20,000 x g ("maximum speed"), the
centrifuge was run at its maximum of 13,000 rpm (= 16,060 x g)
For PAXgene™:
• For the steps requiring centrifuge at 10,000 x g, the centrifuge was run at
10,000 rpm (10,000 x g = 10,000 rpm)
• For the steps requiring centrifuge at less than 1,000 x g, the centrifuge was
run at 2,000 rpm (1,000 xg = 2,250 rpm)
• For the steps requiring centrifuge at over 8,000 x g, the centrifuge was run at
9,200 rpm (8,000 x g = 9,000 rpm)
• For the steps requiring centrifuge at 20,000 x g ("maximum speed"), the
centrifuge was run at its maximum of 13,000 rpm (= 16,060 x g)
• For the experiment using aliquots ofPAXgene™ fluid where the centrifuge
was required to be at 3,000-5,000 x g, the centrifuge was set at 6,500 rpm (=
4000 x g)
For spinning the gel for the RNA 600 Nano Assay for the Agilent Bioanalyzer:
• Centrifuge was required to be set at 1,500 x g +/- 20 %. The centrifuge was
set at 4,000 rpm (= 1500 x g).
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B. EppendorfCentrifuge 581 OR
This table-top centrifuge has Rotor A-4-62.
Maximum speed 4,000
Maximum rcf (at max speed) 3,220
• For TRIzol LS method:
12,000 x g for 15 minutes was recommended but I did not have access to a
machine that was both large enough to take the necessary chemical-resistant
tubes and able to achieve that force.
After discussion with Invitrogen the Eppendorf Centrifuge was set at 4,000
rpm (3,161 x g, using 15 ml NUNC tube)
• For PAXgene™ method:
3,000-4,000 x g was recommended.
Centrifuge set at 4,000 rpm (3,072 x g, using PAXgene™ tube).
2.3 Assessment of RNA Quality
Quantitative Assessment of RNA Using Spectrophotometry
The spectrophotometer used for all of the umbilical cord blood RNA samples was the
ThermoSpectronic Biomate 5 spectrophotometer and VISION 32 (bit Version 1.25).
This was used for quantification and to obtain values to calculate A260:A280 ratio.
88
The initial neonatal blood RNA samples were also run on this spectrophotometer but
later neonatal blood samples and any nucleic acid assessment during the course of
microarray labelling and hybridisation was run on a ThermoSpectronic
NanoDrop™1000 Spectrophotometer. All of the samples to be used with the
Illumina® microarrays (chapter 5) that had initially been run on the Biomate were re¬
run on the NanoDrop™ to ensure consistency. The methods used for both
spectrophotometers are detailed below.
Spectrophotometry Using the ThermoSpectronic Biomate 5
1. Unless otherwise stated in individual experimental methods,
78 pi of 10 mM Tris-Cl pH 7.5 was pipetted into microcentrifuge tubes -
one aliquot for each sample to be assessed.
2. 2 pi of each sample to be assessed was added to one of the tubes
containing the 10 mM Tris-Cl pH 7.5.
3. Each tube was vortexed for several seconds to ensure thorough mixing.
4. The tubes were centrifuged briefly to collect any droplets from the lid
(max 2 seconds).
5. The spectrophotometer was switched on and then the computer switched
on.
6. The "remote operation" option was selected on the spectrophotometer.
7. The VISION software was opened on the computer and the following
parameters were set for measurement:




• Time selected as 3 seconds
• Lamp selected as 324 nm (Blue+ 110-325 nm)
• Width selected as 2 nm
• Number of cycles selected as 3
• Time selected as Auto
• Number of samples was selected for the number of samples to be
processed and the sample names inputted.
• The "one cuvette" option was selected
8. The cuvettes were cleaned thoroughly with RNaseZAP and then with
RNase free water prior to use. Any residual fluid was removed carefully
by pipetting.
9. 80 pi of 10 mM Tris-Cl pH 7.5 was added to each of two cuvettes and the
cuvettes placed in the slot at the back right (black area to front) and the
other in sample space 1 with the frosted end to the front.
10. With the lid of the spectrophotometer closed, the icon with the arrows
pointing down was selected to blank the spectrophotometer.
11. The cuvette from sample space 1 was then removed and the Tris CI
removed by pipetting, ensuring that there was not residual fluid in the
cuvette.
12. 80 pi of the first sample to be analysed was then pipetted into the cuvette
and the cuvette placed back into slot 1.
13. With the lid of the spectrophotometer closed, the run icon (man running)
was selected and the absorbances measured.
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14. The sample was then removed from the cuvette by pipetting, the cuvette
rinsed with 80 pi 10 mM Tris-Cl pH 7.5 and the Tris CI removed by
pipetting to ensure no residual fluid was left in the cuvette.
15. 80 pi of the next sample was then pipetted into the cuvette and the
procedure repeated for this and subsequent samples.
16. At the end of each batch the data was saved.
As described above, the spectrophotometer was set to measure each sample in
triplicate. If the values obtained were the same or similar within 0.002 then the
results were considered valid. On occasion there was wider variation between the
three results for each sample and these samples would be re-run, taking extra care to
ensure adequate mixing prior to measurement.
A26o:A28o ratios were calculated using the A26o and A2ho values obtained from the
spectrophotometer. Quantity of RNA in each sample was calculated using the
following equation:
A26o x dilution factor of sample x 44 = amount in ng/pl.
The dilution factor for each sample was 40 (2 pi sample in 78 pi Tris). 44 was the
multiplier used as all of the samples had been diluted with 10 mM Tris CI with pH
7.5. The total amount of RNA obtained in each case was calculated by multiplying
the result of the above equation by the total amount of sample eluted. For the
PAXgene™ samples this was 75 pi and for the TRIzol® LS or QIAamp® samples
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this was 95 pi. This allowed for a residual 5 pi of dead space during elution using
the spin columns (reference: personal communication with representative ofQiagen).
Spectrophotometry Using The ThermoSpectronic NanoDrop™1000
Spectrophotometer
1. The software was started up and the nucleic acid module selected and the
RNA-40 settings selected.
2. Before each use, the sample pedestal of the spectrophotometer was wiped
using a soft laboratory wipe.
3. The pedestal was then cleaned by pipetting a 2 pi aliquot of RNase-free
water onto the pedestal, closing and opening the pedestal again and wiping it
dry with a soft laboratory wipe.
4. To initialise the spectrophotometer, a further aliquot of water was loaded
onto the pedestal, following the instructions on screen and pressing "OK"
when instructed to do so. The pedestal was again wiped using a laboratory
wipe.
5. Before making any sample measurements, a blank measurement would be
made: 1 pi of RNase-free water was pipetted onto the pedestal, the pedestal
closed and "make a blank measurement" selected on screen.
6. When the blank measurement was complete, both pedestals were wiped
using a laboratory wipe.
7. A test measurement was made using water to check that the result was a
spectrum with a relatively flat baseline and the pedestals wiped afterwards.
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8. For each sample measurement, a 1 pi aliquot of sample was pipetted onto
the pedestal, the pedestal arm closed and "measure" was selected on screen.
The pedestal was observed carefully to ensure that a complete column of
fluid was formed during the measurement: on the occasions where this did
not occur, the measurement was repeated using a slightly bigger aliquot of
sample.
9. For each measurement the following were recorded:
• Absorbance at 260 nm
• Absorbance at 280 nm
• 260/280 ratio
• Amount ofRNA (ng/pi)
10. Following each sample the pedestal was wiped clean with a clean laboratory
wipe, cleaned with an aliquot of water on the pedestal and then wiped dry
with a laboratory wipe. The next sample would then be applied and the
process repeated.
A260:A280 Ratio Target Values
The range of A260:A280 ratio that was considered desirable and indicative of good
quality RNA was 1.8-2.2 (for samples processed in Tris CI).
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Qualitative Assessment of Total RNA Using Agilent 2100 Bioanalyzer
(RNA 6000 Nano Assay)
RNA quality was assessed using both subjective assessment of Bioanalyzer traces
and using RNA integrity number values that were generated by the Bioanalyzer
software. The method of using the Bioanalyzer is detailed below. Notes on
Assessment of the Bioanalyzer traces and on RIN values follow the method.
Before preparing the RNA 6000 Nanochip for analysis:
1. The chip priming station was set up, checking that the syringe was in
place (new syringe used for each reagent kit), the base plate was in
position C and the lever of the clip in the top position.
2. The bioanalyzer was set up and the Agilent 2100 Bioanalyzer
software started.
3. The Bioanalyzer electrodes were decontaminated by filling the wells
of an electrode cleaner with 350 |il RNaseZAP, placing the cleaner in
the bioanalyzer and closing the lid for 1 minute. The electrode
cleaner was then removed and another electrode cleaner filled with
350 pi of RNase-free water and then placed in the Bioanalyzer and the
lid closed for 10 seconds. The electrode cleaner was then removed
and the bioanalyzer lid left open for 10 seconds to allow the water on
the electrodes to evaporate and then closed.
4. All of the reagents for preparation of the chips were allowed to
equilibrate to room temperature for 30 minutes before use.
94
5. All of the RNA samples to be run on the chip and the RNA ladder
were denatured for 2 minutes at 70 °C in an air incubator before use.
Chip preparation:
1. The gel was prepared by placing 550 pi of RNA 6000 Nano gel
matrix (marked in the kit with a red cap) into a spin filter column and
centrifuged at 4,000 rpm in the microfuge for 10 minutes. Aliquots of
65 pi of filtered gel were pipetted into 0.5 ml RNase-free
microcentrifuge tubes. Any aliquots not used on that day were stored
at 4 °C and used within one month.
2. The RNA 6000 Nano dye concentrate was vortexed for 10 seconds
and then spun down in a microcentrifuge for around 2 seconds. The
dye concentrate was protected from light at all times.
3. 1 pi of dye concentrate was pipetted into a 65 pi aliquot of the filtered
gel from step 1. above and the tube capped and vortexed thoroughly,
ensuring proper mixing of the gel and dye.
4. The dye-gel mix was centrifuged at room temperature for 10 minutes
at maximum speed in a microcentrifuge.
5. A new RNA Nano chip was removed from its sealed bag and placed
on the Chip Priming Station.
6. 9 pi of the gel-dye mix were pipetted into the bottom of the well
marked with a white G in a black circle. Care was taken to avoid any
particles from the bottom of the gel-dye tube and the pipette tip was
inserted to the very bottom of the chip well.
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7. The timer was set to 30 seconds, the plunger set to 1 ml and then the
Chip Priming Station was closed ensuring that the latch lock clicked
shut.
8. The plunger was then depressed until held by the syringe clip and held
there for 30 seconds exactly.
9. When the 30 seconds was up, the plunger was released and after 5-10
seconds the plunger was slowly drawn back to the 1ml position.
10. The chip priming station was then opened.
11. 9 pi of gel-dye mix was pipetted into each of the chip wells marked
with a black G on a grey background (2 wells).
12. 5 pi ofRNA 6000 Nano Marker (green cap) was pipetted into the well
marked with the ladder symbol and each of the 12 sample wells.
13. 1 pi ofRNA 6000 Ladder was pipetted into the well marked with the
ladder symbol.
14. 1 pi of each sample was pipetted into a sample well.
15. Any sample wells that did not have a sample added had an extra 1 pi
of RNA 6000 Nano Marker added to ensure that the chip would run
properly.
16. The chip was then placed in the chip adapter for the vortex mixer and
vortexed for 1 minute at 2,400 rpm. The chip run in the Bioanalyzer
was commenced within 5 minutes of this vortex step.
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Running the chip in the Agilent 2100 Bioanalyzer:
1. The bioanalyzer lid was opened, the chip gently inserted and the lid
closed slowly.
2. From the Assay Menu on the software screen, Eukaryote Total RNA
Nano was selected.
3. The start button on the software screen was then clicked.
4. The sample information of the chip and each individual well was then
entered.
5. After the assay was complete, the chip was removed from the
bioanalyzer and disposed of.
6. To clean up, the Bioanalyzer electrodes were decontaminated by
filling the wells of an electrode cleaner with 350 pi RNaseZAP,
placing the cleaner in the bioanalyzer and closing the lid for 1 minute.
The electrode cleaner was then removed and another electrode cleaner
filled with 350 pi of RNase-free water and then placed in the
Bioanalyzer and the lid closed for 10 seconds. The electrode cleaner
was then removed and the bioanalyzer lid left open for 10 seconds to
allow the water on the electrodes to evaporate and then closed.
Notes on the RNA 6000 Nano Assay:
• The above method was taken from the Agilent Technologies Reagent Kit
Guide RNA 6000 Nano Assay Edition April 2003.
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Notes on Bioanalyzer Trace Assessment
A bioanalyzer trace is a graph of fluorescence against time. A good quality trace
from intact RNA should have a marker peak and two crisp peaks corresponding to
18S and 28S fragments. There should also be very little "noise" along the baseline.
The more "noise" there is the more degraded the RNA sample is. As examples of
this, the graph on the left in figure 2.1 is from good quality intact RNA, the graph in
the middle is of RNA showing some degradation and that on the right is from RNA
showing a lot of degradation.
Figure 2.1: Examples of Bioanalyzer Traces for Intact, Partially
Degraded and Very Degraded RNA samples.
EM A






Notes on RNA Integrity Number (RIN)
RIN is a software generated number that gives an indication of RNA quality. The
scale for RIN is 1 to 10. 1 would be poor quality, degraded RNA and 10 would be
intact, high quality RNA. The higher the RIN the better. As an illustration of this, in
figure 2.1 the sample on the left has RIN of 9.3 (good quality), the middle sample of
6.8 (intermediate quality) and the sample on the right of 2.3 (poor quality).
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2.4 Methods Used For Labelling and Hybridisation of
Microarrays.
Choice of Microarray Platform
At the time of study planning three microarray platforms were considered. These
were microarrays produced by GE (CodeLink™ Whole Human Genome arrays),
Affymetrix (GeneChip® Human Genome array) and Agilent. The Illumina® arrays
used later in this thesis were not yet available.
The initial microarray work carried out in this thesis used Codelink™ Whole Human
Genome Bioarrays. There were several reasons for this. Firstly, the platform was
attractive because the amount of starting RNA was smaller than competing platforms
at the outset of the microarray work in this study. Initial manufacturer's data
recommended use of 0.2-2 pg of RNA, subsequently this recommended range was
adjusted downwards to 0.1-1 pg. The small amount of starting material was a major
factor because it meant that we could use some of our smaller neonatal samples on
array.
The other main factors that influenced the choice ofMicroarrays used were:
• Timing. This was a platform that the Divison of Pathway Medicine was
interested in looking into further at the time that my study reached the
relevant stage ofwork.
• Cost. Microarray-based projects are costly. At the time of considering
running my initial neonatal samples on array, each microarray would have
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cost in the region of around £ 1,000 if Affymetrix arrays were used. This
clearly would have limited the number of arrays run and the validity of
any data obtained. At the time, CodeLink™ arrays were competitively
priced compared to rival companies and would have enabled us to
maximise the budget we had available at the time. In practice, the cost of
microarrays has come down considerably during the course of the study.
When we encountered problems with the CodeLink™ system in the latter stages of
the study, we then switched to Illumina® microarrays. The decision to use the
Illumina® arrays was based on the lower amount of starting material required and
cost. The Illumina® platform has been shown to provide good results from blood
RNA extracted using the PAXgene™ system (331).
An overview of the features of these two microarray platforms is outlined below.
CodeLink™ Human Whole Genome Bioarray (as described on the manufacturer's
website: www.appliedmicroarrays.com):
"CodeLink™ Human Whole Genome Bioarray is comprised of approximately 55,000
30-mer probes designed to conserved exons across the transcripts of targeted genes.
These 55,000 probes represent well-annotated, full length and partial human gene
sequences from major public databases. CodeLink™ Human Whole Genome
Bioarrays target most of the known and predictive genes of the human genome as it
is described today in the public domain."
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Illuming® Human Whole Genome Expression BeadChiy (as described on the
manufacturer's website: www.illumina.com):
"The HumanWG-6 v3.0 Expression BeadChip contains six arrays on a single
BeadChip, each with >48,000 probes derived from human genes in the NCBI RefSeq
and UniGene databases. Each array on the BeadChip provides genome-wide
transcriptional coverage of well-characterized genes, gene candidates, and splice
variants. The HumanWG-6 Expression BeadChips are arranged in an Array of
Arrays format, providing multiple arrays on each slide. The arrays are separated from
one another by a seal so that each array can be hybridized to a different sample; six
samples can than be interrogated simultaneously. A minimal amount of total RNA
(50-100 ng) is required for the single-round in-vitro transcription reaction."
The following section details the methods used for labelling, hybridisation and
scanning of the CodeLink™ arrays. I have not included methods for the Ilumina®
microarrays as this work was contracted out to an external laboratory.
Methods Used for CodeLink™ Microarrays
Described below are the CodeLink™ Microarray methods used for manual target
preparation and bioarray hybridisation and detection. During the duration of the
work on this project, the method for Manual Labelled cRNA Target Preparation was
amended slightly by the manufacturers - latterly this was carried out using the
CodeLink™ iExpress Assay Reagent Kit. The method for Bioarray Hybridisation
and Detection remained the same. In practice, only a handful of arrays were run




(From Amersham Biosciences documents: 63005459 {080074-00/Rev. AA/2004-
04} CodeLink Gene Expression System: Manual Labelled cRNA Target
Preparation 63005460 {080075-00/Rev. AA/2004-04) CodeLink Gene Expression
System: Single-Assay Bioarray Hybridization andDetection).
Day 1: Manual Tgreet Preparation
1. Quality and quantity of the RNA was measured as described in section A.
2.1 A working solution of bacterial control mRNA was prepared as follows:
a) 5 pi of each of the 0.1 pg/pl bacterial control mRNAs (araB, entF,
fixB, gnd, hisB and leuB) were mixed in a 2 ml tube by tapping and
then centrifuged for 5 seconds at more than 10,000 x g in order to
obtain a 16.7 ng/pl combined stock solution. This was divided into 3
pi aliquots and stored at -70 °C.
b) 3 pi of combined stock solution from a) above was mixed with 997 pi
of nuclease-free water by pipetting. This achieved a 50.2 pg/pl
combined spike dilution which was then centrifuged for 5 seconds at
more than 10,000 x g.
c) The working solution of bacterial control mRNA was achieved by
mixing 2 pi of the 50.2 pg/pl combined spike dilution from b) above
with 998 pi of nuclease-free water.
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2.2 Each RNA sample was prepared for manual target preparation by using the
maximum quantity ofmRNA that was possible to achieve the final volume of
12 jj.1 in the following:
X pg RNA + X pi bacterial control solution + 1 pi T7 oligo dT primer + Y pi nuclease free water = 12
2.3 This mix was then incubated at 70 °C in a thermal cycler for 10 minutes
followed immediately by 3 minutes on ice.
2.4 The tubes were centrifuged for 5 seconds to collect the samples at the base of
the tubes and then returned to ice.
2.5 While keeping the tubes containing the 12 pi on ice, the following was added
to each tube: 2 pi lOx first strand buffer, 4 pi 5 mM dNTP mix, 1 pi RNase
inhibitor and 1 pi reverse transcriptase to give a final volume of20 pi.
2.6 The tubes were incubated at 42 °C for 2 hours in an air incubator.
2.7 The tubes were centrifuged for 5 seconds to collect the samples at the bottom
of the tubes.
3.1 To each 20 pi first strand cDNA synthesis reaction mix from step 2.7 the
following was added: 63 pi nuclease-free water, 10 pi lOx second-strand
buffer, 4 pi 5 mM dNTP mix, 2 pi DNA polymerase mix and 1 pi RNase H
to give a final volume of 100 pi.
3.2 Mixing was performed by gently tapping the side of each tube and then each
tube was centrifuged for 5 seconds at over 10,000 x g. The tubes were then
incubated at 16 °C for 2 hours.
3.3 The tubes were centrifuged at maximum speed for 5 seconds to collect the
samples at the bottom of each tube. The samples were mixed gently by
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pipetting and then put on ice. On each occasion, step 4 proceeded directly
after step 3.3.
4.1 500 pi of Buffer PB were added to each of the the tubes from step 3.3 and
mixed gently by pipetting.
4.2 A QIAquick spin column for each sample was placed in a 2 ml collecting
tube.
4.3 The cDNA Buffer PB mix was pipetted into the QIAquick spin column.
4.4 The spin column was centrifuged at more than 10,000 x g for 30-60 seconds.
4.5 The flow through was discarded. 700 pi of Buffer RPE was added to the
columns and centrifuged at more than 10,000 x g for 30 seconds.
4.6 The flow though was discarded. The QIAquick spin column was placed in a
new 2 ml collecting tube and centrifuged at more than 10,000 x g for 1
minute.
4.7 The QIAquick column was placed in a clean 1.5 ml microcentrifuge tube.
4.8 30 pi of Buffer EB were pipetted onto the centre of the column membrane,
the column was left to stand at room temperature for 1 minute and then
centrifuged at more than 10,000 x g for 1 minute. Using the same elution
tube this step was repeated once to obtain 60 pi of eluate.
4.9 The cDNA was concentrated in a speedvac concentrator (medium heat) until
a final volume of less than or equal to 9.5 pi was achieved for each tube.
4.10 For each sample, the volume was checked and the volume of each made up to
9.5 pi if necessary with nuclease-free water.
5.1 In a separate tube, the following were added, in the order listed to make up
the IVT mixture: 4 pi of lOx T7 reaction buffer, 4 pi T7 ATP solution, 4pl T7
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GTP solution, 4 jj.1 T7 CTP solution, 3 pi T7 UTP solution, 7.5 pi 10 mM
biotin-11-UTP and 4 jj.1 lOx T7 enzyme mix to give a final volume of 30.5 pi.
5.2 The components of the IVT mixture were mixed by vortexing and then
centrifuged at more than 10,000 x g for 5 seconds. The IVT reaction mixture
(30.5 pi) was then added to each tube from step 4.10 and mixed by gentle
pipetting.
5.3 The reaction was incubated in an air incubator for 14 hours at 37 °C.
Day 2: Manual Target Preparation continued.
6.1 Working solutions ofBuffers RLT and RPE were prepared.
6.2 The IVT reaction tubes were centrifuged briefly to collect the sample at the
bottom of the tube. The sample volume was then adjusted to 100 pi by adding
60 pi of nuclease-free water.
6.3 350 pi ofBuffer RLT was added to the sample and mixed by pipetting.
6.4 250 pi of 100 % Ethanol was added to the sample and mixed by pipetting.
6.5 The sample (700 pi) was added to an RNeasy spin column in a 2 ml
collection tube. The column was centrifuged for 15 seconds at more than
8,000 x g.
6.6 The RNeasy column was transferred to a new 2 ml collection tube. 500 pi of
Buffer RPE were added to the column and the column centrifuged at more
than 8,000 x g for 15 seconds. The flow through was discarded and this wash
step repeated once.
6.7 The RNeasy column was placed in a new 2 ml collection tube and centrifuged
at more than 8,000 x g for 2 minutes to dry the membrane.
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6.8 The RNeasy column was transferred into a new 1.5 ml microcentrifuge tube.
50 pi of nuclease-free water was pipetted directly onto the column membrane.
6.9 The column was left at room temperature for 10 minutes and centrifuged at
more than 8,000 x g for 1 minute.
6.10 Using the same elution tube, a further 50 pi of nuclease-free water were
pipetted onto the column membrane.
6.11 The column was left at room temperature for 10 minutes and then centrifuged
at more than 8,000 x g for 2 minutes.
6.12 The column was removed and the eluate mixed by tapping the side of the
tube.
6.13 In each case the tube was moved directly into step 7.
7.1 cRNA quality and A26o:A28o ratio were measured without dilution using 1.5 pi
of cRNA from step 7 in a nanodrop spectrophotometer.
7.2 Quantity and quality of cRNA were obtained using the nanodrop data and
samples of sufficient quantity with A26o:A28o ratio of 1.8-2.1 were taken
forward into the fragmentation and hybridisation stages.
Day 2 continued: Bioarray Hybridisation and Detection
1.1 For each bioarray to be loaded, 10 pg of cRNA from step 6.13 above was made
up to a volume of 20 pi with nuclease-free water.
1.2 5 pi of 5x fragmentation buffer was added. Each tube was placed in a thermal
cycler set to 94 °C and heated for 20 minutes using the heated lid feature.
1.3 The tubes were then cooled towards 0 °C in the thermal cycler for at least 5
minutes and as they did not reach 0 °C were placed on ice for 5 minutes.
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2.1 The shaker incubator temperature was set to 37 °C and prepared for taking the
12 slide shaker-tray.
2.2 Each cRNA sample was transferred into a 1.5 ml microcentrifuge tube. For
each bioarray to be processed a 260 pi hybridisation solution was prepared as
follows: 78 pi of hybridisation buffer component A, 130 pi of hybridisation
buffer component B, 27 pi of nuclease-free water were added to the 25 pi of
fragmented cRNA (10 pg) from step 1.
2.3 The solution was vortexed for 5 seconds at maximum speed. The hybridisation
mixture was incubated at 90 °C for 5 minutes to denature the cRNA.
2.4 The tubes were cooled on ice for at least 5 and a maximum of 30 minutes
(Bioarrays were loaded within 30 minutes).
3.1 The 12 slide shaker-tray was placed on a level surface. The bioarrays were
placed in the shaker-tray with the input-output ports face up.
3.2 The hybridisation reaction mixture was vortexed for 5 seconds at maximum
speed. The tubes were centrifuged briefly to gather the liquid at the bottom of
the tube and placed back on ice.
3.3 For each Bioarray chamber, 250 pi was drawn into a 1 ml wide-bore pipette tip.
The pipette tip containing the hybridization solution was placed over an array
input port and pressed in until the tip formed a seal with the chamber.
3.4 The entire sample was injected slowly into the Flexchamber without using the
blowout feature of the pipettor. When the Flexchamber was full, pressure was
maintained on the pipettor using the right hand, the left hand held down the
bioarray (over the label) and the pipette was removed from the import port. Any
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excess fluid around the port was aspirated with the pipette and any residual fluid
blotted up with a lint-free wipe (without touching the port).
3.5 After all the Bioarrays were loaded, the ports were sealed using sealing strips
and the port-sealing tool.
4.1 The 12 slide shaker-tray was fixed securely into the shaker incubator, ports
facing up.
4.2 The shaker speed was set at 300 rpm and the slides were incubated for 21 hours
at 37 *C.
4.3 In preparation for the next step, a large reagent reservoir was filled with 240 ml
of filtered 0.75 x TNT Buffer. The reservoir was covered and incubated
overnight at 46 °C.
Day 3: Bioarray Hybridisation and Detection Continued.
5.1 Each slot of the medium reagent reservoir was filled with 13 ml of filtered 0.75
x TNT Buffer. The Bioarray rack was placed in the reservoir and left at room
temperature.
5.2 The 12 slide shaker-tray was removed from the shaker incubator and placed on a
level surface.
5.3 The first Bioarray to be processed was placed into the Flex Chamber removal
tool.
5.4 The Flex Chamber was removed by lifting the tab and slowly pulling it back at
a 60 ° angle.
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5.5 The Bioarray was place into a slot of the Bioarray rack in the medium reservoir
containing the 0.75 X TNT Buffer. The Bioarray position tool (tooth side down)
was used to ensure Bioarray slide was correctly positioned.
5.6 The Flex Chamber removal tool was rinsed with 0.75 x TNT Buffer after each
Bioarray. The medium reagent reservoir was kept at room temperature until all
of the Bioarrays had been processed.
5.7 Steps 5.3 - 5.6 were repeated for each Bioarray to be processed.
5.8 The Bioarray rack with the Bioarrays inside was transferred into the medium
reagent reservoir containing the 0.75 x TNT Buffer that had been incubated at
46 °C overnight. The lid was replaced on the reservoir and the reservoir
incubated at 46 °C for exactly 1 hour.
6.1 Each slot in the small reagent reservoir was filled with 3.5 ml of Cy5-
Streptavidin working solution. The reservoir was covered with a black lid and
left at room temperature.
6.2 The Bioarray rack was removed from the medium reservoir containing the 0.75
x TNT Buffer at 46 °C and placed in the small reagent reservoir containing the
Cy5-Streptavidin working solution. The reservoir was covered with the black
lid and incubated at room temperature for 30 minutes, covered from light with
additional foil.
6.3 During the incubation period for step 6.2 I filled the large reagent reservoirs
with 240 ml of 1 x TNT Buffer at room temperature.
6.4 After the 30 minute incubation period the Bioarray rack was removed from the
reservoir containing the Cy5-streptavidin working solution and transferred to
one of the large reservoirs containing 1 x TNT buffer. Following a gentle up-
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and-down agitation the arrays were incubated in the reservoir for 5 minutes at
room temperature covered from light.
6.5 The Bioarray rack was removed from the first large reservoir and place in the
second reservoir containing 1 x TNT buffer and gently agitated by moving up
and down. The Bioarrays were incubated at ambient temperature for 5 minutes
covered from light. This step was repeated with two additional large reservoirs
containing 1 x TNT buffer to give 3rd and 4th washes.
6.6 During the third wash, a large reagent reservoir was thoroughly rinsed with
distilled water and dried. It was then filled until completely full with 0.1 x
SCC/0.05 % Tween 20 solution.
6.7 After the 4th wash step, the Bioarray rack was transferred into the large
reagent reservoir containing the 0.1 x SCC/0.05 % Tween 20 solution. The
slides were incubated at room temperature for 30 seconds while continually
gently agitating up and down.
6.8 The Bioarray Rack was removed from the large reagent reservoir and the
bottom edges of the slides were blotted on absorbent paper towel. The slides
were removed from the Bioarray rack using the bioarray removal tool. The
Bioarrays were placed in metal slide racks for the centrifuge and centrifuged
at 2000 rpm with acceleration of 9, deceleration of 9 for 3 minutes. The
centrifuge used was an Eppendorf 581OR.
6.9 The dry bioarrays were protected from light until scanned (scanned straight
away).
6.10 The reservoirs were repeatedly rinsed with deionised water and inverted to
dry.
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6.11 The rack was washed thoroughly, rinsed with deionised water and air dried.
7.0 Scanning the CodeLink™ Bioarrays on an Agilent G2565 Microarray
Scanner:
7.1 While wearing gloves, the cover of the Agilent slide holder was opened and
the bioarray placed into the holder with the active bioarray surface facing up
and towards the cover. The cover was locked by gently pressing it down with
one thumb.
7.2 The slide holder was inserted into the carousel slot with the tapered end of the
holder facing towards the centre of the carousel. This was repeated for each
slide and the carousel cover was then closed.
7.3 The carousel was placed in the scanner.
7.4 The scanner was switched on and Agilent scan control was clicked.
7.5 The start and end slots were entered and edited for each slide.
7.6 The scan setting selected was a custom setting labelled Codelink with scan
area 67.2 x 21.6 mm, dye channel red, red PMT 100 % and scan resolution of
5 pm. (The only exceptions to this were where the original few CodeLink
slides were used as there was an issue with persistence of glue around the
perimeter of the array. For some of these slides the scan area was reduced to
62.1 x 18.5 mm in order to allow the scanner to read the array. This included
the entirety of the array and cut out only a margin of glass slide).
7.7 The output path was set to a designated folder in drive D.
7.8 The above values were checked and set.
7.9 Scanning was commenced by hitting "scan slots".
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Codelink™ Microarray Method (2)
(From Amersham CodeLink™ iExpress Assay Reagent Kit Product booklet:
codes 67601000AND).
1. The quality and quantity of total RNA starting material were assessed as
described in section A.
2.1 Bacterial controls were prepared using the "alternative" bacterial mRNA
controls dilution method for use in target synthesis: single concentration
(found in appendix 10.2 of the iExpress Assay kit) as follows:
a) 5 pi of each of the 0.1 pg/pl bacterial control mRNAs (araB, entF,
fixB, gnd, hisB and leuB) were mixed in a 2 ml tube by tapping and
then centrifuged for 5 seconds at more than 10,000 x g in order to
obtain a 16.7 ng/pl combined stock solution. This was divided into 3
pi aliquots and stored at -70 °C.
b) 3 pi of combined stock solution from a) above was mixed with 997 pi
of nuclease-free water by pipetting. This achieved a 50.2 pg/pl
combined spike dilution which was then centrifuged for 5 seconds at
more than 10,000 x g.
c) The working solution of bacterial control mRNA was achieved by
mixing 2 pi of the 50.2 pg/pl combined spike dilution from b) above
with 998 pi of nuclease-free water.
Please note that this method of bacterial control preparation is identical to that in
the original method so as to maintain consistency, i.e. the dynamic method
described in the updated protocol was not used.
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2.2 Each total RNA sample was prepared for target preparation as follows: by
using the maximum quantity of mRNA that was possible to achieve the final
volume of 12 pi in the following:
X pg RNA + X pi bacterial control solution + 1 pi T7 oligo dT primer + Y pi nuclease free water = 12
2.3 This mix was then incubated at 70 °C in a thermal cycler for 10 minutes
followed immediately by 3 minutes on ice.
2.4 The tubes were centrifuged for 5 seconds to collect the samples at the base of
the tubes and then returned to ice.
2.5 While keeping the tubes containing the 12 pi on ice, the following was added
to each tube: 2 pi lOx first strand buffer, 4 pi 5 mM dNTP mix, 1 pi RNase
inhibitor and 1 pi ArrayScript to give a final volume of 20 pi.
2.6 The tubes were centrifuged for 5 seconds at full speed to collect the sample in
the bottom of the tube and then incubated at 42 °C for 2 hours in an air
incubator.
2.7 The tubes were centrifuged for 5 seconds to collect the samples at the bottom
of the tubes.
2.8 The tubes were placed on ice and second-strand cDNA synthesis was
commenced without delay.
3.1 To each 20 pi first strand cDNA synthesis reaction mix from step 2.7 the
following was added: 63 pi nuclease-free water, 10 pi lOx second-strand
buffer, 4 pi 5 mM dNTP mix, 2 pi DNA polymerase mix and 1 pi RNase H to
give a final volume of 100 pi.
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3.2 Mixing was performed by gently tapping the side of each tube and then each
tube was centrifuged for 5 seconds at over 10,000 x g. The tubes were then
incubated at 16 °C for 2 hours.
3.3 The tubes were transferred to ice and taken directly forward to the
purification of double-stranded cDNA steps.
4.0 The nuclease-free water was pre-heated to 50-55 °C and checks to ensure
that the Wash Buffer had already been prepared were made.
4.1 250 pi of cDNA Binding Buffer was added to each tube of cDNA from step
3.3 above and mixed by gentle pipetting.
4.2 When each cDNA filter cartridge was firmly placed in a wash tube, the
cDNA sample/cDNA Binding Buffer mixture from section 4.1 was pipetted
into the centre of each cDNA filter cartridge. The cartridges were then sealed
with the tube caps.
4.3 The spin columns were then centrifuged at 10,000 x g for 1 minute.
4.4 The flow-through was discarded and the cDNA filter cartridges replaced in
wash tubes.
4.5 In order to wash, 500 pi of Wash Buffer was added to each cartridge, each
cartridge sealed and then centrifuged at 10,000 x g for 1 minute.
4.6 The flow-through was discarded. The cDNA filter cartridges were placed in
wash tubes, sealed and centrifuged at 10,000 x g for 1 minute to dry the
column.
4.7 The cDNA filter cartridges were transferred to cDNA elution tubes.
4.8 To elute the cDNA, 12 pi of pre-heated nuclease-free water was pipetted onto
the centre of each cDNA filter cartridge filter. The cartridges were sealed
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and left at room temperature for 2 minutes before being centrifuged at 10,000
x g for 1.5 minutes.
4.9 The elution step in 4.8 was repeated with a further 12 pi of pre-heated
nuclease-free water added to each cartridge filter. This was to generate 20 pi
of eluate from each cartridge.
4.10 The eluate was carried directly to the IVT section.
5.1 The IVT mixture for each sample was made by adding the following
components in the order listed: 12 pi biotin-NTP mix, 4 pi 1 Ox T7 reaction
buffer and 4 pi lOx T7 enzyme mix to give a final volume of 20 pi per
reaction. (Where a master-mix was used for multiple reactions: the volume
of each reagent was multiplied by the number of reactions plus an extra 5 %).
5.2 The components of the IVT mixture were mixed by gentle vortexing and the
tube was centrifuged to collect the reagents at the bottom of the tube. The
tube was then placed on ice.
5.3 Each cDNA sample from 4.10 was measured using a pipette to ensure that it
was exactly 20 pi and, if not, was made up to 20 pi with nuclease-free water.
20 pi of IVT reaction mixture from step 5.2 was then pipetted into each of the
tubes containing cDNA. Mixing was ensured by gentle pipetting followed by
gently flicking the tube several times. The tubes were then centrifuged
briefly at full speed to collect the reagents at the bottom of the tube.
5.4 The reaction was then incubated in a 37 °C air incubator for 14 hours.
6.0 The nuclease-free water was preheated to 50-60 °C for at least 10 minutes
before RNA purification.
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6.1 cRNA filter cartridges, one for each sample to be purified, were placed into
cRNA collection tubes.
6.2 The IVT reaction volume from step 5.4 was then adjusted to 100 pi by adding
60 pi of room temperature nuclease-free water. This was mixed thoroughly
by gentle vortexing. Each tube was then centrifuged briefly to collect the
contents at the bottom of the tube.
6.3 350 pi of cRNA binding buffer was added to each sample.
6.4 Without delay, 250 pi of 100 % ethanol was added to each reaction sample
and mixed well by pipetting.
6.5 Without delay, each sample (700 pi) was applied to a cRNA filter cartridge in
a collection tube. The tubes were sealed and centrifuged for 1 minute at
10,000 x g. It was ensured that all mixture had passed through the filter.
6.6 The flow-through was discarded and the cRNA filter cartridges placed in
collection tubes. 650 pi of wash buffer was added to each cartridge, sealed
and centrifuged for 1 minute at 10,000 x g, ensuring that all the wash buffer
had passed through the filter.
6.7 The flow-through was discarded and the filter cartridges placed in collection
tubes. Each cartridge was re-sealed and centrifuged once more at 10,000 x g
for 1 minute to dry the cartridges.
6.8 Each cRNA filter cartridge was transferred to a new cRNA collection tube
and 100 pi of pre-heated nuclease-ffee water (50-60 °C) was pipetted directly
onto the centre of each cRNA filter cartridge membrane (without touching the
membrane).
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6.9 The filter cartridges were sealed with the lids and incubated at room
temperature for 2 minutes. The cRNA was then eluted by centrifugation at
10,000 x g for 1.5 minutes.
6.10 The columns were then removed. The collection tubes, containing the
labelled cRNA were tapped gently to mix.
6.11 cRNA quality, concentration and purity was then assessed.
7.1 Concentration was measured using the A260 value obtained using a nanodrop
spectrophotometer (undiluted). Although generally not necessary, were any
sample found to have cRNA concentration <0.5 pg/pl, it would be
concentrated in a SpeedVac concentrator before fragmentation.
7.2 Purity was measured using the A26o:A28o ratio obtained using a nanodrop
spectrophotometer. Samples with A26o:A2go ratio of 1.8-2.1 were taken
forward for hybridisation.
7.3 For some samples, size distribution was examined by running the labelled
cRNA on an Agilent bioanalyzer.
Bioarray Hybridisation and Detection was carried out as described in method 1
above. Microarray scanning was carried out as described as in method 1 above.
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Short Notes on Globin Reduction
Globin genes have been described as interfering with the discovery of biomarkers in
whole blood (332). Globin mRNA transcripts have been estimated to constitute a
significant proportion of whole blood mRNA. It is thought that these transcripts
decrease the sensitivity of detection of the other mRNAs of interest when using
microarray technology (333, 334). Indeed, some literature suggests that there is
reduction in percent present cells and increased variability when looking at
microarray data from whole blood mRNA compared to that extracted directly from
white blood cells or compared to protocols incorporating globin reduction (333-335).
Furthermore, globin reduction techniques have been put forward as ways to reduce
this variability and to increase the sensitivity of detecting less abundant mRNAs
(333-335).
We did not use globin reduction methods in our microarray studies for the following
reasons:
• The globin reduction methods on the market were all targeted towards
reduction of adult globin mRNA whereas the haemoglobin in neonatal blood
is predominantly fetal haemoglobin. The effectiveness of globin reduction
methods on neonatal samples was therefore in doubt.
• I investigated the use of a globin reduction method on one of the neonatal
samples, comparing microarrays of the sample with and without globin
reduction. This experiment did not provide evidence that globin reduction
would be useful in neonatal samples. Rather, there was the suggestion that
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omitting the globin reduction step may actually give superior results. I have
provided the details of this experiment in appendix 1 for reference.
• The additional time and cost involved in incorporating a globin reduction step
was felt not to be worthwhile given the doubts over the benefits in neonatal
blood.








When planning gene expression profiling experiments it is very important to pay due
attention to the methods being used. It is known that sample handling conditions
can effect gene expression and therefore minimisation of variation and establishment
of sample handling protocols are paramount (194, 323, 326, 327). The overall aim of
this study was to use neonatal blood in gene expressing profiling work. At the time
of initial study planning and commencement of sampling there was no data in the
literature regarding the use of neonatal whole blood in this respect. It was therefore
necessary, not only to optimise RNA sampling and extraction technique but also to
show that it was possible to extract sufficient amounts of RNA of high enough
quality from small samples of neonatal blood to use for microarray work.
In order to achieve robust, reliable, reproducible results from gene expression
profiling experiments, it is important to minimise any sources of technical variability.
There is evidence that differences in blood collection and preparation can cause ex-
vivo induction of cytokine mRNA (336). For example, anticoagulants can cause ex-
vivo changes in cytokine production (329) and adherence to plastic blood collection
tubes may induce pro-inflammatory cytokines (329). There can be also be changes
in gene expression depending on storage temperature and duration of storage of
whole blood - rapid lysis of whole blood or immediate RNA isolation after sampling
is an important consideration (337, 338). The method of RNA isolation chosen is a
critical source of variability (339). Standardisation of methodology for a study is
therefore vital.
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In order to achieve robust, high quality microarray data, the input RNA should be of
the highest quality possible. High quality RNA has minimal degradation and
minimal contamination with DNA or chemicals used in the extraction process. The
work presented in this chapter was carried out in order to find a suitable method of
RNA extraction from neonatal whole blood, aiming for the highest possible quality
of RNA for use in microarray work. I also present work on optimising sample
storage conditions, again with the aims of achieving consistency of method and of
having the best quality of RNA possible for microarray work. A26o'A2w ratios,
Bioanalyzer graph tracings and RIN values are used as measures of quality. A brief
explanation of these can be found on pages 93 and 98 of chapter 2.
Yield of RNA is also examined for the experiments described in this chapter. The
aim was find a method that consistently yielded sufficient RNA to carry out
microarray work using the CodeLink™ arrays. If the minimum amount of RNA
required for input into the CodeLink™ microarray protocol is taken at 200 ng (in a




The overall aim of this section was to optimise methodology for sample handling and
RNA extraction from neonatal blood samples in order to obtain high quality RNA for
microarray work. I therefore set out to:
• Determine an optimal blood collection tube at the point of clinical sampling
to maximise the quality and quantity ofRNA obtained. (3.1)
• Determine an optimal method ofRNA extraction in order to maximise quality
and quantity ofRNA obtained. (3.2, 3.3, 3.9)
• Examine the volume of neonatal blood required in order to consistently
obtain RNA of high quality and sufficient quantity to use in microarray
experiments. (3.4)
• Determine optimum range of incubation period for neonatal blood in
PAXgene™ Blood RNA Tubes at room temperature to maximise RNA
quality and yield. (3.5, 3.6)
• Examine the feasibility of storing neonatal blood in PAXgene™ Blood RNA
tubes at various temperatures and for various durations of time and to
determine the effects on quality and quantity ofRNA obtained. (3.7, 3.8)
• Assess a filter-paper based technique as a potential way of collecting blood
for RNA extraction. (3.9)
All work in this section was carried out in its entirety by myself, Claire L Smith.
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Methods
The Use of Umbilical Cord Blood
For the work in chapter 3, umbilical cord blood was used as a surrogate for neonatal
blood. It would neither have been practical nor ethical to obtain the volumes of
blood required for comparison from individual neonates in these studies. Umbilical
cord blood is fetal blood and would logically be identical to neonatal blood in the
initial stages of postnatal life. The method of umbilical cord blood sampling used
throughout this chapter is described in chapter 2 (page 61).
Consent
Informed maternal consent for umbilical cord blood sampling was taken for each
sample. In the initial studies samples were taken following elective caesarean
sections, i.e. the mothers were not in labour. In these cases the prospective mothers
were consented prior to delivery. Later studies used samples from normal, assisted
and emergency deliveries. In these circumstances the mother was approached prior
to delivery, i.e. during labour and verbal assent in principle for sampling the cord
blood was obtained. The samples were collected and prepared as normal. These
mothers were approached again after they had recovered from delivery and informed
written consent was obtained at that time to confirm participation in the study. In the
event of the mother declining consent after samples had already been taken, any such
samples would have been destroyed. In fact consent was granted by all of these




In each of the sections that follow, the methods used are stated. The methods
themselves are described in chapter 2. Extracted RNA was stored at -80 °C until
further analysis could be carried out in batches.
Assessment of RNA Quality and Quantity
For all RNA extracted in this chapter, RNA quantity was assessed by
spectrophotometry and quality by running on the Agilent Bioanalyzer and examining
A260"A280 ratios- A26o:A28o ratios were calculated using the A260 and A280 values
obtained from the spectrophotometer. The methods for these are described on pages
89 to 98 (chapter 2).
Statistics
In each section, statistical significance of differences between means for A26o:A28o
ratio, yield of RNA and RIN were calculated using paired t-testing within the
statistical software package SPSS version 12.
Results
The results of each experiment are laid out in the nine sections that follow. I have
included a short background note and listed the methods used in each section so that
this information is in close proximity to the results presented. A discussion of all of
the findings in context of the literature and overall conclusions for this chapter follow
these sections.
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3.1: Optimisation of Blood Collection Tube-
Background
Choice of blood collection tube was an important consideration. Essentially, the
requirement was for a collection tube that enabled extraction of consistently high
quality RNA of sufficient quantity that would enable microarray experiments to be
run. In addition, any tube needed to be easy to use and safe for use in a clinical
setting. I chose to examine three different neonatal blood bottles that were regularly
used on the neonatal unit - lithium heparin, EDTA and sodium citrate. Another
factor that needed to be considered was that any in vitro alteration of RNA
expression profile needed to be minimised, for example it is known that
anticoagulant can lead to changes in RNA expression (323). I therefore included
samples placed directly into TRIzol® LS reagent and samples injected directly into
PAXgene™ Blood RNA tubes. TRIzol® LS reagent is commonly used in nucleic
acid extractions in laboratory practise. The PAXgene™ Blood RNA tubes contain a
proprietary agent which is described as stabilising the RNA at the point of injection
into the tube.
Method Overview
For each of nine umbilical cords sampled, aliquots were injected immediately into
one each of neonatal blood tubes containing Lithium Heparin and Sodium Citrate
and into two tubes containing EDTA. All tubes were filled until full - to the fill line
or as otherwise described by the manufacturer. Blood was also injected directly into
a PAXgene™ blood RNA tube - the intention was to inject 2.5 ml on each occasion.
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A further two aliquots of 0.25 ml of blood were each diluted with 0.25 ml of RNase-
free water and each water/blood aliquot added directly into a micro-centrifuge tube
containing 1.5 ml of TRIzol® LS reagent. With the exception of the PAXgene™
tubes, 0.5 ml of blood from each of the blood collection tubes was processed
immediately using the TRIzol® LS extraction method followed by the QIAamp® on-
column clean up method as described on pages 67 and 69. The PAXgene™ tubes
were processed using the PAXgene™ blood RNA extraction kits after at least 2
hours incubation at room temperature (page 76).
Results
The raw data for each sample can be found in table 3.1.1 along with some
explanatory notes in appendix 2. Figure 3.1.1 displays graphically the yield,
A26o:A28o ratio and RIN values for each blood collection tube. Total yield is
displayed on the purple line graph for each collection tube with an additional blue
line displaying yield per 0.5ml of blood for the PAXgene™ tube. The A26o:A28o ratio
is displayed as a red line graph with the y-axis on the right. The pastel bars represent
the RIN values for each collection tube.
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Figure 3.1.1: Yield, A260:A280 and RIN for each blood collection tube.
Heparin Citrate
Blood Collection Tube
Table 3.1.2: Mean values ofA260:A280, RNA yield per 0.5 ml
















































Table 3.1.2 shows the mean and range of values obtained with each collection tube
for A26o:A28o ratio, yield ofRNA obtained per 0.5 ml of blood and RIN values. From
this table all of the mean A26o:A28o ratios are within the target range of 1.8-2.2 with
PAXgene™ being the only method to have all ratios in the desired range. All
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samples yielded sufficient RNA for microarray work with PAXgene™ having the
lowest yield and TRIzol® LS the highest. PAXgene™ had the highest mean and
best range ofRIN values.
Table 3.1.3: Values ofstatistical significance of difference
between means ofA260:A280 ratio, Yield ofRNA per 0.5 ml
and RIN for pairs of blood collection tubes (p values).
A260:A280 ratio RNA per 0.5 ml ( pg) RIN
EDTA-Li Heparin 0.072 0.057 0.026
EDTA-Na Citrate 0.329 0.760 0.717
EDTA-TRIZol® LS 0.325 0.032 0.022
EDTA-PAXgene™ 0.149 0.489 0.002
LiHep-Na Citrate 0.050 0.064 0.034
LiHep-TRIzoKDLS 0.036 0.151 0.388
LiHep-PAXgene™ 0.937 0.332 <0.001
Na Citrate-TRIzoKDLS 0.903 0.063 0.046
Na Citrate-PAXgene™ 0.032 0.571 0.010
TRIzol®LS-PAXgene™ 0.025 0.035 0.011
Table 3.1.3 displays values of statistical significance when comparing means of each
outcome studied for each pair of blood tubes. Taking p values of less than 0.05 as
significant, the PAXgene™ tube gave statistically significantly higher A26o:A2go
ratios than either TRIzol®LS or sodium citrate, and Lithium heparin tubes gave
statistically higher ratios than TRIzol®LS. In terms of yield, TRIzol®LS gave the
highest yield per 0.5 ml but this was only statistically significant when compared to
EDTA or PAXgene™ tubes. When looking at the RIN values obtained, the
PAXgene™ tubes gave statistically significantly higher RIN values than each of the
other blood collection tubes examined. For the other collection tubes, the
TRIzol®LS tube gave statistically higher RINs than EDTA or sodium citrate, and
Lithium heparin tubes gave statistically significantly higher RINs than EDTA or
sodium citrate. Figure 3.1.2. is a line sequence graph for the RIN values obtained
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from each blood collection tube. The samples 1 to 9 are on the x-axis and the RIN
values are on the y-axis. Each coloured line is a different blood collection tube. The
PAXgene™ tube, for example, is represented by the yellow line and for this line the
RIN can be seen to be between 8.3 and 10. The gap in the line is because there was
no RIN value obtained for PAXgene for sample 3. Similar line sequence graphs are
used in the other sections of this chapter. Bioanalyzer tracings of the RIN values can
be found in table 3.1.4 (a and b) in appendix 2.


















Higher quality RNA is obtained from blood collected into the PAXgene™ blood
RNA tube than blood collected into Lithium Heparin, Sodium Citrate, EDTA or
TRIzol®LS tubes. All samples had mean A26o:A28o ratios in the desired range with
only PAXgene™ having all ratios within the desired range. TRIzol®LS had the
highest yield of RNA but all samples were of sufficient yield to use for microarray
work. In order to obtain the best quality of RNA for microarray analysis the
PAXgene™ RNA collection tube is therefore the best collection tube of those
studied.
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3.2: Optimisation of RNA Extraction Method Part 1.
Background
Once the most promising blood collection tube had been identified, the next step was
to compare RNA extraction methods. The kits chosen were an example of a phenol-
guanidine isothiocyanate based extraction (TRIzol®LS), an example of an on-
column method (QIAamp® RNA Blood Mini Kit), an example of a proprietary RNA
stabilisation agent and extraction kit (PAXgene™ Blood RNA Kit). In addition, the
phenol-guanidine isothiocyanate extraction was combined with the on-column
method's clean up protocol.
Methods
For each of seven umbilical cords, aliquots of blood were collected into EDTA tubes
(at least three 1 ml tubes) and 2.5 ml of blood collected into a PAXgene™ blood
RNA collection tube. For each sample, one each of a TRIzol®LS extraction,
QIAamp® extraction, a TRIzol®LS with QIAamp® on-column clean-up and a
PAXgene™ extraction was performed (pages 67 to 76).
Results
The raw data for each sample according to method of RNA extraction can be found
in table 3.2.1 in appendix 2. This data is displayed graphically in figure 3.2.1,
which displays yield, A26o:A28o and RIN for each extraction method. Total yield is
displayed on the purple line graph for each extraction method with an additional blue
line displaying yield per 0.5ml of blood for the PAXgene™ tube. The A26o:A28o ratio
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is displayed as a red line graph with the y-axis on the right. The pastel bars represent



















Figure 3.2.1: RNA Yield, A260:A280 & RIN for Each Extraction




Table 3.2.2 displays the mean values for A26o:A28o ratio, RNA yield per 0.5 ml of
blood and RIN for each method ofRNA extraction. The means for both the original
and the repeat A26o:A28o ratios are displayed for completeness (see note
accompanying table 3.2.1 in appendix 2 for explanation).
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Table 3.2.2: Mean values ofA260:A280, RNA yield per 0.5 ml ofblood















































The Analyst article table (publication arising from this work) used the original spec values for the
a260/a280 but repeat specs were done. The repeat ratios have now been added to the tables. The
repeat values were the ones used to calculate the yield of RNA (verified). RIN values have also been
checked.
Table 3.2.3: Values ofstatistical significance of difference between
means ofA260:A280 ratio, Yield of RNA per 0.5 ml and RIN for pairs of









QIAamp®-TRIzol®LS 0.312 0.028 0.002 0.316
QIAamp®-TRIzol®LS and QIAamp® 0.364 0.772 0.002 0.090
QIAamp®-PAXgene™ 0.404 0.001 0.010 0.100
TRIzol®LS-TRIzol®LS and QIAamp® 0.101 0.101 0.014 0.006
TRIzol®LS-PAXgene™ 0.002 0.002 0.003 0.001
TRIzol®LS and QIAamp®-
PAXgene™
0.348 0.348 0.003 0.371
Table 3.2.3 displays the values of statistical significance when comparing difference
of means of A26o:A280 ratio, yield of RNA per 0.5 ml and RIN for each pair of
extraction methods. Looking at both Tables 3.2.2 and 3.2.3 it can be seen that in
terms of yield the TRIzol®LS method had significantly greater yields of RNA per
0.5 ml of blood than the QIAamp® method, the TRIzol®LS method followed by the
QIAamp®-on-column clean up and the PAXgene™ method. In addition the
TRIzol®LS method followed by QIAamp®-on-column clean up had significantly
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greater yields than the QIAamp® method alone and the PAXgene™ method. The
PAXgene™ method yielded significantly greater RNA than the QIAamp® method.
In terms of RIN values, although the PAXgene™ values were generally higher than
those for each of the other methods, this difference was only statistically significant
when comparing with the TRIzol®LS values. The only other statistically significant
difference between groups with respect to RIN values was that TRIzol®LS with
QIAamp®-on-column clean-up had higher values than those of TRJzol®LS alone.
In terms of A26o:A28o ratios the only statistically significant differences were that the
PAXgene™ values were higher (but not too high and therefore better) than those
from TRIzol®LS and from QIAamp®, also QIAamp® gave statistically higher
values than TRIzol®LS. Figure 3.2.2 gives a pictorial representation of the trends
towards PAXgene™ having the best and most consistent A26o:A28o ratio, Trizol®LS
having the greatest yield of RNA and PAXgene™ having the trend for highest RIN.
Bioanalyzer graphs and RIN values for each sample can be found in table 3.2.4 in
appendix 2.
Conclusions
From the results obtained in this section PAXgene™ extracted samples had the
highest RIN values when compared to each of the other methods. Although this only
reached statistical significance when compared with the TRIzol®LS method, I was
satisfied that the trend towards better RIN values displayed was convincing enough
to choose the PAXgene™ method as my method of choice for extracting RNA in
future stages of the study. The consistency of the good A260:A280 ratios obtained with
PAXgene™ further consolidated this view. In terms of yield, TRIzol®LS was
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clearly the best but I was happy that PAXgene™ consistently provided sufficient
yield of RNA for use in microarray experiments. As the main priority was to
maximise quality of RNA obtained, and as sufficient yield could be obtained,
PAXgene™ was chosen to be taken forward to use in the next stages of the study as
the optimum extraction method.
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3.3. Optimisation of RNA Extraction Method Part 2 -
PAXqene™ vs MAGAzorb®.
Background
After study 3.2 had been completed, I came across MAGAzorb®, an RNA extraction
kit newly available in the UK that used a magnetic bead separation technology that
did not require any centrifugation steps. As this was an entirely different method to
those tried in 3.2, it was decided that this would be examined further. PAXgene™
blood RNA extraction was compared with MAGAzorb® RNA extraction.
Method
The MAGAzorb® kit contained enough materials for 12 extractions. 6 umbilical
cord samples were used for comparison. These were collected as described
previously. For the first 2 samples, blood was collected into EDTA, lithium heparin,
sodium citrate and fluoride oxalate tubes as well as the PAXgene™ tube. This was
to gain an idea of optimal blood collection tube for the method. The 4 subsequent
cord blood samples were injected into EDTA tubes and PAXgene™ tubes only.
While appreciating that such a small sample number would not give statistical
assurance of best method if they were all similar, I wished only to get an idea if this
method could rival the PAXgene™ method. Had the PAXgene™ and MAGAzorb®
methods been shown to be equally good, I would have optimised the MAGAzorb®
method further and carried out further comparisons
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The cord blood samples in their collection tubes were taken directly to the lab and
the PAXgene samples were left to sit on the bench for 2 hours. The MAGAzorb®
extractions were carried out straight away. The PAXgene™ and MAGAzorb®
RNA extraction methods and methods for assessment of RNA quality and quantity
used are described in chapter 2 (pages 76 and 80).
Results
Table 3.3.1: Raw values for samples according to RNA extraction











cs25 MAGAzorb® EDTA 1.56 0.042 3.99 9.98 1.8
cs25 PAXgene™ 1.29 0.022 2.91 2.91 9.4
cs26 MAGAzorb® EDTA 1.77 0.046 4.37 10.93 1.4
cs26 MAGAzorb® Li Heparin 1.81 0.049 4.66 11.65 1.7
cs26 MAGAzorb® Na Citrate 2.04 0.049 4.66 11.65 1.1
cs26 MAGAzorb® Fl Oxalate 1.73 0.057 5.42 13.55 1
cs26 PAXgene™ 1.9 0.019 2.51 2.51 8.5
cs27 MAGAzorb® EDTA 1.77 0.078 7.41 18.56 1
cs27 MAGAzorb® Li Heparin 2.08 0.05 4.75 11.88 2.1
cs27 MAGAzorb® Na Citrate 1.85 0.048 4.56 11.4 1.7
cs27 MAGAzorb® Fl Oxalate 1.93 0.081 7.7 19.25 1
cs27 PAXgene™ 2.32 0.044 5.81 5.81 9
cs28 MAGAzorb® EDTA 1.66 0.058 5.51 13.78 1.9
cs28 PAXgene™ 2 0.016 2.11 2.11 8.3
cs29 MAGAzorb® EDTA 1.8 0.079 7.51 18.78 2.1
cs29 PAXgene™ 1.92 0.023 3.04 3.04 9.3
cs30 MAGAzorb® EDTA 1.85 0.074 7.03 17.58 2.9
cs30 PAXgene™ 2.29 0.016 2.11 2.11 n/a
cs34 MAGAzorb® EDTA 1.53 0.092 8.74 21.85 2.3
cs34 PAXgene™ 1.31 0.017 2.24 2.24 8.6
Table 3.3.1 displays the raw data for samples according to collection tube and RNA
extraction method. Table 3.3.2 shows the mean and range of values obtained for
A26f>A28o ratio, yield of RNA per 0.5ml of blood sampled and RIN values. For the
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MAGAzorb® extractions, the "0.5 ml of blood" is derived rather than being an
actual value as only 200 microlitres of blood was used for each extraction.
Table 3.3.2: Mean values ofA260:A280, RNA yield per 0.5 ml of



























































*For the PAXgene tube that had RIN value of 0 after RNA extraction at 2 hours,
another tube was processed at 24 hours and the RIN value was 9.4, if this was
factored in instead of the 0: mean RIN= 8.9.
From the data in table 3.3.2 and from the significance values displayed in table 3.3.3,
there is no significant difference between the A260-A280 ratios obtained with each
extraction method. On looking at the data for RNA yield, the MAGAzorb® RNA
yields from an EDTA collection tube were significantly higher than the yields using
PAXgene™ system. Although not reaching statistical significance, all of the other
collection tubes with MAGAzorb® extractions achieved higher yields of RNA than
PAXgene™ per 0.5 ml of blood. When looking at the RIN values however it is clear
that the MAGAzorb® samples were of much poorer quality than the PAXgene™
samples. This difference in quality was highly statistically significant when
comparing PAXgene™ with the MAGAzorb® extracted samples collected in EDTA,
Lithium Heparin or Sodium Citrate tubes. Although statistically the difference in
RIN obtained using MAGAzorb® extracted samples collected in Fluoride Oxalate
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was not significant (0.021), the results suggest that the RNA obtained using
PAXgene™ was of better quality. Of note, one PAXgene™ sample did not give a
reading for RIN on the Bioanalyzer - the graph is displayed in table 3.3.4 (appendix
2). For this same sample as part of another experiment, a further PAXgene™ tube
was incubated at room temperature for 24 hours and gave a RIN value of 9.4. If this
value was used in place of the unreadable RIN, the mean RIN for PAXgene™ would
rise to 8.9 which would only serve to strengthen the evidence that PAXgene™ yields
higher quality RNA.
Table 3.3.3: Values of statistical significance of differ
means of A260.A280 ratio, Yield of RNA per 0.5 ml an





per 0.5 ml of
blood
RIN
MAGAzorb® EDTA - MAGAzorb® Li Heparin 0.418 0.568 0.330
MAGAzorb® EDTA - MAGAzorb® Na Citrate 0.317 0.564 0.758
MAGAzorb® EDTA - MAGAzorb® Fi Oxalate 0.656 0.336 0.500
MAGAzorb® EDTA - PAXgene™ 0.239 <0.001 <0.001
MAGAzorb® Li Heparin - MAGAzorb® Na Citrate 1.000 0.500 0.126
MAGAzorb® Li Heparin - MAGAzorb® FI Oxalate 0.188 0.339 0.139
MAGAzorb® Li Heparin - PAXgene™ 0.272 0.127 0.005
MAGAzorb® Na Citrate - MAGAzorb® FI Oxalate 0.661 0.349 0.410
MAGAzorb® Na Citrate - PAXgene™ 0.684 0.151 0.004
MAGAzorb® FI Oxalate - PAXgene™ 0.238 0.062 0.021
Given the low sample numbers examined in this study, statistical testing should be
viewed with caution, the differences in RIN quality however are striking. Figure
3.3.1 illustrates the RIN values for each sample and method of extraction. These
give clear visual representations of the higher quality of RNA obtained using the
PAXgene™ method compared to the MAGAzorb® method when determining
quality using a Bioanalyzer. Bioanalyzer traces and RIN values for each sample can
be found in table 3.3.4 in appendix 2.
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The MAGAzorb® extracted samples performed uniformly poorly in terms of RIN
values, despite appearing to have acceptable A26<fA28o ratios and yields. It could be
argued that something within the MAGAzorb® extracted samples could be
interfering with the Bioanalyzer analysis. Bioanalyzer results are used to determine
suitability for running individual samples on microarray. The consistently poor
readings therefore ruled MAGAzorb® out as a viable RNA extraction method for
further use in this study.













RNA extracted using MAGAzorb® gave higher yields but consistently poor quality
RNA (as indicated by RINs) compared to PAXgene™. It was therefore decided to
continue using PAXgene™ for RNA extraction for this study.
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3.4: Volume of Blood Required
Most research utilising RNA from whole blood has been restricted to the use of adult
blood samples and it is only recently that data on the use of neonatal blood has begun
to emerge. There are differences that need to be considered in terms of composition
of the blood, for example the white cell count of neonatal blood is generally
considerably higher than in healthy adults. In addition, it is vital to look at the
volume of sample required if any test using neonatal blood is ever going to be
clinically practical. Validation studies carried out on behalf of PreAnalytiX generally
used 3 PAXgene blood RNA tubes per adult patient in order to get sufficient RNA
(337) to carry out microarray studies using the Affymetrix system. In other words
7.5 ml of blood per patient was required. The circulating blood volume of a term
neonate is around 75-85 ml/kg - adult volumes of blood for samples would clearly
not be practical and indeed would almost certainly be detrimental to the infants' well
being. It was therefore necessary to investigate the use of smaller blood volumes
using the PAXgene™ system.
PAXgene™ blood RNA tubes each contain a fixed volume of 6.9 ml RNA
stabilisation agent (I originally obtained this information directly from PreAnalytiX
as a personal communication; later it could also be found in the PAXgene™ Blood
RNA Tube product circular). The tubes are designed for use with a particular blood
collection system that leads to the tubes being filled with 2.5 ml of adult blood,
giving a ratio of 2.76 ml of stabilisation agent per ml of blood. I set out to determine
whether it was feasible to use smaller amounts of umbilical cord blood in each
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PAXgene™ tube (0.5 ml) compared with 2.5 ml of umbilical cord blood. In
addition, I pipetted aliquots of 0.69 ml of PAXgene™ RNA stabilisation agents from
the PAXgene™ blood RNA tubes into two 2 ml microcentrifuge tubes and added
0.25 ml of umbilical cord blood to each at the time of sampling (these two aliquots
were later merged). This was to explore the use of the same proportions of reagents
as those intended for the PAXgene™ tubes filled with 2.5 ml of blood but using the
smaller blood volume of 0.5 ml (reagents used in the subsequent extraction process
were also proportionately reduced).
Methods
Umbilical cord blood was sampled from seven umbilical cords as described
previously. For each sample, 2.5 ml was injected into a PAXgene™ blood RNA
tube, 0.5 ml was injected into another PAXgene™ blood RNA tube and aliquots of
0.25 ml were added to two microcentrifuge tubes each containing an 0.69 ml aliquot
of PAXgene™ blood RNA tube fluid. The samples were transported to the
laboratory and incubated, upright, for at least 2 hours.
For each PAXgene™ blood RNA tube, RNA extraction was performed as described
in chapter 2 (page 76). For the micro-centrifuge tubes containing RNA stabilisation
agent, the protocol was varied slightly in order to keep reagent ratios comparative.
The micro-centrifuge tubes were centrifuged in a Heraeus Biofuge Fresco set to
6,500 rpm for 10 minutes. The supernatant was then removed and 0.5 ml of RNAse
free water added to each tube. The tube was then vortexed thoroughly and
centrifuged for a further 10 minutes at 6,500 rpm. The entire supernatant was
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removed and discarded and then 180 microlitres of Buffer BR1 was added to each
tube. Mixing was achieved by repetitive pipetting followed by thorough vortexing.
The contents of both micro-centrifuge tubes were then pipetted into a single fresh 2
ml micro-centrifuge tube. From the point of addition of 300 microlitres of Buffer
BR2, the RNA extraction process continued as per the original protocol.
Note: From this study, it became apparent that 10 minutes of centrifugation after the
55 degree incubation step was not always sufficient to separate the debris adequately
to allow complete removal of the supernatant. I found that increasing the duration of
centrifugation was effective in leading to adequate separation. The length of
centrifugation was increased for each sample until separation was seen to take place
(the average time of centrifugation required was longer for the 2.5 ml samples in the
PAXgene™ tubes than either of the 0.5 ml sampling methods). The operating
instructions from the manufacturer have since been changed and now recommend
that where a water bath or heating block have been used the sample should be
vortexed for 30 seconds prior to centrifugation or alternatively to transfer the sample
into a QLAshredder™ spin column, centrifuge for 3 minutes at maximum speed then
to transfer the supernatant into a fresh microcentrifuge tube and proceed to the 10
minute centrifugation step as previously.
Results
From the raw data presented in table 3.4.1 and the mean values found in table 3.4.2 it
can be seen that all of the tubes had consistently good A26o:A28o ratios and from the
statistical significance values displayed in table 3.4.3 that there was no statistically
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significant difference between tubes in this respect. In addition, it can be seen as
expected that the greatest overall yields were obtained from the PAXgene™ tubes
with 2.5 ml of blood. When the amount of RNA per 0.5 ml of blood is considered,
the highest yields were obtained from 0.5 ml of blood in aliquots of PAXgene™
fluid, followed by 2.5 ml of blood in the PAXgene tube and were least for 0.5 ml of
blood in the PAXgene™ tube.
Table 3.4.1: Raw values for samples according to volume of blood
sampled and volume ofPAXgene™ RNA stabilisation agent













cslO 2.5 ml in PAXgene™ tube 2 0.43 56.76 11.35 7.1
cs10 0.5 ml in PAXgene™ tube 2.06 0.035 4.62 4.62 8.8
cs10
0.5 ml in aliquot of
PAXgene™ fluid
2.05 0.131 17.29 17.29 8.3
cs11 2.5 ml in PAXgene™ tube 1.98 0.631 83.29 16.66 5.5
cs11 0.5 ml in PAXgene™ tube 2 0.034 4.49 4.49 7.9
cs11
0.5 ml in aliquot of
PAXgene™ fluid
2.07 0.149 19.67 19.67 6.8
cs12 2.5 ml in PAXgene™ tube 1.96 0.167 22.04 4.41 8.2
cs12 0.5 ml in PAXgene™ tube 1.81 0.038 5.02 5.02 9.4
cs12
0.5 ml in aliquot of
PAXgene™fluid
1.88 0.062 8.18 8.18 8.6
cs13 2.5 ml in PAXgene™ tube 1.99 0.358 47.26 9.45 7.5
cs13 0.5 ml in PAXgene™ tube 2 0.07 9.24 9.24 9.4
cs13
0.5 ml in aliquot of
PAXgene™ fluid
1.92 0.123 16.24 16.24 8.5
cs14 2.5 ml in PAXgene™ tube 1.95 0.296 39.08 7.82 8.9
cs14 0.5 ml in PAXgene™ tube 2.14 0.045 5.94 5.94 9.7
cs14
0.5 ml in aliquot of
PAXgene™ fluid
2 0.112 14.78 14.78 9
cs15 2.5 ml in PAXgene™ tube 2.01 0.335 44.22 8.84 7.3
cs15 0.5 ml in PAXgene™ tube 1.83 0.044 5.81 5.81 9.3
cs15
0.5 ml in aliquot of
PAXgene™ fluid
2.12 0.104 13.73 13.73 7.9
cs16 2.5 ml in PAXgene™ tube 2 0.236 31.15 6.23 8
cs16 0.5 ml in PAXgene™ tube 2.05 0.043 5.68 5.68 8.3
cs16
0.5 ml in aliquot of
PAXgene™ fluid
2.11 0.078 10.30 10.30 8.3
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The difference in yields obtained per 0.5 ml of blood in the PAXgene™ tubes with
2.5 ml of blood and those with 0.5 ml ofblood were not statistically significant. The
greater yields obtained using the aliquots were statistically significantly different
when compared with either of the PAXgene™ tube conditions. Importantly, the
yields obtained for the 0.5 ml of blood in the PAXgene™ tubes were still sufficient
for use in microarray experiments with range of yield from 4.49 to 9.24 pg. The RIN
values were seen to be best for the 0.5ml of blood in the PAXgene™ tube, followed
by the 0.5 ml of blood in aliquots of PAXgene™ fluid and least good in the
PAXgene™ tubes with 2.5 ml of blood in them, with mean RIN values of 9, 8.2 and
7.5 respectively. The mean RIN values obtained from the 0.5 ml of blood in
PAXgene™ were statistically significantly better than either of the other 2
conditions.
Table 3.4.2: Mean values ofA260:A280, RNA yield per 0.5 ml of blood































































Table 3.4.3: Values of statistical significance of difference between
means ofA260:A280 ratio, Yield ofRNA per 0.5 ml and RIN forpairs







2.5 ml in PAXgene™ tube - 0.5 ml
in PAXgene™ tube
1.000 0.094 0.002
2.5 ml in PAXgene™ tube - 0.5 ml
in aliquot of PAXgene™ fluid
0.268 <0.001 0.008
0.5 ml in PAXgene™ tube - 0.5 ml
in aliquot of PAXgene™ fluid
0.503 0.002 0.004
Graphs displaying yield per 0.5 ml of blood and RIN value for each sample are
displayed in figure 3.4.1. Bioanalyzer traces and RIN values for each sample can be
found in table 3.4.4 in appendix 2.
Figure 3.4.1: Graphs of Yield per 0.5 ml of blood and RIN values for
each blood/PAXgene™ RNA stabilisation agent volume.
0.5 ml of blood in PAXgene™ tube
2.5 ml of blood in PAXgene™ tube









All three combinations of blood volume/PAXgene™ fluid volume examined gave
consistently good A26o:A2so ratio. All three combinations also consistently yielded
sufficient RNA for reliable use in microarray experiments, however the greatest yield
per 0.5 ml was obtained using the aliquot method. The RIN values were best with
the 0.5 ml of blood injected directly into a PAXgene™ blood RNA tube. As the
main aim was to optimise RNA quality while achieving sufficient yield and having a
requirement for the smallest possible sample, these results indicated that the 0.5 ml
of blood injected into the PAXgene™ was the best to take forward for use in future
work. The additional advantage of this method over the aliquot method is that the
PAXgene™ fluid remains completely isolated within the PAXgene™ tube.
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3.5: Incubation time of PAXqene™ tube prior to RNA
extraction. Part 1
Background
Investigation of optimum incubation period at room temperature was important both
to determine the optimum time to maximise yield and quality of RNA obtained and
also to help set parameters within which clinical sampling could be confidently
carried out. For example, if samples could be incubated at room temperature for 24
or 72 hours this would mean that samples could be transferred to the lab from the
clinical area without freezing and batched for extraction.
Method
Blood was sampled from 12 umbilical cords. For each cord, three aliquots of 0.5 ml
of blood were taken and each injected into a PAXgene™ Blood RNA Tube. The
samples were then taken to the lab and incubated at room temperature. For each cord
sampled one tube was incubated for 2 hours at room temperature, one for 24 hours at
room temperature and the third for 72 hours at room temperature prior to RNA
extraction. RNA extraction, RNA quantification and Bioanalyzer analysis were
carried out as described in chapter 2.
Results
Raw data for each sample with incubation periods 2, 24 and 72 hours can be found
in appendix 2, table 3.5.1. This data is displayed graphically in figure 3.5.1 with
yield, A260:A280 and RIN displayed for each incubation period. Total yield is
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displayed on the purple line graph for each incubation time. The A26o:A28o ratio is
displayed as a red line graph with the y-axis on the right. The pastel bars represent
the REN values for each collection tube.
Figure 3.5.1: RNA Yield, A260:A280 Ratio and RIN for Each Incubation
Time (2, 24 and 72 hours).
Yield (micrograms)




The mean values for A26o:A28o ratio, yield of RNA and RIN values for each
incubation period are displayed in table 3.5.2.
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Table 3.5.2: Mean values of A260:A280, RNA yield per 0.5 ml of









































When examining these results and the significance values for differences in the
means as calculated using paired t-tests (SPSS vl2) that are seen in table 3.5.3, it is
seen that there is no statistically significant differences between incubation periods
for either A260:A280 ratio or yield.
Table 3.5.3: Values ofstatistical significance of difference between
means ofA260:A280 ratio, Yield of RNA per 0.5 ml and RIN for pairs
of incubation periods (p values).
A260:A280
Yield of RNA per
0.5 ml blood
RIN
2 hours - 24 hours 0.199 0.171 0.001
2 hours - 72 hours 0.592 0.218 <0.001
24 hours - 72 hours 0.221 0.316 0.076
When looking at the RIN values however, the samples incubated for 2 hours at room
temperature have significantly higher values than either those incubated for 24 hours
or those incubated for 72 hours. Although there was no statistically significant
difference between RIN values incubated for 24 hours and those incubated for 72
hours, the mean RIN was lower at 72 hours than at 24 hours. This indicates that
with continued incubation at room temperature, RNA degradation occurs by 24 hours
and continues to degrade further by 72 hours. RIN values are displayed in figure
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3.5.2 and Bioanalyzer traces for each sample can be found in appendix 2 (table
3.5.4).
Figure 3.5.2: Graph of RIN values for each incubation period
1 2 3 4 5 6 7 8 9 10 11 12
Sample
Conclusion
On incubation at room temperature, RNA degradation appears to occur by 24 hours
as evidenced by a significant reduction in RIN value. This indicated that further
investigation into optimum duration of incubation for periods less than 24 hours was
warranted.
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3.6: Incubation time of PAXqene™ tube prior to RNA
extraction. Part 2
Background
Following the first part of the study of optimal incubation time presented in 3.5 that
suggested RNA degraded by 24 hours, further examination of optimal incubation
time was carried out by looking at RNA quality and quantity after 2,4,6,8,10 and 12
hours. It was important to explore this in order to define parameters of RNA
handling which would optimize RNA expression.
Method
Blood was sampled from 10 umbilical cords. For each cord, six aliquots of 0.5 ml of
blood were taken and each injected into a PAXgene™ Blood RNA Tube. The
samples were then taken to the lab and incubated at room temperature. For each cord
sampled one tube was incubated for 2 hours at room temperature, one for 4 hours at
room temperature and one each at 6, 8, 10 and 12 hours at room temperature prior to
RNA extraction. RNA extraction, quantification and quality assessment were carried
out as described in chapter 2.
Results
The raw data for A26o:A28o ratio, RNA yield and RIN values for each tube are
displayed in table 3.6.1 (a and b) which can be found in appendix 2. The raw data is
displayed graphically in figure 3.6.1 for each incubation period. Total yield is
displayed on the purple line graph for each incubation time. The A26o:A28o ratio is
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displayed as a red line graph with the y-axis on the right. The pastel bars represent
the RIN values for each collection tube. This data along with the mean values
displayed in table 3.6.2 show similar A26o:A28o ratios and RNA yields for all of the
tubes. In addition there is a suggestion of higher RIN values for those samples
extracted after 2, 4 and 6 hours incubation (mean RIN of 9 - 9.1) compared with
those extracted at 8, 10 or 12 hours incubation (mean RIN of 8.6 - 8.8).
Figure 3.6.1: RNAYield, A260.A280 and RIN for Each Incubation Time
(2, 4, 6, 8, 10 and 12 hours).
Incubation Time
When the statistical significance of differences between the means are examined
(table 3.6.3), it can be seen that there is no statistical significance between any of the
incubation times for A26o:A28o ratios, yields or RIN values except for yield at 2 hours
compared with 10 hours. All incubation conditions produced RNA of sufficient
quantity and of high enough quality to run on microarray. Graphs of A260:A280 ratio,
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yield and RIN for each sample are displayed in figure 3.6.2. Bioanalyzer tracings
and RIN values for each sample can be found in table 3.6.4 in appendix 2.
Table 3.6.2: Mean values of A260:A280, RNA yield according to





























































Table 3.6.3: Values ofstatistical significance of difference between
means ofA260:A280 ratio, Yield of RNA per 0.5 ml and RIN for pairs
of incubation periods (p values).
A260:A280 Yield of RNA RIN
2 hours - 4 hours 0.542 0.374 0.354
2 hours - 6 hours 0.860 0.910 0.328
2 hours - 8 hours 0.918 0.959 0.954
2 hours - 10 hours 0.598 0.011 0.458
2 hours - 12 hours 0.641 0.165 0.852
4 hours - 6 hours 0.687 0.457 0.863
4 hours - 8 hours 0.692 0.396 0.129
4 hours - 10 hours 0.977 0.923 0.227
4 hours - 12 hours 0.899 0.089 0.051
6 hours - 8 hours 0.917 0.842 0.130
6 hours - 10 hours 0.371 0.418 0.263
6 hours - 12 hours 0.560 0.220 0.258
8 hours - 10 hours 0.535 0.369 0.367
8 hours - 12 hours 0.519 0.197 0.487
10 hours - 12 hours 0.883 0.393 0.577
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Conclusions
There is no statistically significant difference either in quality or quantity of RNA
obtained when umbilical cord blood in PAXgene™ Blood RNA tubes is incubated
for 2, 4, 6, 8, 10 or 12 hours at room temperature prior to incubation. All of these
incubation conditions produced RNA good enough for use in microarray
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experiments. There was however a suggestion of slight reduction in RIN by 8 hours
incubation and it may be best to try and keep incubation at room temperature within
the range 2-6 hours.
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3.7: Storage of Samples For Up To One Week at -20 °C
Background
After I had shown that it was feasible to produce high quality microarray results from
RNA extracted from small volumes of neonatal blood, it became important to
consider ways to maximise our ability to study clinical samples. From a study view
point it was important to minimise any variation between handling of samples and to
ensure that conditions of transport and storage of samples were standardised. From a
clinical point of view, samples could be obtained at any time of the day or night and
it would often not be possible for the samples to have RNA extracted after the exact
desired incubation at room temperature. In addition, if the study was to ever become
multi-centred, the time of travel to the laboratory may exceed the desired incubation
period if samples were to be kept at room temperature. Freezing samples at -20 °C
immediately after sampling and transferring to the lab frozen and then defrosting and
incubating at room temperature for a fixed period would make standardisation of
technique much more robust. This however, would only be feasible if RNA quality
and quantity were maintained for samples that were frozen and I therefore set out to
investigate this.
Methods
Blood was sampled from six umbilical cords by the method previously described in
chapter 2 (page 61). For each cord, aliquots of 0.5 ml of blood were injected directly
into six PAXgene™ Blood RNA tubes. The samples were taken straight to the lab -
in practice this took less than 10 minutes and would be a similar time to that required
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to finish off any sampling procedure and label any samples. One of the six tubes
was then left to incubate at room temperature and the other five were placed directly
into a -20 °C freezer. The sample left at room temperature had RNA extraction
performed after 2 hours. The next sample had RNA extraction commenced at 15
hours. All frozen samples were left at room temperature for 4.5 hours (allowing over
2 hours to defrost thoroughly and 2 hours incubation) after removal from the freezer.
The third to sixth sample had RNA extraction commenced after 1 day, 3 days, 4 days
and 7 days respectively: all were removed from the freezer and incubated at room
temperature immediately prior to RNA extraction. These timings were chosen to
investigate the possibility of samples being frozen overnight, over a weekend, long
weekend or longer to facilitate lab extractions during the normal working week for
potential future studies. RNA extractions were performed using the modified
PAXgene™ protocol, RNA was quantified using the spectrophotometer and the
samples run on Bioanalyzer as described in chapter 2.
Results
Raw data for this experiment is shown in table 3.7.1. Cord cs49 only yielded
sufficient blood for five PAXgene™ tubes and the "3 day" incubation was therefore
omitted for this sample.
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Table 3.7.1: Raw data for each sample according to whether frozen at






ratio Total RNA (ng) RIN
cs47 2hr RT only 0.013 1.86 1.72 1.4
cs47a 15 hr at -20 °C 0.054 2 7.13 9.6
cs47b 1 day at -20 °C 0.029 1.93 3.83 9.7
cs47c 3 days at -20 °C 0.034 1.89 4.49 9.3
cs47d 4 days at -20 °C 0.041 1.95 5.41 9.8
cs47e 7 days at -20 °C 0.027 1.93 3.56 9.2
cs48 2hr RT only 0.044 1.91 5.81 9.2
cs48a 15 hrat -20 °C 0.064 1.78 8.45 9.4
cs48b 1 day at -20 °C 0.068 1.89 8.98 9.4
cs48c 3 days at -20 °C 0.048 1.78 6.34 8.6
cs48d 4 days at -20 °C 0.069 1.92 9.11 10
cs48e 7 days at -20 °C 0.06 2 7.92 9.8
cs49 2hr RT only 0.029 1.93 3.83 7.9
cs49a 15 hrat-20 °C 0.05 2 6.6 9.3
cs49b 1 day at -20 °C 0.055 1.96 7.26 9.4
cs49c 3 days at -20 °C
cs49d 4 days at -20 °C 0.015 1.88 1.98 1.3
cs49e 7 days at -20 °C 0.027 18 3.56 8.4
cs50 2hr RT only 0.037 1.85 4.88 9.6
cs50a 15 hrat-20 °C 0.059 1.9 7.79 9.2
cs50b 1 day at -20 °C 0.044 1.91 5.81 8.3
cs50c 3 days at -20 °C 0.063 1.85 8.32 9.5
cs50d 4 days at -20 °C 0.048 1.78 6.34 9.6
cs50e 7 days at -20 °C 0.049 1.81 6.47 9.1
cs51 2hr RT only 0.031 1.55 4.09 9.4
cs51a 15 hrat-20 °C 0.099 1.94 13.07 9.5
cs51b 1 day at -20 °C 0.069 1.97 9.11 10
cs51c 3 days at -20 °C 0.029 1.71 3.83 9.8
cs51d 4 days at -20 °C 0.099 2.02 13.07 9.9
cs51e 7 days at -20 °C 0.038 1.65 5.02 9.9
cs52 2hr RT only 0.035 2.06 4.62 9.5
cs52a 15 hr at-20 °C 0.055 1.72 7.26 9.4
cs52b 1 day at -20 °C 0.05 1.32 6.6 9.7
cs52c 3 days at -20 °C 0.043 1.79 5.68 9.9
cs52d 4 days at -20 °C 0.05 1.79 6.6 9.8
cs52e 7 days at -20 °C 0.054 1.64 7.13 9.7
Table 3.7.2 displays the mean and range of values for A26(fA28o, yield of RNA and
RIN values for each incubation condition. Paired t-tests were performed on the data
using statistical software SPSS vl2 and the results are displayed in table 3.7.3.
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Table 3.7.2: Mean values of A260:A280, RN
blood and RIN for each duration of freezing at




























































Table 3.7.3: Values of statistical s
means ofA260:A280 ratio, Yield o
pairs of duration of freezing (p vai
ignificance of difference between
f RNA per 0.5 ml and RIN for
Jues).
A260:A280 Yield of RNA RIN
2 hours room temp -15 hours frozen 0.784 0.010 0.298
2 hours room temp-1 day frozen 0.852 0.005 0.307
2 hours room temp - 3 days frozen 0.592 0.095 0.370
2 hours room temp - 4 days frozen 0.783 0.100 0.782
2 hours frozen - 7 days frozen 0.524 0.016 0.285
15 hours frozen - 1 day frozen 0.446 0.128 0.936
15 hours frozen -3 days frozen 0.277 0.142 1.000
15 hours frozen - 4 days frozen 1.000 0.147 0.507
15 hours frozen - 7 days frozen 0.281 0.068 0.825
1 day frozen - 3 days frozen 1.000 0.446 1.000
1 day frozen - 4 days frozen 0.521 0.906 0.509
1 day frozen - 7 days frozen 0.795 0.182 0.808
3 days frozen - 4 days frozen 0.250 0.275 0.210
3 days frozen - 7 days frozen 0.976 0.703 0.692
4 days frozen - 7 days frozen 0.253 0.342 0.476
From these tables it can be seen that there is no statistically significant difference in
A26(fA28o ratio or RIN values for any of the incubation conditions. While not
reaching statistical significance, the frozen samples did however seem to have higher
RIN values than the samples incubated at room temperature for 2 hours. In addition,
when considering the yield of RNA obtained for each condition, the amount ofRNA
yielded from samples incubated at room temperature for 2 hours was statistically
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significantly lower than the frozen samples extracted after 15 hours (p = 0.01), 1 day
(p = 0.005) and 7 days (p = 0.16). The RIN values are displayed in figure 3.7.1
along with RNA yields.
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Bioanalyzer tracings along with RIN values for each sample can be found in table
3.7.4 in appendix 2.
Conclusion
There is no statistically significant difference in A26o:A28o ratio or RIN when
comparing samples incubated at room temperature for 2 hours with samples frozen
prior to RNA extraction at 15 hours, 1 day, 3 days, 4 days or 7 days. All samples
yielded sufficient RNA to be used in microarray work. This means that it would be
feasible to freeze samples collected in a clinical setting for up to 1 week, enabling
standardization of incubation time at room temperature, while maintaining the
quality and quantity ofRNA.
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3.8: Examination of Storage Time and Storage Temperature
Background
If neonatal blood in PAXgene™ Blood RNA tubes could be frozen and stored for
longer periods of time without loss of quality of RNA obtained and without
compromising yield, this could have significant benefits for research involving RNA
from neonatal blood. This could mean that samples could be stored and RNA
samples extracted in batches meaning optimal use of laboratory time. In addition, if
samples could be frozen and transported to the laboratory while frozen, they could be
gathered at sites remote to the research laboratory. This could also allow samples to
be gathered in multiple centres and transferred to the research laboratory. I therefore
set out to study a cohort of samples frozen at -20 °C for 1 week and 2 years. In
addition, I had frozen a small number of samples at -80 °C which were studied as
part of this experiment.
Methods
Samples from eight umbilical cords were used in this section. All of the samples in
this section were extracted using the PAXgene™ method described previously (page
76). For each umbilical cord, aliquots of 0.5 ml of cord blood were injected into 2
(csl7, csl8) or 3 (cs45, cs46,cs47, cs48, cs50 and cs52) PAXgene™ Blood RNA
tubes and transported directly to the laboratory. For each sample, one aliquot was
incubated at room temperature for 2 hours prior to having RNA extracted. For
samples csl7 and csl8 and cs45 one aliquot was incubated by immediately placing in
a -20 °C freezer and then transferring to a -80 °C freezer. Extraction of these samples
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was carried out after transferring to a -20 °C freezer for 4 hours, then transferring to a
fridge (4 °C) overnight and then incubating at room temperature for 4 hours. This
was to allow freezing and thorough defrosting without damaging the tubes and
including the minimum of two hours of incubation at room temperature after
defrosting. Csl7 and csl8 were each extracted after 1 year at -80 °C and cs45 after
being frozen for 1 week at -80 °C. An additional aliquot of cs45 was placed directly
in a -20 °C freezer and left there until taken out for extraction after 2 years. For all of
the other samples, two aliquots were placed directly in a -20 °C freezer with one
aliquot extracted after 1 week and the other after 2 years. Frozen samples were
extracted after being transferred onto the benchtop and incubated at room
temperature for 4 hours 30 minutes to allow for thorough defrosting and to include
the minimum 2 hours incubation after defrosting.
Results
Table 3.8.1 displays the raw values and table 3.8.2 displays the mean values for
A.260-A280 ratio, RNA yield and RIN values for each incubation condition. When
examining this data it can be seen that all of the incubation conditions yielded
sufficient RNA for running on microarray. The RIN values on the whole were also
good, with only one sample incubated at room temperature for 2 hours having a
particularly poor RIN value of 1.4. This sample also had a lower yield and when
looking at the Bioanalyzer graph displayed in table 3.8.4 a and b (appendix 2), the
trace does not look degraded and the RIN value is probably more a reflection of low
yield.
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cs17 2hours RT 1.6 0.072 9.50 8.5
cs17y1 1 year -80 °C 2.17 0.052 6.86 7.7
cs18 2hours RT 1.5 0.039 5.15 9.5
cs18y1 1year -80 °C 2.04 0.047 6.20 9.7
cs45 2 hours RT 1.63 0.044 5.81 8.9
cs45w1 1 week -80 °C 1.75 0.042 5.54 9.4
cs45y2 2 years -20 °C 2.29 0.064 8.45 8.3
cs46 2 hours RT 1.69 0.027 3.56 9.7
cs46w1 1 week -20 °C 2.15 0.028 3.70 8.9
cs46y2 2 years -20 °C 1.88 0.047 6.20 8.6
cs47 2 hours RT 1.86 0.013 1.72 1.4
cs47w1 1 week -20 °C 1.93 0.027 3.56 9.2
cs47y2 2 years -20 °C 2 0.046 6.07 8.6
cs48 2 hours RT 1.91 0.044 5.81 9.2
cs48w1 1 week -20 °C 2 0.06 7.92 9.8
cs48y2 2 years -20 °C 1.78 0.073 9.64 7.9
cs50 2 hours RT 1.85 0.037 4.88 9.6
cs50w1 1 week -20 °C 1.81 0.049 6.47 9.1
cs50y2 2 years -20 °C 1.71 0.058 7.66 8.1
cs52 2 hours RT 2.06 0.035 4.62 9.5
cs52w1 1 week -20 °C 1.64 0.054 7.13 9.7
cs52y2 2 years -20 °C 7 0.021 2.77 8.2
Table 3.8.2; Mean values ofA260:A280, RNA yield per 0.5 ml of blood and


















































The A26o:A28o ratios display a bigger spread of values than in previous experiments.
Some of the samples incubated at room temperature for 2 hours had a lower ratio
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than would be expected given the values obtained in experiments 3.1 to 3.7. It is not
clear why this is and may be a feature ofbiological variation between blood samples.
In addition there is one sample that was incubated at -20 °C for 2 years (cs52y2) that
was a significant outlier with a ratio of 7. It would therefore be more informative to
examine the median rather than the mean for the ratio for the samples incubated at -
20 °C for 2 years - this would be 1.94. When this is taken into consideration, the
A26o:A28o ratios are found to be generally acceptable.
Table 3.8.3: Values ofstatistical significance of difference between
means ofA260:A280 ratio, Yield ofRNA per 0.5 ml and RIN for pairs of
RNA storage conditions (p values).
A260:A280 Yield of RNA RIN
2 hours at RT - 1 year at -80 °C 0.017 0.741 0.656
2 hours at RT - 1 week at -20 °C 0.832 0.015 0.424
2 hours at RT - 2 years at -20 °C 0.296 0.044 0.874
1 week at -20 °C - 2 years at -20 °C 0.428 0.611 0.022
Table 3.8.3 displays the significance values for comparison of the means of A26o:A28o
ratio, RNA yield and RIN for each incubation condition. The only means that were
statistically different for yield were those for incubation at -20 °C for 1 week and for
2 years when compared with 2 hours at room temperature, with the frozen samples
yields being greater. There was a statistically significant difference in A26o:A28o ratio
after incubation at room temperature for 2 hours compared with incubation at -80 °C
for 1 year (1.76 compared with 2.11). Both of these means are well within the target
range of 1.8 to 2.2. All of the mean RIN values were above 8 with the only
statistically significant difference being for samples frozen at -20 °C for lweek
compared to those at -20 °C for two years. Graphical representations of A26o:A28o
ratio, RNA yield and RIN values for each sample can be found in figure 3.8.1.
Bioanalyzer traces and RIN values for each sample can be found in table 3.8.4 (a and
b) in appendix 2.
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Conclusions
Neonatal blood samples in PAXgene™ Blood RNA tubes yield RNA of sufficient
quantity and of consistently high quality to run on microarray whether incubated at
room temperature for 2 hours, at -20 °C for 1 week, at -20 °C for 2 years or at -80 °C
for 1 year. Any statistically significant differences between groups were not of any
practical significance, in that all of the samples were suitable to run on microarray.
Comparisons between groups in the main were not statistically significant.
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This has positive implications for storage and batching of samples. This experiment
does not provide any information on the preservation of RNA expression profiles,
only on the quality and quantity of RNA obtained. Examination of preservation of
RNA expression profiles would require multiple microarray or PCR- based
experiments and was beyond the scope of funding for this project.
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3.9: Assessment of a Filter- Paper Based Technique
Background
Neonatal venepuncture requires considerable skill and experience to be consistently
successful. Neonatologists and parents of babies are generally familiar with the
concept of neonatal blood samples being collected on filter paper. This is the method
used for the routine newborn screening tests carried out at 5 days of age. Capillary
blood samples taken by heel prick are sent off for screening for a series of treatable
congenital conditions such as congenital hypothyroidism, phenylketonuria and cystic
fibrosis. The general acceptance of this method of blood collection and the ease of
the procedure means that almost any baby could have blood sampled in this manner.
This made filter paper based collection of whole blood an attractive possibility for
gathering RNA samples that could not be ignored. In addition, dried blood spots are
already used in PCR based and DNA based examinations, for example in the field of
forensic science (321-325).
Whatman FTA® cards are filter-paper type cards that are designed to facilitate
nucleic acid isolation from whole blood samples. The cards are chemically treated in
order to lyse cell membranes and denature proteins on contact. Nucleic acids remain
stable in the card and are protected from microbiological, nuclease, oxidative and
UV radiation actions. In addition the cards render infective pathogens inactive on
contact. These factors make the cards very appealing for use with clinical samples
where nucleic acid isolation is desired. The RNA protocol is described as being
suitable for RT-PCR and northern blot analysis in the company literature.
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My initial excitement regarding this method was tempered somewhat when I
examined the on-line protocol from the company. The protocol, although at first
glance fairly straightforward, contained a few inaccuracies and was vague on some
points. For example, the section describing the need to use the whole disc of cells to
be processed for Northern blot stated that the wash step be "increased to 750 pi
sterile water", then it goes on to describe the wash step being in RNA processing
buffer. I sought clarification from the company directly by telephone and e-mail and
have incorporated their advice into the method described in chapter 2 (page 82).
Aims
To compare quality and quantity of RNA extracted using our preferred method of
PAXgene™ blood RNA system with that extracted using Whatman FTA® cards and
protocol.
Context
After making enquiries I was sent a trial sample pack of Whatman FTA® cards and
punches. This, along with the aliquots of reagents required to make up the RNA
processing buffer, meant that I had sufficient materials to carry out 7 experiments.
The results of this study would be taken as an indication as to whether it would be
worth carrying out further studies of this method.
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Methods
Umbilical cord blood was obtained as described previously. From each cord blood
sample, aliquots of 0.5 ml of blood were injected into PAXgene™ blood RNA bottles
and in addition blood (-125 pi per 1 inch circle) was dropped onto the Whatman
FTA® cards from a syringe. As per Whatman®'s advice, puddling of the blood on
the cards was avoided and the blood was not rubbed or smeared on the card. The
samples were then taken to the lab for processing.
PAXgene™ samples were processed according to the protocol described in chapter 2
after 2 and 24 hours (1st cord sample) and at 2 hours and at 1 week of incubation (2nd
cord sample). The 2 and 24 hour incubations were all at room temperature. The
sample incubated for 1 week (cs45pwl) was frozen to -80 °C and defrosted as
described more fully in section 3.8, with 4 hours incubation at room temperature
immediately before RNA extraction.
The samples on the Whatman FTA® cards were left to air dry at room temperature
for at least 2 hours (minimum recommended is 1 hour). The Whatman® experiments
carried out were:
• cs44W: Whatman® whole 1 inch blood spot
• cs44WX: Whatman® 1 x black (2 mm diameter) Harris punch disc of dried
blood spot
• cs44WX2: Whatman® 2 x black Harris punch disc of dried blood spot
• cs44WD: Whatman® whole blood spot plus DNase step.
• cs44W24: Whatman® whole blood spot left 24 hours to dry.
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• cs45WX2: Whatman® 2 x black Harris punch disc of dried blood spot
• cs45WX2D: Whatman® 2 x black Harris punch discs of dried blood spot plus
DNase step.
The method used for RNA extraction from the Whatman® cards is described in
chapter 2 (page 82).
Results
The raw results are displayed in table 3.9.1 and the mean values are displayed in
table 3.9.2. Looking at this data, although none of the samples had perfect A26o:A28o
ratios, all of the Whatman® samples had exceptionally poor ratios. The RINs
obtained from the PAXgene™ tubes, with the exception of one were good as
expected. The RIN values for the Whatman® samples were, on the other hand,
uniformly poor at 1. Although these results make the results obtained for yield
somewhat inconsequential, the mean yield of the PAXgene™ extracted samples was
higher than the mean yield of Whatman® extracted samples. This is true whether
looking at Whatman® when the whole disc was used, when 1-2 punches were used
and whether or not a DNase step was included.
When the statistical significance values displayed in table 3.9.3 (calculated using
paired t-test within the SPSS v 12 software program) are examined it is clear that
none of the results achieved in this experiment reached statistical significance. This
is due to the fact that only a limited number of Whatman® extractions could be
carried out using the trial kit making the numbers examined too small to reach
statistical significance.
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0.38 0.039 3.43 1
cs44wx 1 punch of Whatman® 0.96 0.049 4.31 1
cs44w24
whole disc Whatman®
at RT for 24 hours
1.7 0.034 2.99 1
cs44pax PAXgene™ at RTfor 2 hours 1.66 0.048 6.34 n/a
cs44pax24 PAXgene™ at RTfor 24 hours 1.4 0.028 3.70 8.4
cs45wx 1 punch of Whatman® 1.43 0.02 1.76 1
cs45wx2 2 punches ofWhatman® 1.2 0.036 3.17 1
cs45wx2d
2 punches of Whatman®
and DNAse step
1 0.018 1.58 1
cs45pax PAXgene™ at RTfor 2 hours 1.63 0.044 5.81 8.9
cs45pw1 PAXgene™ frozenfor 1 week 1.75 0.042 5.54 9.4
Table 3.9.2; Mean values ofA260:A280, RNA yield per 0.5 ml of




































































Table 3.9.3: Values ofstatistical significance of difference between
means ofA260.A280 ratio, Yield of RNA per 0.5 ml and RIN forpairs of





PAXgene™ 2 hours -Whatman® DNase 0.209 0.116 N/A
PAXgene™ 2 hours -Whatman® 1 punch 0.323 0.204 N/A
PAXgene™ other -Whatman® with DNAse step 0.096 0.457 0.040
PAXgene™ other -Whatman® 1 punch 0.100 0.602 0.040
Whatman® with DNase step -Whatman® 1 punch 0.094 0.372 N/A
The raw data, the Bioanalyzer graph tracings (table 3.9.4, appendix 2) and the bar
chart of RIN values for each extraction condition displayed in figure 3.9.1 are fairly
convincing in showing that the quality of RNA obtained using the Whatman®
method was uniformly poor.




















□ PAXgene 2 hours




Although use of a filter-paper based technique would be very attractive for use in
extracting RNA from neonatal blood, it is clear from this data that the Whatman®
based technique was not a viable option for this study. In this experiment it did not
yield any good quality RNA at all. The PAXgene™ method remains the method of
choice for this work.
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Chapter 3: Discussion and Summary of Conclusions
When I embarked upon this work there was no data in the literature regarding
extraction ofRNA from neonatal blood.
From the work presented in sections 3.1, 3.2 and 3.3 it was seen that the PAXgene™
Blood RNA tube and extraction technique were optimal for RNA extraction from
umbilical cord blood from those examined. This concurs with studies using adult
blood which showed PAXgene™ tubes do better than heparinised or EDTA tubes
(298, 299) and that the PAXgene™ RNA extraction method is better than other
methods (327-330). I acknowledge that since I carried out this work there have been
other RNA extraction kits brought onto the market for which there are also
favourable reports in the literature, e.g the Tempus system (340). My main objective
was to find a good, reliable method of RNA extraction which yielded the best
possible results at the time. I achieved this aim and as consistency ofmethod is key
in RNA work, I did not consider it necessary to consider these newer kits in
retrospect.
Having chosen the PAXgene™ system for my study, I then moved on to examine
the use of smaller blood volumes than the recommended 2.5 ml that the PAXgene™
tubes are designed for. This was novel work and my results show that high quality
RNA of sufficient quantity to run on microarray can consistently be achieved by
injecting 0.5 ml of blood directly into the PAXgene™ tubes. This was an important
finding in the context of this study because it showed that the use of small neonatal
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samples is possible using the PAXgene™ method. More recently, Carrol and
colleagues have carried out similar work examining small volumes of blood in a
paediatric population (341). They examined, in a similar manner to me, use of
aliquots of PAXgene™ fluid with small volumes of paediatric blood (0.3 ml) and
found adequate yields and quality for use in RT PCR work (341). My findings that
direct injection of small volumes of blood into the PAXgene™ tubes yielded highest
quality RNA led us to adopt this approach rather than use aliquots. This had the
added advantage that we were able to keep the PAXgene™ fluid enclosed within the
tubes while in the clinical area. The PAXgene™ system was the only blood RNA
extraction method at the time to have FDA approval for clinical use. This was
encouraging because it meant that the tubes were deemed to be safe to use in the
clinical setting and this is an important consideration.
I then concentrated on determining optimal incubation times prior to RNA extraction
and optimum blood tube storage. These are important parameters to consider in
study design and my results were important in deciding how to proceed with the
protocol for this study. I found that incubation at room temperature up to 12 hours
did not lead to any loss of quality ofRNA yielded but that by 24 hours and certainly
by 72 hours there were signs of degradation. This is different to published data using
adult blood which showed increased yield and quality after 24 hours incubation
(342). This could be due to differences in adult compared to neonatal blood and
highlighted the importance of studying neonatal blood before setting parameters for
future work. My finding that blood samples that were frozen at -20 °C showed no
difference in quality from those extracted after 2 hours incubation at room
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temperature alone is supported by findings in the literature that adult blood frozen
and extracted using PAXgene™ system gives better results than heparinised blood
samples (299). In addition, Rainen and colleagues describe freezing as the best
method of storage for PAXgene™ blood samples (298).
Given that filter-paper based techniques have been used in RNA work from forensic
samples and blood spots (321-325), albeit with pooling of samples and amplification
techniques, it was disappointing that the filter-paper based method examined for this
study was found not to be suitable for our purposes. With more time and resources it
may have been possible to find and refine a filter-paper based technique. Despite
this, the work in this chapter identified a robust method ofRNA extraction for future
work with neonatal blood. I have summarised the findings of this chapter below:
• Of the collection tubes studied for use with umbilical cord blood, the
PAXgene™ Blood RNA tube yielded the highest quality RNA and was of
sufficient quantity for use in microarray work.
• The PAXgene™ Blood RNA extraction method studied was found to be
an optimum method for maximising quality of RNA obtained from
umbilical cord neonatal blood. It also consistently gave yields sufficient
for microarray use.
• Sufficient quantity of RNA for microarray use can be consistently
obtained from 0.5 ml of umbilical cord neonatal blood in the PAXgene™
Blood RNA system. Of the variations studied, injection of 0.5 ml of
blood directly into the PAXgene™ tube yielded the highest quality RNA.
182
• Incubation of umbilical cord blood in PAXgene™ Blood RNA Tubes does
not lead to any statistically significant change in quality ofRNA obtained
for incubation periods of 2 to 12 hours. By 24 hours however, there is
statistically significant degradation ofRNA quality and this becomes even
more apparent by 72 hours.
• There is no statistically significant difference in quality or yield of RNA
obtained when comparing umbilical cord blood in PAXgene™ Blood
RNA tubes for those incubated at room temperature for 2 hours and for
those frozen at -20 °C for 15 hours, 1 day, 3 days, 4 days or 7 days.
• There is no statistically significant difference in quality and no practical
difference in yield of RNA obtained from umbilical cord blood in
PAXgene™ Blood RNA tubes for those incubated at room temperature
and for those frozen at -20 °C for 1 week, -20 °C for 2 years or at -80 °C
for 1 year.
• The filter-paper based method of blood RNA extraction examined in this
study was shown not to be feasible for use with umbilical cord blood in
the conditions studied.
These findings enabled me to move forward to the next phase of the study and gather
blood samples from a neonatal population, confident that the RNA obtained should
be of high quality and sufficient quantity to use in microarray work. Chapter 4
describes the neonatal samples in detail.
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Work from this chapter has subsequently been published in the Analyst:
Claire L Smith, Paul Dickinson, Thorsten Forster, Mizanur Khondoker, Marie
Cragion, Alan Ross, Petter Storm, Stewart Burgess, Paul Lacaze, Benjamin J Stenson
and Peter Ghazal. Quantitative assessment of human whole blood RNA as a potential
biomarker for infectious disease. Analyst 2007,132, 1200-1209.
A copy of the paper can be found in Appendix 4: (reproduced by permission of The




Examination of Neonatal Blood Sampling
185
Aims
• To describe the sampling of neonatal blood samples taken for use in the
remainder of this study.
• To examine the quality and quantity of RNA obtained from these clinical
neonatal samples.
• To examine the effects of the following variables on the quality and quantity
ofRNA obtained from neonatal samples:
o Whether samples were taken using a needle or cannula
o Individual taking the blood sample
o Whether or not samples were frozen
o The duration of freezing
o Time at room temperature prior to RNA extraction
o Operator carrying out RNA extraction
o White cell count of samples
o Neutrophil count of samples
Of the 201 samples described in this chapter:
• 77 were consented for and taken by myself and 124 were taken by 38 clinical
colleagues on my behalf (for 1 sample it is not documented who took it).
• 94 samples had the RNA extraction and assessment of quantity and quality of
RNA carried out by me, 107 were carried out by two of my laboratory
colleagues (Alan Ross and Paul Dickinson) on my behalf.
• All of the clinical data collection and all of the analyses and comparisons in
this chapter were done by myself.
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Background
Following the umbilical cord blood validation studies, I then moved on to study
neonatal blood. The data obtained using cord blood suggested that it should be
possible to obtain sufficient quantity and quality of RNA from clinically relevant
small samples of blood from newborn infants. It was important however to confirm
this in the process of gathering clinical neonatal samples for analysis. It also
remained vital to eliminate or reduce as far as possible, any sources of variability in
sampling, transport, storage and analysis.
Population
Eligible Babies
All infants who were admitted to the neonatal unit at Simpson Centre for
Reproductive Health, or who were being reviewed by the neonatal team on either the
postnatal wards or the neonatal unit and who, for clinical reasons, were having blood
cultures taken through a needle or cannula were eligible for inclusion in the study. In
addition, healthy infants who were having blood samples taken on the neonatal unit
for other reasons were eligible as controls. Examples of such other reasons include
screening of infants of mothers with thyroid disease, infants of rhesus negative
mothers who missed having cord blood screening for blood group, screening for
congenital adrenal hyperplasia or infants who were having blood taken as scheduled
preterm clinical blood sampling.
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Exclusions
In order to meet with laboratory regulations, samples that could be considered "high
risk" were excluded. Infants were not included in the study if the mother was known
to be positive for hepatitis B, HIV or hepatitis C viruses. In cases where the mother
was known to have a history of drug misuse and had not had antenatal screening for
blood borne viruses, the infants were also excluded. Other exclusion criteria were
infants who did not require clinical blood samples and infants for whom extra blood
sampling might be of particular risk, e.g. infants with an underlying disorder causing
anaemia.
Consent
All samples were taken with informed parental consent prior to sampling. Parents of
eligible infants were approached and given both verbal and written information
regarding the study. The parents were given the opportunity to ask any questions
regarding the study. If, after hearing the explanation and reading the information
sheet, the parents were satisfied that they had sufficient time to make their decision
and signed a consent form, the infant was considered recruited and blood sampling




The volume of blood sampled for the study in each case was between 0.5 - 1 ml.
These values were chosen in order to display the natural variation in sampling
volume that occurs clinically where precision measuring is not possible and at the
same time reflecting the need to keep sample volumes as small as possible in this
population. The circulating blood volume of a newborn is 75-80 ml per kg body
weight. In general, for consistency, I aimed for samples to be around 0.6 - 0.7 ml in
volume.
No extra venepuncture was performed for the sake of the study; extra blood was
taken at the same time as clinical sampling only. If, after the required clinical
samples were obtained, the needle or cannula did not bleed back or was dislodged, it
was not re-sited for the sake of the study.
All samples for blood culture were taken according to the neonatal unit policy as
much as possible. The sampling technique is described in detail in chapter 2 (page
62).
From late 2006 onwards, clinical colleagues began sharing in the consent and
sampling of neonatal samples. As the project was progressing we felt it was
important that we looked at ways to expand the project and potentially recruit other
centres. We therefore began routinely freezing the PAXgene™ blood RNA tubes at
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-20 °C immediately after sampling and when ready to extract the RNA, the samples
were taken out of the freezer and left at room temperature for 4 hours prior to RNA
extraction.
Review of Clinical Data
Clinical data was gathered for each recruited infant and recorded on a standardised
data sheet. Data was gathered from the infants' paper hospital records (including
medical, nursing and prescription charts), the infants' computerised hospital records
(Badger system), the infants' computerised laboratory results (Apex system) and
maternal paper hospital maternity records.
RNA Extraction
RNA extraction was carried out according to the protocol in chapter 2 (page 76)
using the PAXgene™ blood RNA tubes and reagent kits. For the earlier samples that
were not frozen, the PAXgene™ blood RNA tubes were left upright at room
temperature until transported to the laboratory in a sealed plastic container and the
RNA extraction process commenced. In order to ensure that the samples were given
at least 2 hours in the stabilisation agent, the first centrifugation was aimed to take
place between two and a half and four and a half hours after sampling to reflect
timing consistency within plausible clinical parameters. In practice this was
achieved for the majority of samples but a handful of samples were left longer than
this before processing (longest gap 16 hours 15 minutes) - almost exclusively on
days where there were two or more babies recruited meaning that a choice had to be
made between commencing RNA extraction on the first sample within the target
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timeframe and missing an eligible study subject or collecting both samples and being
outwith the target time frame for the earlier sample.
After 2006 when the samples were frozen at -20 °C immediately following sampling,
the samples were taken in batches to the lab, on ice to prevent thawing and
transferred to a -20 °C freezer in the laboratory until RNA extraction could take
place. The RNA was extracted, usually taking batches of 6 samples which, when
taken from the freezer, were left at room temperature for 4-4.5 hours prior to
commencing the first centrifugation step. All of the samples except three were
extracted before 5 hours 20 minutes at room temperature. Three samples were left to
defrost overnight which was not following the protocol as had been intended.
Assessment of RNA quality and quantity
Extracted RNA was frozen at -80 °C until assessment of RNA quality and quantity
could be carried out in batches. RNA quantity was assessed using spectrophotometry
— either using a ThermoSpectronic Biomate 5 spectrophotometer and VISION 32 (bit
Version 1.25) software or using a Thermo Scientific NanoDrop™ Spectrophotometer
with software v3.5.2 as described in chapter 2 (pages 89 and 92). RNA quality was
assessed using A26o:A28o ratios obtained from the spectrophotometry and from both
RIN values and subjective assessment of the tracings obtained using an Agilent 2100
Bioanalyzer (RNA 6000 Nano Assay) as described in chapter 2 (pages 93 to 98).
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Statistical Testing
For sections 4.2 to 4.9, differences between groups were examined by using SPSS
vl2 statistics software to carry out Kruskal-Wallis testing. ANOVA using the same
software was carried out for any conditions that appeared to show statistical
significance on Kruskal-Wallis testing.
During my discussion of this section I refer to statistical significance and practical
significance. Statistical significance was defined as p value <0.05. The best possible
quality and higher yields of RNA are always desirable. Practically however, RNA
will be suitable for use in microarray work as long as it is of sufficient yield and high
enough quality. Sufficient quality was felt to be indicated by RIN values of 8 and
above and A26o:A28o ratios within the range 1.8 to 2.2. If the minimum amount of
RNA required for input into the CodeLink™ microarray protocol is taken at 200 ng
(in a maximum of 10.8 pi), then the minimum yield required in 75 pi of eluted RNA
is 1.39 pg. The yield I have taken as being sufficient for use on array was therefore
1.39 pg. Provided that the samples met these conditions there would be no practical
consequences for differences in actual values - they would all be able to be run on
array, i.e. any differences in value would not be of practical significance.
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Chapter 4: Results
4.1: Overall Yield and Quality of RNA











csbl 10 1.95 9.77 0.8 6.11
csb2 9.2 1.90 7.79 0.8 4.87
csb3 1 2.20 1.45 0.5 1.45
csb4 9.1 1.84 4.62 0.6 3.85
csb5 10 1.80 4.75 0.7 3.39
csb6 10 1.86 5.15 0.6 4.29
csb7 10 1.71 6.34 0.5 6.34
csb8 9.5 2.19 4.62 0.6 3.85
csb9 1.1 2.80 1.85 0.6 1.54
csb10 9.8 2.03 10.16 ns -
csb11 6.6 1.76 13.73 ns -
csb12 9.2 1.80 4.75 0.5 4.75
csb13 10 1.72 8.18 0.75 5.46
csb14 9.9 1.76 6.73 0.5 6.73
csb15 6.6 1.81 14.78 0.8 9.24
csb16 9.5 1.64 4.75 0.8 2.97
csb17 8.5 1.73 3.43 0.6 2.86
csb18 8.3 1.95 9.77 0.7 6.98
csb19 9.5 1.98 14.39 0.5 14.39
csb20 8.6 1.70 2.24 0.5 2.24
csb21 9.5 1.50 5.54 0.8 3.47
csb22 8.8 1.85 3.17 0.6 2.64
csb23 9.1 2.02 14.39 0.75 9.59
csb24 9.2 1.98 14.39 0.6 11.99
csb25 9.6 2.04 6.73 0.6 5.61
csb26 8.7 2.05 15.18 0.7 10.84
csb27 9.1 2.25 3.56 0.7 2.55
csb28 9.4 2.06 4.88 0.6 4.07
csb29 8.2 1.33 7.39 0.65 5.69
csb30 8.4 1.91 5.81 0.7 4.15
csb31 na 4.50 1.19 0.65 0.91
csb32 6.8 2.50 3.30 0.7 2.36
csb33 9.9 2.47 4.88 0.6 4.07
csb34 10 2.27 7.79 0.6 6.49
csb35 10 2.15 9.37 0.6 7.81
csb36 10 2.31 3.96 0.65 3.05
csb37 9.1 1.40 1.84 0.6 1.53
csb38 9.7 1.98 11.75 0.6 9.79
csb39 9.8 1.94 15.54 0.65 11.95
csb40 7.2 1.71 3.17 0.65 2.44
csb41 8.9 1.58 2.51 0.6 2.09
csb42 8.5 1.80 2.38 0.65 1.83
csb43 9.4 1.24 2.77 0.6 2.31
csb44 9.9 1.84 9.24 0.65 7.11
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csb45 4.8 1.83 18.61 0.75 12.41
csb46 8.8 1.53 3.04 0.65 2.34
csb47 8.9 1.68 4.88 0.6 4.07
csb48 1.7 1.27 2.51 0.45 2.79
csb49 9 1.65 4.36 0.55 3.96
csb50 8.4 1.79 9.24 0.6 7.70
csb51 9.2 2.00 2.64 ns -
csb52 na 2.00 1.32 ns -
csb53 9.4 2.01 21.78 0.8 13.61
csb54 8.2 2.00 9.24 0.7 6.60
csb55 9.4 2.00 7.13 0.75 4.75
csb56 na Error 0.26 0.5 0.26
csb57 7.4 2.00 5.81 0.75 3.87
csb58 9.3 2.00 2.11 0.7 1.51
csb59 9.5 2.08 3.30 2 0.83
csb60 9.4 1.94 16.63 1 8.32
csb61 9.3 1.47 3.70 0.5 3.70
csb62 9.4 1.73 9.11 0.9 5.06
csb63 9.1 1.77 7.00 1 3.50
csb64 9.2 1.96 13.20 1 6.60
csb65 9.3 1.80 5.94 1 2.97
csb66 4.2 1.77 3.04 0.6 2.53
csb67 9.4 1.61 7.00 1 3.50
csb68 9.4 1.83 20.06 1 10.03
csb69 9.6 1.55 6.34 0.8 3.96
csb70 8.8 1.70 6.73 1 3.37
csb71 7.2 1.71 9.50 ns -
csb72 9.6 1.63 8.58 ns -
csb73 9.6 1.94 4.36 1 2.18
csb74 8.3 1.99 43.69 1 21.85
csb75 8.7 1.91 5.81 0.7 4.15
csb76 9 2.01 30.23 0.5 30.23
csb77 2.4 1.93 3.56 0.5 3.56
csb78 1 1.00 4.29 ns -
csb79 9.3 1.87 5.68 1 2.84
csb80 9.8 1.33 24.16 0.5 24.16
csb81 8.8 1.81 4.79 0.9 2.66
csb82 na 1.13 2.81 0.75 1.87
csb83 na 2.45 100.06 0.7 71.47
csb84 na 2.14 309.94 0.6 258.28
csb86 8.8 1.29 2.97 1 1.49
csb87 10 1.83 15.68 1 7.84
csb88 na 2.36 173.05 0.9 96.14
csb89 9.6 1.90 20.96 1 10.48
csb91 9.4 2.00 7.95 1 3.98
csb92 1.1 1.86 0.21 0.5 0.21
csb93 na 1.87 0.56 0.6 0.47
csb94 9.3 1.78 1.94 0.6 1.62
csb95 8.6 2.06 10.29 0.8 6.43
csb96 8.6 2.04 3.92 0.7 2.80
195











csb97 7.9 2.01 3.03 0.7 2.16
csb98 2.2 1.77 0.46 0.5 0.46
csb99 na 2.63 0.98 0.6 0.82
csblOO 8.7 2.61 0.74 ns -
csb101 9.1 2.08 5.98 0.5 5.98
csb102 9.1 2.05 7.06 ns -
csb103 9.1 2.06 4.50 1 2.25
csb104 2.1 2.56 0.84 0.75 0.56
csb105 na 2.14 5.06 0.7 3.61
csb106 na 1.72 0.4 0.5 0.40
csb107 5 1.92 4.43 0.75 2.95
csb108 5.9 1.98 2.60 0.5 2.60
csb109 8.9 2.21 5.34 0.6 4.45
csb110 8.4 1.99 10.31 0.5 10.31
csb111 2.5 2.33 1.1 0.5 1.10
csb112 7.1 2.03 2.7 0.6 2.25
csb113 9.1 2.04 8.88 0.8 5.55
csb114 7.9 2.02 5.38 1 2.69
csb115 7.8 2.19 2.37 1 1.19
csb116 9.7 2.09 7.46 0.8 4.66
csb117 na 2.87 0.84 0.7 0.60
csb118 na 2.14 10.69 0.5 10.69
csb119 na 2.09 3.96 0.5 3.96
csb120 na 3.15 0.45 0.5 0.45
csb121 9.4 2.03 25.3 0.8 15.81
csb122 9.1 2.06 8.17 0.8 5.11
csb124 8.9 2.27 1.86 0.6 1.55
csb125 na 2.12 13.83 0.75 9.22
csb126 8.8 2.00 4.84 0.8 3.03
csb127 na 3.38 0.59 0.5 0.59
csb128 8.8 2.08 32.73 1 16.37
csb129 na 2.12 10.57 1 5.29
csb130 9.6 2.23 4.57 0.5 4.57
csb131 4.7 2.05 1.80 0.6 1.50
csb132 9.5 1.94 3.15 0.8 1.97
csb133 8.8 2.02 6.55 1 3.28
csb134 8.9 1.89 3.84 0.6 3.20
csb137 9.3 2.00 11.14 1 5.57
csb138 9.3 1.95 4.50 0.7 3.21
csb139 9.1 2.11 12.73 0.5 12.73
csb140 9.2 2.00 21.96 1 10.98
csb141 7.6 2.76 1.55 0.6 1.29
csb142 8.9 1.93 5.89 1 2.95
csb143 9.6 2.10 14.94 ns -
csb14S na 1.66 0.78 0.5 0.78
csb146 na 1.87 1.33 0.5 1.33
csb147 8.9 2.01 8.67 0.6 7.23
csb148 8.7 2.28 4.39 1 2.20
csb149 9.6 2.88 1.57 1 0.79
csb150 8.9 2.35 5.93 0.75 3.95
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csb151 na 3.08 0.93 0.7 0.66
csb152 8.7 2.34 4.41 0.5 4.41
csb153 na 1.70 0.17 0.5 0.17
csb154 na 0.26 0.07 0.5 0.07
csb155 9.2 2.21 7.39 0.7 5.28
csb156 8.9 2.10 7.52 0.6 6.27
csb157 9.4 2.56 1.83 0.4 2.29
csb158 9.1 2.15 4.83 0.6 4.03
csb159 9.4 2.19 7.34 0.6 6.12
csb160 9.3 2.21 4.75 0.6 3.96
csb161 9.1 2.40 6.08 1 3.04
csb162 8.5 2.75 2.38 0.6 1.98
csb163 8.7 2.25 4.52 1 2.26
csb164 na 3.19 1.52 0.5 1.52
csb165 9.2 2.29 9.15 0.7 6.54
csb166 na 0.33 0.07 0.5 0.07
csb167 8.8 2.67 1.84 0.9 1.02
csb168 na 1.09 0.49 ns -
csb169 3.3 2.14 10.48 0.8 6.55
csb170 9.1 2.08 27.35 1 13.68
csb171 7.9 2.44 2.77 1 1.39
csb172 8.7 2.05 1.28 1 0.64
csb173 9.2 2.09 22.14 1 11.07
csb174 9.2 2.08 5.40 0.5 5.40
csb175 7.8 2.37 2.45 0.8 1.53
csb176 8.8 2.06 7.05 1 3.53
csb177 9.6 2.09 16.61 1 8.31
csb178 8.5 2.20 3.30 1 1.65
csb179 9.2 2.31 4.48 0.8 2.80
csb180 9 2.11 14.54 1 7.27
csb181 9.4 2.16 11.79 1 5.90
csb182 9.4 2.38 2.95 0.6 2.46
csb183 9.6 2.12 17.12 0.6 14.27
csb184 9.7 2.15 11.24 0.5 11.24
csb185 9.3 2.05 30.32 ns -
csb186 9.6 2.08 10.12 0.6 8.43
csb187 9.4 2.13 8.33 1 4.17
csb188 9.3 2.10 16.48 0.8 10.30
csb189 9.4 2.10 12.29 0.5 12.29
csb190 9.9 2.15 9.15 1 4.58
csb191 6.5 2.42 3.34 0.7 2.39
csb192 8.5 2.14 6.55 1 3.28
csb193 9.4 2.14 8.18 0.5 8.18
csb194 8 2.33 3.00 ns -
csb195 7.4 2.05 15.55 0.7 11.11
csb196 9.2 2.08 23.55 ns -
csb197 9.4 2.07 11.81 1 5.91
csb198 9.6 2.91 1.55 0.5 1.55
csb199 na 6.47 0.58 1 0.29















csb201 Na 5.46 0.61 0.5 0.61
csb202 8.8 2.17 6.23 0.8 3.89
csb203 7.2 2.40 2.14 0.7 1.53
csb204 9.3 2.07 23.82 1 11.91
csb205 8.4 2.17 3.46 0.8 2.16
csb206 8 2.38 2.88 0.8 1.80
csb207 9.1 2.15 6.08 0.8 3.80
The raw data of the 201 neonatal blood samples obtained are displayed in table 4.1.1
(a to e). Samples are numbered csbl-csb207. There are 6 numbers that do not have
a sample - csb85, csb90, csbl23, csbl35, csbl36, csbl44. Four of these tubes were
removed from the sampling box but never found - presumed discarded without
sampling. Two of the tubes had blood samples taken but unfortunately the
accompanying data sheet was not filled in and therefore these samples could not be
identified and therefore could not be used. Immediate efforts were taken to avoid
such a situation being repeated.
Of the 173 samples assigned a RIN value, RIN ranged from 1 to 10. The mean RIN
was 8.5 and the median 9.1 (table 4.1.2). Of the 28 samples who were not assigned a
RIN value (marked as "na" in the RIN column in table 4.1.1), subjective examination
of the Bioanalyzer traces was carried out. The Bioanalzyer traces can be found in
table 4.1.3 (a - j) in appendix 3. This examination revealed that 5 of the traces were
too small on which to make any judgement (csbl20, csbl46, csbl54, csbl66,
csbl68), 2 traces were small but looked poor quality (csbl 17, csbl27) and 21 traces
were small but were suggestive of good quality with two clear peaks (csb31, csb52,
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csb56, csb82, csb83, csb84, csb88, csb93, csb99, csbl05, csbl06, csbll8, csbll9,
csbl25, csbl29, csbl45, csbl51, csbl53, csbl64, csbl99, csb201).
200 of the samples had A26o:A28o ratio values. The remaining sample had a measured
A28o value of 0 so calculation of a ratio was not possible. The A26oA28o ratio values
ranged from 0.26 to 6.47 (table 4.1.2) with a mean of 2.08 and median of2.04.
Table 4.1.2: Overall Quality and Yield of RNA Obtained from Neonatal
Blood Samples
RIN A26o-A280 Ratio Yield
(M9)
Yield per 0.5 ml
of blood (pg)
Mean 8.5 2.08 10.13 7.07







(12 did not state
vol., n=189)
Percentage of samples sufficient for microarray: 88.1%
The actual RNA yield obtained from the samples ranged from 0.07 pg to 309.94 pg
with a mean of 10.13 pg and a median of 5.38 pg. 177 of the 201 samples (88.1 %)
yielded sufficient RNA to take forward for microarray analysis.
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4.2: Yield and Quality of RNA: Sampling With Needle or Cannula.
The vacuum based blood sampling system recommended for use with the
PAXgene™ is unsuitable for use in neonates as the vacuum applied to small neonatal
veins would cause the vein to collapse. At the time of this study there was no data in
the literature regarding alternative sampling methods. Blood sampling in neonates is
usually carried out by slowly aspirating blood into a syringe from a needle or cannula
or by dripping blood directly into a blood tube. The dripping method is not suitable
for PAXgene™ tubes due to the reagents contained in it being harmful. It was
therefore important both to confirm that sampling into a syringe and then injecting
into the PAXgene™ tubes yielded RNA of sufficient quantity and quality, and to
identify if RNA quality or quantity was different depending on whether needle or
cannula was used for sampling. Sampling is sometimes carried out through
heparinised lines but this was generally avoided where possible for this study,
Of the 201 samples in the study 56 were sampled from a cannula, 132 from a needle,
6 from another non-heparinised line (5 from a peripheral arterial line at the time of
insertion and one from a non-heparinised long-line) and 2 from heparinised lines.
For 5 samples it was not stated which means of sampling was used.
Table 4.2.1 displays the mean, median and range of values for RIN, A26o:A2go ratio
and yield for each method of sampling. All modes of sampling are presented in this
table for completeness but I will comment only on needle and cannula. The mean
RIN for samples taken with a needle was 8.1 (median 9.1) and for those taken from a
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cannula was 8.7 (median 9.1). The mean (and median) values for A26o:A28o for
samples taken by needle and those by cannula were well within the target range of
1.8-2.2 with values of 1.92(1.94) and 2.17(2.08) respectively. 89.3 % of samples
taken using a needle gave sufficient yield for microarray work compared to 87.9 %
of those taken from a cannula. Statistical comparison of the two groups using
Kruskal-Wallis testing gave p values of 0.752 for RIN values, 0.006 for A26o:A28o
ratio, 0.006 for yield and 0.007 for yield per 0.5 ml. On carrying out ANOVA for
A26o:A280 ratio, yield and yield per 0.5 ml statistical significance did not persist with
significance values of 0.062, 0.346 and 0.418 respectively.
Table 4.2.1:
of RNA fori
Mean, Median and Range of RIN, A260:A280 Ratio and Yield













Mean 8.7 8.1 7.8 9.3
Median 9.1 9.1 9.0 9.3
Range 2.1-10 1-10 1.1-9.8 8.5-10
A26O:A28O
Ratio
Mean 2.17 1.92 2.00 1.99
Median 2.08 1.94 1.91 1.99
Range 0.26-6.47 0.33-2.91 1.33-2.75 1.83-2.14
Yield
(M9)
Mean 12.59 5.00 7.72 11.12
Median 6.03 3.74 3.40 11.12








Mean 8.78 3.15 6.50 5.56
Median 4.07 2.73 3.20 5.56
Range 0.07-258.28 0.07-11.91 0.21-24.16 3.28-7.84
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4.3: Yield and Quality of RNA: Clinician Taking the Sample.
















In order for any investigation to be useful clinically it is important that sampling can
be done effectively by clinicians at the point of clinical need. It was therefore
important to examine the quality and quantity of RNA obtained from sampling by
multiple clinicians. Overall there were 200 samples taken by 39 clinicians (1 sample
was excluded as sampler not stated). Figure 4.3.1 displays the proportion of samples
taken by each clinician. The mean, median and range of volume sampled, RIN,
A26(fA28o ratio and yield according to clinician sampling are displayed in table 4.3.1.
Any clinician who took less than 4 samples was included in the "other" row.
Looking at these results, with the exception of sampler Rl, the RNA obtained was
generally of good quality as determined by RIN, with the lowest mean RIN being 7.8
and lowest median being 8.8. Mean and median A26o:A28o ratios were generally
within the acceptable range of 1.8 to 2.2 with a few outliers.
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There was considerable variance in the yield obtained. Two clinicians (K1 and Rl)
had only 50 % and 40 % of their samples respectively yielding sufficient RNA for
microarray. This is notably different to the samples from all of the other clinicians
which yielded sufficient RNA 72.7 to 100 % of the time.
Using Kruskal-Wallis testing to examine differences between samplers, there was no
significant difference in RIN between samplers with significance value of 0.306,
there was a significance value of 0.036 for yield and a significance value of less than
0.001 for A26o:A28o ratio. On carrying out ANOVA statistical significance was not
seen to persist for A26o:A2so ratio with significance value of 0.064 but the
significance value for yield was 0.011.
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4.4: Yield and Quality of RNA: Samples Not Frozen or Frozen.
Table 4.4.1: RIN, A260:A280 Ratio and Yield of RNA According to










































Comparison of yield and quality ofRNA depending on whether a sample was frozen
or not prior to extraction was carried out. For both groups the mean and median
values for A26o:A28o were well within the optimal range of 1.8-2.2. The mean and
median values of RIN were also good for both groups with the frozen group having
mean RIN of 8.4 and median of 9.1 compared to 8.6 and 9.2 for the not frozen group.
Although the mean and median values of yield for the frozen samples looked to be
greater, the proportion of samples yielding sufficient RNA for microarray was
greater for the samples not frozen. When differences between the groups were
examined using Kruskal-Wallis testing, there was no significant difference either in
RIN with significance value of 0.079 or in yield with a significance value of 0.773.
Comparison of mean A26o:A28o ratio between groups revealed significance value of
less than 0.001 when comparing groups. On carrying out ANOVA for A26o:A28o, the
statistical significance was found to be 0.036.
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4.5: Yield and Quality of RNA: Duration of Freezing.










































































































































































































Of the samples that had been frozen, more specific comparison of yield and quality
of RNA obtained depending on duration of freezing that was then carried out. 140
samples are examined in this section. It was not possible to calculate the duration of
the remaining one sample from the sampling information that was documented.
Table 4.5.1 displays the mean, median and range ofRIN, A26o:A280 ratio and yield of
RNA for each period of freezing. For most durations of freezing both the median
and mean values for RIN were good at over 8. Four durations of freezing (0-7 day,
5-6 weeks, 8-9 weeks and 10-11 weeks) had lower mean RIN values (6.3-7.65) but
median RIN values of over 8. The samples frozen for between 7 and 8 weeks had
poorer RIN values with both mean and median values of 5.6. With the exceptions of
samples frozen for between 8 and 10 weeks which had slightly high mean and
median A26o:A28o ratios and the 12-13 week group which had a low mean ratio at
1.63, the other groups showed acceptable A26o:A28o ratios (target range 1.8-2.2).
Yield varied between groups with the percentage of samples sufficient for microarray
ranging from 50-100 %. The lowest percentage of sufficient yields occurred after
12-13 weeks freezing and the highest after 6-8 week, 11-12 weeks and over 6
months.
Kruskal-Wallis testing between groups showed no significant difference in RIN with
significance value of 0.107 and no significant difference between groups with respect
to yield with significance value of 0.107. The significance value for difference
between groups in terms of A26o:A28o ratio was 0.004. When ANOVA was carried
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out to look at differences between the groups in terms of A26o:A28o ratio the
significance value was 0.007.
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4.6: Yield and Quality of RNA: Time at Room Temperature Prior to RNA
Extraction.
Yield and quality of RNA were examined depending on time of incubation at room
temperature prior to RNA extraction. Samples were looked at separately depending
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On examination of graphs 4.6.1 and 4.6.2, plotting RIN against incubation time for
samples that were not frozen and were frozen respectively, there is no clear pattern
relating incubation time to RIN value. In both graphs, it can be seen that the
majority of samples have good RIN values and that those at lower RIN do not seem
to occur at a particular duration of incubation.
Graphs 4.6.3 and 4.6.4 plot A26o:A2so ratio against incubation time at room
temperature prior to RNA extraction for samples that were not frozen and frozen
respectively. There is no clear pattern relating A26o:A28o ratio to incubation time. Of
Graph 4.6.1: RIN against incubation time at room temperature for
samples not frozen
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note, there is a greater spread of A26o:A28o ratio values for samples that were frozen
but this does not seem to be related to any particular incubation periods.
Graph 4.6.2:RIN against incubation time at room temperature of
samples that were frozen
10 11 12 13 14 15
Graph 4.6.3: A260:A280 ratio against incubtation time at room




Graph 4.6.4: A260:A280 ratio against incubation time at room
temperature for samples that were frozen
7 8 9
Time (hours)
Looking at graphs 4.6.5 and 4.6.6 which plot total yield (blue diamond) and yield per
0.5 ml of blood (pink square) against incubation time at room temperature for
samples that were not frozen and that were frozen respectively, there is not any clear














Graph 4.6.5: Yield ofRNA against incubation time at room
temperature for samples not frozen
• Total yield of RNA
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4.7: Yield and Quality of RNA: Operator Carrying Out RNA Extraction.





Consistency of RNA extraction method is vital and it is also important for any
method to be reproducible between laboratory workers. Yield and quality of RNA
obtained from three different laboratory workers (myself, Alan Ross and Paul
Dickinson) was therefore examined (Fig 4.7.1). The PAXgene™ Blood RNA
extraction protocol on page 76 was always used. The mean (and median) RIN values
for each operator were similar at 8.3 (9.1) for Claire, 8.5 (9.1) for Alan and 8.8 (8.9)
for Paul. All three operators had mean and median A260:A280 ratios within the
desired range of 1.8 to 2.2. 89.4 % of samples extracted by Claire gave sufficient
yields for microarray compared to 87.1 % of those extracted by Alan and 83.3 % of
those extracted by Paul.
On Kruskal-Wallis testing, there was no significant difference in RIN between
operators with significance value of 0.881. Neither was there significant difference
between operators with respect to overall yield with significance value of 0.961 nor
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with respect to yield per 0.5 ml of blood with significance value of 0.69. The
significance value for difference between operators in terms of A26o:A28o ratio was
0.002. When ANOVA was carried out to look at differences between the operators
in terms of A26o:A28o ratio the significance value was 0.225.
Table 4.7.1: RIN, A260:A280 Ratio and Yield of RNA According to















































































4.8: Yield and Quality of RNA: White Cell Count of Samples
As the RNA content of whole blood is essentially that of the white blood cells, it
would be logical to assume that the white cell count of a blood sample could affect
the yield ofRNA obtained. In practice, the white cell counts of newborn infants can
be very variable and therefore I felt that it was important to assess whether there was
any clear pattern of white cell count relating to RNA yield. In particular, if a baby
has an unusually low white cell count, as can be the case in overwhelming sepsis, is
it still possible or indeed likely that sufficient RNA for microarray analysis could be
obtained?
The white cell count used in this section has been adjusted for volume of blood
obtained, i.e. is an absolute white cell count for each sample. The number of samples
examined in this section was restricted to those who had known white cell counts and
for which the volume of blood taken was documented, a total of 163 samples. Of
these 163, 25 had "na" RINs and one had a "na" A26o:A28o ratio.
Graph 4.8.1 displays RIN against white cell count and shows no clear correlation
between the two. Graph 4.8.2 displays A26o:A2go ratio against white cell count. It
shows that the majority of samples are within the desirable range of 1.8 to 2.2.
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Graph 4.8.1: RIN against white cell count
20 30 40
White Cell Count (x10A6)
Graph 4.8.2: A260:A280 ratio against white cell count
20 30 40
White Cell Count (x10A6)
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Graph 4.8.3: Yield of RNA against white cell count
White Cell Count (x10A6)
Graph 4.8.4: Yield of RNA against white cell count
(magnified for yield under 50 micrograms)
20 30 40
White cell count (x10A6)
Graphs 4.8.3 and 4.8.4 plot yield of RNA against white cell count. Both graphs
display the same data but with 4.8.4 magnifying the yield values of under 50 pg. In
other words this includes all except three of the values from 4.8.3.
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4.9: Yield and Quality of RNA: Neutrophil Count of Samples.
Neutrophil-mediated immune response is particularly important in bacterial
infection. As an additional step, I decided to examine neutrophil count values for the
neonatal blood samples and try and determine if the absolute neutrophil count has
any discernible effect on RNA yield and quality obtained. The neutrophil count
shown in this section has been adjusted for sample volume and is therefore an
absolute neutrophil count. The number of samples with an absolute neutrophil count
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Graph 4.9.1 plots RIN against neutrophil count and does not show a clear
relationship between the two factors. Lower RIN values are found over a wide range
Graph 4.9.1: RIN against neutrophil count
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of neutrophil counts, not just those that were low. Most samples with low neutrophil
counts had good RIN values.
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Graph 4.9.2 plots A26o:A280 ratio against neutrophil count. As for total white cell
count, most of the values are within the desirable range. The A26o:A2go ratio values
that are most extreme appear to occur at the lower end of neutrophil count.
Graphs 4.9.3 and 4.9.4 both plot RNA yield against neutrophil count. Graph 4.9.4
displays identical data points to Graph 4.9.3 but magnifies yield of less than 50 pg.
This excludes only 3 of the data points found in graph 4.9.3. There is a suggestion
that higher neutrophil counts may trend towards higher yields of RNA but there are
many samples where this was not the case.
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Graph 4.9.4: V/'e/rf of RNA against neutrophil count
(yields of less than 50 micrograms magnified)
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As discussed in chapter 3, at the time of this work, there was no data in the literature
regarding the use of neonatal whole blood for use in microarray work. Neonatal
blood composition differs from that of adults, particularly with respect to white cell
count and there are well established reference ranges for the newborn (343). In
addition, neutrophil counts tend to be lower in very low birth weight infants and
separate reference values have been defined (344). These differences in cell
composition along with the absolute requirement of small sample volumes meant that
validation work was essential. From the work in chapter 3 using umbilical cord
blood I could be confident that use of small volumes of neonatal blood for
microarray work would be feasible and therefore neonatal blood sampling
commenced. It was however, still important to take stock and examine the yield and
quality ofRNA obtained from the neonatal samples. Although umbilical cord blood
is a good surrogate for neonatal blood, the samples used in chapter 3 were all taken
from term or near-term births. The neonatal population being studied for the
microarray work includes a large proportion of preterm and growth restricted infants
who may have lower neutrophil counts at birth (344). In addition, the sampling from
the neonatal population was not restricted to the time of delivery so age-related
changes in blood composition may have an affect on yields ofRNA obtained.
It was therefore reassuring to confirm in 4.1 that high quality RNA of sufficient
quantity for microarray use was obtained in the majority of cases sampled.
Examination of tables 4.1.1 and 4.1.2 revealed that RIN values ranged from 1 to 10
with the median and mean values good, at 8.5 and 9.1 respectively. It was also
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reassuring that on examination of the bioanalyzer traces (appendix 3) for the samples
with no RIN, many of the traces looked to have two crisp peaks but only very small.
In other words, it appears likely that if many of the "na" bioanalyzer traces were
repeated with concentrated samples that a higher RIN would be obtained. In
addition, subjective examination of 9 further samples with RIN of 2.5 and under,
showed that two samples (csb3, csb78: both with RIN of 1) were too small to make
any further comment on and the other seven (csb9, csb48, csb77, csb92, csb98,
csbl04, csblll) were small but with two crisp peaks, suggesting that if more
concentrated may have had higher RIN values. The mean and median A26o:A28o
ratios were also both within the target range at 2.08 and 2.04 respectively. There
were a few notable outliers of A26o:A28o values however and on closer examination,
the majority of these were also very small samples that were insufficient to run on
array. It is possible that these smallest samples could be generating aberrant ratios
when measured on the spectrophotometer because small changes in measurement of
either value could make a large difference to the ratio. Overall, I was very pleased
with the quality of RNA obtained. The yield of RNA obtained ranged from 0.07 to
309.94 pg with 177 of the 201 samples (88.1 %) being sufficient to run on
microarray. Overall, although this is a high percentage, I was disappointed with this
level of success with the yield as this would mean that 1 in 10 samples taken was not
sufficient. For interest, I calculated the overall yield of RNA per 0.5 ml of blood
sampled in each case in order to allow comparison with the yields obtained from the
umbilical cord blood studies in chapter 2. From the clinical samples 163/189
samples (86.2 %) yielded sufficient RNA from 0.5ml for microarray analysis. This
compares with 97.1 % of the cord blood samples (0.5ml) from chapter 3.
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I suspect that this difference may be due to over-estimation of the volume of blood
sampled in many clinical cases and that a proportion of the samples were less than
0.5 ml. Unfortunately I did not weigh the samples to verify sample volume prior to
RNA extraction and if I were to do the study again I would weigh each sample to
verify the volume of blood in each tube before RNA extraction. Alternatively, the
wider range of yields obtained may be a reflection of the greater diversity of the
clinical group. The samples in chapter 3 were taken from umbilical cords at
deliveries by elective caesarean section. In general this group would be expected to
be around term in gestation and would be considered a "low risk" group in terms of
ill-health for the baby. In addition, all of these samples were taken in an identical
manner by one person (myself) and RNA was extracted by myself. The samples in
this chapter are taken from a more heterogeneous group in terms of gestation, age,
clinical condition at time of sampling, person sampling, method of sampling and
person extracting RNA. It is likely that both underestimation and increased
heterogeneity of the population play a part in the increased proportion of insufficient
samples. For future sampling, the importance of taking adequate volumes of blood
will be stressed in order to eliminate any avoidable causes of inadequate yields of
RNA. Of note, the calculations used to determine if the yields were sufficient for
microarray use were based on the required starting material for CodeLink™
microarrays. We have subsequently moved onto using Illumina® microarrays
which require 50-100ng starting material. This means that 93.5% of the clinical
samples would have sufficient yield if lOOng was used and 97.5% if 50ng was used.
While this is markedly better, there is still room for improvement and my comments
above remain pertinent.
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From the results presented in 4.2 it can be seen that similar high levels of high
quality RNA are obtained when sampling using a needle or cannula and that the
percentage of samples yielding sufficient RNA are also similar. Statistical testing
did not show any consistently statistically significant difference in the yield or
quality of RNA obtained. This means that either method is suitable for blood
collection. This means that current clinical practice with respect to blood sampling
at the time of suspected sepsis would not need to change.
When the clinician taking the samples was examined in 4.3, it was pleasing that for
the majority of clinicians the RNA quality was good. The notable exception to this
was clinician Rl. On statistical testing there was no persisting statistically
significant difference in terms of RNA quality. There was a wide range of RNA
yields seen however. This did not seem to show any consistent pattern when
compared with the documented volume of blood sampled. As alluded to above I
have concerns over the accuracy of documentation of volume of blood sampled and
that some volumes may be over-estimates. There is wide variation in the percentage
of samples sufficient for microarray between samplers - K1 and Rl are particularly
notable in being low in this respect. In addition, statistical testing revealed that
differences in yield according to clinician sampling were statistically significant. It
may be postulated that samplers K1 and Rl in particular may have over-estimated
their sample volumes. For sampler Rl, the low yields and low quality may both be
consequences of low sample volume. Alternatively, the low quality may have been
due to non-adherence to sampling protocol. For future sampling, more stringent
education on sampling technique, along with demonstration and supervision may
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help improve the yields obtained. In addition, increasing the minimum volume of
blood aimed for from 0.5 to 0.75 ml may help.
When examining samples depending on whether they were frozen or not (4.4) there
was no statistically significant difference in either yield of RNA obtained or in RIN
values. Statistical testing did reveal a statistically significant difference between the
groups for A26o:A28o ratio with frozen samples tending to have higher values. The
mean ratio for frozen samples was 2.13 and that for samples that were not frozen was
1.94. As these values are both well within the target range of 1.8 to 2.2, this
difference is not of any practical significance. Both groups yielded high quality
RNA with a high percentage sufficient for microarray work. This is important as it
confirms the findings from the umbilical cord blood work in chapter 2. Freezing of
samples allows more efficient sample processing. Samples taken off site could also
be included in future studies if they were transported frozen which is very positive.
Duration of freezing (4.5) had no practical or statistically significant effect on RIN or
yield of RNA obtained. On statistical testing there was found to be a statistically
significant difference between groups in terms of A26o:A28o ratio, however this
difference is unlikely to be of any practical significance as all of the groups other
than those frozen for 8-10 weeks and 12-13 weeks had mean and median ratios
within the target range of 1.8 to 2.2. Intuitively, it would seem unlikely that samples
would worsen in terms of high A26o:A2go ratio if frozen for 8-10 or 12-13 weeks and
then improve with further freezing. Overall, this data is encouraging and supports
freezing of samples for up to several months. It would be prudent to keep
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monitoring the A26o:A28o ratios however, and if any significant differences persist to
investigate this further.
When the effect of period of incubation at room temperature prior to RNA extraction
was looked at (4.6), no clear pattern relating time to yield, RIN or A26o:A28o ratio was
seen. This was true both for samples that had been frozen and those that had not. As
almost all of the samples were incubated at room temperature for 2.5 to 5 hours for
fresh samples and 4 to 5 hours for the frozen samples, these observations confirm
what was expected from the umbilical cord blood results in chapter 2.
The operator carrying out the RNA extraction (4.7) did not have any statistically
significant effect on RIN or yield of RNA obtained. Although on Kruskal-Wallis
testing there was a statistically significant difference in A26o:A28o ratio depending on
operator, this statistical significance did not persist on ANOVA. For all three
operators good levels of RIN and sufficient yields in a high percentage of samples
were obtained. This was encouraging but was what was expected as all three
operators were strictly following the same protocol. This may be taken as evidence
that adherence to protocol for RNA extraction leads to consistency of results.
In section 4.8 I examined the quality and yield ofRNA with respect to the white cell
count of the samples. There was no clear correlation seen between RIN and white
cell count (graph 4.8.1). It could be seen that most samples with lower white cell
counts had high RIN values and that the poorer RIN values were spread over a range
of white cell counts including both low counts and counts within the "normal range".
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The few samples with extremely high white cell counts all had RIN values of over 7
but the number of samples is not sufficient to confidently make any statement
regarding trend in this respect. The majority of samples had A26o:A28o ratios within
the desirable range. Interestingly, the samples that were the greatest outliers in terms
of A26o:A28o ratios all had lower white cell counts (graph 4.8.2). The majority of
samples with lower white cell counts were, however, within the desired range. When
the yield of RNA was considered there may be a suggestion of a trend towards
increased white cell count yielding more RNA but there are many samples where this
was not the case. In other words, yield of RNA may be higher for some but not all
samples with higher white cell count. When neutrophil count was examined in
section 4.9 there was no clear-cut relationship seen between neutrophil count and
RIN values, A26o:A28o ratio or RNA yield. It is worth noting that some of the
poorest A26o:A28o ratios were from some of the lowest neutrophil counts but most
samples with low neutrophil count had good A26o:A28o ratios. Yield ofRNA may be
higher for some but not all samples with higher neutrophil count. These findings are
of practical importance when considering clinical neonatal infection. Some of the
sickest infants will have low white cell and neutrophil counts. It is therefore very
encouraging that some of the highest yields of RNA were obtained from samples
with low counts and that most samples with low counts had high RIN values. This
means that the sickest babies with the lowest white cell counts can be included in
these studies and can therefore benefit from any useful results obtained.
These results are novel findings as there are no similar reports specific to neonatal
whole blood in the literature at the time ofwriting.
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Chapter 4: Conclusions
• It is possible to obtain sufficient high quality RNA from neonatal blood
samples in order to carry out microarray experiments.
• The clinician taking the sample did not seem to have any significant effect on
the quality of the RNA obtained but may affect the yield. This may be due to
variation in sampling technique or over-estimation of the blood volume being
sampled. More stringent training on sampling and the importance of
minimum blood volume may help with this.
• There was no statistically significant or practical difference in yield or quality
ofRNA obtained when comparing:
> Sampling using needle or cannula
> Samples being frozen or not prior to RNA extraction
> Incubation time at room temperature prior to RNA extraction (for
either frozen or non-frozen samples)
> Laboratory operator carrying out RNA extraction
• Duration of freezing prior to RNA extraction does not affect RIN values or
yield of RNA but may affect the A26o:A28o ratios achieved. This is not likely
to be of any practical significance.
• There is no clear-cut relationship between either white cell count or
neutrophil count and RIN values, A26o:A28o ratio or RNA yield.
Overall, the work in this chapter confirmed that neonatal whole blood is a suitable
source of high quality RNA for microarray work. These findings meant that studies
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into neonatal RNA expression profiling could be planned with confidence and we
were happy to proceed onto the microarray work presented in the next chapter.
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Chapter 5
Microarray Investigation of Host RNA




As work progressed on this study it became clear that the results looked promising. I
have therefore been fortunate enough to be able to take advantage of the opportunity
to carry out further array experiments. When I set out on this project, the aim was to
show that it was feasible to run human neonatal RNA obtained from whole blood by
using in the region of 6-10 microarrays. In this chapter, this aim is surpassed as I
present larger, more detailed microarray studies examining differences in gene
expression profiles between infected and control neonates.
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Chapter 5.1: Investigation of Neonatal Infection Using
CodeLink™ Microarravs.
Aim
To examine differences in RNA expression profiles between groups of infected and
control and possibly infected infants within a statistically meaningful and balanced
experimental design.
Experimental Design
This experiment was designed so that analysis should include at least 27 in each of
infected, control and possible infection groups. From work carried out within the
Division of Pathway Medicine (345) (Analyst paper, Appendix 4) using some ofmy
non-infected neonatal samples the number projected for each group to achieve 90 %
power for at least 90 % of genes at significance level of a = 0.001 was 100. This
was an early projection and as further results were analysed it became apparent that
robust results were being achieved from smaller group sizes. 27 was chosen as the
group size as this was felt to be achievable in the time frame being considered and
allowed 3 operators for each group. The experiment was designed to ensure that
arrays were run so that the samples for analysis could be operator-balanced in order
to avoid this as a potential source of variation.
27 infected samples were run; 9 each by myself, Marie Craigon and Alan Ross
27 control samples were run: 9 each by myself, Marie Craigon and Alan Ross
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30 possible infection samples were run: 10 each by myself and Marie Craigon and
the other 10 were run by either Alan Ross (3) or Petter Storm (7).
Acknowledgements
RNA. extractions were run by myself (55) and by Alan Ross (29). RNA quality
control was carried out by myself and Alan Ross.
28 microarrays were run by myself, 28 by Marie Craigon and 28 by either Alan Ross
or Petter Storm as detailed above.
Microarray data was sent to A1 Ivens of FIOS Genomics for data quality control, data
filtering and normalisation, statistical comparisons and functional analysis.
Infants studied
Details of eligibility to the study, exclusion criteria and consent were the same as
those described in chapter 4 (page 188).
Infected samples were defined as samples that had positive microbiological evidence
of infection from a usually sterile body fluid, i.e. from blood, cerebrospinal fluid,
peritoneal fluid or fluid from an abscess. Cases of necrotising enterocolitis were
only considered to be infected if there was a positive culture result from a usually
sterile body site. All of these samples were taken from infants at the time of clinical
suspicion of infection.
Control samples were taken from infants who were having clinical blood samples
and for whom there was no clinical suspicion of infection. Specifically, samples
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were taken from a group of term infants who were having their thyroid function
tested in view of maternal thyroid disease, from a group of term infants in whom a
diagnosis of congenital adrenal hyperplasia (CAH) was suspected, and from a group
of preterm infants who were having routine clinical biochemistry/haematology
monitored while clinically well. In order for the control samples to be eligible for
inclusion, the thyroid screening or CAH screening had to be negative, the full blood
count must not have shown any indicators of infection, and the infant must have
remained clinically well. Had there been any doubt on any of these points, the
sample would not have been used as a control on array. A third group of infants
were examined. These were infants who had study blood samples taken because they
were suspected of having sepsis but who subsequently did not have any positive
microbiological culture results obtained from a usually sterile body site. These
infants are referred to as the "possible infection group".
Each sample was from a different infant, i.e. no infant had more than one sample
examined. All samples were taken with written, informed, parental consent. Ethics
committee approval had been obtained for this study. Blood sampling and storage
prior to RNA extraction was carried out as described in detail in chapter 2 (page 62).
RNA extraction and Quality Control
RNA extraction was carried out using the modified PAXgene™ protocol found on
page 76 and assessment of quality and quantity ofRNA was performed as described
on pages 88 to 98.
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Labelling, Hybridisation and Microarray Analysis
Labelling, hybridisation and microarray scanning of samples was carried out as
described on pages 99 to 117.
Data Filtering, Normalisation and Analysis
Microarray data was supplied to FIOS genomics. Normalisation of the arrays was
carried out using the robust multi-array average (RMA) expression measure (346)
with the resulting summarised intensities being expressed in log base 2. FIOS
carried out group to group comparisons using linear modeling and subsequent
empirical Bayesian approaches. This included vertical p value adjustment for
multiple testing (within a given comparison) in order to control for false discovery
rate (Benjamini Hochberg). The Bioconductor package limma was used (347). The
statistical significance level chosen for carrying data on for functional analysis was
adjusted p < 0.01. The functional analysis of significant genes found in these
comparisons was carried out by examining KEGG pathway membership and Gene
Ontology (GO). Assessment for up and down regulation was carried out for
enrichment p values of< 0.05 for KEGG and of< 0.001 for GO.
Results
Quality Concerns
FIOS genomics expressed some concerns about the quality of microarray data
received. Firstly there was some concern about background signals being high.
Secondly, there was concern expressed over the degree of variability between
samples and in particular a lack of mid-range expression genes in some samples.
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Thirdly, there was concern that there seemed to be a distinct divide of the arrays into
two groups (not related to the experimental groups of control, infected and possible),
leading to the suggestion that two separate analyses may be appropriate. We, as a
research group, discussed these concerns. The background issue was not new and
arrays had been successfully analysed in spite of this before. I would postulate, at
least in part, that this was due to the first batch of arrays having a problem with
migration of glue (that was holding the removable cover in situ). It would appear
that these concerns were not confined to the first batch however and this may be
considered to be a drawback of the CodeLink™ set-up. The large number of
differences between samples had been noted for our neonatal samples run on
CodeLink™ previously, and confirmed on Affymetrix chips (data not shown). The
concern over differences ofmid-range expression genes was postulated to be due to a
processing step, possibly due to the use of Cy-5 for labelling. The normalisation
method used was chosen with the potential for biological variation in our sample
population in mind. It was evident that there was a distinct difference seen between
the initial batches of array slides used compared with the last batch of 24 that was
purchased. In other words there was some manufacturing-related batch difference
which was affecting our results. This difference can be seen in the peak density plot
displayed in figure 5.1.1 and in the Boxplot of background corrected data displayed
in figure 5.1.2. For each, the affected batch is on the right of the red line. This was
clearly frustrating to us as it was not related to anything we had control over. I
consider this to be an unfortunate consequence of the fact that we had scaled up the
study gradually as the pilot studies were seen to be promising and more samples
were obtained. To split the results into two groups for analysis would not only
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reduce the power of the study drastically but it would also skew the data. All of the
possible infection samples and more of the controls had been run on earlier batches
than on the 24 latest slides. Our initial intention had been to analyse this data with a
view to publishing the results but with the concerns described above we felt that
results would no longer be of high enough quality as they stood. We therefore
decided to proceed with data analysis on a look and see basis, analysing all of the
results (except the two arrays excluded as significant outliers) as a single batch. It
was decided to re-run as many samples as possible as a single batch on another
microarray platform (presented in chapter 5.2) and that any corroboration of results
between platforms would be considered positive. Although several secondary
comparisons were carried out by FIOS genomics, given the concerns regarding the
quality of the data, I have not presented any of these results here.










Acknowledgement: Figures 5.1.1 and 5.1.2 were generated by Al Ivens of FIOS genomics and
modified by me.
Figure 5.1.2: Boxplot ofBackground Corrected Raw Data
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Samples
Samples: Final data set
86 microarray scans were sent to FIOS genomics with the intention of analysis
consisting of 27 controls, 27 infected and 27 "possible infection". The extra scans
were sent to allow potential substitution for scans that failed on quality control. Two
scans were failed on data quality control due to lack of correlation with the other
samples. In the actual event, 27 infected samples, 27 controls and 30 possible



























































































































































































































































































































































































Samples: RNA quality and operator
Tables 5.1.1, 5.1.2 and 5.1.3 display each of the groups of samples in the final
dataset stating operator and RIN values for each sample. 6 samples did not generate a
RIN. For these and all samples with RIN less than 8, the bioanalyzer graphs were
studied qualitatively and were felt to be acceptable. Of the 78 samples with RIN
values, the range ofRIN was 5-10 with a mean of 9.0 and a median of 9.3.
Samples: Clinical Characteristics
Table 5.1.4 displays the gender, age and weight of the infants sampled in each group.
The control group had a greater proportion of boys than the infected group and
possible group with 63 % compared to 52 % and 53 % respectively. The infected
group was notably more premature and therefore both of lower birthweight and older
when sampled than the controls.
Table 5.1.4: Demographics of Samples Used
Control (n=27) Infected (n=27) Possible Infection (n=30)

















































The possible infection group was more premature than the control group but less so
than the infected group. They tended to be younger in terms of number of postnatal
days than either the infected or control groups. The breakdown of reasons for blood
sampling in the control group is presented in table 5.1.5.
Table 5.1.5: Clinical Reasons for Blood Sampling in
Control Group (n)
Maternal Thyroid Disease 9
Jaundice 4
Screening for Congenital Adrenal Hyperplasia 3
Coombs positive 1
Urea and electrolytes:




"Routine" neonatal screening (preterms) 5
Hypoxic ischaemic encephalopathy 1
Table 5.1.6 lists the micro-organisms isolated from the infected group. The majority
of samples isolated were Coagulase negative staphylococci. One infant had a
positive growth of yeast (Candida albicans) from blood culture and also had
Klebsiella species isolated from peritoneal fluid. One infant had CMV isolated from
both blood and urine. One infant had Enterovirus meningitis and another had
Listeria meningitis. The remaining infants had positive blood cultures with other
pathogenic bacteria.
Table 5.1.6: Microorganisms Isolated from Infected Group
Organism n Comments
Coagulase negative staphylococci 12
Candida albicans 1 Klebsiella was also isolated from peritoneal fluid
Enterobacter species 1
Enterococci (E.faecalis) 3 1 sample also had coagulase negative
staphylococcus in CSF
Group B streptococcus 2 1 sample also had coagulase negative
staphylococcus in CSF
Pseudomonas aeruginosa 1 Coagulase negative staphylococcus in blood too
Cytomegalovirus (CMV) 1 Isolated in blood and urine
Klebsiella species 3
Listeria monocytogenes 1 From CSF only
Enterovirus 1 From CSF only
Escherichia coli 1
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All of the infected samples included were considered to be convincing cases of
infection. Where the organism was viral, was isolated from CSF rather than blood or
where the isolated organism was coagulase negative staphylococcus, there had to be
supporting clinical evidence of significant infection. Evidence for this is presented in
table 5.1.7.
Table 5.1.7: Supporting Evidence for Infection in Viral, Meningitis and
Coagulase Negative Staphylococcal Cases.




• Re-intubated, neutrophilia (5)
• Bradycardias, pyrexia, low platelets (15)
• Apnoeas, bradycardia, temperature instability, lethargy (2)
• Repeat isolate obtained the following day, hypotension,
hyperglycaemia, thrombocytopenia, died (15)
• Bradycardias, desaturations, long line in situ (11)
• Apnoeas, bradycardias, leucopoenia, thrombocytopenia (10)
• Previous isolate, bradycardias, desaturations, mottled (18)
• Previous isolate, long line in situ: also isolated from line tip,
bradycardias, desaturations, reduced perfusion (18)
• Bradycardias, desaturations, reintubated, deranged sugars
(10)
• Previous isolate, hypotension, hypoglycaemia, oedema, died
(16)
• Isolated in 2 separate blood cultures taken at same time,
bradycardia, desaturations, reintubated, temperature instability
(5) "
• Apnoeas, pyrexia, reduced perfusion, elevated white cell
count, infant had two further significant episodes of infection
associated with coagulase negative staphylococcus (>10)




Pyrexia, hypertonia, elevated CSF white cells, neutrophilia in blood
(14)
Cytomegalovirus Profound bradycardias and desaturations (nil)
Table 5.1.8: Possible Infection Grouip: Length of Course ofAntibiotics
Length of Course of Antibiotics (days) Number of infants (n=30)
None 5
Up to 2 days 0
2 or more days but less than 5 days 12
5 days 11
More than 5 days 2
Table 5.1.8 displays the length of course of antibiotics received for infants in the
possible infection group. The range of length of course of antibiotics was zero to
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Control
fifteen days. This table is included to give an indication of the degree of concern
over these infants. For the decision for no antibiotics to be given in 5 cases there
must have been minimal clinical concern. Conversely, those infants with 5 or more
days of antibiotics would be expected to have had significant clinical concern or
significant risk factors for infection.
Figure 5.1.3: Genespring expression profile of significantly differentially
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Acknowledgement: The above figure was generated from Genespring by Paul Dickinson.
The Genespring expression profile of significantly differentially expressed genes
(between infected and control groups) pictured here as figure 5.1.3 shows each
individual sample on the x-axis, with controls on the left, infected samples in the
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middle and possible infection samples on the right. The y-axis is the normalised log
intensity. Blue lines represent significantly down-regulated genes and yellow lines
represent significantly up-regulated genes (1912 genes). There is a discernable
difference in response seen between infected and control infants. For example, the
control infants have a blue band of genes that are expressed at a higher intensity than
a yellow band of genes, the converse being true for the infected infants. The pattern
for the possible infection group appears to be somewhere in between that for the
infected group and that for the control group with some blue peaks and some yellow
peaks.
Infected Compared to Control
Significant Differential Expression
3660 features were significantly differentially expressed with an adjusted p value of
less than 0.01: 967 up-regulated and 2693 down-regulated.
GO Term Enrichment
In the significantly up-regulated genes there were 52 enriched GO terms and in
significantly down-regulated genes there were 94 enriched GO terms. These are
displayed in tables 5.1.9 (a and b) and 5.1.10 (a to c). The ontology categories are
BP (biological process), MF (molecular function) and CC (cellular component).
These abbreviations are used throughout this section. The terms are listed in order of
significance with the most significant first. I have highlighted in red the terms that
are immediately recognisable as being involved in immune response.
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Table 5.1.9a: GO Terms for Up-regulated Genes.
Infected compared to Control
Ontology GO ID GO Term
Enriched
p Value
BP G0:0009611 response to wounding 4.67E-10
BP G0:0002376 immune system process 1.11 E-07
BP G0:0009605 response to external stimulus 1.33E-07
BP G0:0006955 immune response 1.61 E-07
BP G0:0006952 defence response 7.15E-07
BP G0:0006954 inflammatory response 1.81E-06
BP G0:0006950 response to stress 2.96E-06
BP G0:0007599 haemostasis 4.94E-06
BP G0:0007596 blood coagulation 1.09E-05
BP G0:0048522 positive regulation of cellular process 1.16E-05
BP G0:0050817 coagulation 1.24E-05
BP G0:0050878 regulation of body fluid levels 1.33E-05
BP G0:0048518
positive regulation of biological
process 1.67E-05
BP G0:0006935 chemotaxis 4.82E-05
BP G0:0042330 taxis 4.82E-05
BP G0:0007626 locomotory behaviour 5.59E-05
BP G0:0007155 cell adhesion 0.000104544
BP G0:0022610 biological adhesion 0.000104544
BP G0:0065007 biological regulation 0.000117914
BP G0:0007165 signal transduction 0.000194926
BP G0:0007610 behaviour 0.000279811
BP G0:0042060 wound healing 0.000285928
BP G0:0051272 positive regulation of cell motion 0.000353055
BP G0:0051270 regulation of cell motion 0.00036052
BP G0:0031325
positive regulation of cellular metabolic
process 0.000406484
BP G0:0051707 response to other organism 0.000411483
BP G0:0050896 response to stimulus 0.000430816
BP G0:0006928 cell motion 0.000504015
BP GO: 0051674 localisation of cell 0.000504015
BP G0:0012501 programmed cell death 0.000506126
BP G0:0042221 response to chemical stimulus 0.000549588
BP G0:0008284 positive regulation of cell proliferation 0.00060892
BP G0:0031328
positive regulation of cellular
biosynthetic process 0.000661952
BP G0:0008219 cell death 0.000672349
BP GO: 0065008 regulation of biological quality 0.000678745
BP G0:0016265 death 0.000747207
BP G0:0006915 apoptosis 0.000760179
BP G0:0009891
positive regulation of biosynthetic
process 0.000827454
BP G0:0009893
positive regulation of metabolic
process 0.00095447
BP G0:0009607 response to biotic stimulus 0.000977322
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Table 5.1.9b: GO Terms fc
Infected compared to Com
r Up-regulated Genes,
rol
MF G0:0032403 protein complex binding 0.000157948
MF G0:0005509 calcium ion binding 0.00022189
MF G0:0004871 signal transducer activity 0.000369437
MF G0:0060089 molecular transducer activity 0.000369437
MF G0:0019865 immunoglobulin binding 0.000810849
MF G0:0005100 Rho GTPase activator activity 0.000969558
CC G0:0042405 nuclear inclusion body 5.53E-05
CC G0:0031091 platelet alpha granule 0.000190492
CC G0:0005886 plasma membrane 0.000208567
CC G0:0005615 extracellular space 0.000393516
CC G0:0016020 membrane 0.000643486
CC G0:0031225 anchored to membrane 0.00071491
Table 5.1.10a: GO Terms for Down-Regulated Genes:
Infected compared to Control
Ontology GO ID GO Term
Enriched
p Value
BP G0:0010467 gene expression 8.81 E-24














BP G0:0043284 biopolymer biosynthetic process 3.36E-18







BP G0:0008152 metabolic process 2.02E-15
BP G0:0044238 primary metabolic process 4.84E-15
BP G0:0044237 cellular metabolic process 8.75E-15
BP G0:0044249 cellular biosynthetic process 1.08E-13
BP G0:0009058 biosynthetic process 1.46E-13
BP G0:0016070 RNA metabolic process 4.32E-12
BP G0:0006139
nucleobase, nucleoside,





BP G0:0034660 ncRNA metabolic process 4.55E-10
BP G0:0034470 ncRNA processing 1.03E-09
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Table 5.1.1 Ob: GO Terms for Down-Regulated Genes:
Infected compared to Control
BP G0:0042254 ribosome biogenesis 1.04E-08
BP G0:0006396 RNA processing 1.78E-08
BP G0:0006350 Transcription 6.85E-08
BP G0:0006364 rRNA processing 1.66E-07
BP G0:0016072 rRNA metabolic process 3.81 E-07
BP G0:0002504
antigen processing and
presentation of peptide or
polysaccharide antigen via MHC
class II 4.71 E-07
BP G0:0006351 transcription, DNA-dependent 2.99E-06
BP G0:0009987 cellular process 3.11E-06
BP G0:0032774 RNA biosynthetic process 3.38E-06








regulation of RNA metabolic
process 1.33E-05
BP G0:0006355
regulation of transcription, DNA-
dependent 1.43E-05
BP G0:0010468 regulation of gene expression 1.55E-05




nucleic acid metabolic process 3.86E-05
BP G0:0031326





BP G0:0019222 regulation of metabolic process 8.73E-05
BP G0:0031323
regulation of cellular metabolic
process 0.000104809
BP G0:0042110 T cell activation 0.000138833
BP G0:0002696





BP G0:0009451 RNA modification 0.000315192
BP G0:0050867
positive regulation of cell
activation 0.00037817
BP G0:0001510 RNA methylation 0.000689262




BP G0:0046649 lymphocyte activation 0.000921125
MF G0:0003735 structural constituent of ribosome 1.21E-17
MF G0:0003676 nucleic acid binding 3.90E-14
MF G0:0003723 RNA binding 1.17E-08
MF G0:0032395 MHC class II receptor activity 1.43E-06
MF G0:0008168 methyltransferase activity 1.45E-05
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Table 5.1.10c: GO Terms forDown-Regulated Genes:




MF GO: 0003677 DNA binding 2.59E-05
MF G0:0008270 zinc ion binding 5.43E-05
MF G0:0046914 transition metal ion binding 0.000284282
MF G0:0045182 translation regulator activity 0.000942185
CC G0:0005622 intracellular 3.31 E-22
CC G0:0044424 intracellular part 5.25E-19
CC G0:0005840 ribosome 2.23E-18




CC G0:0043227 membrane-bounded organelle 1.34E-15
CC G0:0043229 intracellular organelle 4.55E-15
CC GO: 0043226 organelle 5.00E-15
CC G0:0005634 nucleus 1.30E-13
CC G0:0033279 ribosomal subunit 7.20E-13
CC GO: 0044464 cell part 1.23E-12
CC G0:0005623 cell 1.33E-12
CC G0:0022626 cytosolic ribosome 1.47E-11
CC G0:0005829 cytosol 3.16E-09
CC G0:0005739 mitochondrion 4.45E-09
CC G0:0042613 MHC class II protein complex 1.61 E-08
CC G0:0022625 cytosolic large ribosomal subunit 6.67E-08
CC G0:0005737 cytoplasm 6.87E-08
CC G0:0015934 large ribosomal subunit 8.60E-08
CC G0:0044445 cytosolic part 2.46E-07
CC G0:0032991 macromolecular complex 5.93E-07
CC G0:0015935 small ribosomal subunit 1.86E-06
CC G0:0044444 cytoplasmic part 4.82E-06
CC GO:0044428 nuclear part 8.11E-06
CC G0:0044429 mitochondrial part 1 46E-05
CC G0:0070013 intracellular organelle lumen 2.46E-05
CC G0:0042611 MHC protein complex 3.97E-05
CC G0:0031974 membrane-enclosed lumen 5.78E-05
CC G0:0043233 organelle lumen 6.83E-05
CC G0:0042101 T cell receptor complex 0.000103417
CC G0:0031981 nuclear lumen 0.000111046
CC G0:0022627 cytosolic small ribosomal subunit 0.000117166
CC G0:0005730 nucleolus 0.000366846
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KEGG Pathway Enrichment
There were found to be 11 enriched KEGG pathways in significantly up-regulated
genes (displayed in Table 5.1.11) and 19 enriched KEGG pathways in significantly
down-regulated genes (displayed in Table 5.1.12).
Table 5.1.11: Kegg Pathways for Up-Regulated Genes.
Infected compared to Control.
Pathway
ID Pathway Description p Value
4060 Cytokine-cytokine receptor interaction 0.002389079
4610 Complement and coagulation cascades 0.005371016
530 Aminosugars metabolism 0.006040276
4640 Hematopoietic cell lineage 0.007304653
4910 Insulin signaling pathway 0.010435325
4510 Focal adhesion 0.014617217
4620 Toll-like receptor signalling pathway 0.016858824
4512 ECM-receptor interaction 0.021752537
4210 Apoptosis 0.024699901
4810 Regulation of actin cytoskeleton 0.04115909
51 Fructose and mannose metabolism 0.049818179
Table 5.1.12: Kegg Pathways for Down-Regulated
Genes. Infected compared to Control.
Pathway
ID Pathway Description p Value
3010 Ribosome 2.15E-15
5332 Graft-versus-host disease 4.68E-08
4660 T cell receptor signalling pathway 2.34E-06
5330 Allograft rejection 3.86E-06
5310 Asthma 7.46E-06
4640 Hematopoietic cell lineage 1.32E-05
4940 Type I diabetes mellitus 2.52E-05
5320 Autoimmune thyroid disease 0.000152039
970 Aminoacyl-tRNA biosynthesis 0.00065215
4612 Antigen processing and presentation 0.001981931
5340 Primary immunodeficiency 0.00621127
4650 Natural killer cell mediated cytotoxicity 0.012287985
4370 VEGF signaling pathway 0.020515548
240 Pyrimidine metabolism 0.022336428
290 Valine, leucine and isoleucine biosynthesis 0.023052917
4310 Wnt signaling pathway 0.025003562
4514 Cell adhesion molecules (CAMs) 0.028900544
3020 RNA polymerase 0.029943213




Before statistical filtering there were 626 features exhibiting greater than 2-fold up-
regulation and 1818 features exhibiting greater than 2-fold down-regulation. After
statistical filtering (p < 0.001) there were 220 features with greater than 2-fold up-
regulation and 986 with greater than 2-fold down regulation. The genes for the
features with the twenty largest fold changes are described in tables 5.1.13(a and b)
for up-regulated genes and 5.1.14 (a and b) for down-regulated genes (the full lists of
statistically filtered genes with fold changes of greater than 2 can be found on the
enclosed CD). Each line represents one feature on the array with the largest fold
changes being listed first. Phrases readily recognisable as being immune function
related are highlighted in red.
Table 5.1.13a:
Table ofFold Changes (> Log 2) for Up-Regulated Genes.
Infected compared to control.
(Each line represents 1 feature on array).
Feature ID Description Pathway Description
Fold
Change
GE61410 CD177 molecule - 18.10285
GE572841 ankyrin repeat domain 22 - 11.19002




GE79166 resistin - 7.14978
GE57919
tumor necrosis factor,
alpha-induced protein 6 6.769111
GE60514




Systemic lupus erythematosus 6.387135
GE537401 ankyrin repeat domain 22 - 5.953429
GE545552
chromosome 19 open
reading frame 59 5.879541
GE61045
DnaJ (Hsp40) homolog,
subfamily C, member 5 5.783771
GE58106 carbonic anhydrase IV Nitrogen metabolism 5.585605
GE57860 annexin A3 - 5.584148
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Table 5.1.13b:
Table of Fold Changes (> Log 2) for Up-Regulated Genes.
Infected compared to control.




























gelatinase, 92kDa type IV
collagenase)
Leukocyte transendothelial
migration, Bladder cancer 4.810045
GE60380
proteoglycan 2, bone







localization signals 1 4.754757
Table 5.1.14a: Table of Fold Changes (> Log 2) for Down-Regulated
Genes. Infected compared to control.
(Each line represents 1 feature on array).






GE61347 ribosomal protein L23a Ribosome -7.32457








GE61920 melanoma antigen family H, 1 - -6.182
GE612668 Fc receptor-like 6 - -5.89332





Table 5.1.14b: Table of Fold Changes (> Log 2) for Down-Regulated
Genes. Infected compared to control.



















GE61919 transmembrane protein 204 - -5.44077
GE85839 NA - -5.43182
GE539361
BTB and CNC homology 1,
basic leucine zipper
transcription factor 2 -5.30172
GE53988 leucine rich repeat neuronal 3 - -5.23077
GE59630




STAT signalling pathway -5.17507
GE519859 OCIA domain containing 2 - -4.96511
GE81550
RAS guanyl releasing protein
1 (calcium and DAG-
regulated)
MAPK signalling







phosphoprotein 1 . -4.8916
The whole list of genes with fold change > 2 and p < 0.001 was further examined by
gene ontology using the online tool DAVID 2008 (348, 349). The result for the
DAVID gene ontology lists for up-regulated genes is found in table 5.1.15 and for
down-regulated genes in table 5.1.16 (a and b).
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Table 5.1.15: DAVID GO Terms for Fold-Change > 2:
Up-Regulated Genes. Infected compared to control.




BP Response to wounding 18 4.9E-7
BP Response to external
stimulus
20 7.5E-6
BP Inflammatory response 12 1.1E-4
BP Response to stress 24 1.4E-4
BP Regulation of body fluid levels 8 1.4E-4
BP Blood coagulation 7 3.1 E-4
BP Coagulation 7 3.5E-4
BP Hemostasis 7 4.1 E-4
BP Response to other organism 9 5.6E-4
BP Defence response 15 9.2E-4
MF Calcium ion binding 20 8.1 E-1
Table 5.1.16a: DAVID GO Terms for Fold-Change > 2:
Down-Regulated Genes. Infected compared to control.
Ontology GO Term No. of Genes
(from 986)
p value
BP Gene expression 197 3.3E-12




BP Primary metabolic process 341 3.0E-7
BP Cellular process 482 9.5E-7
BP Regulation of cell activation 15 1.6E-6
BP T cell activation 17 2.4E-6
BP Translation 46 2.4E-6
BP RNA processing 37 3.0E-6
BP Metabolic process 365 3.3E-6
BP Regulation of lymphocyte
activation
14 4.5E-6
BP Lymphocyte activation 21 5.6E-6
BP Biopolymer metabolic process 232 8.5E-6
BP Regulation of T cell activation 12 9.8E-6
BP Cellular metabolic process 332 1.1E-5
BP Leukocyte activation 22 1.1E-5
BP Ribosome biogenesis and
assembly
14 1.3E-5
BP Regulation of biological process 208 2.1E-5
BP Cell activation 23 2.4E-5
BP Cellular biosynthetic process 67 2.6E-5
BP Nucleobase, nucleoside,
nucleotise and nucleic acid
metabolic process
181 3.1E-5




BP Biological regulation 219 2.1 E-4
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Table 5.1.16b: DAVID GO Terms for Fold-Change > 2:
Down-Regulated Genes. Infected compared to control.
BP Transcription 125 2.2E-4
BP rRNA processing 10 3.1E-4
BP rRNA metabolic process 10 4.4E-4
BP Transcription, DNA-dependent 115 4.9E-4
BP RNA biosynthetic process 115 5.1E-4
BP T cell differentiation in the
thymus
5 5.4E-4
BP Positive regulation of lymphocyte
activation
9 6.8E-4
BP Regulation of transcription, DNA-
dependent
112 7.0E-4
BP Regulation of metabolic process 132 8.8E-4
BP Biosynthetic process 76 9.2E-4
CC Cytosolic ribosome (sensu
Eukaryota)
20 1.7E-11
CC Ribosomal subunit 23 6.9E-9
CC Cytosolic large ribosomal
subunit (sensu Eukaryota)
13 7.1E-9
CC Intracellular 443 9.5E-9
CC Cytosolic part 23 1.2E-8
CC Ribonucleoprotein complex 50 3.6E-8
CC Large ribosomal subunit 16 6.0E-8
CC Ribosome 34 1.0E-7
CC Immunological synapse 9 2.4E-7
CC Intracellular part 413 8.1E-7
CC Cell part 564 9.6E-6
CC Cell 564 9.9E-6
CC Nucleus 216 1.3E-5
CC Intracellular organelle 350 1.4E-5
CC Organelle 350 1.4E-5




CC Membrane-bound-organelle 305 1.0E-4
CC Cytoplasm 267 2.1E-4
CC Cytosol 35 7.5E-4
MF Structural constituent of
ribosome
33 7.7E-9
MF Binding 469 1.7E-5
MF Nucleic acid binding 163 2.2E-5
MF Zinc ion binding 114 3.4E-5
MF RNA binding 46 7.9E-5
MF Transition metal ion binding 131 8.7E-5
MF MHC class II receptor acticity 5 2.1E-4
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Infected compared to possible samples
Significant Differential Expression
1616 features were significantly differentially expressed with an adjusted p value of
less than 0.01: 770 up-regulated and 846 down-regulated.
GO Term Enrichment
In the significantly up-regulated genes there were 48 enriched GO terms and in
significantly down-regulated genes there was 1 enriched GO term. These are
displayed in tables 5.1.17(a and b) and 5.1.18. The terms are listed in order of
significance with the most significant first. I have highlighted in red the terms that
are immediately recognisable as being involved in immune response.
Table 5.1.17a: GO Terms for Up-Regulated Genes.
Infected compared to possible.
Enriched
Ontology GO ID GO Term p Value
BP G0:0002376 immune system process 8.70E-10
BP G0:0006955 immune response 1.05E-06
BP G0:0009611 response to wounding 2.28E-06
BP G0:0002682 regulation of immune system process 8.62E-06
BP G0:0001775 cell activation 1.19E-05
BP G0:0045321 leukocyte activation 1.23E-05
BP G0:0006954 inflammatory response 3.69E-05
adaptive immune response based on
somatic recombination of immune
BP G0:0002460
receptors built from immunoglobulin
superfamily domains 4.79E-05
BP G0:0002250 adaptive immune response 5.36E-05
BP G0:0009605 response to external stimulus 5.96E-05
BP G0:0006952 defence response 8.11E-05





positive regulation of immune system
process 0.000131
BP G0:0006935 chemotaxis 0.000141
BP G0:0042330 taxis 0.000141
BP G0:0031325
positive regulation of cellular metabolic
process 0.000164
BP G0:0001817 regulation of cytokine production 0.000194
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Table 5.1.17b: GO Terms for Up-Regulated Genes.
Infected compared to possible.
BP G0:0007155 cell adhesion 0.00021
BP G0:0022610 biological adhesion 0.00021
BP G0:0007596 blood coagulation 0.000292
BP G0:0001816 cytokine production 0.00031
BP G0:0002252 immune effector process 0.00031
BP G0:0050817 coagulation 0.000321
BP G0:0042088 T-helper 1 type immune response 0.000368
BP G0:0031328
positive regulation of cellular
biosynthetic process 0.000374
BP G0:0009893 positive regulation of metabolic process 0.000391
BP G0:0009891
positive regulation of biosynthetic
process 0.000466
BP G0:0007599 Hemostasis 0.000507
BP G0:0002449 lymphocyte mediated immunity 0.000514
BP G0:0030307 positive regulation of cell growth 0.000537
BP G0:0010604






regulation of cytokine biosynthetic
process 0.000666
BP G0:0048518 positive regulation of biological process 0.000676
BP G0:0006950 response to stress 0.000719
BP GO: 0048247 lymphocyte chemotaxis 0.000736
BP G0:0032609 interferon-gamma production 0.000743
BP G0:0019724 B cell mediated immunity 0.000749
BP G0:0050878 regulation of body fluid levels 0.000762
BP G0:0002520 immune system development 0.000843
BP G0:0045087 innate immune response 0.000951
BP G0:0010557
positive regulation of macromolecule
biosynthetic process 0.000968
MF G0:0005518 collagen binding 0.000205
MF G0:0005548 phospholipid transporter activity 0.000257
MF G0:0005515 protein binding 0.000274
MF G0:0005319 lipid transporter activity 0.00063
CC G0:0005615 extracellular space 0.000573
Table 5.1.18: GO Terms for Down-Regulated Genes.
Infected compared to possible.
Ontology GO ID GO Term
Enriched
p Value
CC G0:0045211 postsynaptic membrane 0.000428
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KEGG Pathway Enrichment
There were found to be 5 enriched KEGG pathways in significant up-regulated genes
(displayed in Table 5.1.19) and 6 enriched KEGG pathways in significantly down-
regulated genes (displayed in Table 5.1.20).
Table 5.1.19: KEGG Pathways for Up-Regulated Genes.
Infected compared to possible.
Pathway ID Pathway Description p Value
4610 Complement and coagulation cascades 0.004513
4620 Toll-like receptor signaling pathway 0.014177
4520 Adherens junction 0.029785
5220 Chronic myeloid leukemia 0.029785
5120 Epithelial cell signaling in Helicobacter pylori infection 0.039417
Table 5.1.20: KEGG Pathways for Down-Regulated Genes.
Infected compared to possible.
Pathway ID Pathway Description p Value
480 Glutathione metabolism 0.024297
3010 Ribosome 0.024861
4920 Adipocytokine signaling pathway 0.030363
590 Arachidonic acid metabolism 0.035783
4120 Ubiquitin mediated proteolysis 0.040034
430 Taurine and hypotaurine metabolism 0.046659
Largest Fold Changes
Before statistical filtering there were 555 features exhibiting greater than 2-fold up-
regulation and 941 features exhibiting greater than 2-fold down-regulation. After
statistical filtering (p < 0.001) there were 140 features with greater than 2-fold up-
regulation and 222 with greater than 2-fold down regulation. The twenty features
with the largest fold changes are described in tables 5.1.21 for up-regulated genes
and 5.1.22 for down-regulated genes (the full lists can be found on the enclosed CD).
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Table 5.1.21: Table ofFold Changes > 2 for Up-Regulated Genes.
Infected compared to possible.
(Each line represents 1 feature on array)

























GE572841 ankyrin repeat domain 22 - 5.346185
GE60514






GE53687 hect domain and RLD 5 - 5.006804











GE484349 NA - 3.729362
GE537401 ankyrin repeat domain 22 - 3.570259



















Table 5.1.22: Table ofFold Changes > 2 for Down-Regulated
Genes. Infected compared to possible.
(Each line represents 1 feature on array)





H2ad Systemic lupus erythematosus -15.1675
GE62790






























N, member 2 Olfactory transduction -4.97609











transcription factor Melanogenesis, Melanoma -4.56203
GE872322 lamin A/C Cell junctions -4.5045











(liprin), alpha 2 -4.24457
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The significant GO terms as determined using DAVID 2008 (348, 349) from the full
lists of up- and down-regulated genes with fold changes > 2 and p values of less than
0.001, are displayed in tables 5.1.23 and 5.1.24 respectively.
Table 5.1.23: DAVID GO Terms for Fold-Change > 2 and p < 0.001:
Up-Regulated Genes. Infected compared to possible















MF Protein binding 64 1.7E-5
Table 5.1.24: DAVID GO Terms for Fold-Change > 2 and p < 0.001:
Down-Regulated Genes. Infected compared to possible.
Ontology GO Term No. of Genes
(from 222)
p value
cc Cytoplasm 69 2.9E-4
Possible compared to control samples
Significant Differential Expression
4517 features were significantly differentially expressed with an adjusted p value of
less than 0.01: 2000 up-regulated and 2517 down-regulated.
GO Term Enrichment
In the significantly up-regulated genes there were 20 enriched GO terms and in
significantly down-regulated genes there were 131 enriched GO terms. These are
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displayed in tables 5.1.25 and 5.1.26 (a to d). The terms are listed in order of
significance with the most significant first.
Table 5.1.25: GO Terms for Up-regulated Genes.
Possible compared to controls.




transmembrane receptor protein tyrosine
phosphatase signaling pathway 9.20E-06
BP G0:0030036 actin cytoskeleton organization 0.000156
BP G0:0030029 actin filament-based process 0.000281
BP G0:0015669 gas transport 0.000327
BP G0:0051056
regulation of small GTPase mediated signal
transduction 0.000415
BP G0:0007169
transmembrane receptor protein tyrosine
kinase signaling pathway 0.000833
BP G0:0007010 cytoskeleton organization 0.0009
BP G0:0055072 iron ion homeostasis 0.000944
MF G0:0008092 cytoskeletal protein binding 4.27E-07
MF G0:0003779 actin binding 3.92E-06
MF G0:0030695 GTPase regulator activity 7.32E-05
MF G0:0005096 GTPase activator activity 0.000142
MF G0:0005085 guanyl-nucleotide exchange factor activity 0.000377
MF G0:0005083 small GTPase regulator activity 0.000645
MF G0:0008601
protein phosphatase type 2A regulator
activity 0.000789
MF G0:0005310
dicarboxylic acid transmembrane transporter
activity 0.000926
CC G0:0005886 plasma membrane 6.78E-06
CC G0:0044459 plasma membrane part 0.000278
CC G0:0005833 hemoglobin complex 0.000466
CC G0:0016020 membrane 0.000926
Table 5.1.26a: GO Terms for Down-regulated Genes.
Possible compared to controls.
Ontology GO ID GO Term
Enriched
p Value
BP G0:0010467 gene expression 5.97E-21
BP G0:0043170 macromolecule metabolic process 4.03E-19
BP G0:0043283 biopolymer metabolic process 7.44E-19
BP G0:0044260 cellular macromolecule metabolic process 8.39E-19
BP G0:0034960 cellular biopolymer metabolic process 1.01E-18
BP G0:0044237 cellular metabolic process 1.33E-17
BP G0:0008152 metabolic process 7.12E-17
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Table 5.1.26b: GO Terms forDown-regulated Genes.
Possible compared to controls.
BP G0:0044238 primary metabolic process 3.36E-16
nucleobase, nucleoside, nucleotide and
BP G0:0006139 nucleic acid metabolic process 3.97E-15
BP G0:0016070 RNA metabolic process 3.96E-13




BP G0:0034961 cellular biopolymer biosynthetic process 1.28E-12
BP G0:0043284 biopolymer biosynthetic process 1.28E-12
BP G0:0006396 RNA processing 1.36E-11
BP G0:0006412 translation 1.52E-11
BP G0:0044249 cellular biosynthetic process 7.24E-10
BP G0:0009058 biosynthetic process 9.33E-10
BP G0:0022613 ribonucleoprotein complex biogenesis 1.02E-07
BP G0:0006605 protein targeting 1.20E-07
BP G0:0060255
regulation of macromolecule metabolic
process 6.95E-07
BP G0:0034660 ncRNA metabolic process 9.39E-07
BP G0:0042110 T cell activation 1.21 E-06
BP G0:0006397 mRNA processing 1.80E-06
BP G0:0010468 regulation of gene expression 1.88E-06
BP G0:0008380 RNA splicing 2.27E-06
BP G0:0010556
regulation of macromolecule biosynthetic
process 4.21 E-06
BP G0:0009987 cellular process 5.27E-06
BP G0:0019222 regulation of metabolic process 6.81 E-06
BP G0:0016071 mRNA metabolic process 8.62E-06
BP G0:0034470 ncRNA processing 8.75E-06
BP G0:0046649 lymphocyte activation 1.18E-05
BP G0:0006399 tRNA metabolic process 1.65E-05
BP G0:0006350 transcription 1.82E-05
BP G0:0031323 regulation of cellular metabolic process 1.85E-05
BP G0:0009889 regulation of biosynthetic process 2.67E-05
BP G0:0031326 regulation of cellular biosynthetic process 3.49E-05
regulation of nucleobase, nucleoside,
nucleotide and nucleic acid metabolic
BP G0:0019219 process 5.62E-05
BP G0:0006351 transcription, DNA-dependent 7.20E-05
BP G0:0032774 RNA biosynthetic process 8.01 E-05
BP G0:0017038 protein import 8.10E-05
cellular macromolecular complex subunit
BP G0:0034621 organization 9.50E-05
macromolecular complex subunit
BP G0:0043933 organization 9.51 E-05
BP G0:0045321 leukocyte activation 0.00011
BP G0:0065003 macromolecular complex assembly 0.00011
BP G0:0051252 regulation of RNA metabolic process 0.000111
BP G0:0045449 regulation of transcription 0.00012
BP G0:0006996 organelle organization 0.000138
BP G0:0043368 positive T cell selection 0.000156
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Table 5.1.26c: GO Terms for Down-regulated Genes.
Possible compared to controls.
BP G0:0006607 NLS-bearing substrate import into nucleus 0.000201
BP G0:0006355 regulation of transcription, DNA-dependent 0.000208
BP G0:0031341 regulation of cell killing 0.000231
BP G0:0006886 intracellular protein transport 0.000291
BP G0:0006414 translational elongation 0.000292
BP G0:0022618 ribonucleoprotein complex assembly 0.000294
BP G0:0006974 response to DNA damage stimulus 0.00031
BP G0:0008033 tRNA processing 0.000331
cellular macromolecular complex
BP G0:0034622 assembly 0.000337
BP G0:0034613 cellular protein localization 0.000348
BP G0:0031343 positive regulation of cell killing 0.000364
BP G0:0001775 cell activation 0.000408
BP G0:0022607 cellular component assembly 0.000529
BP G0:0006913 nucleocytoplasmic transport 0.000597
BP G0:0010608
posttranscriptional regulation of gene
expression 0.000638
BP G0:0006606 protein import into nucleus 0.000638
BP G0:0006413 translational initiation 0.000687
BP G0:0051170 nuclear import 0.000738
BP G0:0016043 cellular component organization 0.000744
BP G0:0051169 nuclear transport 0.000748
BP G0:0034984 cellular response to DNA damage stimulus 0.000805
BP G0:0000018 regulation of DNA recombination 0.000878
MF G0:0003676 nucleic acid binding 5.71 E-11
MF G0:0003723 RNA binding 1.57E-10
MF G0:0003735 structural constituent of ribosome 3.96E-07
MF G0:0008270 zinc ion binding 2.32E-06
MF G0:0005488 binding 7.80E-06
MF G0:0005515 protein binding 2.35E-05
MF G0:0046914 transition metal ion binding 3.92E-05
MF G0:0003743 translation initiation factor activity 0.000107
MF GO: 0045182 translation regulator activity 0.00017
MF G0:0004549 tRNA-specific ribonuclease activity 0.000531
CC G0:0005622 intracellular 1.65E-29
CC GO: 0044424 intracellular part 2.77E-29
CC G0:0043231 intracellular membrane-bounded organelle 2.28E-25
CC G0:0043227 membrane-bounded organelle 2.74E-25
CC G0:0043229 intracellular organelle 2.86E-23
CC G0:0043226 organelle 3.22E-23
CC G0:0005634 nucleus 1.96E-21
CC G0:0030529 ribonucleoprotein complex 4.04E-14
CC G0:0005840 ribosome 1.84E-11
CC GO: 0044428 nuclear part 3.02E-11
CC G0:0032991 macromolecular complex 3.25E-11
CC G0:0005739 mitochondrion 5.76E-11
CC G0:0044464 cell part 1.60E-10
CC G0:0005623 cell 1.71E-10
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Table 5.1.26d: GO Terms for Down-regulated Genes.
Possible compared to controls.
cc G0:0044429 mitochondrial part 2.04E-08
cc G0:0005737 cytoplasm 5.35E-08
cc G0:0070013 intracellular organelle lumen 7.72E-08
cc G0:0031975 envelope 1.38E-07
cc G0:0031967 organelle envelope 2.40E-07
cc G0:0044422 organelle part 2.79E-07
cc G0:0043233 organelle lumen 2.88E-07
cc G0:0044446 intracellular organelle part 3.81 E-07
cc G0:0031974 membrane-enclosed lumen 8.48E-07
cc G0:0015935 small ribosomal subunit 1.43E-06
cc G0:0031981 nuclear lumen 1.55E-06
cc G0:0044444 cytoplasmic part 1.81 E-06
cc G0:0005829 cytosol 1.85E-06
cc G0:0031966 mitochondrial membrane 7.04E-06
cc G0:0033279 ribosomal subunit 8.23E-06
cc G0:0000313 organellar ribosome 1.08E-05
cc G0:0005761 mitochondrial ribosome 1.08E-05
cc G0:0005654 nucleoplasm 2.90E-05
cc G0:0005740 mitochondrial envelope 4.00E-05
cc G0:0005759 mitochondrial matrix 4.78E-05
cc G0:0031980 mitochondrial lumen 4.78E-05
cc G0:0042101 T cell receptor complex 9.20E-05
cc G0:0044455 mitochondrial membrane part 0.000194
cc G0:0043234 protein complex 0.000211
cc G0:0044451 nucleoplasm part 0.000213
cc G0:0005743 mitochondrial inner membrane 0.000226
cc G0:0044445 cytosolic part 0.000244
cc G0:0019866 organelle inner membrane 0.000255
cc G0:0005681 spliceosome 0.000269
cc G0:0022627 cytosolic small ribosomal subunit 0.00051
cc G0:0005643 nuclear pore 0.000602
cc G0:0022626 cytosolic ribosome 0.000602
cc G0:0005635 nuclear envelope 0.000631
cc G0:0000314 organellar small ribosomal subunit 0.000893
cc G0:0005763 mitochondrial small ribosomal subunit 0.000893
cc G0:0042613 MHC class II protein complex 0.000899
KEGG Pathway Enrichment
There were found to be 7 enriched KEGG pathways in significant up-regulated genes
(displayed in Table 5.1.27) and 24 enriched KEGG pathways in significant down-
regulated genes (displayed in Table 5.1.28).
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Table 5.1.27: KEGG Pathways for Up-Regulated Genes.
Possible compared to controls.
Pathway ID Pathway Description. p Value
860 Porphyrin and chlorophyll metabolism 0.005517
4520 Adherens junction 0.008852
4140 Regulation of autophagy 0.021283
4810 Regulation of actin cytoskeleton 0.02878
5213 Endometrial cancer 0.03712
2010 ABC transporters - General 0.04242
5223 Non-small cell lung cancer 0.04514
Table 5.1.28: KEGG Pathways for Down-Regulated Genes.
Possible compared to controls.
Pathway ID Pathway Description p Value
4660 T cell receptor signalling pathway 2.56E-05
5330 Allograft rejection 0.000117
5012 Parkinson's disease 0.000535
4514 Cell adhesion molecules (CAMs) 0.000811
790 Folate biosynthesis 0.001682
5332 Graft-versus-host disease 0.001682
5010 Alzheimer's disease 0.001832
4940 Type I diabetes mellitus 0.001908
190 Oxidative phosphorylation 0.005443
5340 Primary immunodeficiency 0.006211
5320 Autoimmune thyroid disease 0.006402
3010 Ribosome 0.006488
51 Fructose and mannose metabolism 0.00767
970 Aminoacyl-tRNA biosynthesis 0.007771
3050 Proteasome 0.009325
240 Pyrimidine metabolism 0.010528
310 Lysine degradation 0.010622
632 Benzoate degradation via CoA ligation 0.016508
5310 Asthma 0.020213
620 Pyruvate metabolism 0.022467
290 Valine, leucine and isoleucine biosynthesis 0.023053
4612 Antigen processing and presentation 0.028692
20 Citrate cycle (TCA cycle) 0.029485
3020 RNA polymerase 0.029943
Largest Fold Changes
Before statistical filtering there were 1431 features exhibiting greater than 2-fold up-
regulation and 1242 features exhibiting greater than 2-fold down-regulation. After
statistical filtering (p < 0.001) there were 392 features with greater than 2-fold up-
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regulation and 547 with greater than 2-fold down regulation. The twenty features
with the largest fold changes are described in tables 5.1.29 for up-regulated genes
and 5.1.30 for down-regulated genes (the full lists can be found on the enclosed CD).
Table 5.1.29: Table of Fold Changes > 2 for Up-Regulated Genes.
Possible compared to controls.
(Each line represents 1 feature on array)
Feature ID Description Pathway Description
Fold
change
GE79550 histone cluster 1, H2ad
Systemic lupus
erythematosus 6.341961
GE56370 transmembrane protein 158 - 5.710848
GE782559
insulin-like growth factor 2
(somatomedin A) 5.653595
GE59782 glycophorin E - 5.12556
GE59884
Rh blood group, CcEe
antigens 4.928375
GE81117




coil domain family 2 4.880993
GE498697 tripartite motif-containing 10 - 4.754302
GE59837




transcription factor Melanogenesis, Melanoma 4.565678
GE55112 NA - 4.537659
GE56647 RUN domain containing 3A - 4.473495
GE501834
erythrocyte membrane
protein band 4.2 4.447314






protein band 4.2 4.335315
GE490042










Table 5.1.30: Table of Fold Changes > 2 for Down-Regulated Genes.
Possible compared to controls (Each line represents 1 feature on array)



























Natural killer cell mediated






GE53976 ABI family, member 3 - -3.75101
GE61110 interleukin 32 - -3.6856




regulated kinase 2 -3.60975
GE59854
transcription factor 7 (T-
cell specific, HMG-box)
Wnt signalling pathway, Adherens
junction, Melanogenesis,
Colorectal cancer, Endometrial
cancer, Prostate cancer, Thyroid
cancer, Basal cell carcinoma,
Acute myeloid leukemia -3.60748
GE81458 CD8b molecule
Cell adhesion molecules (CAMs),
Antigen processing and
presentation, Hematopoietic cell
























Urea cycle and metabolism of
amino groups -3.39487
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The full lists of genes with fold changes of greater than 2 and p value of less than
0.001 were examined further using DAVID 2008 (348, 349). The list of significant
GO terms for up-regulated genes is displayed in table 5.1.31 and for down-regulated
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Table 5.1.32a: DAVID GO Terms for Fold-Change > 2
andp < 0.001:
Down-Regulated Genes. Possible compared to control





BP Primary metabolic process 223 1.1E-7




BP T cell activation 14 1.2E-6
BP Biopolymer metabolic process 155 2.4E-6
BP Leukocyte activation 18 2.5E-6
BP Cellular metabolic process 217 2.8E-6
BP Metabolic process 235 3.3E-6
BP Regulation of lymphocyte
activation
11 1.0E-5
BP Cell activation 18 1.3E-5
BP Regulation of cell activation 11 1.7E-5
BP Protein metabolic process 112 2.4E-5
BP Cellular process 301 2.8E-5
BP Regulation of T cell activation 301 5.9E-5
BP Gene expression 108 1.7E-4
BP Biopolymer modification 63 2.4E-4




Table 5.1.32b: DAVID GO Terms for Fold-Change > 2
and p < 0.001:







BP Positive regulation of
biological process
42 3.4E-4
BP Positive regulation of cellular
process
38 6.4E-4
BP Protein modification process 59 7.8E-4
CC Immunological synapse 11 4.6E-12
CC Intracellular part 269 3.3E-7
CC Intracellular 281 5.9E-7
CC T cell receptor complex 6 4.0E-6
CC Cell part 355 2.5E-5
CC Cell 355 2.6E-5
CC Cytoplasm 179 2.9E-5
CC Nuclear part 43 2.7E-4
CC Membrane-bound organelle 194 6.4E-4
CC Receptor complex 9 7.2E-4




MF Protein binding 210 1.5E-9
MF Binding 311 7.3E-6
MF Identical protein binding 20 5.3E-4
MF Protein dimerization activity 18 6.7E-4
Discussion
When the population characteristics displayed in table 5.1.4 are considered, overall
the infected group can be seen to be more premature and therefore of lower birth
weight and also older in terms of postnatal days when sampled than the controls.
This was partly because in the early stages of the study all of the controls were term
babies attending the neonatal unit for blood screening to exclude thyroid or adrenal
problems in the early days of life. In the latter stages of the study care was taken to
ensure that the control group also included preterm infants and infants more than a
few days old. The possible infection group was also more premature than the control
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group but less so than the infected group. The possible infection group tended to be
younger in terms of number of postnatal days than either the infected or control
groups. These findings may be a reflection of the low threshold for investigation for
infection in premature infants during the early days of life and the relatively low
yield of microbiological investigations in this group. It is not surprising that
premature infants account for a significant proportion of those sampled due to
suspicion of infection because these are the infants that are more at risk for infection
and who make up a large proportion of the population of the neonatal unit. The
inclusion of a wide range of gestations in the control group and the fact that the
infected and possible infected samples are representative of the neonatal population
most at risk of infection mean that the comparisons between groups presented in this
chapter are valid and useful.
The particular organisms responsible for the infections in the infected group are
listed in table 5.1.6. The particular infections included were always going to be
dependent on the infections encountered during the study period. As would be
expected, not all infants who had clinical samples taken for suspected infection
would have had study samples taken due to absence of parental consent, insufficient
blood for the study sample or oversight on the part of the clinician taking the sample.
It is therefore reassuring to note that the range of organisms in our infected group is
representative of that encountered in the neonatal unit. I was very careful to ensure
that all of the infected samples included were clearly infected and supporting
evidence for inclusion of some of the samples is presented in table 5.1.7. In addition,
the decision for inclusion or exclusion of culture-positive samples in the infected
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group was independently verified by a neonatal consultant (Ben Stenson). Any
sample where there was doubt was not included in the infected group and not run on
microarray.
The Genespring expression profile (figure 5.1.3) for significantly differentially
expressed genes between the infected and control group (fold change greater than 2
and p < 0.01) is very encouraging. There is a discernable difference in response seen
between infected and control infants. What is particularly interesting and exciting is
that the possible infection groups seems to be composed of some samples that look
more like the control samples and others that look more like the infected group. This
looks promising in terms of future studies of gene expression profiling being able to
distinguish between infected and non-infected infants.
Infected compared to control samples
From the examination of significantly differentially expressed genes (p < 0.01) for
the infected compared to control group, a notable proportion of significantly up-
regulated GO terms in the infected group are immune related (table 5.1.9). This is
especially true for the terms that are most significantly enriched but there are
immune related terms throughout the list. The most enriched terms included response
to wounding, immune system process, response to external response, immune
response, defence response, inflammatory response and response to stress. There is
also enrichment of immune-related pathways within the up-regulated genes on
KEGG analysis (table 5.1.11), in particular cytokine-cytokine receptor interaction,
274
complement and coagulation pathways and TLR signalling. This concurs with the
findings of Wong and colleagues when comparing paediatric patients with septic
shock with controls (152). On examination of the GO terms for the down-regulated
genes (table 5.1.10), there are immune-related terms but not in such a sizeable
proportion than was seen in the up-regulated terms. The down-regulated immune
terms include antigen processing via MHC II, T cell/leukocyte/lymphocyte activation
and MHC II receptor activity. KEGG analysis (table 5.1.12) mapped down-regulated
genes to T cell receptor signalling, antigen processing/presentation and natural killer
cell mediated cytotoxicity related pathways. This again concurs with findings in the
literature with respect to down-regulated genes in paediatric septic shock (152, 153,
282). The enriched down-regulated KEGG pathways also included terms related to
allergy, autoimmunity and graft versus host disease. Simplistically, it may be that
such immune processes are damped down during infection to enable the immune
system to concentrate on responding to the invading pathogen.
When fold change is taken into consideration, and genes with fold change of greater
than 2 for significance level of p < 0.001 are examined, there are both up- and down-
regulated genes related to immune functions. For up-regulated genes (table 5.1.13)
these included genes related to cluster of differentiation molecules CD 177 (human
neutrophil alloantigen), CD64 (related to the Fc portion of IgG) and CD 55 (decay
accelerating factor for complement). Up-regulated genes related to cytokines and
cytokine receptors included those for TNFa induced protein 6, IL-1 receptor
antagonist, IL-1 receptor associated kinase 3 and IL-17 receptor A. In addition there
was up-regulation of genes involved in the interferon response, of TLR 8, of
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chemokine (C-C) ligands 3 and 4 and of proteoglycan 2 (involved in NK activation).
Down-regulated genes included cluster of differentiation molecules involved in T
cell function, NK cell mediated immunity and antigen presentation (CDlc, CD3(d,z)
CD7, CD 8b, CD28, CD40 ligand, CD96, CD 226, CD 247 and CD 248). Down-
regulated genes related to cytokines and cytokine receptors included IL-23 (involved
in cytokine interactions and the Jak-Stat pathway), IL-7 receptor, IL-21 receptor and
TNF receptor associated factor 1. Chemokine (C-C) ligands 1 and 9 were also down-
regulated. When the whole list of genes with fold change > 2 and p < 0.001 is
further examined by gene ontology using the online tool DAVID 2008 (348, 349) it
is clear that there are a notable proportion of immune related processes related to
these genes. The up-regulated genes ontology (table 5.1.15) showed enrichment of
terms such as response to wounding, response to external stimulus, inflammatory
response, response to stress, response to other organisms and defence response. The
down-regulated genes (table 5.1.16) showed enrichment of terms related to T
cell/lymphocyte activation and differentiation and MHC II receptor activity. This
again concurs with findings in the literature (152, 153).
I have chosen a few of the genes listed above to consider in light of their function
and in the context of existing literature. This is not meant to be an exhaustive
examination of genes involved, but rather to help put the findings into context. In
terms of the up-regulated genes, TNFa induced protein 6 was found to be part of the
common response to infection by Huang and colleagues in their study of dendritic
cells (145). TNF is pro-inflammatory and is itself elevated in infection (1, 45). TLR
8 has been previously been described as being up-regulated in surgical patients with
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SIRS who go on to develop sepsis (156). Interleukin-1 receptor antagonist has
previously been described as being elevated in paediatric sepsis (350) and prior to the
diagnosis of infection in neonates (351). Chemokine (C-C) ligands 3 and 4 have
been described as being up-regulated in the common host response to infection as
described by both Hossain and Jenner (146, 159). These are chemokines that are
pro-inflammatory and involved in chemotaxis. CD 55 antigen (also known as DAF)
is involved in protecting the host from tissue damage due to complement. For the
down-regulated genes, CD28 antigen has previously been noted to be down-
regulated in surgical patients with SIRS which was subsequently found to be sepsis
(156). Neonatal monocytes have been previously shown to have lower expression of
MHC II in response to bacterial antigens compared to adult monocytes (78).
Neonatal monocytes have also been shown to be selectively defective in MHC II
antigen presentation not related to expression (352). In particular HLA-DR
expression has been described as being reduced in infected neonates (353-355).
While there is a paucity of data in the literature describing the neonatal host response
to infection, it is really exciting that many of the results presented in this chapter
corroborate work found in the literature regarding other groups of patients with
infection. Where I have not referenced other groups with respect to our findings it is
because I found nothing in the literature regarding these genes in this context. These
previously undecribed genes are likely to reflect results that will be corroborated as
more studies emerge and some unique neonatal responses. It is gratifying that our
results make physiological sense and affirm that neonates are capable of mounting a
substantial immune response to infection. Our results show differential expression
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not only of genes involved in a wide range of the innate immune responses
(cytokines, chemokines, Toll like receptors, complement, natural killer cells) but also
genes involved in T cell and antibody responses.
In terms of the findings above, it could be argued that the infected group were more
premature than the control group and that some of the differences seen could be
gestation-related rather than infection-related. Given that immunological immaturity
is more marked in premature infants and given that immune-related gene expression
changes are expected in infection, I would expect that the findings are genuinely
infection related. Studies of the effect of gestational age on gene expression are
however needed to be completely sure of this and would likely enhance
understanding of neonatal immunology greatly.
Infected compared to possible infected group
From the examination of significantly differentially expressed genes (p < 0.01) for
the infected compared to possible infection group, a notable proportion of
significantly up-regulated GO terms in the infected group are immune related (table
5.1.17). GO terms including immune system process, immune response, response to
wounding, regulation of immune response and leukocyte activation are most
enriched but there are several other cytokine related, interferon related, B cell related
and innate immune response related terms that are also significantly enriched.
KEGG pathway analysis of the up-regulated genes (table 5.1.19) mapped them to
complement and coagulation pathways and TLR related pathways. Significantly
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down-regulated genes did not have obvious immune related functions when enriched
GO terms (table 5.1.18) or KEGG analysis results (table 5.1.20) were examined.
When fold change is taken into consideration and genes with a fold change of greater
than 2 at significance level p < 0.001 are examined, some up-regulated genes can be
immediately recognised as being linked to immune function but this is not the case
for down-regulated genes (tables 5.1.21 and 5.1.22). Examples of immune related
genes in the up-regulated groups include TNFa induced protein 6, interferon induced
protein, C-X-C ligand 10, Fc of IgG, IL-1 receptor antagonist, NFkB, and C-C ligand
4. When these genes are examined by gene ontology using DAVID it becomes even
more apparent that the up-regulated genes (table 5.1.23) can be linked to immune
function (response to stress, response to wounding, response to external stimulus,
immune system process) but this is still not obviously the case for down-regulated
genes (table 5.1.24).
The implication from this is that the infected group are showing more in the way of
immune response than the possible infection group. As the possible group is
probably a mix of cases of infection and cases of non-infection this would make
sense. The lack of comparative down-regulation of immune related genes suggests
that the possible infection group is different from the control group.
Possible infection compared to control group
From the examination of significantly differentially expressed genes (p < 0.01) for
the possible infection compared to control group, a small proportion of significantly
279
down-regulated GO terms in the possible infection group are immune related (table
5.1.26) but this is not the case for significantly up-regulated genes (table 5.1.25).
The down-regulated terms that are immune related include T cell activation,
leukocyte activation and MHC class II. Overall, in comparison with the results
already examined above there is a marked absence of immune related enriched
ontology terms.
There are no clearly immune-related pathways enriched for the up-regulated genes
on KEGG analysis (table 5.1.27). For the down-regulated genes (table 5.1.28) the
immune related pathways include T cell receptor signalling, primary immune
deficiency and antigen presentation and processing. There is also down-regulation of
pathways related to autoimmune disease such as diabetes and thyroid disease and of
graft versus host disease.
When fold change is taken into consideration and genes with a fold change of greater
than 2 at significance level p < 0.001 are examined, none of the gene descriptions for
the up-regulated genes (table 5.1.29) are immediately recognisable as immune
related although on examination of the full list (on enclosed CD) IL-28a (interferon
related) and TLR4 were up-regulated. Some down-regulated genes (table 5.1.30) are
readily seen to be involved in immune function. These genes include IL-23
(involved in cytokine receptor activation and Jak Stat pathways), IL-32, CD 7 (T and
B cell interaction), CD8b (involved in antigen processing and presentation, T cell
signalling), CD 28 (T cell signalling) and CD 248. When DAVID was used to
examine these genes for ontology, there were no immune related terms enriched in
280
up-regulated genes (table 5.1.31) but terms related to T cell activation, T cell
regulation and T cell receptor were enriched in down-regulated genes (table 5.1.32).
These findings again make the possible infection group look like something in
between the control and infected groups. This is as would be expected as the
possible infected group is heterogeneous and likely to included both infected and
non-infected infants. Ideally, if a set of candidate genes for use in a diagnostic tool
could be identified, the possible infected group could be used as a training set to try
and differentiate into infected and uninfected groups.
Summary
Overall, despite the concerns regarding the data quality, it can still be clearly seen
that there is immune-related differential gene expression between infected and
control infants. This is very encouraging. Up-regulated genes in the infected group
include those involved in cytokine, complement, interferon and TLR related
processes. Down-regulated genes in the infected group include genes involved in
antigen processing, MHC II activity and T cell activation and signalling. It is
exciting that the possible infection group appears to be made up of some samples
which have gene expression profiles looking more like the infected group and others
more like the control group (as seen in the Genespring diagram, figure 5.1.3). This
bodes well for the use of these samples as a training set in the future and looks
promising in terms of being able to distinguish infected from non-infected infants.
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Conclusions
Infected infants show significant up-regulation and down-regulation of genes
involved in immune processes when compared to controls. These results provide
corroboration of some already published findings for adult and paediatric
populations. The results from this chapter may provide useful corroboration of
results obtained from other microarray platforms.
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Section 5.2: Investigation of Neonatal Infection Using
Illumina® Microarravs
Background
Following the problems experienced with the CodeLink™ platform it was decided,
where possible, to hybridise the samples again using an Illumina® platform. This
decision provided several advantages. Temporally the hybridisations would be
performed together therefore minimising technical variation, the samples would be
run on one batch of arrays minimising inter-array variation and it would be possible
to compare results with those achieved using CodeLink™ for corroboration. In
addition, the hybridisation and scanning of the arrays would be performed by a single
operator, so any inter-operator variability would be eliminated.
The Division of Pathway Medicine is not currently running Illumina® arrays and
therefore the hybridisation and scanning of the arrays was contracted out to a
company: Gen-Probe, formerly Tepnel.
Ideally, I would have liked to have run the same samples on Illumina® as those that
had been run on CodeLink™, i.e. 27 positive, 27 control and 30 possible infection
samples. This would have allowed direct comparison between platforms and any
corroboration of results would have been very encouraging. Unfortunately this was
not possible for a number of reasons. Firstly, for cost and platform reasons we were
able to commission the running of only 72 samples. This meant that we were not
able to run the requisite target of at least 27 for each subgroup of infected, control
and possible infection groups. It was therefore decided that none of the "possible
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infection" samples would be run in order to concentrate on identifying differences
between positives and controls. Secondly, six of the original samples (3 controls, 3
infected) had been used up in previous work and were therefore not available to run.
However, the Illumina® platform required a smaller starting amount ofRNA, which
gave the potential to run some samples that had been too small to run on Codelink™.
Aim
To examine differences in blood RNA expression profiles between infected and
control infants using Illumina® microarrays.
Acknowledgements
RNA extractions of the samples in the final dataset were performed by myself (32),
Alan Ross (30) and by Paul Dickinson (1). Quality control was carried out initially
by myself and Alan Ross. Paul Dickinson ran repeat quality control steps for many
of the samples included in this analysis.
Marie Craigon and Paul Dickinson adjusted the volume/concentration of any samples
that did not meet the starting requirements set out by Gen-Probe.
Hybridisation and scanning of the arrays was carried out by Gen-Probe.
Microarray data was sent to A1 Ivens of FIOS Genomics for data quality control, data
filtering and normalisation, statistical comparisons and functional analysis. The
results presented here include data from FIOS Genomics along with analysis and
interpretation of the results that I have carried out using the raw and normalised data.
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Methods
RNA that had previously been collected and extracted for the Codelink™ study was
used. Although quality control steps had been carried out previously any samples
that had been run on the BioMate spectrophotometer were re-run using the Nanodrop
spectrophotometer in order to maximise uniformity of data.
37 infected samples (using the definition on page 236) and 36 control samples were
selected. They were transported on ice directly to Gen-Probe's laboratory where
further quality control steps were carried out and the samples run on Illumina®
Human Whole-Genome Expression BeadChips each comprising 48802 features.
Raw data obtained from Gen-Probe was then passed to FIOS genomics for analysis.
In addition, the raw data was used to perform unsupervised analysis and I have
presented the unsupervised results below before presenting the filtered data.
The quality control analysis carried out by FIOS genomics used the array quality
metrics package in Bioconductor (356). Arrays were scored using maplot, boxplot
and heatmap. Although the arrays contained 48802 features, many of these features
did not give a signal on any of the arrays and were therefore removed from analysis.
This left 23342 features for which normalisation was carried out. The raw data was
transformed using a variance stabilising transformation prior to being subjected to
robust spline normalisation resulting in intensities in log base 2. In addition, a gender
check of each sample was performed using Y-chromosome specific loci to identify
male samples - all of the samples were correctly assigned.
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FIOS Genomics carried out a series of comparisons using linear modelling and
subsequent empirical Bayesian approaches. This included vertical p value adjustment
for multiple testing (within a given comparison) in order to control for false
discovery rate (Benjamini Hochberg). The Bioconductor package limma was used
(347). The statistical significance level chosen for carrying data on for functional
analysis was adjusted p < 0.001. The functional analysis of significant genes found
in these comparisons was carried out by examining KEGG pathway membership and
Gene Ontology (GO). Assessment for up and down regulation was carried out for
enrichment p values of < 0.05 for KEGG and of< 0.001 for GO.
Results
Samples: Quality control and exclusion
73 samples were sent to Gen-Probe - 36 controls and 37 positives (two positives
were very small and only sufficient for one reaction, the extra positive was sent as
back up). A minimum starting amount of 50 ng in 11 pi was required; we aimed for
100 ng in 11 pi and sent 250 ng of each sample where possible. Despite several
attempts, two samples did not generate a RIN - the bioanalyzer traces for each case
were felt to be acceptable however. The RIN values for each sample are summarised
in table 5.2.1. The range ofRIN values for the samples selected was 5 to 10 (those
with values of less than 8 had the bioanalyzer graphs reviewed and were felt to be
acceptable). The mean RIN of the 71 samples for which an RIN was generated was
8.7 and the median 9.
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Table 5.2.1: RIN values of samples sent for
hybridisation
Key:
Final dataset i.e. run on array and data analysed
Sample sent to Gen-probe but not run on array
Sample run on array but excluded from data analysis
Sample Category RIN Sample Category RIN
csb001 Control 10 csb009 nfected 9.1
csb017 Control 8.5 csb016 nfected 9.5
csb021 Control 9.5 csb047 nfected 8.9
csb022 Control 8.8 csb075 nfected 8.7
csb028 Control 9.4 csb082 nfected 8.6
csb029 Control 8.2 csb083 nfected 8.5
csb040 Control 7.2 csb084 nfected Null
csb042 Control 8.5 csb089 nfected 9.6
csb043 Control 9.4 csb091 nfected 9.4
csb046 Control 8.8 csb098 nfected 7.8
csb048 Control 8.3 csb102 nfected 9.1
csb049 Control 9 csb107 nfected 5
csb051 Control 9.2 csb108 nfected 5.9
csb058 Control 9.3 csb111 nfected 8.4
csb062 Control 9.4 csb112 nfected 7.1
csb063 Control 9.1 csb114 nfected 7.9
csb065 Control 9.3 csb116 nfected 9.7
csb067 Control 9.4 csb118 nfected 9
csb069 Control 9.6 csb119 nfected 7.4
csb071 Control 7.2 csb125 nfected 5
csb072 Control 9.6 csb132 nfected 9.5
csb073 Control 9.6 csb133 nfected 8.8
csb077 Control 8 csb137 nfected 9.3
csb079 Control 9.3 csb138 nfected 9.3
csb081 Control 8.8 csb145 nfected 9.7
csb086 Control 8.8 csb149 nfected 9.6
csb087 Control 10 csb152 nfected 8.7
csb096 Control 8.6 csb155 nfected 9.2
csb097 Control 7.9 csb157 nfected 9.4
csb165 Control 9.2 csb159 nfected 9.4
csb179 Control 9.2 csb161 nfected 9.1
csb181 Control 9.4 csb162 nfected 8.5
csb200 Control 9.3 csb164 nfected 7.3
csb202 Control 8.8 csb191 nfected 6.5
csb206 Control 8 csb198 nfected 9.6
csb207 Control 9.1 csb201 nfected Null
csb203 nfected 7.2
84 microarray scan results were generated by Gen-Probe from 70 samples (9 samples
were run on either 2 or 3 scans as technical replicates) and had data quality control
carried out. Those samples for which we did not receive array results presumably
failed Gen-Probe's quality control checks or failed to hybridise.
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10 scan results failed on two or three of the quality control metrics - maplot, boxplot
and heatmap - and were therefore excluded from analysis. 4 scan results were
removed from analysis as they exhibited a mean correlation, compared with all of the
other samples, of less than 0.65. 2 further scan results were removed on the basis of
poor sample relation QC plots. Sample csb201 was excluded from analysis at my
request. Although it had been chosen to fill a space on the arrays for interest it did
not fully fit the criteria because the only positive culture was a clean catch urine
culture. As culture of clean catch urine in neonates can easily be affected by
contaminants it could not be considered a robust infected sample but neither was it a
control. (Interestingly, it clustered with the controls on analysis of raw data -data
not shown). Where more than one scan was received for a sample, the scan with the
highest mean correlation to all of the other samples was retained and the others were
discarded prior to normalisation. In other words, no technical replicates were used
for analysis. This gave a final dataset of 63 samples - 28 infected samples and 35
control samples. The 28 infected samples were taken from 23 infants. 5 infants had
two samples included in the analysis — in each case these were samples taken during
separate episodes of infection.
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Samples: Clinical Characteristics
Table 5.2.2: Demographics of Samples Used
Controls (n=35) Infected (n=28)

























Table 5.2.2 displays the gender, age and weight of the infants sampled in each group.
The control group had a greater proportion of boys than the infected group with 63 %
compared to 54 %. The breakdown of reasons for blood sampling in the control
group is presented in table 5.2.3. Of the control group, 2 had previously had a
documented episode of infection. 9 had previously had antibiotics but none were on
antibiotics at the time of sampling. Within the dataset presented here, none of the
control samples were duplicated from the same baby.
Table 5.2.3: Clinical Reasons for Blood Sampling in
Control Group (n)
Maternal Thyroid Disease 17
Jaundice 5
Screening for Congenital Adrenal Hyperplasia 2
Coombs positive 1
Urea and electrolytes:
repeat after previous abnormality (hypo or hypernatraemia)
3
Guthrie screening 1
"Routine" neonatal screening (preterms) 5
Hypoxic ischaemic encephalopathy 1
The organisms isolated from the infected infants are listed in table 5.2.4. Coagulase
negative staphylococci were the organisms most frequently isolated. 26 of the 28
infected samples were bacterial with the exceptions being one case of Candida
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albicans, although this patient also had Klebsiella isolated from their peritoneal fluid,
and one case of cytomegalovirus. 25 of the samples had positive blood cultures, the
case of CMV had virus isolated from blood and urine, one case of Coagulase
Negative Staphylococcus was an isolate from an abscess (this patient had also had
recent Coagulase Negative Staphylococcus in blood culture) and one patient had
negative blood cultures but had Klebsiella isolated from cerebrospinal fluid.




15 One of these was an isolate from an abscess
Candida albicans 1 Klebsiella was also isolated from peritoneal
fluid
Enterobacter 1
Enterococci (E faecalis) 4
Group B streptococcus 2
Pseudomonas aeruginosa 1 Coagulase negative staphylococcus in blood
too
Cytomegalovirus (CMV) 1 Isolated in blood and urine
Klebsiella 2 One of these was isolated from CSF only
Escherichia coli 1
Of the infected group, 14 had previously had a documented episode of infection.
Only 2 had not previously had antibiotics. 17 were on antibiotics at the time of
sampling. 5 babies each had two samples included in the dataset presented here.
These samples were taken on separate occasions of clinical concern of infection.
Three of these infants grew Coagulase Negative Staphylococci on both occasions,
one grew Enterococcus faecalis on both occasions, and the fifth grew Coagulase
Negative Staphylococcus on one occasion and Klebsiella species on the other. One
of the infected infants did not have any antibiotics (the infant with CMV); another
had only two days of antibiotics, the remaining 26 infants were treated with 5 to
more than 25 days of antibiotics. With regard to the infants with Coagulase Negative
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Staphylococcal infection and the infant with CMV, I have presented supporting
evidence of infection in table 5.2.5.
Table 5.2.5: Supporting Evidence for Infection in Viral and Coagulase
Negative Staphylococcal Cases.




• Also on long line tip. Pyrexia, tachycardia, respiratory distress,
low platelets (>21)
• Bradycardias, pyrexia, low platelets (15)
• Apnoeas, bradycardia, temperature instability, lethargy (2)
• Isolated in 2 blood cultures. Apnoeas, bradycardias, lethargy,
poor perfusion - 2 fluid boluses given (9)
• Bradycardias, desaturations, long line in situ (11)
• Red hot fluctuant abscess (14)
• Apnoeas, bradycardias, low temperature, lethargy, low
platelets, ventilated, poor colour (18)
• Previous isolate, bradycardias, desaturations, mottled (18)
• Apnoeas, bradycardias, jaundice, hyperglycaemia (10)
• Bradycardias, desaturations, reintubated, deranged sugars,
long line, poor handling (10)
• Previous isolate, hypotension, hypoglycaemia, oedema, died
(16)
• Lethargy, wound abscess, central line, recent surgery for NEC,
low platelets (16)
• Isolated in 2 separate blood cultures taken at same time,
bradycardia, desaturations, reintubated, temperature instability
(5) '
• Apnoeas, pyrexia, reduced perfusion, elevated white cell
count, infant had two further significant episodes of infection
associated with coagulase negative staphylococcus (>10)
• Apnoeas, pyrexia, tachypneoa, bradycardia, poor perfusion,
poor colour, lethargy, low platelets (6)
Cytomegalovirus Profound bradycardias and desaturations (nil)
More detailed information for each sample regarding gender, gestation at birth
(completed weeks), corrected gestation at time of sampling (completed weeks) and
infecting organism (if relevant) is displayed in table 5.2.6 (a and b). The sample
numbers that are coloured link the samples that were taken from the same baby.
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csbOOl control Boy 31 35
cst>009
Coagulase negative
staphylococcus Girl 28 33
csb017 control Boy 40 41
csb021 control Girl 40 41
csb022 control Girl 41 41
csb028 control Girl 36 37
csb029 control Boy 39 39
csb040 control Boy 39 40
csb042 control Boy 42 43
csb043 control Boy 41 42
csb046 control Girl 39 40
csb047 Candida Boy 29 30
csb048 control Boy 38 39
csb049 control Girl 41 41
csb051 control Boy 39 40
csb058 control Boy 39 40
csb062 control Girl 41 42
csb063 control Boy 40 44
csb065 control Girl 41 42
csb067 control Boy 39 40
csb069 control Boy 40 40
csb071 control Boy 42 43
csb072 control Boy 40 41
csb073 control Boy 36 37
csb075 CMV Girl 26 37
csb077 control Girl 41 42
csb079 control Girl 40 40
csb081 control Girl 41 42
csb082 Enterobacter cloacae Boy 29 30
csb083 E faecium Girl 29 35
csb084
Coagulase negative
staphylococcus Boy 28 30
csb086 control Boy 39 43
csb087 control Girl 34 34
csb089
Coagulase negative
staphylococcus Boy 27 28
csb091 Group B Streptococcus Girl 38 39
csb096 control Boy 37 38
csb097 control Boy 42 42
csbl02 Pseudomonas aeuruginosa Girl 27 32
csblll
Coagulase negative
staphylococcus Boy 28 30
csbll2 Group B Streptococcus Girl 24 26
csbll4
Coagulase negative
staphylococcus Girl 26 27
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Table 5.2.6b: Gestation, age and condition of each sample.
Gestation Corrected
at birth Gestation
Sample Organsim/Control Gender (weeks) (weeks)
csbll6
Coagulase negative
staphylococcus Boy 28 30
csbll9
Coagulase negative
staphylococcus Girl 28 30
csbl25
Coagulase negative
staphylococcus Girl 28 29
csbl32 E faecalis Boy 27 30
csbl33
Coagulase negative
staphylococcus Boy 27 28
csbl38
Coagulase negative
staphylococcus Girl 25 27
csbl45 Enterococcus faecalis Boy 27 29
csbl49 Klebsiella species Girl 27 29
csbl52
Coagulase negative
staphylococcus Boy 28 31
csbl57
Coagulase negative
staphylococcus Girl 28 31
csbl59 Enterococcus Boy 30 31
csbl62
Coagulase negative
staphylococcus Boy 27 27
Klebsiella oxytoca Girl 28 32
csbl65 control Girl 28 31
csbl81 control Girl 26 34
csbl91 E coli Boy 37 37
csbl98
Coagulase negative
staphylococcus Boy 32 33
csb200 control Boy 32 35
csb202 control Boy 31 35
csb203
Coagulase negative
staphylococcus Boy 32 39
csb206 control Boy 29 33
csb207 control Boy 41 42
Figure 5.2.1 is a boxplot of samples before normalisation and figure 5.2.2 a boxplot
of samples after normalisation. This shows good data consistency following
normalisation.

























































































Infected compared to control samples
Figure 5.2.3 is a sample relation graph, grouping samples with respect to similarity
of gene variability. This was before statistical filtering of data. It was very
encouraging to see that even on this unfiltered data, there was a split between control
and infected groups. The only sample that did not group neatly was that of csb75.
This sample is from the infant with CMV infection and it is seen to group with the
controls.
Figure 5.2.4 is a heat map. This is after filtering of genes and is displaying intensity
values of genes significantly differentially expressed (fold change of > 2 and p <
0.01) between control and infected samples. The intensity values are in log 2 scale
of expression, per gene normalised across the dataset. Genes that are up-regulated in
the infected group compared to the control group are yellow and those that are
comparatively down-regulated are blue. The more yellow or the bluer, the more up
or down regulated respectively. Again, there is a separation of patterns between
control and infected samples with the CMV infected sample being the exception.
There seem to be 3 distinct groups of genes (marked at left of figure). The infected
samples show down-regulation of group 1 and up-regulation of groups 2 and 3
whereas most of the controls show the converse. There is group of nine samples (8
controls and the CMV infected sample) however that shows up-regulation of groups
1 and 3 and down-regulation of group 2.






















With an adjusted p value of < 0.001, there were 6,221 features significantly
differentially expressed: 2,550 up-regulated and 3,671 down-regulated.
GO Term Enrichment
In the significantly up-regulated genes there were 232 enriched GO terms and in the
significantly down-regulated genes there were 152. The 232 GO terms for up-
regulated genes consisted of 140 Biological Process ontology terms, 36 Molecular
Function terms and 56 Component terms. The Molecular Function and Cellular
Component terms are too vague to be able to be attributed to immune-related
functions or not, e.g. "kinase activity", "cell part". I have therefore not displayed
them here. The Biological Processes Ontology terms are displayed in Table 5.2.7 (a
to d). The terms are listed in order of significance with the most significant first. I
have highlighted in red the terms that are immediately recognisable as being
involved in immune response.
Table 5.2.7a: GO Terms( Biological Processes) for Up-regulated Genes
Infected compared to control.
GO ID GO Term
Enriched
p Value
G0:0002376 immune system process 3.67E-17
G0:0006952 defence response 2.15E-16
G0:0009605 response to external stimulus 3.77E-16
G0:0007243 protein kinase cascade 2.06E-15
G0:0007242 intracellular signalling cascade 3.79E-15
G0:0009611 response to wounding 5.04E-15
G0:0006950 response to stress 7.46E-13
G0:0006954 inflammatory response 2.04E-12
G0.0006955 immune response 4.01E-12
G0:0012501 programmed cell death 1.56E-10
G0:0007249 l-kappaB kinase/NF-kappaB cascade 1.68E-10
G0:0015031 protein transport 1.87E-10
G0:0045184 establishment of protein localization 2.07E-10
G0:0006915 Apoptosis 2.69E-10
G0:0016192 vesicle-mediated transport 4.10E-10
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Table 5.2.7b: GO Terms (Biological Processes) for Up-regulated
Genes. Infected compared to control.
G0:0010627 regulation of protein kinase cascade 7.29E-10
G0:0008104 protein localization 1.10E-09
G0:0043122 regulation of l-kappaB kinase/NF-kappaB cascade 1.87E-09
G0:0033036 macromolecule localization 4.69E-09
G0:0008219 cell death 5.11E-09
G0:0016265 death 5.11E-09
G0:0016044 membrane organization 6.66E-09
G0:0009967 positive regulation of signal transduction 7.04E-09
G0:0043123 Positive regulation of l-kappaB kinase/NF-kappaB cascade 2.24E-08
G0:0050793 regulation of developmental process 3.25E-08
G0:0051707 response to other organism 8.66E-08
GO:0051179 localization 9.63E-08
G0:0042981 regulation of apoptosis 9.97E-08
G0:0043067 regulation of programmed cell death 1.02E-07
G0:0065008 regulation of biological quality 1.03E-07
G0:0009607 response to biotic stimulus 1.13E-07
G0:0006897 endocytosis 1.27E-07
G0:0010324 membrane invagination 1.27E-07
G0:0051704 multi-organism process 1.33E-07
G0:0006793 phosphorus metabolic process 4.49E-07
G0:0006796 phosphate metabolic process 4.49E-07
G0:0030099 myeloid cell differentiation 5.72E-07
G0:0006464 protein modification process 6.33E-07
G0:0016310 Phosphorylation 1.15E-06
G0:0043687 post-translational protein modification 1.67E-06
G0:0006629 lipid metabolic process 1.79E-06
G0:0007264 small GTPase mediated signal transduction 2.22E-06
G0:0002274 myeloid leukocyte activation 2.33E-06
G0:0043412 biopolymer modification 2.39E-06
G0:0044255 cellular lipid metabolic process 3.06E-06
G0:0051234 establishment of localization 3.11E-06
GO:0006468 protein amino acid phosphorylation 3.71 E-06
G0:0006810 Transport 4.16E-06
G0:0009966 regulation of signal transduction 5.87E-06
G0:0050896 response to stimulus 6.41 E-06
G0:0048518 positive regulation of biological process 7.22E-06
G0:0009615 response to virus 8.44E-06
G0:0043066 negative regulation of apoptosis 8.86E-06
G0:0030097 hemopoiesis 9.29E-06
G0:0042221 response to chemical stimulus 1.22E-05
G0:0043069 negative regulation of programmed cell death 1.29E-05
G0:0045087 innate immune response 1.36E-05
G0:0048522 positive regulation of cellular process 1.41E-05
G0:0051641 cellular localization 1.63E-05
G0:0044419 interspecies interaction between organisms 1.73E-05
G0:0001816 cytokine production 1.81E-05
G0:0006928 cell motion 1.85E-05
G0:0051674 localization of cell 1.85E-05
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Table 5.2.7c: GO Terms(Biological Processes) for Up-regulated Genes
Infected compared to control.
G0:0006643 membrane lipid metabolic process 2.20E-05
G0:0008654 phospholipid biosynthetic process 2.46E-05
G0:0048534 hemopoietic or lymphoid organ development 2.49E-05
G0:0030036 actin cytoskeleton organization 2.84E-05
G0:0065009 regulation of molecular function 2.86E-05
G0:0007599 Hemostasis 3.11E-05
G0:0050878 regulation of body fluid levels 3.19E-05
G0:0051649 establishment of localization in cell 3.98E-05
G0:0046467 membrane lipid biosynthetic process 4.08E-05
G0:0016050 vesicle organization 4.18E-05
G0:0007596 blood coagulation 4.21 E-05
G0:0002520 immune system development 4.65E-05
G0:0048872 homeostasis of number of cells 5.02E-05
G0:0050817 Coagulation 5.12E-05
G0:0002237 response to molecule of bacterial origin 5.50E-05
G0:0042089 cytokine biosynthetic process 5.95E-05
G0:0000165 MAPKKK cascade 6.36E-05
G0:0006935 Chemotaxis 6.57E-05
G0:0042330 Taxis 6.57E-05
G0:0042107 cytokine metabolic process 7.45E-05
G0:0007010 cytoskeleton organization 7.83E-05
G0:0008610 Lipid biosynthetic process 8.04E-05
G0:0006886 intracellular protein transport 8.44E-05
G0:0006914 Autophagy 9.65E-05
G0:0034101 erythrocyte homeostasis 9.97E-05
G0:0009617 response to bacterium 0.000101952
G0:0019221 cytokine-mediated signaling pathway 0.000109354
G0:0032640 tumor necrosis factor production 0.00011891
G0:0008286 insulin receptor signaling pathway 0.000120966
G0:0030029 actin filament-based process 0.000121824
G0:0006066 cellular alcohol metabolic process 0.000136509
G0:0019318 hexose metabolic process 0.000138255
G0:0042060 wound healing 0.000141475
GO.0006826 Iron ion transport 0.000142536
G0:0001775 cell activation 0.000170662
G0:0007265 Ras protein signal transduction 0.000178475
G0:0043068 positive regulation of programmed cell death 0.000186198
G0:0006916 anti-apoptosis 0.000190149
G0:0044275 cellular carbohydrate catabolic process 0.000200538
G0:0051094 positive regulation of developmental process 0.000207026
G0:0007165 signal transduction 0.000219967
G0:0050790 regulation of catalytic activity 0.000248993
G0:0016052 carbohydrate catabolic process 0.000249272
G0:0042108 positive regulation of cytokine biosynthetic process 0.000252165
G0:0000041 transition metal ion transport 0.000258967
G0:0046631 alpha-beta T cell activation 0.000266475
G0:0043065 positive regulation of apoptosis 0.000267844
G0:0005996 monosaccharide metabolic process 0.0002738
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Table 5.2.7d: GO Terms(Biological Processes) for Up-regulated Genes
Infected compared to control.
G0:0051093 negative regulation of developmental process 0.000284405
GO:0044262 cellular carbohydrate metabolic process 0.000290782
G0:0030100 regulation of endocytosis 0.000291985
G0:0005975 carbohydrate metabolic process 0.00031263
G0:0030218 erythrocyte differentiation 0.000322403
G0:0009991 response to extracellular stimulus 0.000326692
G0:0045080 positive regulation of chemokine biosynthetic process 0.000335141
G0:0002252 immune effector process 0.00034676
G0:0042035 regulation of cytokine biosynthetic process 0.000350674
G0:0007202 activation of phospholipase C activity 0.000418559
G0:0000187 activation of MAPK activity 0.00047484
G0:0051050 positive regulation of transport 0.000514586
G0:0043406 positive regulation of MAP kinase activity 0.000574075
G0:0006644 phospholipid metabolic process 0.000625131
G0.0051336 regulation of hydrolase activity 0.000628101
G0:0046907 intracellular transport 0.000667671
G0:0006901 vesicle coating 0.000707542
G0:0050900 leukocyte migration 0.000755122
G0:0044260 cellular macromolecule metabolic process 0.000772095
G0:0002467 germinal centre formation 0.00077553
G0:0043300 regulation of leukocyte degranulation 0.00077553
G0:0031667 response to nutrient levels 0.000860368
G0:0051345 positive regulation of hydrolase activity 0.000878847
G0:0031347 regulation of defence response 0.000880902
G0:0042592 homeostatic process 0.000911753
G0:0019320 hexose catabolic process 0.000944357
G0:0007154 cell communication 0.00095694
G0:0003013 circulatory system process 0.000985052
G0:0008015 blood circulation 0.000985052
The 152 GO terms for down-regulated genes consisted of 75 Biological Process
terms, 15 Molecular Function terms and 62 Cellular Component terms. Again, I
have not displayed the Molecular Function or Cellular Component terms here. The
Biological Processes Ontology terms for significantly down-regulated genes are
displayed in Table 5.2.8 (a and b) with the most significant listed first.
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Table 5.2.8a: GO Terms (Biological Processes): Down-Regulated
Genes. Infected compared to control.
Enriched
GO ID GO Term p Value
G0:0010467 gene expression 4.26E-65
G0:0006412 Translation 3.23E-57
G0:0043170 macromolecule metabolic process 1.60E-46
G0:0044237 cellular metabolic process 9.51 E-42
G0:0008152 metabolic process 1.71E-39
G0:0006414 translational elongation 1.29E-36
G0:0044238 primary metabolic process 1.54E-35
G0:0006396 RNA processing 2.58E-35
G0:0009059 macromolecule biosynthetic process 8.21 E-34
G0:0043283 biopolymer metabolic process 1.13E-33
nucleobase, nucleoside, nucleotide and nucleic acid
G0:0006139 metabolic process 7.52E-32
GO:0044249 cellular biosynthetic process 1.56E-28
G0:0022613 ribonucleoprotein complex biogenesis 4.91 E-28
G0:0016070 RNA metabolic process 8.30E-27
G0:0009058 biosynthetic process 3.87E-25
G0:0008380 RNA splicing 8.76E-21
G0.0042254 ribosome biogenesis 1.49E-20
G0:0006397 mRNA processing 1.86E-19
G0:0016071 mRNA metabolic process 4.95E-19
G0:0034470 ncRNA processing 1.81E-18
G0:0000375 RNA splicing, via transesterification reactions 3.60E-16
G0:0000377
RNA splicing, via transesterification reactions with bulged
adenosine as nucleophile 3.60E-16
G0:0000398 nuclear mRNA splicing, via spliceosome 3.60E-16
G0:0043284 biopolymer biosynthetic process 3.73E-16
G0:0016072 rRNA metabolic process 9.98E-15
G0:0006364 rRNA processing 1.11E-14
G0:0044267 cellular protein metabolic process 3.52E-12
G0:0019538 protein metabolic process 1.18E-11
G0:0044260 cellular macromolecule metabolic process 2.16E-11
G0:0022618 ribonucleoprotein complex assembly 4.07E-09
G0:0006399 tRNA metabolic process 2.69E-08
G0:0009987 cellular process 3.17E-08
G0:0010468 regulation of gene expression 4.56E-08
G0:0006350 Transcription 1.08E-07
G0:0010556 regulation of macromolecule biosynthetic process 1.41E-07
G0:0009889 regulation of biosynthetic process 5.33E-07
G0:0060255 regulation of macromolecule metabolic process 8.89E-07
G0:0006119 oxidative phosphorylation 1.42E-06
G0:0008033 tRNA processing 2.00E-06
G0:0032774 RNA biosynthetic process 2.66E-06
G0:0006351 transcription, DNA-dependent 4.02E-06
G0:0045449 regulation of transcription 4.18E-06
regulation of nucleobase, nucleoside, nucleotide and nucleic
G0:0019219 acid metabolic process 9.17E-06
G0:0006413 translational initiation 1.03E-05
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Table 5.2.8b: GO Terms (Biological Processes): Down-Regulated
Genes. Infected compared to control.
G0:0031323 regulation of cellular metabolic process 1.31 E-05
G0:0019222 regulation of metabolic process 1.45E-05
G0:0006355 regulation of transcription, DNA-dependent 1.53E-05
G0:0051252 regulation of RNA metabolic process 1.68E-05
G0:0000387 spliceosomal snRNP biogenesis 1.78E-05
G0:0006457 protein folding 3.88E-05
G0:0009451 RNA modification 5.62E-05
G0:0002504
antigen processing and presentation of peptide or
polysaccharide antigen via MHC class II 5.65E-05
G0:0009260 ribonucleotide biosynthetic process 6.79E-05
G0:0032259 Methylation 8.84E-05
G0:0034621 cellular macromolecular complex subunit organization 0.000110568
G0:0010608 posttranscriptional regulation of gene expression 0.000174097
G0:0034622 cellular macromolecular complex assembly 0.000194224
G0:0006417 regulation of translation 0.000203268
G0:0015985
energy coupled proton transport, down electrochemical
gradient 0.000208861
G0:0015986 ATP synthesis coupled proton transport 0.000208861
G0:0006446 regulation of translational initiation 0.000343353
G0:0009152 purine ribonucleotide biosynthetic process 0.000348601
G0:0050657 nucleic acid transport 0.000372816
G0:0050658 RNA transport 0.000372816
G0:0051236 establishment of RNA localization 0.000372816
G0:0051028 mRNA transport 0.000411664
G0:0006403 RNA localization 0.000454121
G0:0009060 aerobic respiration 0.00051651
G0:0006921 cell structure disassembly during apoptosis 0.000604717
G0:0022411 cellular component disassembly 0.000604717
G0:0034220 transmembrane ion transport 0.000604717
G0:0006886 intracellular protein transport 0.000662901
G0:0015931
nucleobase, nucleoside, nucleotide and nucleic acid
transport 0.000682094
G0:0006164 purine nucleotide biosynthetic process 0.000728556
G0:0009259 ribonucleotide metabolic process 0.000889407
KEGG Pathway Enrichment
There were found to be 40 enriched KEGG pathways for significantly up-regulated
genes (displayed in Table 5.2.9) and 31 enriched KEGG pathways for significantly





2.9 Kegg Pathways: Up-Regulated Genes
compared to control.
Pathway
ID Pathway Description p Value
4620 Toll-like receptor signalling pathway 4.82E-07
4920 Adipocytokine signalling pathway 5.32E-05
5221 Acute myeloid leukaemia 5.64E-05
5215 Prostate cancer 8.40E-05
4210 Apoptosis 8.54E-05
5220 Chronic myeloid leukaemia 0.000133
4540 Gap junction 0.000317
4630 Jak-STAT signalling pathway 0.000631
5120
Epithelial cell signalling in Helicobacter pylori
infection 0.00074
4520 Adherens junction 0.000862
4810 Regulation of actin cytoskeleton 0.001137
4010 MAPK signalling pathway 0.001282
5213 Endometrial cancer 0.001851
5211 Renal cell carcinoma 0.001995
600 Sphingolipid metabolism 0.002874
3320 PPAR signalling pathway 0.003028
4910 Insulin signalling pathway 0.004092
4662 B cell receptor signalling pathway 0.004584
5040 Huntington's disease 0.005612
51 Fructose and mannose metabolism 0.005703
5216 Thyroid cancer 0.006916
5212 Pancreatic cancer 0.009193
4610 Complement and coagulation cascades 0.010138
770 Pantothenate and CoA biosynthesis 0.011861
4012 ErbB signalling pathway 0.014274
4650 Natural killer cell mediated cytotoxicity 0.016634
4510 Focal adhesion 0.017056
900 Terpenoid biosynthesis 0.017814
5223 Non-small cell lung cancer 0.018249
561 Glycerolipid metabolism 0 020073
5130 Pathogenic Escherichia coli infection - EHEC 0.023406
5131 Pathogenic Escherichia coli infection - EPEC 0.023406
564 Glycerophospholipid metabolism 0.025439
4370 VEGF signalling pathway 0.025439
1032 Glycan structures - degradation 0.02743
4670 Leukocyte transendothelial migration 0.028729
4664 Fc epsilon Rl signalling pathway 0.028771
521 Streptomycin biosynthesis 0.031077
5214 Glioma 0.036488
5219 Bladder cancer 0.038773
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Table 5.2.10 Kegg Pathways: Down-Regulated Genes
Infected compared to control.
Pathway
ID Pathway Description p Value
3010 Ribosome 7.39E-34
190 Oxidative phosphorylation 1.09E-07
970 Aminoacyl-tRNA biosynthesis 0.000133
4660 T cell receptor signalling pathway 0.000258
5310 Asthma 0.000526
5332 Graft-versus-host disease 0.001934
280 Valine, leucine and isoleucine degradation 0.001976
271 Methionine metabolism 0.002979
5330 Allograft rejection 0.00309
5340 Primary immunodeficiency 0.00309
240 Pyrimidine metabolism 0.003286
230 Purine metabolism 0.003905
340 Histidine metabolism 0.003934
4940 Type I diabetes mellitus 0.003934
4612 Antigen processing and presentation 0.006232
4120 Ubiguitin mediated proteolysis 0.00882
3020 RNA polymerase 0.009959
620 Pyruvate metabolism 0.01146
130 Ubiguinone biosynthesis 0.012051
5060 Prion disease 0.01222
450 Selenoamino acid metabolism 0.012671
440 Aminophosphonate metabolism 0.01508
785 Lipoic acid metabolism 0.016278
5320 Autoimmune thyroid disease 0.017677
640 Propanoate metabolism 0.019212
20 Citrate cycle (TCA cycle) 0.020264
4640 Hematopoietic cell lineage 0.030615
520 Nucleotide sugars metabolism 0.030752
5322 Systemic lupus erythematosa 0.041064
720 Reductive carboxylate cycle (C02 fixation) 0.04154
71 Fatty acid metabolism 0.04668
Largest Fold Changes
Before statistical filtering there were 490 features exhibiting greater than 2-fold up-
regulation and 344 features exhibiting greater than 2-fold down-regulation. After
statistical filtering (p < 0.001) there were 448 features with greater than 2-fold up-
regulation and 341 with greater than 2-fold down regulation. The genes for the forty
features with the largest fold-changes are described in tables 5.2.11 (a to c) for up-
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regulated genes and 5.2.12 (a to c) for down-regulated genes (the full lists of genes
are found on the enclosed CD). Each line represents one feature on the array with
the largest fold changes being listed first. Phrases readily recognisable as being
immune function related are highlighted in red.
Table 5.2.11a: Fold Changes > 2 for Up-Regulated Genes.
Infected compared to control.
(Each line represents 1 feature on array).
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Table 5.2.11b: Fold Changes > 2 for Up-Regulated Genes.
Infected compared to control.
(Each line represents 1 feature on array).
T.OKIGre72HS
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Table 5.2.11c: Fold Changes > 2 for Up-Regulated Genes.
Infected compared to control.
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Table 5.2.12a: Fold Changes > 2 for Down-Regulated Genes.
Infected compared to control.
(Each line represents 1 feature on array).
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Table 5.2.12b: Fold Changes > 2 for Down-Regulated Genes.
Infected compared to control.
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Table 5.2.12c: Fold Changes > 2 for Down-Regulated Genes.
Infected compared to control.
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The Gene Ontology for these genes was examined using the online tool DAVID
2008 (348, 349). The results are displayed in tables 5.2.13 (a and b) for up-regulated
genes and 5.2.14 (a and b) for down regulated genes.
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Table 5.2.13a: DAVID GO Terms for Fold-Change > 2 and p < 0.001:
Up-Regulated Genes. Infected compared to control.




BP Defence response 56 1.1E-23
BP Inflammatory response 38 8.5E-20
BP Response to wounding 39 2.4E-15
BP Response to external stimulus 46 2.9E-14
BP Immune system process 62 2.3E-13
BP Response to stress 53 4.1E-10
BP Response to stimulus 102 2.6E-9
BP Immune response 47 2.7E-9
BP Taxis 16 1.6E-7
BP Chemotaxis 16 1.6E-7
BP Response to other organism 18 3.0E-7
BP Multi-organism process 22 8.7E-7
BP Response to biotic stimulus 21 2.4E-6
BP Response to chemical stimulus 30 4.9E-6
BP Locomotory behaviour 16 5.9E-6
BP Apoptosis 35 6.2E-6
BP Programmed cell death 35 7.4E-6
BP Regulation of biological quality 37 1.2E-5
BP Localisation of cell 23 1.9E-5
BP Cell motility 23 1.9E-5
BP Death 35 2.2E-5
BP Cell death 35 2.2E-5
BP Response to bacterium 11 2.4E-5
BP Negative regulation of apoptosis 16 3.5E-5
BP Negative regulation of programmed cell death 16 4.1E-5
BP Cell proliferation 33 5.2E-5
BP Myeloid cell differentiation 10 5.3E-5
BP Acute inflammatory response 9 8.7E-5
BP Intracellular signalling cascade 49 2.1E-4
BP Cellular chemical homeostasis 14 2.3E-4
BP Cellular ion homeostasis 14 2.3E-4
BP Chemical homeostasis 16 2.6E-4
BP l-kappaB kinase/NF-kappaB cascade 11 2.9E-4
BP Elevation of cytosolic calcium ion concentration 8 3.0E-4
BP Cytosolic calcium ion homeostasis 8 3.0E-4
BP Immune effector process 10 3.0E-4
BP Acute phase response 6 3.2E-4
BP Defence response to bacterium 9 3.4E-4
BP Signal transduction 98 4.2E-4
BP Immunoglobulin mediated immune response 7 5.4E-4
BP Behaviour 17 5.6E-4
BP Response to virus 9 5.9E-4
BP Ion homeostasis 14 6.0E-4
BP Regulation of apoptosis 23 6.4E-4
BP B cell mediated immunity 7 6.6E-4
BP Erythrocyte differentiation 6 7.2E-4
BP Regulation of programmed cell death 23 7.4E-4
BP Adaptive immune response based on somatic




Table 5.2.13b: DAVID GO Terms for Fold-Change > 2 and p < 0.001:
Up-Regulated Genes. Infected compared to control.
BP Leukocyte mediated immunity 8 8.1E-4
BP Adaptive immune response 8 8.1E-4
BP Cellular di-, tri-valent inorganic cation homeostasis 11 9.8E-4
CC Cytoplasm 155 5.7E-6
CC Vacuole 16 2.0E-5
CC Integral to plasma membrane 45 3.3E-5
CC Intrinsic to plasma membrane 45 4.4E-5
CC Membrane 168 1.7E-4
MF Binding 271 6.9E-8
MF Protein binding 173 4.4E-7
MF Interleukin receptor activity 7 2.3E-5
MF Interleukin binding 7 6.2E-5
MF Cytokine binding 9 2.3E-4
Table 5.2.14a: DAVID GO Terms for Fold-Change > 2 andp < 0.001
Down-Regulated Genes. Infected compared to control.
Ontology GO Term No. of Genes
(from 341)
p Values







BP Biosynthetic process 51 6.5E-12
BP Gene expression 77 2.6E-8
BP Protein metabolic process 76 6.7E-8






BP Immune system process 31 2.8E-5
BP Immune reponse 27 3.0E-5














BP Cellular defence response 7 2.3E-4
BP RNA processing 16 2.8E-4
BP Lymphocyte activation 10 3.1 E-4
BP Lymphocyte differentiation 7 3.3E-4
BP T cell activation 16 4.2E-4
BP Leukocyte activation 10 7.7E-4




Table 5.2.14b: DAVID GO Terms for Fold-Change > 2 and p < 0.001
Down-Regulated Genes. Infected compared to control.
cc Ribosome 35 4.8E-22
cc Ribnucleoprotein complex 43 6.1E-21
cc Ribosomal subunit 24 1.3E-19
cc Cytosolic part 23 4.3E-18
cc Immunological synapse 10 8.0E-13
cc Macromolecular complex 74 1.1E-12
cc Cytosolic large ribosomal
subunit (sensu Eukaryota)
11 2.9E-11
cc Cytosolic small ribosomal
subunit (sensu Eukaryota)
10 2.9E-10
cc Small ribosomal subunit 12 6.1E-10
cc Large ribosomal subunit 12 1.8E-9
cc Cytosol 25 3.0E-8








cc Cytoplasm 107 1.2E-5
cc Cytoplasmic part 72 2.9E-5
cc Receptor complex 8 9.0E-5
cc Organelle part 65 3.5E-4
cc Intracellular organelle part 64 5.7E-4
MF Structural constituent of
ribosome
35 3.3E-24
MF RNA binding 36 6.9E-13
MF Structural molecule activity 37 2.0E-11




FIOS Genomics carried out statistical comparisons of groups other than infected and
control using clinical data that was supplied for the samples. Bearing in mind the
risks of over-interpreting differences in groups other than those for primary analysis,
I have selected only 2 comparisons to present here. I present the comparison made
between whether or not samples were frozen. In addition I have presented the data
on male compared to female. I have not presented any comparisons where there
were obvious confounders nor have I presented comparisons of clinical features, e.g.
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whether had antenatal steroids or not, whether ventilated or not. I felt that the
comparisons of clinical features were not of any practical use and in some cases
(despite my best efforts) the datasets risked being incomplete. An example of
potential incomplete data is that administration of antenatal steroids to the mother
was not always clearly documented in the infant's notes and therefore there could be
overlap between groups. Also, some differences between groups could be explained
at least in part by gestational age and unfortunately gestational age was not examined
statistically during analysis by FIOS genomics.
Comparison ofSamples that were Frozen Compared to those Not Frozen
Significant Differential Expression
With an adjusted p value of < 0.001, there were 145 features significant differentially
expressed: 22 up-regulated and 123 down-regulated.
GO Term Enrichment
In the significantly up-regulated genes there were 7 enriched GO terms and in
significantly down-regulated genes there were 65. The ontology terms are displayed
in Table 5.2.15. for up-regulated and Table 5.2.16(a and b) for down-regulated
genes. The terms are listed in order of significance with the most significant first.
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Table 5.2.15.: GO Terms
Frozen compared to no
for Up-regulated Genes,
frozen groups.
Ontology GO ID GO Term
Enriched
p Value
BP G0:0006898 receptor-mediated endocytosis 1.12E-05
BP G0:0006897 endocytosis 0.000921
BP G0:0010324 membrane invagination 0.000921
MF G0:0004402 histone acetyltransferase activity 0.000204
MF G0:0004468 lysine N-acetyltransferase activity 0.000204
MF G0:0043426 MRF binding 0.000899
MF G0:0051577 MyoD binding 0.000899
Table 5.2.16a: GO Terms for Down-regulated Genes.
Frozen compared to not frozen groups.
Enriched
Ontology GO ID GO Term p Value
BP GO: 0006412 translation 3.52E-13
BP G0:0010467 gene expression 3.75E-08
BP GO: 0006396 RNA processing 2.04E-05
BP G0:0006414 translational elongation 2.07E-05
BP GO: 0044237 cellular metabolic process 4.19E-05
mitochondrial electron transport, NADH to
BP G0:0006120 ubiguinone 5.24E-05
BP G0:0042773 ATP synthesis coupled electron transport 0.000143
BP G0:0042775
mitochondrial ATP synthesis coupled
electron transport 0.000143
BP G0:0008380 RNA splicing 0.000176
BP G0:0043170 macromolecule metabolic process 0.000179
BP G0:0022904 respiratory electron transport chain 0.000184
BP G0:0022900 electron transport chain 0.000199
BP G0:0006119 oxidative phosphorylation 0.000592
BP G0:0044249 cellular biosynthetic process 0.000737
BP G0:0009059 macromolecule biosynthetic process 0.000756
BP G0:0008152 metabolic process 0.000783
MF G0:0003735 structural constituent of ribosome 2.05E-16
MF G0:0005198 structural molecule activity 7.77E-08
MF G0:0003723 RNA binding 2.45E-05
MF G0:0003954 NADH dehydrogenase activity 6.35E-05
MF G0:0008137 NADH dehydrogenase (ubiguinone) activity 6.35E-05
MF G0:0050136 NADH dehydrogenase (quinone) activity 6.35E-05
MF G0:0016655
oxidoreductase activity, acting on NADH or
NADPH, quinone or similar compound as
acceptor 9.56E-05
MF G0:0016651
oxidoreductase activity, acting on NADH or
NADPH 0.00051
CC G0:0030529 ribonucleoprotein complex 1.45E-21
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Table 5.2.16b: GO Terms for Down-regulated Genes.
Frozen compared to not frozen groups.
cc G0:0005840 ribosome 3.08E-17
cc G0:0032991 macromolecular complex 2.10E-13
cc G0:0033279 ribosomal subunit 3.54E-12
cc G0:0005739 mitochondrion 7.53E-12
cc G0:0000313 organellar ribosome 3.36E-10
cc G0:0005761 mitochondrial ribosome 3.36E-10
cc G0:0044429 mitochondrial part 2.05E-09
cc G0:0044444 cytoplasmic part 3.12E-09
cc G0:0015934 large ribosomal subunit 4.95E-08
cc G0:0043229 intracellular organelle 2.29E-07
cc G0:0043226 organelle 2.34E-07
cc G0:0005759 mitochondrial matrix 2.51 E-07
cc G0:0031980 mitochondrial lumen 2.51 E-07
cc G0:0015935 small ribosomal subunit 1.33E-06
cc GO: 0044446 intracellular organelle part 3.08E-06
cc G0:0044422 organelle part 3.32E-06
cc G0:0000314 organellar small ribosomal subunit 3.91 E-06
cc G0:0005763 mitochondrial small ribosomal subunit 3.91 E-06
cc G0:0044424 intracellular part 4.14E-06
cc G0:0005737 cytoplasm 8.48E-06
cc G0:0043231 intracellular membrane-bounded organelle 9.70E-06
cc G0:0043227 membrane-bounded organelle 9.81 E-06
cc G0:0005622 intracellular 1.50E-05
cc G0:0043228 non-membrane-bounded organelle 3.03E-05
intracellular non-membrane-bounded
cc G0:0043232 organelle 3.03E-05
cc G0:0005746 mitochondrial respiratory chain 3.66E-05
cc G0:0031974 membrane-enclosed lumen 3.67E-05
cc G0:0043233 organelle lumen 3.67E-05
cc G0:0044455 mitochondrial membrane part 4.41 E-05
cc G0:0022626 cytosolic ribosome 4.98E-05
cc G0:0005829 cytosol 6.02E-05
cc G0:0000315 organeiiar iarge ribosomai subunit 6.24E-05
cc G0:0005762 mitochondrial large ribosomal subunit 6.24E-05
cc G0:0005747 mitochondrial respiratory chain complex I 6.91 E-05
cc G0:0030964 NADH dehydrogenase complex 6.91 E-05
cc G0:0045271 respiratory chain complex I 6.91 E-05
cc G0:0044445 cytosolic part 0.000123
cc G0:0005681 spliceosome 0.000152
cc G0:0030532 small nuclear ribonucleoprotein complex 0.000421
cc G0:0005743 mitochondrial inner membrane 0.000923
316
KEGG Pathway Enrichment
There were found to be 5 enriched KEGG pathways in significantly up-regulated
genes (displayed in Table 5.2.17) and 7 enriched KEGG pathways in significantly
down-regulated genes (displayed in Table 5.2.18).
Table 5.2.17: Kegg Pathways: Up-Regulated Genes.
Frozen compared to not frozen.
Pathway ID Pathway Description. p Value
4520 Adherens junction 0.002616
4630 Jak-STAT signalling pathway 0.010456
5040 Huntington's disease 0.035285
1510 Neurodegenerative diseases 0.041789
4330 Notch signalling pathway 0.048258
Table 5.2.18: Kegg Pathways: Down-Regulated Genes.
Frozen compared to not frozen.
Pathway ID Pathway Description p Value
3010 Ribosome 1.40E-07
190 Oxidative phosphorylation 3.01 E-05
3050 Proteasome 0.005904
3020 RNA polymerase 0.00832
3440 Homologous recombination 0.009669
785 Lipoic acid metabolism 0.011151
730 Thiamine metabolism 0.043891
Largest Fold Changes
Before statistical filtering there were 233 features exhibiting greater than 2-fold up-
regulation and 39 features exhibiting greater than 2-fold down-regulation. After
statistical filtering (p < 0.001) there were 8 features with greater than 2-fold up-
regulation and 8 with greater than 2-fold down regulation. These are displayed in




: Up-regulated genes with fold change > 2, p < 0.001
pared to not frozen.
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: Down-regulated genes with fold change > 2, p < 0.001
pared to not frozen.































elongation factor 1 delta
(guanine nucleotide
exchange protein) -2.02171
When the genes with significant fold changes were examined using DAVID 2008
(348, 349) there were no GO terms that were significantly enriched (p < 0.001).
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Comparison ofMale and Female Sample Groups
Significant Differential Expression
With an adjusted p value of < 0.001, there were 14 features significant differentially
expressed: 11 up-regulated and 3 down-regulated.
GO Term Enrichment
There were no enriched GO terms in either significantly up-regulated or in
significantly down-regulated genes.
KEGG Pathway Enrichment
There were found to be 10 enriched KEGG pathways in significantly up-regulated
genes (displayed in Table 5.2.21) and no enriched KEGG pathways in significantly
down-regulated genes.
Table 5.2.21. : Kegg Pathways: Up-Regulated Genes.
Male compared to female..
Pathway ID Pathway Description. p Value
4742 Taste transduction 0.011404
4340 Hedgehog signalling pathway 0.012522
5110 Vibrio cholerae infection 0.013193
4720 Long-term potentiation 0.015206
4540 Gap junction 0.021243
4912 GnRH signalling pathway 0.021691
4916 Melanogenesis 0.022138
4910 Insulin signalling pathway 0.030411
4310 Wnt signalling pathway 0.031977
4020 Calcium signalling pathway 0.038462
Largest Fold Changes
Before statistical filtering there were 4 features exhibiting greater than 2-fold up-
regulation and 1 feature exhibiting greater than 2-fold down-regulation. After
statistical filtering (p < 0.001) there were 4 features with greater than 2-fold up-
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regulation and one with greater than 2-fold down regulation. These up-regulated
genes are displayed in table 5.2.22 and the down-regulated gene in table 5.2.23.
When these features were examined further using DAVID 2008 (348, 349) there
were no GO terms that were significantly enriched (p < 0.001).
Table 5.2.22.: Fold C
Male compared to ft
(Each line represen
Changes > 2 for Up-Regulated Genes,
imale.
s 1 feature on array).
Feature ID Description Chromosome
Fold
Change
QEpD 70uProlBdrbvo NA - 26.43253
WeKOvcS O.6U00FCCI
eukaryotic translation
initiation factor 1A, Y-linked Y 15.82515
BqhAqDI EXrh0452BT0
ribosomal protein S4, Y-
linked 2 Y 2.216063
reXjDTnq9wwlcfUXDc
eukaryotic translation
initiation factor 1A, Y-linked Y 2.149208
Table 5.2.23.: Fold C
Male compared to ft
(Each line represent
Changes > 2 for Down-Regulated Genes,
imale.
fs 1 feature on array).









The sample population in this chapter consisted entirely of infected and control
infants. The samples used for these groups were predominantly but not entirely the
same samples used in the previous section. The demographics of the study
population overall therefore are similar and are presented in table 5.2.2. In other
words, the infected group was notably more premature and therefore of lower birth
weight and was also older in terms of postnatal age when sampled than the controls.
As explained in chapter 5.1, in the early stages of the study all of the controls were
term babies attending the neonatal unit for blood screening to exclude thyroid or
adrenal problems in the early days of life. In the latter stages of the study care was
taken to ensure that the control group also included preterm infants and infants more
than a few days old. The population studied is representative of the neonatal unit
population whilst ensuring that the control group contained infants from a wide range
of gestations.
In terms of the organisms isolated in the infected group, coagulase negative
staphylococci were the organisms most frequently isolated, reflecting the prematurity
and vulnerability of the neonatal unit population. The full list of organisms isolated
is displayed in table 5.2.4. The range of organisms isolated from this group is
representative of the organisms encountered most commonly in our neonatal unit.
Samples with positive cultures were only included in the infected group if the
diagnosis of infection was felt to be robust. I was very careful to select only cases
where there was clear clinical signs of infection and looked for repeat culture results,
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isolates from other sites and haematological or biochemical supporting evidence
wherever possible. I have presented supporting evidence for the use of cases of
coagulase negative staphylococci and CMV in table 5.2.5. To be clear for the infant
with CMV; CMV can be asymptomatic in neonates but this infant was clearly
symptomatic and underwent repeated investigations. In all cases, the decision for
inclusion or exclusion of culture-positive samples in the infected group was
independently verified by a neonatal consultant (Ben Stenson). Any sample where
there was doubt was not included in the infected group and not run on microarray.
Infected compared to control samples
It was very encouraging to see that the sample relation graph shown as figure 5.2.3
showed a split between control and infected groups. The only sample that did not
group neatly was that of csb75. This sample was from the infant with CMV
infection and was seen to group with the controls. This was an interesting finding in
itself given that all of the other infected infants had bacterial infections. These
observations are even more pleasing when you consider that this figure was
generated before statistical filtering.
After statistical filtering of genes (p < 0.01) it can be seen from the heat map in
figure 5.2.4 that there is again a separation of patterns between control and infected
samples with the CMV infected sample being the exception. There seem to be 3
distinct groups of genes (marked at left of figure). The infected samples show down-
regulation of group 1 and up-regulation of groups 2 and 3 whereas most of the
controls show the converse. There is group of nine samples however that shows up-
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regulation of groups 1 and 3 and down-regulation of group 2. This is very interesting
as this group is made up of the majority of the preterm controls, one term baby, one
growth restricted baby with neonatal encephalopathy and the infant with CMV. It is
particularly interesting that the preterm controls have grouped together and are
distinct from the infected preterms. This is very exciting and confirms that future
studies on effects of gestation are warranted.
From examining the gene ontology terms for significantly up-regulated genes in the
infected group compared to controls (table 5.2.7), it can be seen that a significant
proportion are immune related. The most significantly enriched terms include
immune system process, defence response, response to external stimulus, response to
wounding, response to stress and inflammatory response. There are immune related
terms throughout the list however and some that may be worth noting in particular
are I-kappa B kinase/NK kappa B cascade, cytokine production, TNF production and
a(3 T cell activation. When KEGG analysis of up-regulated genes is examined (table
5.2.9) pathways related to TLR signalling, apoptosis, Jak-Stat and MAPK pathways
are among the most enriched pathways with B cell receptor signalling,
complement/coagulation and NK cell mediated cytotoxicity pathways also featuring.
Many of these findings concur with other groups who have investigated sepsis in
children and presepsis in adults and I list these here. NFkB and NFkB signalling
have been noted to be up regulated in both adult presepsis and paediatric septic shock
(152, 156) and up regulated as part of the common host response as described by
Hossain and by Jenner (146, 159). TLRs 1, 4, 5 and 8 have been found to be up-
regulated in adult presepsis (155, 156) and TLR signalling to be up-regulated in
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children with septic shock (152). Up-regulation of MAPK14 was found to be up
regulated in adults with sepsis (357) and other MAPK genes described as being part
of the common host response (146, 159). TNF and cytokines such as IL1(3, IL-6, and
IL-8 have been described as being up regulated in the context of the common host
response to infection (146, 159). In addition, it is known that blood levels of
cytokine such as IL-ip, IL-6, IL-8 and TNFa are increased in sepsis (358). It is
very encouraging that our findings concur with existing knowledge.
The gene ontology for most significantly down regulated genes is displayed in table
5.2.8 with "antigen processing and presentation of antigen via MHC II" being the
only term that is clearly immune related. When KEGG analysis is performed the
significantly down-regulated genes can be seen to map to T cell receptor signalling
and antigen processing and presentation pathways (table 5.2.10). Down-regulation
of T cell signalling, antigen processing and NK cell signalling have been described
previously in children with septic shock (152, 153) and T cell response as being
reduced in adult sepsis (282). As for with the CodeLink™ data, the down-regulated
genes also map to pathways related to graft versus host disease, asthma and
autoimmune diseases such as diabetes and thyroid disease (highlighted in green). It
could be suggested that suppression of such processes may expected in order to allow
response to infection.
When fold change is taken into account (fold change of greater than 2 and p value of
less than 0.001) the genes related to immune functions that are up-regulated (table
5.2.11) include IL-1 receptor II which is involved in cytokine signalling, interferon
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induced transmembrane protein, interleukin 1 receptor antagonist and TNFa induced
protein 6. In addition to those with the largest fold changes listed above, other genes
that mapped to these terms included (not exhaustively) Toll Like receptors 5 and 8,
IL-ip, IL-8 receptors a and (3, IL-18 receptor 1, IL-4 receptor, NFkB , GCSF 3,
chemokine (C-C) receptors 1 and 3, interferon regulatory factor 7, metallopeptidase
and complement components C5aRl and7 C3aRl. In addition the following cluster
of differentiation molecules were also up-regulated: CD55 (decay accelerating factor
for complement), CD14 (involved in innate immunity), CD24 (cell adhesion
molecule found on B cells), CD 82, CD97 (found on leukocytes) and CD163 (soluble
form has anti-inflammatory role). It is reassuring to note that many of these were
also up-regulated in the CodeLink™ study. In addition, CD 14 has been previously
identified as being involved in the common host response (146) and Jiang and
colleagues observed elevated levels of IL-ip, IL-4 receptor and GCSF on stimulation
of cord blood monocytes with LPS (78). IL-4 receptor and IL-18 receptor 1 have
previously been found to be up-regulated in adult presepsis (155). In addition, both
TLR 5 and TLR 8 have been previously described as up-regulated in adult presepsis
(155, 156). TLR 8 agonists have been shown to activate neonatal antigen presenting
cells (94) and to increase the magnitude and reduce duration of early systemic
inflammatory response in neonatal mice (359). Interleukin 1 receptor antagonist
levels have been noted to be elevated in children with sepsis (350) and to be elevated
up to 2 days before the diagnosis of infection in neonates (351). When the up-
regulated genes are examined by ontology (table 5.2.13) there are many enriched
terms seen - the most significantly enriched being defence response, inflammatory
response, response to wounding, response to external stimulus, immune system
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process and response to stress. Other notable up-regulated terms include NFkB
cascade, acute phase response, immunoglobulin mediated immune response, B cell
mediated immunity, leucocyte mediated immunity, interleukin receptor activity,
interleukin binding and cytokine binding.
The genes with fold change of greater than 2 and p < 0.001 that are down regulated
and are related to immune functions (table 5.2.12) include MHC II, IL-7 receptor,
IL11 receptor alpha, IL-2 inducible T cell kinase, TNF receptor factor 5, Fc receptors
and chemokine (C-C) receptor 7 and ligand 5. In addition, there is down regulation
of many T cell related cluster of differentiation molecules (CD2, CD3d, CD6, CD7,
CD8a, CD52, CD96 and CD 247). Of these CD 2 and CD96 are also involved in NK
cell function. CD79a and CD79b which are B cell receptor related were also down-
regulated, as was CD27 which is a TNF receptor. These findings again concur with
previous findings of reduced MHC II expression (78, 153, 353-355) and of down-
regulated T cell functioning (152, 153, 282) in adult and paediatric sepsis. In
addition, chemokine (C-C) ligand 5 has been found to be down-regulated in adult
presepsis (155). Interestingly however, IL-7 receptor in the work of Jiang and
colleagues on stimulating cord blood monocytes with LPS showed up-regulation
(78). Jiang's work reflects in vitro stimulation. Our population were exposed to a
range of pathogens in vivo and there could be pathogen related reasons or host
physiological reasons why our samples show the opposite. The immune-related GO
terms that are enriched for down-regulated genes (table 5.2.14) include
lymphocyte/T cell/leukocyte activation, T cell receptor complex and MHC II
receptor activity.
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There is in summary, up-regulation of components of the immune system involved in
both innate and adaptive immunity. There is up-regulation of cytokine and
chemokine components, kinases and NF-kB signalling representing both pro- and
anti- inflammatory processes. Complement related genes, Toll like receptors
(specifically 5 and 8) and interferon related genes are also up-regulated. There is
down-regulation of adaptive immune function particularly in relation to T cell
function and regulation, as well as down regulation of antigen presentation and of
MHC II activity.
Overall these results are very exciting. It looks likely that, with larger studies and
with examination of training sets of data, immune gene expression signatures for
neonatal infection will be able to be defined. The work presented here is novel in
that it is describing host gene expression profiling of infection in a neonatal
population. A proportion of the neonates being studied will be encountering
infection for the first time. In the context of a developing immune system and
possible gestational effects on immune response, it is very encouraging to see
differential gene expression that has previously been described in older subjects. It is
likely however that with further work expression patterns that are seen only in
neonatal infection and not in older populations will be found. Some of the findings
described in this chapter are not yet found in the literature and this probably
represents a combination of this being a new field of research and expression patterns
unique to neonates. Carrying out work such as presented in this chapter is an
important step forward in moving towards using microarrays to diagnose neonatal
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infection using host response patterns. The results presented here are part of ongoing
work and I am pleased to have been able to do so in more in depth than originally
intended in the context of this thesis. The findings so far are really encouraging and I
am optimistic that our ongoing work will continue to lead to progress in this area.
Comparison ofsamples that werefrozen with those that were notfrozen.
For significantly differentially expressed genes, there were none of the gene ontology
terms (tables 5.2.15 and 5.2.16) that were specifically immune related. Table 5.2.17
shows KEGG analysis of significantly up-regulated genes and of these only the Jak-
Stat pathway was enriched (enriched p value of 0.0104). None of the enriched
pathways for significantly down-regulated genes were immune-related (table 5.2.18).
When taking fold change into account (fold change of greater than 2, p < 0.001) only
one gene term in the up-regulated group was identifiable as immune related
(Pathogenic E coli related) and none in the down-regulated group (tables 5.2.19 and
5.2.20). There were no GO terms identified for genes differentially expressed with
fold change greater than 2. The lack of immune related differential gene expression
between samples that were frozen prior to RNA extraction in relation to those not
frozen is encouraging. This supports use of either fresh or frozen samples for studies
of neonatal blood. Laboratory processing of samples can therefore be batched
efficiently. It would also facilitate expedient extraction of local samples while
allowing samples transported from elsewhere to be frozen if a multi-centre study
were to follow. These findings agree with the findings of Vartanian and colleagues
who found little or no difference in expression profiling from PAXgene™ blood
samples whether they were fresh or frozen when RNA was extracted (360).
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Comparison ofsamplesfrom males compared tofemales.
It was both expected and encouraging that there was little difference in gene
expression between the male and female groups. It is reassuring that the genes with
the largest fold changes of differential expression, displayed in tables 5.2.22 and
5.2.23, were either found on the Y chromosome (relatively up-regulated in boys) or
the X chromosome (relatively down-regulated in boys). This provides confidence
that the arrays were correctly differentiating between samples. There were no GO
terms enriched for differentially expressed genes either using significance alone or
when considering fold change. The KEGG pathways enriched for up-regulated
genes are displayed in table 5.2.21 and of these, only "Vibrio cholerae infection"
relates to immune function (p value 0.013). The actual significance of this is not
clear.
Note on GestationalAge
Although gestational age was not examined statistically for this data, I believe that
the effect of gestational age on gene expression in response to infection is an area
that needs to be studied further. The heat-map at the beginning of this section
showing clustering of premature infants confirms this. This indicated that preterm
control infants showed different gene expression profiles from infected preterm
infants and from term controls. I do not think that the differences seen between the
control and infected groups in this chapter can be explained by gestational
differences as it would be expected that premature infants would be less able to show
significant up-regulation of immune genes than less premature infants if there indeed
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were to be any difference at all. This data does however show that neonates are
capable of producing significant immune responses to infection.
Conclusions
Differences in gene expression can be detected between infected and control
neonates. Many of these differences are immune-function related. The ability to
detect such differences could have diagnostic potential but this would clearly require
further investigation. Such data also provides evidence that neonates are capable of
mounting a substantial immune response.
Freezing samples prior to RNA extraction does not lead to significant differences in
immune related gene expression compared to fresh samples. This has positive
implications for expanding future studies to include other centres.
Gestational age may affect the patterns of RNA expression profile seen and this
needs further investigation.
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Section 5.3: Comparison of CodeLink™ and lllumina®
Findings
Background
Having run infected and control samples on two different microarray platforms, I
present here a comparison of the ontology of significantly up- and down-regulated
genes for each platform. The infected and control groups for each platform consist
of mostly but not entirely the same samples. In other words, this is not a direct
comparison and therefore some differences would be expected. Also, as would be
expected, the two platforms are not looking at exactly the same gene fragments. This
makes it very difficult to compare the genes themselves and is why I have opted to
look at the ontology and pathway comparisons. It should also be noted that the cut¬
offs for significance in order to carry the genes of interest on for ontology and
pathway examinations differed between groups: p < 0.001 for the Illumina® samples
and p < 0.01 for CodeLink™ samples.
Aim
To provide a brief comparison of the results obtained for the CodeLink™ and
Illumina® studies (chapters 5.1 and 5.2) with the focus being on shared findings.
Comparison of Gene Ontology
The top ten most significantly enriched GO terms for significantly up-regulated
genes for each platform are displayed in table 5.3.1 and those for significantly down-
regulated genes in table 5.3.2. Seven terms are shared between platforms in the top
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ten up-regulated group and six terms in the ten down-regulated terms. Shared terms
are highlighted in pink.
Table 5.3.1: Top 10 most significantly enriched GO terms for each
platform: Up-regulated genes.
CodeLink™ lllumina®
GO ID GO Term GO ID GO Term
G0:0009611 response to wounding G0:0002376 immune system process






G0:0006955 immune response G0:0007243 protein kinase cascade
G0:0006952 defence response G0:0007242
intracellular signalling
cascade
G0:0006954 inflammatory response G0:0009611 response to wounding
G0:0006950 response to stress G0:0006950 response to stress
G0:0007599 haemostasis G0:0006954 inflammatory response
G0:0007596 blood coagulation G0:0006955 immune response
G0:0048522
positive regulation of
cellular process G0:0012501 programmed cell death
Table 5.3.2: Top 10 most significantly enriched GO terms for each
platform: Down-regulated genes.
CodeLink™ illumina®
GO ID GO Term GO ID GO Term
G0:0010467 gene expression G0:0010467 gene expression








biosynthetic process GO: 0044237
cellular metabolic
process
GO:0006412 Translation G0:0008152 metabolic process
G0:0043170
macromolecule metabolic



















Comparison of KEGG Pathway Enrichment
The top ten most significantly enriched KEGG pathways for significantly up-
regulated genes for each platform are displayed in table 5.3.3 and those for
significantly down-regulated genes in table 5.3.4. Two pathways are shared between
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platforms in the top ten up-regulated group and six of the top ten down-regulated
pathways.
Table 5.3.3: Top 10 most significantly enriched KEGG Pathways for
each platform: Up-regulated genes.
CodeLink™ lllumina®











530 Aminosugars metabolism 5221 Acute myeloid leukaemia
4640 Hematopoietic cell lineage 5215 Prostate cancer
4910 Insulin signalling pathway 4210 Apoptosis





pathway 4540 Gap junction









cytoskeleton 4520 Adherens junction
Table 5.3.4: Top 10 most significantly enriched KEGG Pathways for
each platform: Down-regulated genes.
CodeLink™ lllumina®
Pathway ID Pathway Description Pathway ID Pathway Description
3010 Ribosome 3010 Ribosome








5330 Allograft rejection 4660
T cell receptor signalling
pathway
5310 Asthma 5310 Asthma
4640 Hematopoietic cell lineage 5332
Graft-versus-host
disease





disease 271 Methionine metabolism
970
Aminoacyl-tRNA







Comparison by Largest Fold-Change
For the largest fold-change, the statistical significance cut-offs were the same for
both groups: fold change of greater than log 2 and p < 0.001. Due to the difference
in probes used for each platform it may be difficult to compare the gene-sets directly.
On direct comparison of genes with significant fold changes between platforms there
were 61 shared up-regulated genes and 87 shared down-regulated genes - found by
matching Entrez IDs. These shared genes are displayed in tables 5.3.5 (a to c) and
5.3.6(ato d).






249 alkaline phosphatase, liver/bone/kidney
gamma-Hexachlorocyclohexane
degradation, Folate biosynthesis
306 annexin A3 -
366 aquaporin 9 -
383 arginase, liver
Urea cycle and metabolism of
amino groups, Arginine and
proline metabolism
602 B-cell CLL/lymphoma 3 -
634
carcinoembryonic antigen-related cell
adhesion molecule 1 (biliary
glycoprotein)
762 carbonic anhydrase IV Nitrogen metabolism
1604
CD55 molecule, decay accelerating






growth arrest and DNA-damage-
inducible, alpha
MAPK signalling pathway, Cell
cycle, p53 signaling pathway
2180
acyl-CoA synthetase long-chain family
member 1
Fatty acid metabolism, PPAR
signalling pathway,
Adipocytokine signalling pathway















Table 5.3.5b: Shared Genes Between Microarray Platforms with
Significant Fold Changes.
Up-regulated Genes






3557 interleukin 1 receptor antagonist -
3687
integrin, alpha X (complement
component 3 receptor 4 subunit) Regulation of actin cytoskeleton
3726 jun B proto-oncogene -
4318
matrix metallopeptidase 9 (gelatinase B,





nuclear factor of kappa light polypeptide
gene enhancer in B-cells inhibitor, alpha
Apoptosis, Toll-like receptor
signalling pathway, T cell
receptor signalling pathway, B
cell receptor signalling pathway,
Adipocytokine signalling
pathway, Epithelial cell signalling
in Helicobacter pylori infection,









proteoglycan 2, bone marrow (natural
killer cell activator, eosinophil granule
major basic protein) Asthma
6005 Rh-associated glycoprotein -
6272 sortilin 1 -
6283 S100 calcium binding protein A12 -
6478
seven in absentia homolog 2
(Drosophila)
7057 thrombospondin 1
Cell junctions, p53 signalling
pathway, TGF-beta signalling










structures - biosynthesis 2






dysferlin, limb girdle muscular dystrophy
2B (autosomal recessive)
8530 cystatin F (leukocystatin) -








structures - biosynthesis 1
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cAMP responsive element binding
protein 5 Prostate cancer







10900 RUN domain containing 3A -
23569 peptidyl arginine deiminase, type IV -
23765 interleukin 17 receptor A
Cytokine-cytokine receptor
interaction
51311 toll-like receptor 8
Toll-like receptor signalling
pathway
51312 solute carrier family 25, member 37 -
51327 erythroid associated factor -
53831 G protein-coupled receptor 84 -
54498 spermine oxidase -
55331 phytoceramidase, alkaline Sphingolipid metabolism
55432
YOD1 OTU deubiquinating enzyme 1
homolog (S. cerevisiae)
Benzoate degradation via CoA






60675 prokineticin 2 -
64092
SAM domain, SH3 domain and nuclear
localization signals 1
80216 alpha-kinase 1 -
84418 chromosome 5 open reading frame 32 -
91543
radical S-adenosyl methionine domain
containing 2
116496
family with sequence similarity 129,
member A
116844 leucine-rich alpha-2-glycoprotein 1 -
118932 ankyrin repeat domain 22 -
120892 leucine-rich repeat kinase 2 Neurodegenerative diseases
199675 chromosome 19 open reading frame 59 -
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ID Description Pathway Description
274 bridging integrator 1 -
914 CD2 molecule
Cell adhesion molecules (CAMs),
Hematopoietic cell lineage
915
CD3d molecule, delta (CD3-TCR
complex)




CD3g molecule, gamma (CD3-TCR
complex)
Hematopoietic cell lineage, T cell
receptor signaling pathway
919 CD247 molecule
Natural killer cell mediated
cytotoxicity, T cell receptor
signalling pathway




1043 CD52 molecule -








v-ets erythroblastosis virus E26
oncogene homolog 1 (avian)
3003 granzyme K (granzyme 3; tryptase II) -
3094






class II, DM beta
3113
major histocompatibility complex,
class II, DP alpha 1
Cell adhesion molecules (CAMs),
Antigen processing and
presentation, Type I diabetes
mellitus, Asthma, Autoimmune




inhibitor of DNA binding 3, dominant
negative helix-loop-helix protein
Cell adhesion molecules (CAMs),
Antigen processing and
presentation, Hematopoietic cell





3575 interleukin 7 receptor
Cell adhesion molecules (CAMs),
Antigen processing and
presentation, Hematopoietic cell






Table 5.3.6b: Shared Genes Between Microarray Platforms with
Significant Fold Changes.
Down-regulated Genes






killer cell lectin-like receptor subfamily
B, member 1
T cell receptor signalling pathway,
Leukocyte transendothelial
migration
3945 lactate dehydrogenase B
Calcium signalling pathway,
Phosphatidylinositol signalling









4068 SH2 domain protein 1A
Cytokine-cytokine receptor
interaction, Antigen processing and
presentation, Type I diabetes
mellitus






Natural killer cell mediated
cytotoxicity
5583 protein kinase C, eta
Focal adhesion, Long-term
potentiation, Regulation of actin
cytoskeleton, Insulin signalling
pathway
5859 glutaminyl-tRNA synthetase -
6015 ring finger protein 1 -
6124 ribosomal protein L4 -
6137 ribosomal protein L13 Ribosome
6138 ribosomal protein L15 Ribosome
6146 ribosoma! protein L22 Ribosome
6152 ribosomal protein L24 -
6160 ribosomal protein L31 Ribosome
6208 ribosomal protein S14 Ribosome
7188 TNF receptor-associated factor 5 -
7423 vascular endothelial growth factor B -
8445
dual-specificity tyrosine-(Y)-
phosphorylation regulated kinase 2
8631
src kinase associated phosphoprotein
1
8725
chromosome 19 open reading frame
2
9214 Fas apoptotic inhibitory molecule 3 Ribosome
9452 integral membrane protein 2A -
9806
sparc/osteonectin, cwcv and kazal-









RAS guanyl releasing protein 1
(calcium and DAG-regulated)
10225 CD96 molecule -
10412 TGF beta-inducible nuclear protein 1 -
10480
eukaryotic translation initiation factor
3, subunit M
10801 septin 9 -
23180 raftlin, lipid raft linker 1 -
23521 ribosomal protein L13a -
25777 unc-84 homolog B (C. elegans) -
26053 autism susceptibility candidate 2 -
27040 linker for activation of T cells -
28955 dexamethasone-induced transcript -
Natural killer cell mediated
29121
C-type lectin domain family 2,
member D
cytotoxicity, T cell receptor
signalling pathway, Fc epsilon Rl
signalling pathway
51020 HD domain containing 2 -
51176 lymphoid enhancer-binding factor 1 -
51275




family with sequence similarity 134,
member B
54674 leucine rich repeat neuronal 3 -
55013 coiled-coil domain containing 109B -
55340 GTPase, IMAP family member 5 -
59338
pleckstrin homology domain
containing, family A (phosphoinositide
binding specific) member 1
79058
alveolar soft part sarcoma
chromosome region, candidate 1
79961 DENN/MADD domain containing 2D -
80212 coiled-coil domain containing 92 -
80342 TRAF3 interacting protein 3 -
81606
limb bud and heart development
homolog (mouse)
84678






TOX high mobility group box family
member 2
85315
progestin and adipoQ receptor family
member VIII
91523
family with sequence similarity 113,
member B
114932
Morf4 family associated protein 1 -like
1
132299 OCIA domain containing 2 -
339




sterile alpha motif domain containing
3
155066
ATPase, H+ transporting V0 subunit
e2
168537 GTPase, I MAP family member 7
Oxidative phosphorylation, Vibrio
cholerae infection, Epithelial cell
signalling in Helicobacter pylori
infection
170622 COMM domain containing 6 -
220433
similar to 40S ribosomal protein S4, X
isoform
387751
GTPase, very large interferon
inducible 1
389289
chromosome 5 open reading frame
39
399665
family with sequence similarity 102,
member A
439949
hypothetical gene supported by
AY007155 .
Of these shared genes with significant fold changes those highlighted in red can be
easily identified as having immune related-functions. Tables 5.3.7 (up-regulated
genes) and table 5.3.8 a and b (down-regulated genes) display the top DAVID
derived GO terms (biological process terms) from all of the genes with significant
fold changes from each platform. In the top up-regulated terms the platforms shared
four terms and in the top down-regulated terms they shared seven. It is also clear
that many of the other terms listed are similar but not exactly the same.
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Table 5.3.7: DAVID GO terms(Biological process) for each platform:
Significantly up-regulated genes with fold change > 2
lllumina® CodeLink™
GO Term No of
genes
P value GO Term No of genes P value
Defence
response

































102 2.6E-9 Coagulation 7 3.5E-4
Immune
response
47 2.7E-9 Hemostasis 7 4.1 E-4





Table 5.3.8a: DAVID GO terms(Biological process) for each platform:
Significantly down-regulated genes with fold change > 2
llumina® CodeLink™
GO Term No of
genes
P value GO Term No of genes P value




































Table 5.3.8b: DAVID GO terms(Biological process) for each platform:
Significantly down-regulated genes with fold change > 2
lllumina® CodeLink™
GO Term No of
genes
P value GO Term No of genes P value
Cellular 71 7.1E-7 Translation 46 2.4E-6
macromolecule
metabolic process
Immune system 31 2.8E-5 RNA 37 3.0E-6
process processing
Immune reponse 27 3.0E-5 Metabolic
process
365 3.3E-6


















Macromolecule 109 1.5E-4 Regulation of T 12 9.8E-6
metabolic process cell activation
Immune system 11 2.3E-4 Cellular 332 1.1 E-5
development metabolic
process
Cellular defence 7 2.3E-4 Leukocyte 22 1.1E-5
response activation












7 3.3E-4 Cell activation 23 2.4E-5















When comparing the results of the work presented in 5.1 with that in 5.2, some
differences in expression profiles dependent on the microarray platform used are to
be expected. In addition, the study cohorts run on each platform, although made up
of predominantly the same samples were not identical. It is encouraging that so
many of the most significantly enriched functional terms for both up-regulated and
down-regulated genes are shared by both platforms.
The up-regulated terms consistently include immune response, inflammatory
response, response to stimulus, response to stress and response to wounding (tables
5.3.1 and 5.3.7). The common up-regulated pathways included apoptosis and TLR
signalling (table 5.3.3). Shared up-regulated genes with fold change greater than 2
include CD55 (involved in complement and coagulation functions), MAPK, IL-1
receptor antagonist, matrix metallopeptidase 9, integrin, nuclear factor of kappa light
polypeptide gene enhancer in B-cells inhibitor alpha, TNF alpha induced protein 6,
IL-1 receptor type 2, interferon induced transmembrane protein 3, IL-17 receptor
antagonist and TLR 8. Many of these genes have been discussed already in chapters
5.1 and 5.2. Up-regulation of such genes makes physiological sense in a host
fighting infection, with several of the genes having been observed to be up-regulated
in infection in adults and children with sepsis (146, 152, 156, 357).
KEGG pathways that were enriched for significantly down-regulated genes in both
platforms included T cell receptor signalling pathway, graft versus host disease,
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allograft rejection and asthma (table 5.3.6). The shared down-regulated ontology
terms in table 5.3.2 are not clearly specific to immune function but when fold change
is taken into account the shared down-regulated ontology terms are seen to include T
cell activation, lymphocyte activation and leukocyte activation (table 5.3.8). Down-
regulated genes with fold changes of over two on both platforms included cluster of
differentiation molecules CD2, CD3, CD247, CD7, and CD5. MHC II, interleukin 7
receptor, interleukin-2 inducible T cell kinase, Killer cell lectin-like receptor B, mal
T cell differentiation protein and TNF receptor associated factor 5 were also down-
regulated. The down-regulation of T cell activity and MHC II function has been
previously been described in paediatric septic shock (152, 153).
Results shared between platforms are likely to be of particular interest when looking
at potential signature sets of genes. Ongoing genomic and pathway analysis within
the department is likely to include further examination of these terms.
Conclusion
This comparative data acts as corroboration that neonatal samples can be run on
different microarray platforms and that neonates with infection show differential







My central hypothesis was that distinct patterns of host transcriptional response
detected from neonatal whole blood may enable diagnosis of neonatal infection.
When I embarked on this project there was no literature regarding the use of neonatal
whole blood for gene expression profiling. In addition, potential clinical applications
of gene expression profiling were only just starting to appear, making this a very
exciting area of research to be involved in. In order to address this hypothesis the
questions of whether indeed it would be possible to use neonatal whole blood for
expression profiling in the first place, and, whether differences in gene expression
profiles between infected and control infants could be detected using microarray
technology needed to be resolved. It is these questions that the work in this thesis
addresses.
It is very satisfying on reaching the end of this thesis to have achieved more than I
originally set out to do. From the outset, for financial reasons, this was planned to
be a small-scale study using in the region of 6-12 microarrays as a feasibility study
leading to something potentially larger. I have been immensely privileged to have
had the opportunity, on achieving my initial aims, to be able to carry out further
microarray studies examining differences in RNA expression profiles between
infected and control neonates.
Due to the necessity of blood samples from neonates being small, there was always
the possibility that such samples could not yield sufficient RNA for microarray work
or that poor RNA quality may hamper progress. Fortunately, this was not the case
and I have demonstrated that high quality RNA can consistently be obtained from
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small neonatal samples. Furthermore, I was able to determine that the PAXgene™
Blood RNA system yielded the highest quality RNA of the tubes and methods
investigated. In addition, I was able to set parameters of incubation time and sample
storage for use in future studies. In generating gene expression profiles from the
neonatal samples, this study has yielded lots of information, examining multiple
markers simultaneously from low volumes of blood. To gain this volume of
information using other techniques would require prohibitive amounts of blood, time
and labour. In addition, I have shown it is possible to obtain samples to achieve such
data without disrupting clinical care or altering the practice of clinical sampling. In
refining the techniques used, this work, in addition to the potential diagnostic
benefits, will undoubtedly be useful for future clinical research.
As with any investigative tool, there are also disadvantages to the approach we have
adopted. The expression profiles obtained represent a snapshot in time and changes
may occur depending on the exact time point of sampling within the course of the
illness. The samples described in this thesis were taken at the point of clinical
suspicion of infection. As this is also the point where clinical decision making
becomes necessary, our samples represent an important clinical point in time. Future
studies into the progression of neonatal expression profiles within the time course of
an infection would be informative and indeed, other groups have begun doing this
with adult and paediatric populations (153-155, 285). In addition, host
transcriptional profiling does not reflect every aspect of biology but it does present a
large amount of increased information. One aspect of biology that is not examined is
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that of protein function. It may be that in future combined approaches will be
adopted both in terms of research and in clinical application.
Due to the paucity of previous work in this area it was never certain that our
microarray data would be informative. On progressing to gene expression profiling
it could have been the case that the results obtained would be too variable to allow
any response to infection to be elucidated. Also, given the known susceptibility of
neonates to infection, it could have been the case that very little in the way of
immune response be seen at all. In fact, this was not true. What I have presented in
this thesis is evidence of a very clear, substantial immune response being detected. It
is exciting that many of the differentially expressed genes identified in this work
have immune and inflammatory functions and that the profiles being detected are
therefore clearly disease related. It is also encouraging that many of our findings
concur with those found in studies of adult and paediatric sepsis (146, 152, 153, 155,
156, 159, 282). Our results also show differential expression of genes that have not
previously been described in studies of host transcriptional response to infection.
There are likely to be differences in the profiles found in a neonatal population
compared to older populations, reflecting the developing immune system and in
some cases, the first encounter with infection. Deeper analyses which were beyond
the scope of this study and further neonatal studies will help elucidate this further. In
addition, there are still relatively few publications in this area. It would be expected
that as more publications emerge, even greater understanding of the host
transcriptional response to infection will be achieved. Definition of a signature set of
genes for infection is now closer to reality.
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The work presented in this thesis is clearly supportive of the hypothesis that distinct
patterns of host transcriptional response detected from neonatal whole blood can
enable diagnosis of neonatal infection. More work however needs to be done to
prove this. Validation of microarray findings is necessary - for example confirming
the presence of genes of interest with RT-PCR would provide useful corroboration.
The next steps would be to define a set of signature genes and to test this with
expression profiles from future samples. In addition, as collaboration, potential
signature sets of genes could be tested against sets of infected and control profiles
from other groups. Closer examination of the group of samples with suspected
infection (the possible infection group from chapter 5.1) would also be valuable. It
would be in this group especially, for whom more accurate diagnosis could well
change clinical management, that clear and accurate division into infected and not
infected would be greatly beneficial. Unfortunately such analyses are beyond the
time and budget set out for this project but there are plans for future work in this
area. Also, greater understanding of the effects of factors such as gestation, postnatal
age, drugs including antibiotics and steroids, and co-existent medical conditions is
needed. This will require large-scale studies.
Furthermore, translation of the use of diagnostic host expression signatures from
research tools to clinical tools will require further work. Currently, the costs
involved in the use ofmicroarray technology are prohibitive and the detection of host
expression patterns takes several days. Once a robust set of genes is validated as
being able to diagnose infection then production of a custom microarray would be
possible, therefore reducing the cost of further studies. Results of such studies could
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then be used to enable development of a more closed system that would be rapid and
streamlined, potentially giving results within a few hours. The final diagnostic tests
need not be microarray based. Markers identified and validated from microarray
work could be detected using a PCR platform for example. In addition, if the
signatures pointed towards protein markers of infection then use of more traditional
techniques of protein detection may be appropriate. Ultimately, I would hope that
rapid bedside testing for infection would be possible. From a clinical viewpoint, the
aim would be bedside devices that could determine not only the presence or absence
of infection but if the infection is caused by bacteria, virus, fungus and the specific
microorganism responsible. It may be the case that host gene expression profiles
can be used to determine not only the presence of infection but also the group of
organisms that the pathogen responsible belongs to or even to identify the individual
organism. However, this may not be necessary if host gene expression profiling is
used in conjunction with organism detection. Methods of rapid pathogen detection
using gene expression profiling are emerging and look very promising in terms of
diagnostics. I would envisage that bedside diagnostic tests would incorporate both
pathogen detection and host response profiling. This would enable specific diagnosis
of presence of a pathogenic microorganism, potentially give specific information on
sensitivity or resistance to antimicrobials and also determine whether the organism
was causing infection as opposed to being a contaminant or being carried without
symptoms. It may be that host expression profiling will also yield valuable
information regarding prognosis. Any diagnostic test would need to have very high
sensitivity and specificity as the consequences of missing neonatal infection can be
catastrophic. Neonatologists are therefore likely to need complete confidence in any
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test in order for it to be accepted into clinical practise and used as a gold standard.
Successful development of such tools that could diagnose neonatal infection more
accurately and rapidly than is currently possible would be greatly beneficial.
Although such tests are likely to be financially expensive to begin with, the costs
associated with production would be expected to come down with time and should be
off-set with savings made due to expected reduction in morbidity and mortality,
reduced hospital stay, more tailored antibiotic therapy and reduced iatrogenic
complications. The benefits of reduced parental anxiety and the neonatal and long-
term benefits to the babies' emotional as well as physical wellbeing are
immeasurable.
In summary, the work presented in this thesis has shown that it is possible to
consistently obtain high quality RNA from neonatal blood in sufficient quantity to
use for microarray work. It has also shown that it is possible to detect differences in
host gene expression profile between infected and non-infected neonates. Many of
these differences are seen to be related to immune functions. The results are highly
supportive of the hypothesis that distinct patterns of host transcriptional response
detected from neonatal whole blood may enable diagnosis of neonatal infection.
This is an exciting time in the world of infection diagnostics and I believe that the
work presented in this thesis represents some significant strides towards microarray
diagnosis of infection in the newborn.
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Appendix 1
Short Notes on Investigation of Globin Reduction
Background
As gene expression profiling of whole blood has become more commonplace, methods
to try and overcome the challenges presented by the heterogeneous nature of whole
blood have emerged. In particular, methods for globin reduction have come onto the
market. Globin mRNA transcripts have been estimated to constitute a significant
proportion of whole blood mRNA. It is thought that these transcripts decrease the
sensitivity of detecting the other mRNAs of interest when using microarray technology
(333, 334). Indeed, some literature suggests that there is reduction in percent present
cells and increased variability when looking at microarray data from whole blood
mRNA compared to that extracted directly from white blood cells or compared to where
globin reduction has been incorporated (333-335). Furthermore, globin reduction
techniques have been put forward as ways to reduce this variability and to increase
sensitivity of detecting less abundant mRNAs (333-335).
With such data emerging, I felt that it was important to consider using a globin reduction
technique on my extracted RNA. However I was wary that adding an additional step
would increase the time of sample processing and would introduce another possible
source of variation between samples.
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There was a significant problem when it came to considering the use of globin reduction
techniques for my samples however. The globin reduction methods on the market were
all targeted towards reduction of adult globin mRNAs, i.e. alpha and beta globin
polypeptides whereas the haemoglobin in neonatal blood is predominantly fetal
haemoglobin. Adult haemoglobin is a tetramer composed of two alpha and two beta
subunits, fetal haemoglobin is a tetramer composed of two alpha and two gamma
subunits. It is probably worth commenting on the fact that any blood transfusions given
to newborns would be from adult donors. The donated blood is white cell depleted so
should not affect the RNA expression profiles of interest when considering response to
infection. The globin composition will differ from that in non-transfused infants
however due to the higher Haemoglobin A in the transfused blood.
Through studying product literature (GeneChip® Globin-Reduction Kit,
Troubleshooting Guide) and a personal communication with Ambion (GLOBINclear™-
Human Kit) I confirmed that the available methods targeted alpha and beta globin
mRNA and would not be expected to reduce gamma globin polypeptides. I further
confirmed this by comparing the published target areas in company literature with the
sequences published for each homo sapiens haemoglobin (haemoglobins Alpha 1, Alpha
2, Beta, Gamma, Gamma 2) on Entrez Nucleotide using NCBI Sequence Viewer v 2.0
(361). I also sought advice from GE who marketed the CodeLink™ arrays for any
experience they had on the use of globin reduction.
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Despite confirmation that the use of globin reduction techniques would only target a
small proportion of neonatal haemoglobin, I decided to try out a globin reduction
method. This was to try and get an indication as to whether or not globin reduction
would be useful in my neonatal samples. Of the several globin reduction methods
available I chose the GLOBINclear™-Human kit (Ambion®) because this method
avoided use of RNase H treatments which we were concerned could degrade or even
alter the expression profiles of our small precious samples. The other main contender
was the GeneChip® Globin-Reduction method (Affymetrix®/PreAnalytiX) which
utilises peptide nuceleic acid (PNA) oligonucleotides and was designed for use with the
PAXgene™ system. There were two problems with the GeneChip® method with
respect to this study. Firstly, it was meant for use with the target preparation protocol
for GeneChip® arrays. Secondly, the yield of cDNA achieved with the GeneChip® was
reduced and therefore the amount of input RNA needed for this protocol was higher at 8
pg. Pooling of PAXgene™ Blood RNA Tubes was recommended. This meant that the
GeneChip® method was clearly not feasible for use with the neonatal samples. The
GLOBINclear™ protocol also required an increased starting amount of RNA: 3 pg of
RNA inputted into the globin reduction protocol would be required to provide 1 pg for
the CodeLink™ labelling protocol. This level of reduction was however at least feasible
to investigate further.
Due to financial constraints, at the time of carrying out this exploratory work we had
only 6 Codelink™ Whole Human Genome Arrays available. It was therefore only
possible to spare one array to investigate globin reduction. I therefore used a
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GLOBINclear™-Human kit and protocol from Ambion® on sample csbl which had
already been run on microarray without globin reduction.
Acknowledgements
Running of the microarrays was carried out by me and supervised by Marie Craigon.
The analysis and tabulation of comparisons of the arrays was carried out by Thorsten
Forster. All of the other work in this section was carried out by myself.
Aim
To get an indication of potential benefit of using a globin reduction step with neonatal
samples.
Method
Two microarrays of a single neonatal sample (csbl) were compared: one array without
globin reduction, the other with globin reduction using the GLOBINclear protocol as
found in the GLOBINclear™Kit Instruction Manual from Ambion®, Catalog #1980.
Manual Version 0506.
Csbl was the first of our RNA samples to be run on CodeLink™. It was initially
labelled, hybridised and run on array (method 1) as described on page 101. On a
separate occasion, 14 microlitres (1.82 micrograms) of the RNA sample was used for
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globin reduction. No precipitation step was used. The same method of labelling,
hybridisation and microarray analysis was then carried out.
Results
Table A. 1.1 shows the spot quality data for each of the two arrays. From this it can be
seen that there were more good quality spots, less contamination and less low signal
spots with the sample that had not been subjected to globin reduction.
Table A.1.1: Comparison ofArray Quality for a










MSR file but no intensity data 122 110
Low - below background
intensity 16125 18972
Irregular shape 605 166
Spot manually excluded 0 error 1
Separately to the above experiment, when examining Bioanalyzer traces of cRNA from
neonatal blood, there was an interesting observation made. In the literature (technical
notes) (333, 335), the electrophoresis traces of PAXgene™ cRNA were described as
having a significant peak due to globin transcripts, with this peak being reduced with
globin reduction. In figure A. 1.1 I have drawn an outline to show the type of
bioanalyzer traces these notes describe. Figure A. 1.2 shows Bioanalyzer graphs of
cRNA for a selection ofmy neonatal blood samples. It was interesting to note that many
of the neonatal samples had cRNA profiles which were closer to those having been
subjected to globin reduction than those not. This may mean that the globin peak is not
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such a prominent feature in neonatal blood, giving further doubt to the potential utility of
globin reduction in neonatal samples.
Figure A.1.1: Expected shape ofcRNA traces as described in the literature
for PAXgene ™and Globin reduced samples.
Globin reduced
Figure A.1.2: Bioanalyzer traces for neonatal cRNA
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Discussion
This comparison was carried out on a look and see basis to give an indication of the
usefulness of globin reduction. A comparison of two samples cannot be considered to
give statistically significant results and caution must therefore be exercised in
extrapolating too much from this data. It is possible that the differences seen could be
due to normal technical variation. In addition, as both arrays were from the same sample
it was not possible to assess inter-individual variability. While bearing these caveats in
mind, the quality data presented here seems to indicate that the sample that had not had
globin reduction carried out fared better in terms of the number of probes that gave good
quality data. Why this should be the case is not clear and it may be a reflection that
globin reduction based on adult sequences does not give full benefit to neonatal samples
and may even have detrimental effects. The observation that the bioanalyzer traces
obtained from neonatal blood appear closer in shape to globin reduced adult samples
may suggest that the globin predominance is not such an issue in neonatal samples.
Further work would clearly be required to elucidate this further.
Conclusions
This experiment did not provide evidence that globin reduction would be useful in
neonatal samples. There was a suggestion that omitting the globin reduction step may
actually give superior results. It was therefore decided that globin reduction would not
be incorporated into the protocol for this study.
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Appendix 2
The tables in this section contains raw data, Bioanalyzer traces and RIN values for
the work carried out on umbilical cord blood RNA from chapter 3.
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Notes on table 3.1.1
There were 5 individual tubes for which there are no data available. Sample csl
Lithium Heparin tube had the wrong cap placed on it in error at the time of sampling.
This meant that there would have been contamination from other chemicals in this
tube and therefore RNA was not extracted. Sample cs3 PAXgene™ was eluted in
the wrong buffer and therefore no valid data for comparison was available on this
sample. In addition sample cs4 clotted in all three of the clinical blood tubes on
route to the lab and these were therefore unable to be used. As the volume of blood
required from each cord was fairly large, it proved difficult to achieve sufficient for
all the tests on all occasions - this was especially true for the first few umbilical
cords sampled and I got more proficient at obtaining more blood with experience.
Where insufficient blood was obtained, all of the clinical and TRIzol®LS tubes were
filled first and the PAXgene™ tube was injected with the remaining volume of blood
(0.8 - 2 ml). 2.5 ml of blood was available for the PAXgene™ tube for each of the
last 5 cords.
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cs1 EDTA 1.01 0.07 11.70 11.70 1
cs1 Li Heparin - - - - Wrong cap on
cs1 Na Citrate 1.88 0.079 13.21 13.21 8.1
cs1 TRIzol®LS 1.89 0.066 11.04 11.04 9
cs1 PAXgene™ 2.15 0.101 13.33 3.33 9.4 PAX: 2ml blood
cs2 EDTA 1.38 0.022 3.68 3.68 5.8
cs2 Li Heparin 1.79 0.034 5.68 5.68 8.9
cs2 Na Citrate 1.62 0.034 5.68 5.68 8.3
cs2 TRIzol®LS 1.63 0.031 5.18 5.18 8.9
cs2 PAXgene™ 1.93 0.106 13.99 3.50 9.8 PAX: 2ml
cs3 EDTA 1.76 0.037 6.19 6.19 7.6
cs3 Li Heparin 2.09 0.113 18.89 18.89 8.4
cs3 Na Citrate 1.87 0.073 12.21 12.21 7.4
cs3 TRIzol®LS 1.73 0.064 10.70 10.70 8.7
cs3 PAXgene™ - - - - - Elution error
cs4 EDTA - - - - - Blood clotted
cs4 Li Heparin - - - - - Blood clotted
cs4 Na Citrate - - - - - Blood clotted
cs4 TRIzol®LS 1.87 0.103 17.22 17.22 7.1
cs4 PAXgene™ 2.20 0.088 11.62 7.26 10 PAX: 0.8ml
cs5 EDTA 1.77 0.076 12.71 12.71 4.1
cs5 Li Heparin 1.90 0.146 24.41 24.41 7.4
cs5 Na Citrate 1.75 0.077 12.87 12.87 2.2
cs5 TRIzol®LS 1.72 0.239 39.96 39.96 9.2
cs5 PAXgene™ 1.95 0.409 53.99 10.80 9.5 PAX: 2.5ml
cs6 EDTA 2.10 0.021 3.51 3.51 6.1
cs6 Li Heparin 2.00 0.026 4.35 4.35 7.7
cs6 Na Citrate 2.00 0.014 2.34 2.34 6.6
cs6 TRIzol®LS 1.83 0.033 5.52 5.52 6.8
cs6 PAXgene™ 1.96 0.499 65.87 13.17 9.5 PAX:2.5ml
cs7 EDTA 1.93 0.058 9.70 9.70 7.3
cs7 Li Heparin 1.97 0.059 9.86 9.86 7.7
cs7 Na Citrate 2.00 0.076 12.71 12.71 2.3
cs7 TRIzol®LS 2.02 0.127 21.23 21.23 8.1
cs7 PAXgene™ 2.01 0.358 47.26 9.45 9.7 PAX:2.5ml
cs8 EDTA 1.89 0.036 6.02 6.02 1.1
cs8 Li Heparin 2.17 0.039 6.52 6.52 7.1
cs8 Na Citrate 1.75 0.014 2.34 2.34 1.1
cs8 TRIzol®LS 2.04 0.096 16.05 16.05 8.3
cs8 PAXgene™ 2.02 0.24 31.68 6.34 8.3 PAX:2.5ml
cs9 EDTA 2.01 0.149 24.91 24.91 7.3
cs9 Li Heparin 2.01 0.183 30.60 30.60 7.9
cs9 Na Citrate 1.95 0.121 20.23 20.23 8
cs9 TRIzol®LS 2.01 0.221 36.95 36.95 7.4
cs9 PAXgene™ 1.99 0.432 57.02 11.40 9.6 PAX:2.5ml
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Table 3.1.4a: Bioanalyzer graphs and RIN values for RNA extracted
after collection in EDTA, Lithium Heparin, Sodium Citrate, TRIzol®LS
or PAXgene™ tubes.
Sample EDTA Li Heparin Na Citrate TRIzol®LS PAXgene1
RIN 1.0
cs1
RIN 8.1 RIN 9.0
K*hJLA i w *.MUX^
RIN 9.4
cs2
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Table 3.1.4b: Bioanalyzer graphs and RIN values for RNA extracted
after collection in EDTA, Lithium Heparin, Sodium Citrate,
TRIzol®LS or PAXgene™ tubes.
EDTA Li Heparin Na Citrate TRIzoKDLS PAXgene1
cs6












.RIN 1.1 RIN 7.1
A





RIN 7.9 RIN 8.0 RIN 7.4 RIN 9.6
;;_U^A U,
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cs10 QIAamp® 0(E) 2.0 0.008 1.34 1.34 1
cs10 Trizol®LS 1.92 - 0.169 28.25 28.25 1
Trizol®LS +
cs10 QIAamp® 2.02 - 0.105 17.56 17.56 7.1
cs10
PAXgene™
(2.5 ml) 2 0.43 56.76 11.35 7.1
cs11 QIAamp® 1.88 1.86 0.013 2.18 2.18 5.7
cs11 Trizol®LS 1.82 - 0.266 44.48 44.48 n/a
Trizol®LS +
cs11 QIAamp® 1.95 - 0.152 25.41 25.41 7
cs11
PAXgene™
(2.5 ml) 1.98 0.631 83.29 16.66 5.5
cs12 QIAamp® 1.46 1.83 0.022 3.68 3.68 1.1
cs12 Trizol®LS 1.65 - 0.162 27.08 27.08 1.2
Trizol®LS +
cs12 QIAamp® 1.97 - 0.057 9.53 9.53 6.4
cs12
PAXgene™
(2.5 ml) 1.96 0.167 22.04 4.41 8.2
cs13 QIAamp® 1.91 1.9 0.019 3.17 3.17 8.2
cs13 Trizol®LS 1.91 - 0.181 30.27 30.27 3.3
Trizol®LS +
cs13 QIAamp® 1.99 - 0.135 22.57 22.57 7.4
cs13
PAXgene™
(2.5 ml) 1.99 0.358 47.26 9.45 7.5
cs14 QIAamp® 4.67 1.82 0.02 3.34 3.34 1.6
cs14 Trizol® LS 1.76 - 0.183 30.60 30.60 6.4
Trizol®LS +
cs14 QIAamp® 1.92 - 0.096 16.06 16.06 7.8
cs14
PAXgene™
(2.5 ml) 1.95 0.296 39.08 7.82 8.9
cs15 QIAamp® 2.5 1.92 0.025 4.18 4.18 7.9
CS15 Trizol®LS 1.69 - 0.071 11.88 11.88 1
Trizol®LS +
cs15 QIAamp® 1.5 - 0.054 9.03 9.03 n/a
cs15
PAXgene™
(2.5 ml) 2.01 0.335 44.22 8.84 7.3
cs16 QIAamp® 7 1.88 0.015 2.51 2.51 7.4
cs16 Trizol®LS 1.82 - 0.071 11.88 11.88 2.3
TrizoKDLS +
cs16 QIAamp® 2.02 - 0.083 13.88 13.88 6.6
cs16
PAXgene™
(2.5 ml) 2 . 0.236 31.15 6.23 8
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Notes on table 3.2.1
The A26o:A28o ratios were noted to vary widely for the samples extracted by
QIAamp® and on reflection I realised that these samples may have sat for longest
after preparation for spectrophotometry prior to being analysed on the
spectrophotometer. The QIAamp® samples were therefore re-run on the
spectrophotometer after making up the dilutions freshly and ensuring that they were
run as soon as possible after mixing by vortexing. Both sets of results for A26o:A28o
ratios are displayed in table 3.2.1 for completeness. The A260 values displayed are
those used for calculation ofRNA yield. As always, the A260 values were considered
valid if the spectrophotometry A260 values for each of the three cycles agreed within
0.002. In the unusual event of having repeated a sample and having two valid
results, the highest A260 value would have been selected.
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Table 3.2.4: Bioanalyzer Graphs and RIN values for RNA extracted
using QIAamp®, TRIzol®LS, TRIzol®LS followed by QIAamp®
clean-up and PAXgene™ methods.
QIAamp® TRIzol®LS TRIzol®LS &
QIAamp®
PAXgene™
























































































































































































Table 3.4.4: Bioanalyzer graphs and RIN values of RNA extracted
using 2.5 ml of blood in PAXgene™ tube, 0.5 ml of blood in
PAXgene™ tube or 0.5 ml of blood in an aliquot of PAXgene™
stabilization agent.
sample
2.5 ml in PAXgene™
tube
0.5 ml in PAXgene™
tube

































RIN 9.3 RIN 7.9
JU
cs16
RIN 8.0 RIN 8.3 RIN 8.3
UL
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Table 3.5.1: Raw values forsamplt
before RNA extraction: 2,24 or 72







A260 Total RNA (ng) RIN
cs19 2 1.3 0.026 3.43 9.5
cs19 24 1.66 0.068 8.98 8.6
cs19 72 1.47 0.044 5.81 7.9
cs20 2 1.41 0.055 7.26 8.8
cs20 24 1.47 0.047 6.20 7.7
cs20 72 1.35 0.042 5.54 7.3
cs21 2 1.13 0.026 3.43 7.6
cs21 24 1.4 0.049 6.47 6.8
cs21 72 1.28 0.037 4.88 n/a
cs22 2 2.16 0.067 8.84 8.6
cs22 24 1.19 0.259 34.19 7.2
cs22 72 2.04 0.051 6.73 8.1
cs23 2 1.62 0.021 2.77 9
cs23 24 2 0.038 5.02 8.7
cs23 72 1.87 0.043 5.68 7.6
cs24 2 1.34 0.047 6.20 9.9
cs24 24 1.71 0.036 4.75 9.1
cs24 72 1.85 0.037 4.88 8.6
cs28 2 2 0.016 2.11 8.3
cs28 24 2 0.026 3.43 8.5
cs28 72 1.46 0.019 2.51 7.6
cs29 2 1.92 0.023 3.04 9.3
cs29 24 2.43 0.017 2.24 7.3
cs29 72 2.16 0.041 5.41 7.8
cs30 2 2.29 0.016 2.11 n/a
cs30 24 2.36 0.026 3.43 9.4
cs30 72 2.5 0.015 1.98 6.8
cs31 2 2.67 0.008 1.06 9.4
cs31 24 4 0.008 1.06 8.4
cs31 72 1.67 0.01 1.32 7.8
cs32 2 2 0.014 1.85 8.6
cs32 24 1.87 0.028 3.70 8.5
cs32 72 1.26 0.024 3.17 8.2
cs33 2 av.1.26 av.0.020 2.64 9.4
cs33 24 av.1.49 av.0.017 2.24 8
cs33 72 av.1.32 av.0.034 4.49 7.8
397
398
Table 3.5.4b: Bioanalyzergraphs and RIN values for RNA extracted
at 2, 24 and 72 hours.






































































Table 3.6.1a: Raw data for each sample according to













cs34 2 1.31 0.017 2.24 8.6
cs34 4 2.33 0.021 2.77 9
cs34 6 2.18 0.024 3.17 8.6
cs34 8 2.08 0.025 3.3 9.1
cs34 10 1.91 0.021 2.77 9.4
cs34 12 1.69 0.022 2.90 9.7
cs35 2 1.44 0.013 1.72 9
cs35 4 1.8 0.018 2.38 9.5
cs35 6 2 0.018 2.38 9.8
cs35 8 1.79 0.025 3.3 9.3
cs35 10 1.83 0.022 2.90 8.9
cs35 12 2.67 0.016 2.11 8.6
cs36 2 2 0.016 2.11 9.4
cs36 4 1.7 0.017 2.24 8.8
cs36 6 2.5 0.02 2.64 9.6
cs36 8 1.81 0.029 3.83 9.3
cs36 10 2.17 0.013 1.72 8.2
cs36 12 1.79 0.025 3.3 7.8
cs37 2 2 0.01 1.32 8.1
cs37 4 2.2 0.011 1.45 8.8
cs37 6 2 0.012 1.58 8.1
cs37 8 1.83 0.011 1.45 8.4
cs37 10 1.92 0.025 3.3 9.2
cs37 12 1.7 0.017 2.24 8
cs38 2 2 0.026 3.43 9.4
cs38 4 1.24 0.079 10.43 9.4
cs38 6 1.85 0.024 3.17 8.7
cs38 8 2 0.026 3.43 8.3
cs38 10 1.6 0.04 5.28 8.9
cs38 12 1.14 0.124 16.37 9.1
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Table 3.6.1b: Raw data for each sample according to












cs39 2 1.78 0.016 2.11 8.7
cs39 4 1.5 0.012 1.58 n/a
cs39 6 1.67 0.015 1.98 9.3
cs39 8 3 0.015 1.98 9.2
cs39 10 1.8 0.018 2.38 8.1
cs39 12 2.33 0.014 1.85 10
cs40 2 4 0.008 1.06 9
cs40 4 3 0.012 1.58 8.7
cs40 6 1.93 0.029 3.83 9.4
cs40 8 2 0.018 2.38 8.7
cs40 10 2.1 0.021 2.77 8.7
cs40 12 1.87 0.028 3.70 8.6
cs41 2 2.07 0.029 3.83 9.4
cs41 4 1.8 0.027 3.56 10
cs41 6 1.73 0.038 5.02 9.7
cs41 8 1.93 0.029 3.83 9.8
cs41 10 2.14 0.03 3.96 8.4
cs41 12 1.56 0.028 3.70 9.6
cs42 2 1.78 0.016 2.11 9.9
cs42 4 1.68 0.037 4.88 9.9
cs42 6 2.07 0.029 3.83 9.7
cs42 8 1.67 0.025 3.3 9.3
cs42 10 1.78 0.016 2.11 n/a
cs42 12 2.29 0.032 4.22 9.6
cs43 2 1.91 0.18 23.76 n/a
cs43 4 1.9 0.156 20.59 6.9
cs43 6 1.9 0.129 17.03 7.1
cs43 8 1.9 0.131 17.29 6.5
cs43 10 1.86 0.19 25.08 n/a
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Table 3.8.4b can be found on the next page. Please note that the column headings for
table 3.8.4b differ from those in table 3.8.4a.
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Table 3.8.4b: Bioanalyzer graphs and RIN values for RNA extracted
after storage at 2 hours at room temperature, 1 week at -80 °C, 1










flIN 8.9 tRIN 9.4 RIN 8.3
\J
cs46
RIN 9.7 RIN 8.9 RIN 8.6
cs47
RIN 1.4 RIN 9.2 RIN 8.6
CS48
RIN 9.2 RIN 9.8 RIN 7.9
cs50
RIN 9.6 RIN 9.1 RIN 8.1
cs52









































































































This section contains tables ofBioanalyzer traces and RIN values for the RNA of the
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Appendix 4: Publications and Presentations Arising From
This Study
The following article was published in 2007 and it has been reproduced here by
permission of The Royal Society of Chemistry and can also be found at:
http://www.rsc.org/publishing/journals/AN/article.asp?doi=b707122c
Claire L Smith, Paul Dickinson, Thorsten Forster, Mizanur Khondoker, Marie
Cragion, Alan Ross, Petter Storm, Stewart Burgess, Paul Lacaze, Benjamin J Stenson
and Peter Ghazal. Quantitative assessment of human whole blood RNA as a potential
biomarker for infectious disease. Analyst 2007,132, 1200-1209.
I presented the results of an earlier pilot of this study (9 infected and 28 control
samples) at the following scientific meetings:
European Society ofPaediatric Research Meeting, October 2007, Prague.
Scottish Paediatric Society, St Andrews Day Symposium, November 2007,
Edinburgh.
The abstract appeared in the ESPR book of conference abstracts as:
Investigation of Host RNA Responses to Infection in Neonates: A New Avenue for
Diagnosis? CL Smith, P Dickinson, T Forster, P Lacaze, BJ Stenson, P Ghazal
(p8).
Paul Lacaze analyzed results from some of our earliest microarray work from my
neonatal samples (3 infected, 3 control and 4 with suspected sepsis). This work was
submitted as his MSc. By Research in Life Sciences Maxi-Project entitled:
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"A Pathway Biology Investigation of Systemic Host Responses to Infection in
Newborn Infants."
2006, University of Edinburgh.
I have subsequently presented results of the work in Chapter 5 at several scientific
meetings (listed below) and work is ongoing to submit this work for publication in
peer-reviewed journal(s).
Edinburgh Perinatal Festival, May 2010, Edinburgh.
Neonatal Society Summer Meeting, June 2010, Nottingham.
REaSoN Meeting, July 2010, Coventry (poster presentation).
I will also be presenting at the European Academy of Paediatric Societies Congress
in October 2010, Copenhagen. The abstract submitted to this conference will appear
in Pediatric Research Journal.
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Quantitative assessment of human whole blood RNA as a potential
biomarker for infectious diseaset
Claire L. Smith,"* Paul Dickinson," Thorsten Forster," Mizanur Khondoker," Marie Craigon," Alan Ross,"
Petter Storm," Stewart Burgess," Paul Lacaze," Benjamin J. Stenson* and Peter Ghazal*"
Received IOth May 2007, Accepted 15th October 2007
First published as an Advance Article on the web 31st October 2007
DOl: 10.1039/b707122c
Infection remains a significant cause of morbidity and mortality especially in newborn infants.
Analytical methods for diagnosing infection are severely limited in terms of sensitivity and
specificity and require relatively large samples. It is proposed that stringent regulation of the
human transcriptome affords a new molecular diagnostic approach based on measuring a highly
specific systemic inflammatory response to infection, detectable at the RNA level. This
proposition raises a number of as yet poorly characterised technical and biological variation issues
that urgently need to be addressed. Here we report a quantitative assessment of methodological
approaches for processing and extraction of RNA from small samples of infant whole blood and
applying analysis of variation from biochip measurements. On the basis of testing and selection
from a battery of assays we show that sufficient high quality RNA for analysis using multiplex
array technology can be obtained from small neonatal samples. These findings formed the basis of
implementing a set of robust clinical and experimental standard operating procedures for whole
blood RNA samples from 58 infants. Modelling and analysis of variation between samples
revealed significant sources of variation from the point of sample collection to processing and
signal generation. These experiments further permitted power calculations to be run indicating the
tractability and requirements of using changes in RNA expression profiles to detect different
states between patient groups. Overall the results of our investigation provide an essential first
step toward facilitating an alternative way for diagnosing infection from very small neonatal
blood samples, providing methods and requirements for future chip-based studies.
Introduction
Infection is an important source of morbidity and mortality in
neonates and infants. In the developed world, 65% of
extremely low birth weight infants develop presumed sepsis
in the neonatal period.' With mortality rates of 10-50%, a
four-fold increase in cerebral palsy and increased risk of
hearing, growth and neuro-developmental impairments, the
costs are great.1 On a global perspective, infection accounts for
more than half of all deaths worldwide of children younger
than age 5.2 During the first year of life, the developing human
immune system encounters many challenges from both
infections and vaccinations. Systemic deficiencies of both
innate and adaptive immunity are thought to contribute to
impaired neonatal host defences while protection through
maternal antibodies, which is deficient in preterm babies,
wanes after approximately six months in term infants. Early
diagnosis of infection is key to providing timely and
appropriate treatment. Blood is the primary source of clinical
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Diagnostic Testing of Infection and Disease States.
material available and when one considers that some patients
may have no more than 40 ml total blood volume and that
current procedures often withdraw several millilitres for
various blood tests then this sets a stringent ethical and
research challenge of working with extremely small quantities
of blood. It is noteworthy that the standard diagnostic tool for
infection is the blood culture, but this does not give a rapid
result (up to 48 h), has poor sensitivity (50-80% at best but
often considerably less ) and requires blood volumes that
represent a significant proportion of an infant's circulating
blood volume.
Many signaling molecules and concurrent biological
pathways responsible for the initiation and propagation of
an inflammatory response to infection have been identified in
circulating serum - constituting what has been termed
'Systemic Inflammatory Response'. Individual molecular
components identified as part of the systemic inflammatory
response have been helpful toward understanding the under¬
lying physiology of inflammation and have also shown
potential diagnostic and therapeutic value, including
C-reactive protein (CRP) and tumor necrosis factor-a
(TNF-a).4 From early developmental stages onward, the
various activities of circulating immune cells contribute to
local as well as systemic levels of cytokines and inflammatory
molecules. In this context, blood serves as an integrative tissue
whereby its cells and associated signaling and cytokine
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networks relay or enhance the contribution made by sites of
infection or tissue damage, to effect protection or cell injury
repair responses.
Infections not only elicit but also modify, in a pathogen-
specific manner, immune inflammatory responses. This
occurs at two levels, the infected cell and the systemic host
response levels. At the cell level, analysis of a wide range of
studies looking at infection in tissue-culture experiments has
defined differential and common host transcriptional
responses.3 This is due in part to the recognition of
pathogen-associated molecular patterns by an array of cellular
receptors to specific pathogen products. This is especially true
for professional antigen presenting cells which orchestrate the
selective and appropriate protective immunity. Accordingly,
the nature of the systemic inflammatory response generated
in vivo to an infective agent will also vary depending upon
the specific pathogen resulting in both qualitative and
quantitative aspects of the immune response being markedly
influenced by the various countermeasures enacted by the
pathogen. The systemic responses can be seen in altered
cytokine levels, specific lymphocyte responses and can also be
detected by alterations in the host RNA phenotype in
response to infection.6-10 Microarrays have proven themselves
to be useful means for global analysis of gene or protein
content and expression. Studies of variation in gene expression
among individuals has revealed a surprising consistency, but
also evidence of distinct patterns of inter-individual and
temporal variation." Microarray technology has shown
many potential clinical applications including classification
of cancer patients on the basis of disease outcome and
prediction of treatment response.12-15 In recent months there
have been increasing numbers of publications reporting
microarray experiments using RNA extracted from clinical
whole blood samples in adults and children."16-30 In this
report we show for the first time that it is feasible to
isolate RNA of sufficient quality and quantity from small
volumes of whole blood collected from neonates in order to be




Ethical permission was obtained from the local research ethics
committee for this study. Written informed consent was taken
from the parent(s) in each case.
Sample collection
Work to determine optimal RNA extraction from neonatal
blood was carried out using umbilical cord blood. Umbilical
cord blood sampling took place from the cord segment still
attached to the placenta after the cord was cut at delivery. The
umbilical cord was cleaned with a sterile swab soaked in
phosphate buffered saline and the cord cut using sterile
scissors. The umbilical vein was then catheterised with a
sterile 5-gauge nasogastric tube and blood aspirated into sterile
syringe(s). The samples were then injected immediately into
sample collection tubes.
For array analysis neonatal whole blood was used. For these
samples neonatal blood sampling was performed by trained
members of clinical staff. Gloves were worn during the
procedure to avoid contamination. The infant's skin was
cleaned with an iodine-based solution and then washed with
sterile saline and dried with a sterile swab. The needle or
cannula was then inserted and a blood sample of approxi¬
mately 0.5 ml drawn into a syringe. The sample was injected
immediately into a PAXgene™ blood RNA tube which was
then inverted ten times. Samples were taken from needles,
newly inserted venous cannulae or newly inserted arterial
cannulae. Samples were not taken from heparinised lines. If
samples were to be processed the same day they were
transferred to the laboratory and incubated at room tempera¬
ture for a minimum of 2 h. Otherwise samples were put directly
into a -20 °C freezer located within the clinical area until they
were transported to the laboratory. In each case data were
gathered for each infant including the age of the infant and the
mode of sampling (needle or cannula).
Blood collection tube assessment
Five different blood collection media were investigated. Blood was
injected into one each of clinical blood tubes containing EDTA,
Lithium Heparin and Sodium Citrate. Blood was also injected
directly into a PAXgene™ blood RNA tube and into a micro¬
centrifuge tube containing TR1ZOL® LS reagent. All tubes were
transferred to the laboratory on ice with the exception of the
PAXgene™ tube which was transferred at room temperature.
With the exception of the PAXgene™ tubes, 0.5 ml of blood from
each of the blood collection tubes was processed immediately using
the TRlZOL® LS extraction method followed by an on-column
cleanup. The PAXgene™ tubes were processed using the
PAXgene™ blood RNA extraction kits after at least 2 h
incubation at room temperature.
RNA extraction assessment
Five different methods for RNA extraction were performed
ranging from organic phase extraction to the use of magnetic
bead technology. These were TRlZOL® LS (Invitrogen™
Corporation), QIAamp RNA Blood Mini Kit (QIAgen Ltd.),
TRlZOL1® LS followed by QIAamp RNA Blood Mini Kit.
MagaZorb® (CorTex Biochem™, Inc., San Leandro, CA)
and PAXgene™ (PreAnalytiX GmbH).
At the time of sampling for these experiments, blood was
injected into PAXgene™ and EDTA tubes. RNA extraction
was performed using the PAXgene™ system and using 0.5 ml
of blood from the EDTA for each of the other methods except
MagaZorb®. As a separate experiment later, 0.5 ml of blood
processed in a PAXgene™ tube was compared to 0.2 ml of
blood collected in a clinical EDTA tube and processed using
the MagaZorb® magnetic bead extraction (results shown later
for the MagaZorb®' yield in Table 2 multiplied to give the yield
equivalent to 0.5 ml).
TRlZOL® LS extraction
0.5 ml of RNase-free water was added to 0.5 ml of blood, then
3 ml of TRlZOL" LS solution was added and repetitive
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pipetting was carried out to lyse the cells. RNA extraction was
carried out as per TRIZOL® LS instructions with the exception
of the initial centrifugation step being carried out at 4000 rpm
in an Eppendorf 5810R centrifuge for 1 h.
On-colunw cleanup following TRlzOL® LS RNA extraction
100 pi samples obtained from the TRIZOL1' LS reaction were
carried into the first step of the QIAamp RNA Mini Protocol
for RNA Cleanup and this protocol was followed to the end.
The optional on-column DNase step, second centrifugation
step and repeated elution step (to give a final elution volume of
100 pi) were incorporated.
QIAamp RNA extraction
The QIAamp RNA Mini Protocol for Isolation of Total
Cellular RNA from Whole Human Blood was followed with
the following variations: the blood/Buffer EL mix was
incubated on ice for 20 min; after centrifugation and removal
of the supernatant the pellet was incubated on ice for a further
10 min; and after further addition of Buffer EL, 600 pi (rather
than 350 pi) of buffer RLT was added to the sample. The
optional on-column DNase step and second centrifugation
step after the addition of buffer RPE were incorporated. The
sample was eluted in 100 pi of RNase-free water.
PAXgene™ blood RNA extraction
Each of the PAXgene™ tubes was processed according to the
PAXgene™ blood RNA protocol from PreAnalytix dated
April 2001. Variations from the protocol were: the incubator
steps were carried out in a water bath rather than a shaker-
incubator (in step 5 the samples were vortexed once during the
incubation), the centrifugation step was increased to 10 min,
the optional on-column DNase step and the 1 min drying
centrifugation were incorporated.
MagaZorblp extraction
RNA extraction was carried using 200 pi of whole umbilical
cord blood according to the MagaZorb®' RNA Purification
Protocol (CorTex Biochem™) with Supplementary Protocol
B (DNase protocol) incorporated.
Quantification and quality assessment of RNA
RNA was quantified and an A260 : 42x0 ratio calculated for
each sample after analysis on a ThermoSpectronic Biomate
5 vl.6 spectrophotometer. RNA quality was assessed running
each sample on an Agilent 2100 Bioanalyser using an RNA
LabChip kit. RNA quality was assessed qualitatively by
looking at the electropherogram of each sample, and
quantitatively by means of the RNA Integrity Number (RIN).
Microarray processing and analysis
The CodeLink™ Human Whole Genome Bioarray was
comprised of approximately 55 000 30-mer probes designed
to conserve exons across the transcripts of targeted genes.
These 55 000 probes represent well-annotated, full length, and
partial human gene sequences from major public databases.
The biotin-labelled cRNA target is prepared by a linear
amplification method using tailed oligo dT priming of total
RNA. After second-strand cDNA synthesis, the cDNA
undergoes an in vitro transcription (IVT) reaction to produce
the target cRNA. This method produces approximately 1000-
fold to 5000-fold linear amplification. Various quality control
procedures are incorporated. Hybridisation is performed
overnight and post-hybridisation processing includes a strin¬
gent wash to remove unbound and non-specifically hybridised
target molecules and staining with Cy™5-streptavidin con¬
jugate. Several non-stringent washes remove unbound con¬
jugate. The bioarrays are then dried and scanned on the
Agilent G2567A scanner at 5 pm resolution. Raw data were
obtained from the scanned images using CodeLink™
EXPv4.1 (GE Healthcare) feature extraction software.
Subsequent data validation comprising data quality control
and normalisation involved the use of the statistical software
package R (v 2.2.1) and Bioconductor modules for R (v 1.7).
Microarray data have been deposited in the GPX M1AME
compliant database at http://www.pathwaymedicine.ed.ac.uk/
gpx (Accession number: GPX000071 will be made available
upon publication).
Statistical methodology and analysis
For comparison of blood collection methods, sample storage
and RNA extraction procedures a two-tailed paired Student's
/-test was employed. For microarray data analysis, a simple
(per-gene) analysis of variance model was employed. To define
the model, suppose that the median spot intensity X^j
corresponds to the gth gene, tth operator, /th way of taking the
sample, Ath freezing status, /th level of time to extraction, /nth
category of age, and nth sample. We assume that the median
intensity 4/^,n) consists of a systematic component
and a non-systematic (random error) component
and are related by a multiplicative relationship.
That is,
Xo{i:hk.tjn.n I — Sg(iJ,kJ,m) X Rg(ij,k,l,m,n)> (1)
where the random component R^aj^.t.m.n) is distributed as log-
normal with scale parameter 1 [or, loge(l) = 0] and shape
parameter agiijkim). Therefore,
RgiiJ,k,l,m,n) /-A(0,(7 (2)
A random variable X has the distribution LAr(//,cr2) if Y -
logc(A) has the normal distribution N(ti,o2). Therefore, fitting
of a log-normal distribution, in principle, reduces to fitting of a
normal distribution. Now with the transformations
XJ.m) ~ eXp{ ;./,/■:././>?)). and RgO'j,k,l.m,n) e\p( t kJ.ni.n))-
model corresponding to eqn (1) for log-intensity Y^,jkjmn) =
logJ.Xgojjcjjnj,)) can be written as
Yg(iJ,k,l,m,n) ~ *1 + r-g(i,/\kJ,m,n)> (3)
where is the log-systematic component and
is the log-error. Assuming that the log-systematic component
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f1g{i,i,k,i,m) is as an additive function of the effects of the
systematic sources of variation,
1g(ij,k,l,m,n) = Hg + %/) + Pgm + Yg(k) + SgiD + (4)
the per-gene analysis of variance (ANOVA) model for log-
intensity YgUJtkjm<n) is expressed as,
Yg(iJ,k,l,m,n) ~ /% + + Pg(j) + Vg(.k) +
3g(0 + Tjrh") + sgiij,k,l,tn,n)-> (5)
where fig is the overall log-expression of gene g, the effect
of the /th operator, Pg(J) the effect of the /th way of taking
blood, y^k) the effect of the /rth freezing status, the effect
of the /th level of time to extraction, T^m) the effect of the /nth
category of age, and is the corresponding log-error
term distributed as
£g(ij,k,l,m,n) ~ N(0,O^g{ijjc,l,m,ri))- (6)
The parameters of model (5) can be estimated using a least-
squares method by minimising the error sum of squares given
by,
SSEg = ^ = 5Z ^ ~
iJJc,l,mji ijjc,l,m,n
+ <Xg(i) + figU) +7g(k) + bg(I) + 1g(m)}) •
This is done by partially differentiating SSEg with respect to
each of the parameters, and then solving the resulting
equations by setting them equal to zero. Details of the
methods have previously been described31 and are implemen¬
ted in all standard statistical analysis software. We used the R
program aov to fit the model (5). If the normality assumption
of the log-errors (6) is true, then the least-squares estimates of
the model (5) are equivalent to the maximum likelihood
estimates. We employed a factorial design to analyse the data.
There are five factors with a number of levels resulting in
144 factor combinations. The experiment was difficult to
implement as balanced for such multi-factor analysis and
therefore have cell frequencies ranging from 0 to 5. The
reason for this primarily relates to lack of control on the
selection of infants, ages and clinical procedures performed.
Thus, while interpretation of results obtained from analysis of
variance of unbalanced factorials may sometimes be less
precise, the current analysis should reflect the overall
behaviors of data in terms of the multiple factors, and provide
guidelines for future designs and analyses using larger
replication studies.
Results and discussion
Sample collection and processing
Sample collection was performed using a closely defined set of
standard operating procedures as in the Experimental section.
Tables 1 and 2 show results of the investigations into finding
the optimal blood collection tube and extraction method
(using umbilical cord blood as a surrogate for neonatal blood)
comparing five different commercial RNA extraction proce¬
dures. The PAXgene™ blood RNA system consistently gave
the best quality RNA while yielding sufficient quantity for
microarray analysis. Using standardised protocols for sample
collection and processing following identification of optimal
methods means that data are as robust and reproducible as
possible. Importantly our subsequent studies using neonatal
samples have shown that it is possible to obtain sufficient
RNA of consistently high quality from neonatal whole blood
samples of 0.5 ml. For the 58 samples examined in this report,
the mean yield of RNA was 8.45 gg (range 1.84—43.82), the
mean RIN value was 9.1 (range 6.6-10) and the mean A
A2go ratio was 1.86 (range 1.24—2.47). We also show in Table 3
that storage of these PAXgene™ blood samples at -20 °C for
7 days prior to RNA extraction leads to no loss in quality of
RNA.
Chip-based measurements - contending with systematic and non-
systematic variation
Next we implemented the defined clinical and RNA extraction
standard operating procedures for collection and processing of
Table T Comparison of blood collection tubes
Mean (range) RNA Mean (range) Mean (range) RIN //-value cf

























Table 2 Comparison of RNA extraction methods
Mean (range) RNA Mean (range) Mean (range) RIN //-value cf.
RNA extraction method n per 0.5 ml blood/pg ^260 : 280 RIN values PAXgene™
MagaZorb® 7 15.92 (9.98-21.85) 1.71 (1.53-1.85) 1.9(1.0-2.9) 0.008
QIAamp 7 2.91 (1.34-4.18) 2.77 (0-7) 4.7 (1.0-8.2) 0.1
TRIzol " LS 7 26.35 (11.88-44.48) 1.80 (1.65-1.92) 2.2 (0.0-6.4) 0.00009
TRIZOL® LS and QIAamp 7 16.29 (9.03-25.41) 1.91 (1.5-2.02) 6.0 (0.0-7.8) 0.2
PAXgene™ 7 9.25 (4.41-16.66) 1.98 (1.95-2.01) 7.5 (5.5-8.9)
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Table 3 Comparison of storage conditions
Sample storage n Mean (range) RNA/pg Mean (range) Alfks. 280 Mean (range) RIN values RIN p-value
Not frozen 6 4.16(1.72-5.81) 1.86 (1.55-2.06) 7.8 (1.4-9.6) 0.29
Frozen at -20 °C for 7 days 6 5.61 (3.56-7.92) 1.81 (1.64-2.00) 9.4 (8.4-9.9)
58 neonatal whole blood samples. Whole blood RNA samples
are comprised of RNA from a range of blood cells including
reticulocytes, and the presence of high levels of globin mRNA
from these cells has led to the use of globin reduction protocols
for whole blood samples.29 We evaluated the use of a globin
reduction protocol for our samples (data not shown) but
observed limited improvement on sensitivity and specificity of
chips. For this reason we processed our samples directly
without globin reduction. Gene expression data were deter¬
mined for the 58 neonatal whole blood samples and analysed
for the purpose of investigating the sources and magnitude of
systematic and non-systematic (random) variation and to
explore an appropriate error model for such data. Specifically,
five sources of variation were examined: age of patient
(<5 days, 5-10 days or >10 days), blood sample collection
method (needlc/cannula), freezing status of sample (frozen/not
frozen), time to extraction (<3 h, 3-4 h or >4 h), and technical
operator (one of four operators). The data were comprised of
58 samples, corresponding to RNA extracted from neonatal
whole blood of 58 infants and these samples were analysed
using CodeLink™ Human Whole Genome Bioarrays
(GE Healthcare), providing expression profiling of ca. 55 000
human gene targets in a single array. The first step of our
analysis was to look for any significant operator variation in
the data. We employed a simple (per-gene) analysis of variance
model as outlined in the Experimental section [eqn (5)]. Results
of applying the model to the first row of data (g = 1) are
summarised in Table 4 and show that the factor 'time to
extraction' has the highest level of variation, but none of
these sources of variation are statistically significant. A
summary of these results is graphically presented in Fig. 1.
The top panel, Fig. 1A shows the number of genes with a
mean squared error (MSE) greater than or equal to a
certain level plotted against that level of variation. The
bottom panel, Fig. IB shows the number of genes having a
significance level less than or equal to a certain value
plotted against the corresponding level of /^-values. Mean
squared error (MSE) due to all the systematic sources of
variation and error, and the p-values for the significance
of systematic sources of variation, are computed on the basis
of the per-gene ANOVA model (5). These analyses show that a
significant source of variation can be attributed to the
Table 4 Results ofapplying the analysis of variance model to the first
row of data (g = 1)
Source of variation Mean squared error (MSE) p-Value
Operator 0.42 0.48
Blood draw method 0.19 0.55
Freezing status 0.78 0.22
Time to extraction 1.21 0.10
Age 0.21 0.67
Random error 0.51
'operator'. Another significant source appears to be the
factor 'blood draw method'. That is whether a needle or a
cannula was used for taking blood. We see that up to a
certain level of variation (MSE - 1.4) the number of genes
exceeding a certain threshold of operator variation is higher
than that exceeding the same level of variation due to other
sources. However, after the level 1.4, 'blood draw method'
takes over the 'operator'. Testing if other confounding
variables also contribute to these particular variations will
require further investigation. Nevertheless, the proportion of
genes showing significant variation at p - 0.05 for all five
sources of variation considered in this study are shown in
Table 5.
Error models and power calculations required for RNA
biomarker identification
We assumed in our basic model (1) that the error associated
with the untransformed spot intensity XgUjkimn) is Rg^j.kj.m.„)
and follows a log-normal distribution, Rg{ij,k,i.m n) ~
LN(0yg(W_m,„)). Equivalently, the distribution of log-error,
which is the error associated with the log-spot-intensity
^giij,k,i,m,n) logel^is denoted by i-g(ij.kj.m.n)- and
follows a normal distribution
~ A7(0,P yjij.k J.in 1 )-
So, fitting a log-normal distribution to errors R^ij^jjn^) is
equivalent to fitting a normal distribution to log-errors Sgffjjcjjnjiy
The second option is more commonly used and convenient in
many ways. Our per-gene ANOVA model (5) actually fits a
normal distribution to the log-errors. Therefore, if log-normal is an
appropriate choice for errors RfUj.kjjn.m- residuals from the fitted
model (5), given by,
eg(iJ,k,ljn,n) = Yg(ijJc,ljn,n) ~
{fig + &g(i) + pg{j) + yg(k) + Sg(/) + ig(m) |
should be approximately normally distributed. Empirical
distributions and the corresponding fitted normal distributions
to the residuals (log-errors) corresponding to ten randomly
selected genes are plotted in Fig. 2. It is seen that except for the
minor multimodal features of the empirical distributions, normal
distributions provide a reasonable fit to the data. General
conclusion from Fig. 2 may be that model (5) with normally
distributed log-errors provides a reasonable fit to the data. It
would, however, be worth investigating if the multimodality as
seen in Fig. 2A may be captured with a more appropriate
distribution.
These analyses support the possibility of performing
microarray experiments on neonatal whole blood and raise
the question of whether or not patient group variance is
amenable to profiling RNA biomarkers. Fig. 3A shows the
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Fig. 1 Investigation of systematic and non-systematic variation in microarray data generated from neonatal whole blood samples. The number of
genes having mean squared error (MSE) greater than or equal to a certain level plotted against the level of variation (A), and number of genes
having a significance level less than or equal to a certain value plotted against the level of p-values (B). Mean squared error (MSE) due to the
systematic sources and random error, and the p-values for the significance of systematic variations are computed on the basis of the ANOVA model
(5).
Table 5 Proportion of genes having significant variation correspond¬
ing to all five systematic sources considered in this study (p = 0.05)
Proportion of genes showing
significant variation at p - 0.05
Needle/ Time to
Sources Operator cannula Freezing extraction Age
Proportion 0.89 0.38 0.05 0.01 0.25
level of variation seen in the expression data generated
from the preliminary clinical data. Plots of coefficient of
variation of patient samples show acceptable levels of
variation. Some exploratory plots of the data are shown in
Fig. 3A. If we ignore the outliers in the mean vs. CV plot a
non-linear trend can be seen in the mean-CV relationship.
Determining sample size per experimental condition for a
given level of confidence in inferring differential expressions is
an important issue, and needs to be decided as an essential
first step. The multiple number of RNA markers estimated
for each sample makes it difficult to apply traditional
sample size calculation techniques and has left most
practitioners to rely on rule-of-thumb techniques. A
method for computing the sample size for microarray
experiments for a given pre-determined level of confidence
(power) in inferring differential expressions has been
described.32 The method is based on the assumption that
the microarray is set up to compare gene expressions
between one treatment group and one experimental group. It
is further assumed that the data have been normalised and
transformed so that the data for each gene are sufficiently
close to a normal distribution so that a standard two-sample
pooled variance /-test will reliably detect differentially
expressed genes. Here we compute the sample size separately
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where TJ^Iff) is the cumulative distribution function for non-
central /-distribution with d degrees of freedom and the non-
centrality parameter 6.
We apply the above method to calculate the sample size to
achieve 90% power on the basis of the standard deviations
computed from the quantile normalised data of 58 control
samples of the neonatal whole blood gene expression study.
The results are plotted in Fig. 3B representing the sample size
required to achieve 90% power for a given proportion of genes
on the arrays. Power calculations and sample size estimates
based on 71 = 58 samples with the same type of sample and on
the same microarray platform suggest that 100 samples per
group will be required to detect two-fold differential expres¬
sion with 90% power for at least 90% of the probes on the
array, at a significance level of a = 0.001 (corrected for
multiple testing by the Bonferroni method33). We conclude
from these analyses that identifying RNA biomarkers is
tractable with a case control group size of 100 patients.
Stringency of transcriptome and variation of RNA phenotype
The above studies indicate that while there is a significant level
of variation there is nevertheless a relatively stable, well-
correlated RNA phenotype that can be used to identify a
specific set of RNAs as potential biomarkers. Overall, this
observation is indicative of homeostatic mechanisms under¬
pinning a stringently regulated genome. In support there are a
number of well-documented genetic diseases, mainly of non¬
protein coding mutations, that lead to an alteration of very
subtle changes (up to two-fold or less) in gene expression in
comparison with normal individuals and which result in
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A Coefficient of variation (CV) plot (n = 58 arrays)
CV vs. mean plot
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Fig. 3 Scatter plots of inter-patient variance and power calculations.
marked clinical phenotypes.34-37 These studies indicate that
gene expression is tightly regulated and relatively intolerant of
dramatic variation. In support, microarray studies of variation
in expression among individuals have revealed a surprising
level of overall consistency but also evidence of distinct
patterns of inter-individual and temporal variation." A recent
chip study shows the possibility of even detecting slight
alterations in gene expression due to allelic variation.38 Our
recent experience in performing a range of clinical molecular
profiling studies from intestinal, mammary, adult blood,
endometrial, ovarian and testicular biopsies supports the view
for a remarkable stringency in the inter-individual regulation
of the transcriptome (see ref. 39 and unpublished observa¬
tions). To date, neonatal whole blood shows the highest level
of variability in our experience. This could be due to greater
levels of complexity of procedural, sample handling and age
differences as well as a degree of biological variation.
Nevertheless, even with these samples our microarray profiling
observations show an excellent correlation between indivi¬
duals, further indicating the human transcriptome to be under
stringent homeostatic regulation. Accordingly, even without
standardisation, early microarray studies have shown potential
clinical applications including classification of cancer patients
on the basis of disease outcome and prediction of treatment
12-15
response.
RNA phenotype of systemic host response
One particularly exciting application of microarrays could be
investigating infection by detecting alteration in host RNA
phenotype in response to infection.6-9 This would be
particularly useful if unique host signatures could identify
individual pathogens.10 Recently, there have been a few small/
pilot studies looking at gene expression profiling in response to
infection.I7'19,23'27 Also, there have been an increasing number
of publications reporting microarray experiments using
RNA from clinical whole blood samples in adults and
children.11,16-30,40 These reports are at this time limited not
only in terms of statistical power but also to the gene-analytic
approach applied. However, one study has attempted to
explore networks of inter-related genes.41 In this connection it
is worth noting that biological pathways provide a central level
of physiological organisation and, to date, a pathway-centric
approach is markedly absent.
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Perspective: bio-chip platforms for point-of-care
Biochip platforms based on pathogen detection both at the
nucleic acid42 and protein43 level are seen as key in the accurate
diagnosis of infection. However, the multi-parameter testing of
changes in whole blood RNA expression has the potential to
use extremely small quantities of material which does not
require the presence of the infective agent in the sample. It is
possible to envision that micro-devices would have the
capacity not only to process and extract RNA but also to
detect directly the presence of specific host pathway responses
to infection. It is also likely that these pathway responses may
also be detected at the protein level based on predictions from
the RNA phenotype. Biochips incorporating a combination of
both pathogen detection and host response would give the
widest possible coverage to detect signatures diagnostic of
infection. Nevertheless, regardless of the platform technology
used to detect such signatures it is of fundamental importance
that a clear understanding of the levels and contributions of
systematic and non-systematic variation are fully appreciated.
In this report we have shown that the operator and the point of
collection can provide a significant source of changes in gene
expression. Therefore if RNA is to fulfil a future role as a
potential biomarker it is essential that appropriately powered
studies are performed which account for known systematic
variation and error models developed to account for non-
systematic variation.
Conclusion
In conclusion we show that multi-parameter testing of changes
in RNA expression offers innovative potential and an
amenable means for measuring an RNA phenotype using
relatively small quantities of whole blood. We provide optimal
methods and procedures and attendant clinical and experi¬
mental SOPs for applying a rigorous, chip-based investigation.
Even with such methods, significant challenges and limitations
remain, related to both systematic and non-systematic varia¬
tions. From an analysis of the RNA phenotypes from
58 samples of neonatal whole blood considered in this study
we identify among the systematic sources of variation as
potentially contributing variability: laboratory operator, the
way the blood is drawn (by needle/cannula), and the age of the
infants. Further case studies are required to validate these
findings. We show that a linear additive analysis of variance
model for log-transformed data with Gaussian-distributed log-
errors seems reasonable to adjust the data for systematic
variation. Except for the minor multimodal features of the
empirical distributions, log-normal distributions for errors or,
equivalently, normal distributions for log-errors provide a
reasonable fit to the data accounting for non-systematic
variation. A sample size of about 100 per-group seems
reasonable to achieve 90% power for 90% of markers on the
chip.
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